{"idB": "886163_12_item1_p59_s3", "idA": "886163_11_item1_p0_s0", "sentA": "Caution: This discussion and analysis may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed in Item 1A. Risk Factors.", "sentB": "For a discussion of the risks associated with competition, see below under Item 1A. Risk Factors.", "type": 2, "words": ["<tag1>", "Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors.", "<tag2>", "For", "a", "discussion", "of", "the", "risks", "associated", "with", "competition,", "see", "below", "under", "Item", "1A.", "Risk", "Factors.", "<tag3>"], "wordsA": ["Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors."], "wordsB": ["For", "a", "discussion", "of", "the", "risks", "associated", "with", "competition,", "see", "below", "under", "Item", "1A.", "Risk", "Factors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s7", "idA": "886163_11_item1_p0_s0", "sentA": "Caution: This discussion and analysis may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed in Item 1A. Risk Factors.", "sentB": "For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors.", "type": 2, "words": ["<tag1>", "Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors.", "<tag2>", "For", "a", "discussion", "of", "the", "risks", "associated", "with", "government", "regulations,", "see", "below", "under", "Item", "1A.", "Risk", "Factors.", "<tag3>"], "wordsA": ["Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors."], "wordsB": ["For", "a", "discussion", "of", "the", "risks", "associated", "with", "government", "regulations,", "see", "below", "under", "Item", "1A.", "Risk", "Factors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s8", "idA": "886163_11_item1_p0_s0", "sentA": "Caution: This discussion and analysis may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed in Item 1A. Risk Factors.", "sentB": "For a discussion of the risks associated with patent and proprietary rights, see below under Item 1A. Risk Factors.", "type": 2, "words": ["<tag1>", "Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors.", "<tag2>", "For", "a", "discussion", "of", "the", "risks", "associated", "with", "patent", "and", "proprietary", "rights,", "see", "below", "under", "Item", "1A.", "Risk", "Factors.", "<tag3>"], "wordsA": ["Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors."], "wordsB": ["For", "a", "discussion", "of", "the", "risks", "associated", "with", "patent", "and", "proprietary", "rights,", "see", "below", "under", "Item", "1A.", "Risk", "Factors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p9_s5", "idA": "886163_11_item1_p10_s5", "sentA": "Our Asset Portfolio We have a portfolio of over sixty current and future potential revenue generating programs.", "sentB": "Our Asset Portfolio We have a portfolio of over 60 current and future potential revenue generating programs, over 50 of which are fully funded by our partners.", "type": 2, "words": ["<tag1>", "Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "sixty", "current", "and", "future", "potential", "revenue", "generating", "programs.", "<tag2>", "Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "60", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "50", "of", "which", "are", "fully", "funded", "by", "our", "partners.", "<tag3>"], "wordsA": ["Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "sixty", "current", "and", "future", "potential", "revenue", "generating", "programs."], "wordsB": ["Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "60", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "50", "of", "which", "are", "fully", "funded", "by", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p9_s6", "idA": "886163_11_item1_p10_s6", "sentA": "We expect to receive royalties from eight marketed products in 2011 and have multiple programs at Phase IIb through NDA submission (as illustrated below) which represent our future upcoming potential revenue generating programs.", "sentB": "We expect to receive royalties from eight marketed products in 2012 and have multiple programs at Phase IIb through NDA submission which represent our future upcoming potential revenue generating programs.", "type": 2, "words": ["<tag1>", "We", "expect", "to", "receive", "royalties", "from", "eight", "marketed", "products", "in", "2011", "and", "have", "multiple", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "(as", "illustrated", "below)", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs.", "<tag2>", "We", "expect", "to", "receive", "royalties", "from", "eight", "marketed", "products", "in", "2012", "and", "have", "multiple", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs.", "<tag3>"], "wordsA": ["We", "expect", "to", "receive", "royalties", "from", "eight", "marketed", "products", "in", "2011", "and", "have", "multiple", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "(as", "illustrated", "below)", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs."], "wordsB": ["We", "expect", "to", "receive", "royalties", "from", "eight", "marketed", "products", "in", "2012", "and", "have", "multiple", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p11_s0", "idA": "886163_11_item1_p11_s0", "sentA": "In November 2008, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of GSK s PROMACTA (Eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "chronic immune (idiopathic) thrombocytopenic purpura, or ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "type": 2, "words": ["<tag1>", "In", "November", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "GSK", "s", "PROMACTA", "(Eltrombopag)", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag3>"], "wordsA": ["In", "November", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "GSK", "s", "PROMACTA", "(Eltrombopag)", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p12_s1", "idA": "886163_11_item1_p11_s1", "sentA": "PROMACTA is also approved under the trade name Revolade(R) in Japan, Europe, Venezuela, Kuwait, Chile and Russia.", "sentB": "Eltrombopag is also authorized for use in all 27 member states of the European Union, as well as India, Australia, Ireland, Japan, Taiwan, Turkey, Singapore, Kuwait, Chile, Russia and Bahrain under the trade name REVOLADE.", "type": 2, "words": ["<tag1>", "PROMACTA", "is", "also", "approved", "under", "the", "trade", "name", "Revolade(R)", "in", "Japan,", "Europe,", "Venezuela,", "Kuwait,", "Chile", "and", "Russia.", "<tag2>", "Eltrombopag", "is", "also", "authorized", "for", "use", "in", "all", "27", "member", "states", "of", "the", "European", "Union,", "as", "well", "as", "India,", "Australia,", "Ireland,", "Japan,", "Taiwan,", "Turkey,", "Singapore,", "Kuwait,", "Chile,", "Russia", "and", "Bahrain", "under", "the", "trade", "name", "REVOLADE.", "<tag3>"], "wordsA": ["PROMACTA", "is", "also", "approved", "under", "the", "trade", "name", "Revolade(R)", "in", "Japan,", "Europe,", "Venezuela,", "Kuwait,", "Chile", "and", "Russia."], "wordsB": ["Eltrombopag", "is", "also", "authorized", "for", "use", "in", "all", "27", "member", "states", "of", "the", "European", "Union,", "as", "well", "as", "India,", "Australia,", "Ireland,", "Japan,", "Taiwan,", "Turkey,", "Singapore,", "Kuwait,", "Chile,", "Russia", "and", "Bahrain", "under", "the", "trade", "name", "REVOLADE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p10_s0", "idA": "886163_11_item1_p12_s0", "sentA": "PROMACTA is the first oral thrombopoietin, or TPO, receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "PROMACTA (GSK) GSK s PROMACTA (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.", "type": 2, "words": ["<tag1>", "PROMACTA", "is", "the", "first", "oral", "thrombopoietin,", "or", "TPO,", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag3>"], "wordsA": ["PROMACTA", "is", "the", "first", "oral", "thrombopoietin,", "or", "TPO,", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p34_s0", "idA": "886163_11_item1_p12_s0", "sentA": "PROMACTA is the first oral thrombopoietin, or TPO, receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "(IRAK4) inhibitors for the treatment of inflammatory and immune disorders.", "type": 2, "words": ["<tag1>", "PROMACTA", "is", "the", "first", "oral", "thrombopoietin,", "or", "TPO,", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders.", "<tag3>"], "wordsA": ["PROMACTA", "is", "the", "first", "oral", "thrombopoietin,", "or", "TPO,", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p35_s1", "idA": "886163_11_item1_p12_s0", "sentA": "PROMACTA is the first oral thrombopoietin, or TPO, receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "Inhibitors of IRAK4 may also be useful for the treatment of certain leukemias and lymphomas.", "type": 2, "words": ["<tag1>", "PROMACTA", "is", "the", "first", "oral", "thrombopoietin,", "or", "TPO,", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas.", "<tag3>"], "wordsA": ["PROMACTA", "is", "the", "first", "oral", "thrombopoietin,", "or", "TPO,", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p12_s3", "idA": "886163_11_item1_p12_s3", "sentA": "Eltrombopag may also be considered as second-line treatment for adult non-spenectomized patients where surgery is contraindicated.", "sentB": "Eltrombopag may also be considered as second-line treatment for adult non-splenectomized patients where surgery is contraindicated.", "type": 2, "words": ["<tag1>", "Eltrombopag", "may", "also", "be", "considered", "as", "second-line", "treatment", "for", "adult", "non-spenectomized", "patients", "where", "surgery", "is", "contraindicated.", "<tag2>", "Eltrombopag", "may", "also", "be", "considered", "as", "second-line", "treatment", "for", "adult", "non-splenectomized", "patients", "where", "surgery", "is", "contraindicated.", "<tag3>"], "wordsA": ["Eltrombopag", "may", "also", "be", "considered", "as", "second-line", "treatment", "for", "adult", "non-spenectomized", "patients", "where", "surgery", "is", "contraindicated."], "wordsB": ["Eltrombopag", "may", "also", "be", "considered", "as", "second-line", "treatment", "for", "adult", "non-splenectomized", "patients", "where", "surgery", "is", "contraindicated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p11_s1", "idA": "886163_11_item1_p13_s1", "sentA": "GSK has listed a patent in the FDA s Orange Book for PROMACTA with an expiration date in 2024.", "sentB": "In February 2011, the FDA granted GSK full approval status for PROMACTA in the US following the submission of long term safety data from post-marketing clinical studies, as well as the completion of other commitments that verify the clinical benefit to patients.", "type": 2, "words": ["<tag1>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "PROMACTA", "with", "an", "expiration", "date", "in", "2024.", "<tag2>", "In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "PROMACTA", "in", "the", "US", "following", "the", "submission", "of", "long", "term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients.", "<tag3>"], "wordsA": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "PROMACTA", "with", "an", "expiration", "date", "in", "2024."], "wordsB": ["In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "PROMACTA", "in", "the", "US", "following", "the", "submission", "of", "long", "term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p14_s0", "idA": "886163_11_item1_p14_s0", "sentA": "AVINZA (Pfizer) We currently receive royalty revenues from King Pharmaceuticalsfor sales from the pain therapeutic AVINZA .", "sentB": "We currently receive royalty revenues from Pfizer, Inc. for sales from the pain therapeutic AVINZA .", "type": 2, "words": ["<tag1>", "AVINZA", "(Pfizer)", "We", "currently", "receive", "royalty", "revenues", "from", "King", "Pharmaceuticalsfor", "sales", "from", "the", "pain", "therapeutic", "AVINZA", ".", "<tag2>", "We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.", "for", "sales", "from", "the", "pain", "therapeutic", "AVINZA", ".", "<tag3>"], "wordsA": ["AVINZA", "(Pfizer)", "We", "currently", "receive", "royalty", "revenues", "from", "King", "Pharmaceuticalsfor", "sales", "from", "the", "pain", "therapeutic", "AVINZA", "."], "wordsB": ["We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.", "for", "sales", "from", "the", "pain", "therapeutic", "AVINZA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s3", "idA": "886163_11_item1_p14_s1", "sentA": "In February 2007, we completed the sale of our AVINZA product line to King.", "sentB": "Royalties we currently receive from Pfizer, as successor to King on AVINZA represent a portion of our ongoing revenue.", "type": 2, "words": ["<tag1>", "In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "AVINZA", "product", "line", "to", "King.", "<tag2>", "Royalties", "we", "currently", "receive", "from", "Pfizer,", "as", "successor", "to", "King", "on", "AVINZA", "represent", "a", "portion", "of", "our", "ongoing", "revenue.", "<tag3>"], "wordsA": ["In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "AVINZA", "product", "line", "to", "King."], "wordsB": ["Royalties", "we", "currently", "receive", "from", "Pfizer,", "as", "successor", "to", "King", "on", "AVINZA", "represent", "a", "portion", "of", "our", "ongoing", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p28_s1", "idA": "886163_11_item1_p15_s1", "sentA": "According to Pfizer, the transaction is expected to close in the first quarter of 2011.", "sentB": "DARA, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.", "type": 2, "words": ["<tag1>", "According", "to", "Pfizer,", "the", "transaction", "is", "expected", "to", "close", "in", "the", "first", "quarter", "of", "2011.", "<tag2>", "DARA,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies.", "<tag3>"], "wordsA": ["According", "to", "Pfizer,", "the", "transaction", "is", "expected", "to", "close", "in", "the", "first", "quarter", "of", "2011."], "wordsB": ["DARA,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p16_s1", "idA": "886163_11_item1_p16_s1", "sentA": "The drug is also marketed in Spain under the brand name CONBRIZA (R) through a co-promotion with Almirall, an international pharmaceutical company based in Spain.", "sentB": "The drug is also marketed in Spain under the brand name CONBRIZA through a co-promotion with Almirall, an international pharmaceutical company based in Spain.", "type": 2, "words": ["<tag1>", "The", "drug", "is", "also", "marketed", "in", "Spain", "under", "the", "brand", "name", "CONBRIZA", "(R)", "through", "a", "co-promotion", "with", "Almirall,", "an", "international", "pharmaceutical", "company", "based", "in", "Spain.", "<tag2>", "The", "drug", "is", "also", "marketed", "in", "Spain", "under", "the", "brand", "name", "CONBRIZA", "through", "a", "co-promotion", "with", "Almirall,", "an", "international", "pharmaceutical", "company", "based", "in", "Spain.", "<tag3>"], "wordsA": ["The", "drug", "is", "also", "marketed", "in", "Spain", "under", "the", "brand", "name", "CONBRIZA", "(R)", "through", "a", "co-promotion", "with", "Almirall,", "an", "international", "pharmaceutical", "company", "based", "in", "Spain."], "wordsB": ["The", "drug", "is", "also", "marketed", "in", "Spain", "under", "the", "brand", "name", "CONBRIZA", "through", "a", "co-promotion", "with", "Almirall,", "an", "international", "pharmaceutical", "company", "based", "in", "Spain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p59_s1", "idA": "886163_11_item1_p16_s2", "sentA": "Pfizer received manufacturing and marketing approval for the product in Japan in July 2010.", "sentB": "Many of these companies also have extensive experience in preclinical testing and human clinical trials, obtaining FDA and other regulatory approvals and manufacturing and marketing pharmaceutical products.", "type": 2, "words": ["<tag1>", "Pfizer", "received", "manufacturing", "and", "marketing", "approval", "for", "the", "product", "in", "Japan", "in", "July", "2010.", "<tag2>", "Many", "of", "these", "companies", "also", "have", "extensive", "experience", "in", "preclinical", "testing", "and", "human", "clinical", "trials,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "and", "manufacturing", "and", "marketing", "pharmaceutical", "products.", "<tag3>"], "wordsA": ["Pfizer", "received", "manufacturing", "and", "marketing", "approval", "for", "the", "product", "in", "Japan", "in", "July", "2010."], "wordsB": ["Many", "of", "these", "companies", "also", "have", "extensive", "experience", "in", "preclinical", "testing", "and", "human", "clinical", "trials,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "and", "manufacturing", "and", "marketing", "pharmaceutical", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s1", "idA": "886163_11_item1_p16_s2", "sentA": "Pfizer received manufacturing and marketing approval for the product in Japan in July 2010.", "sentB": "We also are subject to foreign regulatory requirements governing human clinical trials and marketing approval for drugs.", "type": 2, "words": ["<tag1>", "Pfizer", "received", "manufacturing", "and", "marketing", "approval", "for", "the", "product", "in", "Japan", "in", "July", "2010.", "<tag2>", "We", "also", "are", "subject", "to", "foreign", "regulatory", "requirements", "governing", "human", "clinical", "trials", "and", "marketing", "approval", "for", "drugs.", "<tag3>"], "wordsA": ["Pfizer", "received", "manufacturing", "and", "marketing", "approval", "for", "the", "product", "in", "Japan", "in", "July", "2010."], "wordsB": ["We", "also", "are", "subject", "to", "foreign", "regulatory", "requirements", "governing", "human", "clinical", "trials", "and", "marketing", "approval", "for", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p24_s1", "idA": "886163_11_item1_p17_s0", "sentA": "VIVIANT was approved in April 2009 by the European Commission (under the trade name CONBRIZA) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.", "sentB": "Pfizer is now combining VIVIANT with Premarin to create a combination therapy called Aprela for the treatment of post-menopausal symptoms in women.", "type": 2, "words": ["<tag1>", "VIVIANT", "was", "approved", "in", "April", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "CONBRIZA)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture.", "<tag2>", "Pfizer", "is", "now", "combining", "VIVIANT", "with", "Premarin", "to", "create", "a", "combination", "therapy", "called", "Aprela", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag3>"], "wordsA": ["VIVIANT", "was", "approved", "in", "April", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "CONBRIZA)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture."], "wordsB": ["Pfizer", "is", "now", "combining", "VIVIANT", "with", "Premarin", "to", "create", "a", "combination", "therapy", "called", "Aprela", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p44_s1", "idA": "886163_11_item1_p18_s0", "sentA": "VIVIANT, a selective estrogen receptor modulator (SERM), is a result of the successful research collaboration between Wyeth (now a subsidiary of Pfizer) and us that began in 1994.", "sentB": "Under the License Agreement, we granted to Chiva an exclusive worldwide license, with sub-license rights, to our intellectual property rights related to Fablyn, a selective estrogen receptor modulator.", "type": 2, "words": ["<tag1>", "VIVIANT,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994.", "<tag2>", "Under", "the", "License", "Agreement,", "we", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator.", "<tag3>"], "wordsA": ["VIVIANT,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994."], "wordsB": ["Under", "the", "License", "Agreement,", "we", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p24_s3", "idA": "886163_11_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "We are entitled to receive tiered royalties on all net sales of bazedoxifene, whether alone or in combination with other products.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "all", "net", "sales", "of", "bazedoxifene,", "whether", "alone", "or", "in", "combination", "with", "other", "products.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "all", "net", "sales", "of", "bazedoxifene,", "whether", "alone", "or", "in", "combination", "with", "other", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p29_s0", "idA": "886163_11_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "We are entitled to receive a net up front payment of $1 million, and may receive, net of amounts owed to third parties, over $75 million in milestones as well as 9% in royalties on potential future worldwide sales by Retrophin.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p42_s2", "idA": "886163_11_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "We are entitled to potentially receive up to $22 million of milestone payments.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "We", "are", "entitled", "to", "potentially", "receive", "up", "to", "$22", "million", "of", "milestone", "payments.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["We", "are", "entitled", "to", "potentially", "receive", "up", "to", "$22", "million", "of", "milestone", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p42_s3", "idA": "886163_11_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "We are also eligible to receive, under the License Agreement, a substantial royalty on worldwide net sales of The Medicines Company s intravenous clopidogrel formulated with CAPTISOL, and we also expect to manufacture and sell clinical and commercial supplies of CAPTISOL to The Medicines Company.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "We", "are", "also", "eligible", "to", "receive,", "under", "the", "License", "Agreement,", "a", "substantial", "royalty", "on", "worldwide", "net", "sales", "of", "The", "Medicines", "Company", "s", "intravenous", "clopidogrel", "formulated", "with", "CAPTISOL,", "and", "we", "also", "expect", "to", "manufacture", "and", "sell", "clinical", "and", "commercial", "supplies", "of", "CAPTISOL", "to", "The", "Medicines", "Company.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["We", "are", "also", "eligible", "to", "receive,", "under", "the", "License", "Agreement,", "a", "substantial", "royalty", "on", "worldwide", "net", "sales", "of", "The", "Medicines", "Company", "s", "intravenous", "clopidogrel", "formulated", "with", "CAPTISOL,", "and", "we", "also", "expect", "to", "manufacture", "and", "sell", "clinical", "and", "commercial", "supplies", "of", "CAPTISOL", "to", "The", "Medicines", "Company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p43_s4", "idA": "886163_11_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "Merck also will pay an increased supply price in lieu of a royalty on net sales of the licensed product.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "Merck", "also", "will", "pay", "an", "increased", "supply", "price", "in", "lieu", "of", "a", "royalty", "on", "net", "sales", "of", "the", "licensed", "product.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["Merck", "also", "will", "pay", "an", "increased", "supply", "price", "in", "lieu", "of", "a", "royalty", "on", "net", "sales", "of", "the", "licensed", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s2", "idA": "886163_11_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "Upon commercialization, we could potentially receive milestone payments for CAPTISOL-enabled programs, plus tiered royalties on net sales for products that use the CAPTISOL technology.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "Upon", "commercialization,", "we", "could", "potentially", "receive", "milestone", "payments", "for", "CAPTISOL-enabled", "programs,", "plus", "tiered", "royalties", "on", "net", "sales", "for", "products", "that", "use", "the", "CAPTISOL", "technology.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["Upon", "commercialization,", "we", "could", "potentially", "receive", "milestone", "payments", "for", "CAPTISOL-enabled", "programs,", "plus", "tiered", "royalties", "on", "net", "sales", "for", "products", "that", "use", "the", "CAPTISOL", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s7", "idA": "886163_11_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "We are also eligible to receive royalty payments on worldwide net sales of any products that are successfully commercialized.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "We", "are", "also", "eligible", "to", "receive", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "any", "products", "that", "are", "successfully", "commercialized.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["We", "are", "also", "eligible", "to", "receive", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "any", "products", "that", "are", "successfully", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p24_s4", "idA": "886163_11_item1_p18_s3", "sentA": "Any such royalties may be subject to reduction or offset for past milestone payments and/or may be subject to other terms and conditions set forth in our agreement.", "sentB": "Any such royalties may be subject to reduction or offset against past milestone payments and/or may be subject to other terms and conditions set forth in our agreement.", "type": 2, "words": ["<tag1>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement.", "<tag2>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement.", "<tag3>"], "wordsA": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement."], "wordsB": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s0", "idA": "886163_11_item1_p19_s0", "sentA": "Abilify IM (BMS) Cydex Pharmaceuticals, Inc., or CyDex, and BMS entered into license and supply agreements on July 1, 1998 to use Captisol in development and commercialization of an oncology product.", "sentB": "In October 2011, we entered into a License Agreement with SAGE Therapeutics, Inc., or SAGE, granting SAGE an exclusive right to use CAPTISOL in SAGE s development and commercialization of therapeutic drugs formulating certain allosteric receptor modulators with CAPTISOL against identified central nervous system disorders.", "type": 2, "words": ["<tag1>", "Abilify", "IM", "(BMS)", "Cydex", "Pharmaceuticals,", "Inc.,", "or", "CyDex,", "and", "BMS", "entered", "into", "license", "and", "supply", "agreements", "on", "July", "1,", "1998", "to", "use", "Captisol", "in", "development", "and", "commercialization", "of", "an", "oncology", "product.", "<tag2>", "In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "SAGE", "Therapeutics,", "Inc.,", "or", "SAGE,", "granting", "SAGE", "an", "exclusive", "right", "to", "use", "CAPTISOL", "in", "SAGE", "s", "development", "and", "commercialization", "of", "therapeutic", "drugs", "formulating", "certain", "allosteric", "receptor", "modulators", "with", "CAPTISOL", "against", "identified", "central", "nervous", "system", "disorders.", "<tag3>"], "wordsA": ["Abilify", "IM", "(BMS)", "Cydex", "Pharmaceuticals,", "Inc.,", "or", "CyDex,", "and", "BMS", "entered", "into", "license", "and", "supply", "agreements", "on", "July", "1,", "1998", "to", "use", "Captisol", "in", "development", "and", "commercialization", "of", "an", "oncology", "product."], "wordsB": ["In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "SAGE", "Therapeutics,", "Inc.,", "or", "SAGE,", "granting", "SAGE", "an", "exclusive", "right", "to", "use", "CAPTISOL", "in", "SAGE", "s", "development", "and", "commercialization", "of", "therapeutic", "drugs", "formulating", "certain", "allosteric", "receptor", "modulators", "with", "CAPTISOL", "against", "identified", "central", "nervous", "system", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s1", "idA": "886163_11_item1_p1_s0", "sentA": "This outlook represents our current judgment on the future direction of our business.", "sentB": "Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business.", "type": 2, "words": ["<tag1>", "This", "outlook", "represents", "our", "current", "judgment", "on", "the", "future", "direction", "of", "our", "business.", "<tag2>", "Our", "policy", "is", "to", "file", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "our", "inventions", "that", "are", "considered", "important", "to", "the", "development", "of", "our", "business.", "<tag3>"], "wordsA": ["This", "outlook", "represents", "our", "current", "judgment", "on", "the", "future", "direction", "of", "our", "business."], "wordsB": ["Our", "policy", "is", "to", "file", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "our", "inventions", "that", "are", "considered", "important", "to", "the", "development", "of", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p33_s2", "idA": "886163_11_item1_p21_s1", "sentA": "The last of such patents expires in 2013.", "sentB": "We anticipate filing an IND for our lead program in 2013.", "type": 2, "words": ["<tag1>", "The", "last", "of", "such", "patents", "expires", "in", "2013.", "<tag2>", "We", "anticipate", "filing", "an", "IND", "for", "our", "lead", "program", "in", "2013.", "<tag3>"], "wordsA": ["The", "last", "of", "such", "patents", "expires", "in", "2013."], "wordsB": ["We", "anticipate", "filing", "an", "IND", "for", "our", "lead", "program", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s3", "idA": "886163_11_item1_p21_s4", "sentA": "We are also obligated to disclose our (or our licensees ) improvements to Captisol to Pfizer, which Pfizer may use consistent with the other rights granted.", "sentB": "We are also increasingly subject to regulation by the states.", "type": 2, "words": ["<tag1>", "We", "are", "also", "obligated", "to", "disclose", "our", "(or", "our", "licensees", ")", "improvements", "to", "Captisol", "to", "Pfizer,", "which", "Pfizer", "may", "use", "consistent", "with", "the", "other", "rights", "granted.", "<tag2>", "We", "are", "also", "increasingly", "subject", "to", "regulation", "by", "the", "states.", "<tag3>"], "wordsA": ["We", "are", "also", "obligated", "to", "disclose", "our", "(or", "our", "licensees", ")", "improvements", "to", "Captisol", "to", "Pfizer,", "which", "Pfizer", "may", "use", "consistent", "with", "the", "other", "rights", "granted."], "wordsB": ["We", "are", "also", "increasingly", "subject", "to", "regulation", "by", "the", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p20_s0", "idA": "886163_11_item1_p23_s0", "sentA": "In 2006, CyDex outlicensed Nexterone , an injectable formulation combining amiodarone and Captisol , to Prism Pharmaceuticals.", "sentB": "In 2006, CyDex outlicensed Nexterone , an injectable formulation combining amiodarone and CAPTISOL , to Baxter International Baxter (formerly Prism Pharmaceuticals, Inc.).", "type": 2, "words": ["<tag1>", "In", "2006,", "CyDex", "outlicensed", "Nexterone", ",", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol", ",", "to", "Prism", "Pharmaceuticals.", "<tag2>", "In", "2006,", "CyDex", "outlicensed", "Nexterone", ",", "an", "injectable", "formulation", "combining", "amiodarone", "and", "CAPTISOL", ",", "to", "Baxter", "International", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.).", "<tag3>"], "wordsA": ["In", "2006,", "CyDex", "outlicensed", "Nexterone", ",", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol", ",", "to", "Prism", "Pharmaceuticals."], "wordsB": ["In", "2006,", "CyDex", "outlicensed", "Nexterone", ",", "an", "injectable", "formulation", "combining", "amiodarone", "and", "CAPTISOL", ",", "to", "Baxter", "International", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p20_s1", "idA": "886163_11_item1_p23_s1", "sentA": "Under the terms the agreement, Prism is responsible, under an exclusive worldwide license from CyDex, for all development and commercialization of Nexterone at its sole expense.", "sentB": "Under the terms of the agreement, Baxter is responsible, under an exclusive worldwide license, for all development and commercialization of Nexterone at its sole expense.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag3>"], "wordsA": ["Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p20_s2", "idA": "886163_11_item1_p23_s2", "sentA": "CyDex is supplying Captisol to Prism for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "We are supplying CAPTISOL to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement.", "type": 2, "words": ["<tag1>", "CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "We", "are", "supplying", "CAPTISOL", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag3>"], "wordsA": ["CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["We", "are", "supplying", "CAPTISOL", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p35_s2", "idA": "886163_11_item1_p23_s2", "sentA": "CyDex is supplying Captisol to Prism for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "We have identified orally available small molecule inhibitors of IRAK4 which are under investigation for use in cancer and autoimmune diseases.", "type": 2, "words": ["<tag1>", "CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "We", "have", "identified", "orally", "available", "small", "molecule", "inhibitors", "of", "IRAK4", "which", "are", "under", "investigation", "for", "use", "in", "cancer", "and", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["We", "have", "identified", "orally", "available", "small", "molecule", "inhibitors", "of", "IRAK4", "which", "are", "under", "investigation", "for", "use", "in", "cancer", "and", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p62_s4", "idA": "886163_11_item1_p23_s2", "sentA": "CyDex is supplying Captisol to Prism for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "To supply products for use in the United States, foreign manufacturing establishments must comply with cGMP and are subject to periodic inspection by the FDA or by regulatory authorities in such countries under reciprocal agreements with the FDA.", "type": 2, "words": ["<tag1>", "CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "To", "supply", "products", "for", "use", "in", "the", "United", "States,", "foreign", "manufacturing", "establishments", "must", "comply", "with", "cGMP", "and", "are", "subject", "to", "periodic", "inspection", "by", "the", "FDA", "or", "by", "regulatory", "authorities", "in", "such", "countries", "under", "reciprocal", "agreements", "with", "the", "FDA.", "<tag3>"], "wordsA": ["CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["To", "supply", "products", "for", "use", "in", "the", "United", "States,", "foreign", "manufacturing", "establishments", "must", "comply", "with", "cGMP", "and", "are", "subject", "to", "periodic", "inspection", "by", "the", "FDA", "or", "by", "regulatory", "authorities", "in", "such", "countries", "under", "reciprocal", "agreements", "with", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s7", "idA": "886163_11_item1_p23_s2", "sentA": "CyDex is supplying Captisol to Prism for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "Subject to compliance with the terms of the respective agreements, our rights under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "type": 2, "words": ["<tag1>", "CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag3>"], "wordsA": ["CyDex", "is", "supplying", "Captisol", "to", "Prism", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p20_s3", "idA": "886163_11_item1_p23_s3", "sentA": "Prism has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through March 2029.", "sentB": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through March 2029.", "type": 2, "words": ["<tag1>", "Prism", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029.", "<tag2>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029.", "<tag3>"], "wordsA": ["Prism", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029."], "wordsB": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p44_s2", "idA": "886163_11_item1_p23_s3", "sentA": "Prism has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through March 2029.", "sentB": "Chiva is obligated to pay us a non-refundable license issuance fee of $4 million on or before June 1, 2012.", "type": 2, "words": ["<tag1>", "Prism", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029.", "<tag2>", "Chiva", "is", "obligated", "to", "pay", "us", "a", "non-refundable", "license", "issuance", "fee", "of", "$4", "million", "on", "or", "before", "June", "1,", "2012.", "<tag3>"], "wordsA": ["Prism", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029."], "wordsB": ["Chiva", "is", "obligated", "to", "pay", "us", "a", "non-refundable", "license", "issuance", "fee", "of", "$4", "million", "on", "or", "before", "June", "1,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p20_s4", "idA": "886163_11_item1_p23_s4", "sentA": "On November 19, 2010, Prism received marketing approval from the FDA for Nexterone and has announced plans to launch Nexterone in the United States in 2011.", "sentB": "On November 19, 2010, Prism, who was subsequently acquired by Baxter, received marketing approval from the FDA for Nexterone and launched Nexterone in the United States in 2011.", "type": 2, "words": ["<tag1>", "On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011.", "<tag2>", "On", "November", "19,", "2010,", "Prism,", "who", "was", "subsequently", "acquired", "by", "Baxter,", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "launched", "Nexterone", "in", "the", "United", "States", "in", "2011.", "<tag3>"], "wordsA": ["On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011."], "wordsB": ["On", "November", "19,", "2010,", "Prism,", "who", "was", "subsequently", "acquired", "by", "Baxter,", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "launched", "Nexterone", "in", "the", "United", "States", "in", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p60_s0", "idA": "886163_11_item1_p23_s4", "sentA": "On November 19, 2010, Prism received marketing approval from the FDA for Nexterone and has announced plans to launch Nexterone in the United States in 2011.", "sentB": "The manufacturing and marketing of our products, our ongoing research and development activities and products being developed by our collaborative partners are subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.", "type": 2, "words": ["<tag1>", "On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011.", "<tag2>", "The", "manufacturing", "and", "marketing", "of", "our", "products,", "our", "ongoing", "research", "and", "development", "activities", "and", "products", "being", "developed", "by", "our", "collaborative", "partners", "are", "subject", "to", "regulation", "for", "safety", "and", "efficacy", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries.", "<tag3>"], "wordsA": ["On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011."], "wordsB": ["The", "manufacturing", "and", "marketing", "of", "our", "products,", "our", "ongoing", "research", "and", "development", "activities", "and", "products", "being", "developed", "by", "our", "collaborative", "partners", "are", "subject", "to", "regulation", "for", "safety", "and", "efficacy", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s0", "idA": "886163_11_item1_p23_s4", "sentA": "On November 19, 2010, Prism received marketing approval from the FDA for Nexterone and has announced plans to launch Nexterone in the United States in 2011.", "sentB": "For marketing outside the United States before FDA approval to market, we must submit an export permit application to the FDA.", "type": 2, "words": ["<tag1>", "On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011.", "<tag2>", "For", "marketing", "outside", "the", "United", "States", "before", "FDA", "approval", "to", "market,", "we", "must", "submit", "an", "export", "permit", "application", "to", "the", "FDA.", "<tag3>"], "wordsA": ["On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011."], "wordsB": ["For", "marketing", "outside", "the", "United", "States", "before", "FDA", "approval", "to", "market,", "we", "must", "submit", "an", "export", "permit", "application", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p21_s0", "idA": "886163_11_item1_p24_s0", "sentA": "In an effort to expand PROMACTA S use, GSK is currently running two large Phase III studies designed to demonstrate PROMACTA S value in treatment of thrombocytopenia in patients with Hepatitis C.", "sentB": "In an effort to expand PROMACTA s use, GSK has recently completed two large Phase III studies (ENABLE 1 and 2) designed to demonstrate PROMACTA s value in treatment of thrombocytopenia in patients with Hepatitis C. In November 2011, GSK presented data at the annual meeting of the American Association for the Study of Liver Disease (AASLD) where it was reported that both studies met their primary endpoint with high statistical significance.", "type": 2, "words": ["<tag1>", "In", "an", "effort", "to", "expand", "PROMACTA", "S", "use,", "GSK", "is", "currently", "running", "two", "large", "Phase", "III", "studies", "designed", "to", "demonstrate", "PROMACTA", "S", "value", "in", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "Hepatitis", "C.", "<tag2>", "In", "an", "effort", "to", "expand", "PROMACTA", "s", "use,", "GSK", "has", "recently", "completed", "two", "large", "Phase", "III", "studies", "(ENABLE", "1", "and", "2)", "designed", "to", "demonstrate", "PROMACTA", "s", "value", "in", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "Hepatitis", "C.", "In", "November", "2011,", "GSK", "presented", "data", "at", "the", "annual", "meeting", "of", "the", "American", "Association", "for", "the", "Study", "of", "Liver", "Disease", "(AASLD)", "where", "it", "was", "reported", "that", "both", "studies", "met", "their", "primary", "endpoint", "with", "high", "statistical", "significance.", "<tag3>"], "wordsA": ["In", "an", "effort", "to", "expand", "PROMACTA", "S", "use,", "GSK", "is", "currently", "running", "two", "large", "Phase", "III", "studies", "designed", "to", "demonstrate", "PROMACTA", "S", "value", "in", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "Hepatitis", "C."], "wordsB": ["In", "an", "effort", "to", "expand", "PROMACTA", "s", "use,", "GSK", "has", "recently", "completed", "two", "large", "Phase", "III", "studies", "(ENABLE", "1", "and", "2)", "designed", "to", "demonstrate", "PROMACTA", "s", "value", "in", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "Hepatitis", "C.", "In", "November", "2011,", "GSK", "presented", "data", "at", "the", "annual", "meeting", "of", "the", "American", "Association", "for", "the", "Study", "of", "Liver", "Disease", "(AASLD)", "where", "it", "was", "reported", "that", "both", "studies", "met", "their", "primary", "endpoint", "with", "high", "statistical", "significance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p23_s2", "idA": "886163_11_item1_p24_s0", "sentA": "In an effort to expand PROMACTA S use, GSK is currently running two large Phase III studies designed to demonstrate PROMACTA S value in treatment of thrombocytopenia in patients with Hepatitis C.", "sentB": "Onyx is continuing to run two large Phase III studies in support of this program, the ASPIRE and FOCUS trials, which should complete in 2013.", "type": 2, "words": ["<tag1>", "In", "an", "effort", "to", "expand", "PROMACTA", "S", "use,", "GSK", "is", "currently", "running", "two", "large", "Phase", "III", "studies", "designed", "to", "demonstrate", "PROMACTA", "S", "value", "in", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "Hepatitis", "C.", "<tag2>", "Onyx", "is", "continuing", "to", "run", "two", "large", "Phase", "III", "studies", "in", "support", "of", "this", "program,", "the", "ASPIRE", "and", "FOCUS", "trials,", "which", "should", "complete", "in", "2013.", "<tag3>"], "wordsA": ["In", "an", "effort", "to", "expand", "PROMACTA", "S", "use,", "GSK", "is", "currently", "running", "two", "large", "Phase", "III", "studies", "designed", "to", "demonstrate", "PROMACTA", "S", "value", "in", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "Hepatitis", "C."], "wordsB": ["Onyx", "is", "continuing", "to", "run", "two", "large", "Phase", "III", "studies", "in", "support", "of", "this", "program,", "the", "ASPIRE", "and", "FOCUS", "trials,", "which", "should", "complete", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p21_s1", "idA": "886163_11_item1_p24_s1", "sentA": "These trials are expected to be completed in the third quarter of 2011.", "sentB": "Full analysis of all safety data should be completed in the first half of 2012 and we expect an sNDA filing during 2012.", "type": 2, "words": ["<tag1>", "These", "trials", "are", "expected", "to", "be", "completed", "in", "the", "third", "quarter", "of", "2011.", "<tag2>", "Full", "analysis", "of", "all", "safety", "data", "should", "be", "completed", "in", "the", "first", "half", "of", "2012", "and", "we", "expect", "an", "sNDA", "filing", "during", "2012.", "<tag3>"], "wordsA": ["These", "trials", "are", "expected", "to", "be", "completed", "in", "the", "third", "quarter", "of", "2011."], "wordsB": ["Full", "analysis", "of", "all", "safety", "data", "should", "be", "completed", "in", "the", "first", "half", "of", "2012", "and", "we", "expect", "an", "sNDA", "filing", "during", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p22_s0", "idA": "886163_11_item1_p24_s2", "sentA": "GSK is also conducting Phase II clinical studies in patients with solid tumors, sarcoma and advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS.", "sentB": "GSK is also conducting Phase II clinical studies for oncology-related thrombocytopenia in patients with solid tumors, sarcoma and advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS.", "type": 2, "words": ["<tag1>", "GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS.", "<tag2>", "GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS.", "<tag3>"], "wordsA": ["GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS."], "wordsB": ["GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p32_s3", "idA": "886163_11_item1_p25_s1", "sentA": "Onyx has recently reported positive Phase II data for this program and has initiated the filing of a rolling NDA with the FDA based upon this data.", "sentB": "In December 2011, we reported final phase II bioequivalence data from this program and expect to initiate a pivotal study in 2012 to support a US 505(b)(2) filing with the FDA in 2013.", "type": 2, "words": ["<tag1>", "Onyx", "has", "recently", "reported", "positive", "Phase", "II", "data", "for", "this", "program", "and", "has", "initiated", "the", "filing", "of", "a", "rolling", "NDA", "with", "the", "FDA", "based", "upon", "this", "data.", "<tag2>", "In", "December", "2011,", "we", "reported", "final", "phase", "II", "bioequivalence", "data", "from", "this", "program", "and", "expect", "to", "initiate", "a", "pivotal", "study", "in", "2012", "to", "support", "a", "US", "505(b)(2)", "filing", "with", "the", "FDA", "in", "2013.", "<tag3>"], "wordsA": ["Onyx", "has", "recently", "reported", "positive", "Phase", "II", "data", "for", "this", "program", "and", "has", "initiated", "the", "filing", "of", "a", "rolling", "NDA", "with", "the", "FDA", "based", "upon", "this", "data."], "wordsB": ["In", "December", "2011,", "we", "reported", "final", "phase", "II", "bioequivalence", "data", "from", "this", "program", "and", "expect", "to", "initiate", "a", "pivotal", "study", "in", "2012", "to", "support", "a", "US", "505(b)(2)", "filing", "with", "the", "FDA", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p23_s1", "idA": "886163_11_item1_p25_s2", "sentA": "Onyx expects to complete filing of the NDA by mid-2011 and will receive expedited review by the FDA because of the program s FDA-granted Fast Track status.", "sentB": "Onyx completed filing of the NDA in 2011 and was granted a standard review by the FDA, with a Prescription Drug User Fee Act (PDUFA) date set as July 27, 2012.", "type": 2, "words": ["<tag1>", "Onyx", "expects", "to", "complete", "filing", "of", "the", "NDA", "by", "mid-2011", "and", "will", "receive", "expedited", "review", "by", "the", "FDA", "because", "of", "the", "program", "s", "FDA-granted", "Fast", "Track", "status.", "<tag2>", "Onyx", "completed", "filing", "of", "the", "NDA", "in", "2011", "and", "was", "granted", "a", "standard", "review", "by", "the", "FDA,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act", "(PDUFA)", "date", "set", "as", "July", "27,", "2012.", "<tag3>"], "wordsA": ["Onyx", "expects", "to", "complete", "filing", "of", "the", "NDA", "by", "mid-2011", "and", "will", "receive", "expedited", "review", "by", "the", "FDA", "because", "of", "the", "program", "s", "FDA-granted", "Fast", "Track", "status."], "wordsB": ["Onyx", "completed", "filing", "of", "the", "NDA", "in", "2011", "and", "was", "granted", "a", "standard", "review", "by", "the", "FDA,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act", "(PDUFA)", "date", "set", "as", "July", "27,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p25_s2", "idA": "886163_11_item1_p25_s3", "sentA": "We are eligible to receive milestones, royalties and Captisol material sales revenue from this program.", "sentB": "Financial terms of the relationship remain undisclosed, but we expect to generate substantial material sales revenue through the supply of CAPTISOL for this program.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "milestones,", "royalties", "and", "Captisol", "material", "sales", "revenue", "from", "this", "program.", "<tag2>", "Financial", "terms", "of", "the", "relationship", "remain", "undisclosed,", "but", "we", "expect", "to", "generate", "substantial", "material", "sales", "revenue", "through", "the", "supply", "of", "CAPTISOL", "for", "this", "program.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "milestones,", "royalties", "and", "Captisol", "material", "sales", "revenue", "from", "this", "program."], "wordsB": ["Financial", "terms", "of", "the", "relationship", "remain", "undisclosed,", "but", "we", "expect", "to", "generate", "substantial", "material", "sales", "revenue", "through", "the", "supply", "of", "CAPTISOL", "for", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s3", "idA": "886163_11_item1_p25_s3", "sentA": "We are eligible to receive milestones, royalties and Captisol material sales revenue from this program.", "sentB": "We are also eligible to receive material sales revenue from the shipment of CAPTISOL to SAGE for clinical and commercial activities.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "milestones,", "royalties", "and", "Captisol", "material", "sales", "revenue", "from", "this", "program.", "<tag2>", "We", "are", "also", "eligible", "to", "receive", "material", "sales", "revenue", "from", "the", "shipment", "of", "CAPTISOL", "to", "SAGE", "for", "clinical", "and", "commercial", "activities.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "milestones,", "royalties", "and", "Captisol", "material", "sales", "revenue", "from", "this", "program."], "wordsB": ["We", "are", "also", "eligible", "to", "receive", "material", "sales", "revenue", "from", "the", "shipment", "of", "CAPTISOL", "to", "SAGE", "for", "clinical", "and", "commercial", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s2", "idA": "886163_11_item1_p2_s1", "sentA": "For example, there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s), that we will be able to retain our key employees or that we will be able to enter into any strategic partnerships or other transactions.", "sentB": "The requirements relating to the conduct of clinical trials, product licensing, pricing and reimbursement vary widely from country to country and there can be no assurance that we or any of our partners will meet and sustain any such requirements.", "type": 2, "words": ["<tag1>", "For", "example,", "there", "can", "be", "no", "assurance", "that", "our", "revenues", "or", "expenses", "will", "meet", "any", "expectations", "or", "follow", "any", "trend(s),", "that", "we", "will", "be", "able", "to", "retain", "our", "key", "employees", "or", "that", "we", "will", "be", "able", "to", "enter", "into", "any", "strategic", "partnerships", "or", "other", "transactions.", "<tag2>", "The", "requirements", "relating", "to", "the", "conduct", "of", "clinical", "trials,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country", "and", "there", "can", "be", "no", "assurance", "that", "we", "or", "any", "of", "our", "partners", "will", "meet", "and", "sustain", "any", "such", "requirements.", "<tag3>"], "wordsA": ["For", "example,", "there", "can", "be", "no", "assurance", "that", "our", "revenues", "or", "expenses", "will", "meet", "any", "expectations", "or", "follow", "any", "trend(s),", "that", "we", "will", "be", "able", "to", "retain", "our", "key", "employees", "or", "that", "we", "will", "be", "able", "to", "enter", "into", "any", "strategic", "partnerships", "or", "other", "transactions."], "wordsB": ["The", "requirements", "relating", "to", "the", "conduct", "of", "clinical", "trials,", "product", "licensing,", "pricing", "and", "reimbursement", "vary", "widely", "from", "country", "to", "country", "and", "there", "can", "be", "no", "assurance", "that", "we", "or", "any", "of", "our", "partners", "will", "meet", "and", "sustain", "any", "such", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p62_s6", "idA": "886163_11_item1_p2_s3", "sentA": "In addition, future arbitration, litigation or disputes with third parties may have a material adverse effect on us.", "sentB": "In addition, changes in existing regulations could have a material adverse effect to us.", "type": 2, "words": ["<tag1>", "In", "addition,", "future", "arbitration,", "litigation", "or", "disputes", "with", "third", "parties", "may", "have", "a", "material", "adverse", "effect", "on", "us.", "<tag2>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "to", "us.", "<tag3>"], "wordsA": ["In", "addition,", "future", "arbitration,", "litigation", "or", "disputes", "with", "third", "parties", "may", "have", "a", "material", "adverse", "effect", "on", "us."], "wordsB": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "to", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p44_s3", "idA": "886163_11_item1_p33_s3", "sentA": "We are eligible to receive milestones and royalties from this program.", "sentB": "We are also eligible to receive, under the License Agreement, both milestones and royalty payments on worldwide net sales of Fablyn.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "milestones", "and", "royalties", "from", "this", "program.", "<tag2>", "We", "are", "also", "eligible", "to", "receive,", "under", "the", "License", "Agreement,", "both", "milestones", "and", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "Fablyn.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "milestones", "and", "royalties", "from", "this", "program."], "wordsB": ["We", "are", "also", "eligible", "to", "receive,", "under", "the", "License", "Agreement,", "both", "milestones", "and", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "Fablyn."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s14", "idA": "886163_11_item1_p33_s3", "sentA": "We are eligible to receive milestones and royalties from this program.", "sentB": "We are also eligible to receive milestone payments upon the occurrence of certain specified sales goals.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "milestones", "and", "royalties", "from", "this", "program.", "<tag2>", "We", "are", "also", "eligible", "to", "receive", "milestone", "payments", "upon", "the", "occurrence", "of", "certain", "specified", "sales", "goals.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "milestones", "and", "royalties", "from", "this", "program."], "wordsB": ["We", "are", "also", "eligible", "to", "receive", "milestone", "payments", "upon", "the", "occurrence", "of", "certain", "specified", "sales", "goals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p57_s0", "idA": "886163_11_item1_p35_s0", "sentA": "Internal Product Development Programs As summarized in the table below, we are developing several proprietary products for a variety of indications.", "sentB": "Competition Some of the drugs we are developing may compete with existing therapies or other drugs in development by other companies.", "type": 2, "words": ["<tag1>", "Internal", "Product", "Development", "Programs", "As", "summarized", "in", "the", "table", "below,", "we", "are", "developing", "several", "proprietary", "products", "for", "a", "variety", "of", "indications.", "<tag2>", "Competition", "Some", "of", "the", "drugs", "we", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag3>"], "wordsA": ["Internal", "Product", "Development", "Programs", "As", "summarized", "in", "the", "table", "below,", "we", "are", "developing", "several", "proprietary", "products", "for", "a", "variety", "of", "indications."], "wordsB": ["Competition", "Some", "of", "the", "drugs", "we", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p20_s6", "idA": "886163_11_item1_p35_s1", "sentA": "These programs represent our future licensing opportunities to expand our partnered asset portfolio.", "sentB": "These programs represent the next series of potential royalty generating assets in our portfolio.", "type": 2, "words": ["<tag1>", "These", "programs", "represent", "our", "future", "licensing", "opportunities", "to", "expand", "our", "partnered", "asset", "portfolio.", "<tag2>", "These", "programs", "represent", "the", "next", "series", "of", "potential", "royalty", "generating", "assets", "in", "our", "portfolio.", "<tag3>"], "wordsA": ["These", "programs", "represent", "our", "future", "licensing", "opportunities", "to", "expand", "our", "partnered", "asset", "portfolio."], "wordsB": ["These", "programs", "represent", "the", "next", "series", "of", "potential", "royalty", "generating", "assets", "in", "our", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s2", "idA": "886163_11_item1_p35_s1", "sentA": "These programs represent our future licensing opportunities to expand our partnered asset portfolio.", "sentB": "We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.", "type": 2, "words": ["<tag1>", "These", "programs", "represent", "our", "future", "licensing", "opportunities", "to", "expand", "our", "partnered", "asset", "portfolio.", "<tag2>", "We", "also", "rely", "upon", "trade", "secrets,", "know-how,", "continuing", "technological", "innovations", "and", "licensing", "opportunities", "to", "develop", "and", "maintain", "our", "competitive", "position.", "<tag3>"], "wordsA": ["These", "programs", "represent", "our", "future", "licensing", "opportunities", "to", "expand", "our", "partnered", "asset", "portfolio."], "wordsB": ["We", "also", "rely", "upon", "trade", "secrets,", "know-how,", "continuing", "technological", "innovations", "and", "licensing", "opportunities", "to", "develop", "and", "maintain", "our", "competitive", "position."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p62_s5", "idA": "886163_11_item1_p37_s1", "sentA": "Preclinical studies conducted with LGD-4033 suggest that the compound may have favorable activity in the treatment of cachexia, frailty, osteoporosis, hypogonadism as well as other disorders.", "sentB": "For both currently marketed and future products, failure to comply with applicable regulatory requirements after obtaining regulatory approval can, among other things, result in the suspension of regulatory approval, as well as possible civil and criminal sanctions.", "type": 2, "words": ["<tag1>", "Preclinical", "studies", "conducted", "with", "LGD-4033", "suggest", "that", "the", "compound", "may", "have", "favorable", "activity", "in", "the", "treatment", "of", "cachexia,", "frailty,", "osteoporosis,", "hypogonadism", "as", "well", "as", "other", "disorders.", "<tag2>", "For", "both", "currently", "marketed", "and", "future", "products,", "failure", "to", "comply", "with", "applicable", "regulatory", "requirements", "after", "obtaining", "regulatory", "approval", "can,", "among", "other", "things,", "result", "in", "the", "suspension", "of", "regulatory", "approval,", "as", "well", "as", "possible", "civil", "and", "criminal", "sanctions.", "<tag3>"], "wordsA": ["Preclinical", "studies", "conducted", "with", "LGD-4033", "suggest", "that", "the", "compound", "may", "have", "favorable", "activity", "in", "the", "treatment", "of", "cachexia,", "frailty,", "osteoporosis,", "hypogonadism", "as", "well", "as", "other", "disorders."], "wordsB": ["For", "both", "currently", "marketed", "and", "future", "products,", "failure", "to", "comply", "with", "applicable", "regulatory", "requirements", "after", "obtaining", "regulatory", "approval", "can,", "among", "other", "things,", "result", "in", "the", "suspension", "of", "regulatory", "approval,", "as", "well", "as", "possible", "civil", "and", "criminal", "sanctions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p3_s2", "idA": "886163_11_item1_p3_s2", "sentA": "Our principal executive offices are located at 11085 North Torrey Pines Road, Suite 300, La Jolla, California, 92037.", "sentB": "Our principal executive offices are located at 11085 North Torrey Pines Road, Suite 100, La Jolla, California, 92037.", "type": 2, "words": ["<tag1>", "Our", "principal", "executive", "offices", "are", "located", "at", "11085", "North", "Torrey", "Pines", "Road,", "Suite", "300,", "La", "Jolla,", "California,", "92037.", "<tag2>", "Our", "principal", "executive", "offices", "are", "located", "at", "11085", "North", "Torrey", "Pines", "Road,", "Suite", "100,", "La", "Jolla,", "California,", "92037.", "<tag3>"], "wordsA": ["Our", "principal", "executive", "offices", "are", "located", "at", "11085", "North", "Torrey", "Pines", "Road,", "Suite", "300,", "La", "Jolla,", "California,", "92037."], "wordsB": ["Our", "principal", "executive", "offices", "are", "located", "at", "11085", "North", "Torrey", "Pines", "Road,", "Suite", "100,", "La", "Jolla,", "California,", "92037."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p26_s0", "idA": "886163_11_item1_p41_s0", "sentA": "Clopidogrel is the active ingredient in PLAVIX (clopidogrel bisulfate), an orally available antiplatelet drug marketed by BMS and Sanofi-Aventis.", "sentB": "Clopidogrel is the active ingredient in PLAVIX , the world s leading anti-platelet medication which is currently only available in an oral formulation.", "type": 2, "words": ["<tag1>", "Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", "(clopidogrel", "bisulfate),", "an", "orally", "available", "antiplatelet", "drug", "marketed", "by", "BMS", "and", "Sanofi-Aventis.", "<tag2>", "Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", ",", "the", "world", "s", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation.", "<tag3>"], "wordsA": ["Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", "(clopidogrel", "bisulfate),", "an", "orally", "available", "antiplatelet", "drug", "marketed", "by", "BMS", "and", "Sanofi-Aventis."], "wordsB": ["Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", ",", "the", "world", "s", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p32_s0", "idA": "886163_11_item1_p44_s0", "sentA": "Our Captiol-enabled form of melphalan does not require a special non-aqueous dissolving solvent system containing high levels of propylene glycol for reconstitution, and can be dissolved directly into saline.", "sentB": "Our Captisol-enabled form of melphalan does not require a special non-aqueous dissolving solvent system - containing high levels of propylene glycol for reconstitution, and can be dissolved directly into saline.", "type": 2, "words": ["<tag1>", "Our", "Captiol-enabled", "form", "of", "melphalan", "does", "not", "require", "a", "special", "non-aqueous", "dissolving", "solvent", "system", "containing", "high", "levels", "of", "propylene", "glycol", "for", "reconstitution,", "and", "can", "be", "dissolved", "directly", "into", "saline.", "<tag2>", "Our", "Captisol-enabled", "form", "of", "melphalan", "does", "not", "require", "a", "special", "non-aqueous", "dissolving", "solvent", "system", "-", "containing", "high", "levels", "of", "propylene", "glycol", "for", "reconstitution,", "and", "can", "be", "dissolved", "directly", "into", "saline.", "<tag3>"], "wordsA": ["Our", "Captiol-enabled", "form", "of", "melphalan", "does", "not", "require", "a", "special", "non-aqueous", "dissolving", "solvent", "system", "containing", "high", "levels", "of", "propylene", "glycol", "for", "reconstitution,", "and", "can", "be", "dissolved", "directly", "into", "saline."], "wordsB": ["Our", "Captisol-enabled", "form", "of", "melphalan", "does", "not", "require", "a", "special", "non-aqueous", "dissolving", "solvent", "system", "-", "containing", "high", "levels", "of", "propylene", "glycol", "for", "reconstitution,", "and", "can", "be", "dissolved", "directly", "into", "saline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p25_s1", "idA": "886163_11_item1_p44_s2", "sentA": "We are currently completing a phase II study for this program.", "sentB": "Merck is currently conducting a pivitol study for this program and we expect Merck to potentially file a 505(b)(2) in 2013 for approval to market this CAPTISOL program.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "completing", "a", "phase", "II", "study", "for", "this", "program.", "<tag2>", "Merck", "is", "currently", "conducting", "a", "pivitol", "study", "for", "this", "program", "and", "we", "expect", "Merck", "to", "potentially", "file", "a", "505(b)(2)", "in", "2013", "for", "approval", "to", "market", "this", "CAPTISOL", "program.", "<tag3>"], "wordsA": ["We", "are", "currently", "completing", "a", "phase", "II", "study", "for", "this", "program."], "wordsB": ["Merck", "is", "currently", "conducting", "a", "pivitol", "study", "for", "this", "program", "and", "we", "expect", "Merck", "to", "potentially", "file", "a", "505(b)(2)", "in", "2013", "for", "approval", "to", "market", "this", "CAPTISOL", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p61_s0", "idA": "886163_11_item1_p44_s3", "sentA": "The Captisol-enabled melphalan program has also obtained orphan drug designation from the FDA.", "sentB": "In the United States, pharmaceuticals are subject to rigorous regulation by federal and various state authorities, including the FDA.", "type": 2, "words": ["<tag1>", "The", "Captisol-enabled", "melphalan", "program", "has", "also", "obtained", "orphan", "drug", "designation", "from", "the", "FDA.", "<tag2>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag3>"], "wordsA": ["The", "Captisol-enabled", "melphalan", "program", "has", "also", "obtained", "orphan", "drug", "designation", "from", "the", "FDA."], "wordsB": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s4", "idA": "886163_11_item1_p44_s3", "sentA": "The Captisol-enabled melphalan program has also obtained orphan drug designation from the FDA.", "sentB": "The United States patent on AVINZA is not expected to expire until November 2017; however, applications for generic forms of AVINZA have been submitted to the FDA.", "type": 2, "words": ["<tag1>", "The", "Captisol-enabled", "melphalan", "program", "has", "also", "obtained", "orphan", "drug", "designation", "from", "the", "FDA.", "<tag2>", "The", "United", "States", "patent", "on", "AVINZA", "is", "not", "expected", "to", "expire", "until", "November", "2017;", "however,", "applications", "for", "generic", "forms", "of", "AVINZA", "have", "been", "submitted", "to", "the", "FDA.", "<tag3>"], "wordsA": ["The", "Captisol-enabled", "melphalan", "program", "has", "also", "obtained", "orphan", "drug", "designation", "from", "the", "FDA."], "wordsB": ["The", "United", "States", "patent", "on", "AVINZA", "is", "not", "expected", "to", "expire", "until", "November", "2017;", "however,", "applications", "for", "generic", "forms", "of", "AVINZA", "have", "been", "submitted", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p33_s0", "idA": "886163_11_item1_p47_s0", "sentA": "Glucagon Receptor Antagonist Research Program We are developing small molecule glucagon receptor antagonists for the treatment of Type 2 diabetes mellitus.", "sentB": "HepDirect HCV Inhibitor Program We are developing novel small molecule inhibitors of the Hepatitis C virus using our HepDirect technology platform.", "type": 2, "words": ["<tag1>", "Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "HepDirect", "HCV", "Inhibitor", "Program", "We", "are", "developing", "novel", "small", "molecule", "inhibitors", "of", "the", "Hepatitis", "C", "virus", "using", "our", "HepDirect", "technology", "platform.", "<tag3>"], "wordsA": ["Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["HepDirect", "HCV", "Inhibitor", "Program", "We", "are", "developing", "novel", "small", "molecule", "inhibitors", "of", "the", "Hepatitis", "C", "virus", "using", "our", "HepDirect", "technology", "platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p4_s0", "idA": "886163_11_item1_p4_s0", "sentA": "We are a biotechnology company focused on developing or acquiring revenue generating assets and coupling them to a lean corporate cost structure.", "sentB": "We are a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them to a lean corporate cost structure.", "type": 2, "words": ["<tag1>", "We", "are", "a", "biotechnology", "company", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure.", "<tag2>", "We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure.", "<tag3>"], "wordsA": ["We", "are", "a", "biotechnology", "company", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure."], "wordsB": ["We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p4_s2", "idA": "886163_11_item1_p4_s2", "sentA": "Since our business model is based on the goal of partnering with other pharmaceutical companies to commercialize and market our assets, the revenue that supports our business is based largely on payments made to us by partners for royalties, milestones, license fees and our material sales of Captisol .", "sentB": "Since a portion of our business model is based on the goal of partnering with other pharmaceutical companies to commercialize and market our assets, a significant amount of our revenue is based largely on payments made to us by partners for royalties, milestones and license fees.", "type": 2, "words": ["<tag1>", "Since", "our", "business", "model", "is", "based", "on", "the", "goal", "of", "partnering", "with", "other", "pharmaceutical", "companies", "to", "commercialize", "and", "market", "our", "assets,", "the", "revenue", "that", "supports", "our", "business", "is", "based", "largely", "on", "payments", "made", "to", "us", "by", "partners", "for", "royalties,", "milestones,", "license", "fees", "and", "our", "material", "sales", "of", "Captisol", ".", "<tag2>", "Since", "a", "portion", "of", "our", "business", "model", "is", "based", "on", "the", "goal", "of", "partnering", "with", "other", "pharmaceutical", "companies", "to", "commercialize", "and", "market", "our", "assets,", "a", "significant", "amount", "of", "our", "revenue", "is", "based", "largely", "on", "payments", "made", "to", "us", "by", "partners", "for", "royalties,", "milestones", "and", "license", "fees.", "<tag3>"], "wordsA": ["Since", "our", "business", "model", "is", "based", "on", "the", "goal", "of", "partnering", "with", "other", "pharmaceutical", "companies", "to", "commercialize", "and", "market", "our", "assets,", "the", "revenue", "that", "supports", "our", "business", "is", "based", "largely", "on", "payments", "made", "to", "us", "by", "partners", "for", "royalties,", "milestones,", "license", "fees", "and", "our", "material", "sales", "of", "Captisol", "."], "wordsB": ["Since", "a", "portion", "of", "our", "business", "model", "is", "based", "on", "the", "goal", "of", "partnering", "with", "other", "pharmaceutical", "companies", "to", "commercialize", "and", "market", "our", "assets,", "a", "significant", "amount", "of", "our", "revenue", "is", "based", "largely", "on", "payments", "made", "to", "us", "by", "partners", "for", "royalties,", "milestones", "and", "license", "fees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p40_s1", "idA": "886163_11_item1_p51_s0", "sentA": "On January 26, 2011, we completed the acquisition of CyDex following approval of the transaction by CyDex stockholders.", "sentB": "Acquisition On January 26, 2011, we completed the acquisition of CyDex Pharmaceuticals, Inc. or CyDex.", "type": 2, "words": ["<tag1>", "On", "January", "26,", "2011,", "we", "completed", "the", "acquisition", "of", "CyDex", "following", "approval", "of", "the", "transaction", "by", "CyDex", "stockholders.", "<tag2>", "Acquisition", "On", "January", "26,", "2011,", "we", "completed", "the", "acquisition", "of", "CyDex", "Pharmaceuticals,", "Inc.", "or", "CyDex.", "<tag3>"], "wordsA": ["On", "January", "26,", "2011,", "we", "completed", "the", "acquisition", "of", "CyDex", "following", "approval", "of", "the", "transaction", "by", "CyDex", "stockholders."], "wordsB": ["Acquisition", "On", "January", "26,", "2011,", "we", "completed", "the", "acquisition", "of", "CyDex", "Pharmaceuticals,", "Inc.", "or", "CyDex."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p40_s3", "idA": "886163_11_item1_p51_s2", "sentA": "We paid $31.2 million in cash, of which $20.0 million was financed, with an additional $4.3 million to be paid on the one-year anniversary of the transaction.", "sentB": "We paid $31.6 million in cash, of which $20.0 million was financed, with an additional $4.3 million paid on the one-year anniversary of the transaction.", "type": 2, "words": ["<tag1>", "We", "paid", "$31.2", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "to", "be", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction.", "<tag2>", "We", "paid", "$31.6", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction.", "<tag3>"], "wordsA": ["We", "paid", "$31.2", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "to", "be", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction."], "wordsB": ["We", "paid", "$31.6", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p4_s3", "idA": "886163_11_item1_p52_s3", "sentA": "This transaction further diversifies our business by adding a proprietary and well-validated platform in the increasingly important drug reformulation segment of the pharmaceutical industry, which we believe has become an increasingly valuable solution to the issues related to market erosion due to generic competition and continued clinical and regulatory uncertainty.", "sentB": "We recognized the important role of the drug reformulation segment in the pharmaceutical industry and in 2011 added CAPTISOL to our technology portfolio.", "type": 2, "words": ["<tag1>", "This", "transaction", "further", "diversifies", "our", "business", "by", "adding", "a", "proprietary", "and", "well-validated", "platform", "in", "the", "increasingly", "important", "drug", "reformulation", "segment", "of", "the", "pharmaceutical", "industry,", "which", "we", "believe", "has", "become", "an", "increasingly", "valuable", "solution", "to", "the", "issues", "related", "to", "market", "erosion", "due", "to", "generic", "competition", "and", "continued", "clinical", "and", "regulatory", "uncertainty.", "<tag2>", "We", "recognized", "the", "important", "role", "of", "the", "drug", "reformulation", "segment", "in", "the", "pharmaceutical", "industry", "and", "in", "2011", "added", "CAPTISOL", "to", "our", "technology", "portfolio.", "<tag3>"], "wordsA": ["This", "transaction", "further", "diversifies", "our", "business", "by", "adding", "a", "proprietary", "and", "well-validated", "platform", "in", "the", "increasingly", "important", "drug", "reformulation", "segment", "of", "the", "pharmaceutical", "industry,", "which", "we", "believe", "has", "become", "an", "increasingly", "valuable", "solution", "to", "the", "issues", "related", "to", "market", "erosion", "due", "to", "generic", "competition", "and", "continued", "clinical", "and", "regulatory", "uncertainty."], "wordsB": ["We", "recognized", "the", "important", "role", "of", "the", "drug", "reformulation", "segment", "in", "the", "pharmaceutical", "industry", "and", "in", "2011", "added", "CAPTISOL", "to", "our", "technology", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s0", "idA": "886163_11_item1_p53_s0", "sentA": "CyDex Brings the Following to us The CyDex acquisition brings numerous benefits to our business.", "sentB": "We believe that patents and other proprietary rights are important to our business.", "type": 2, "words": ["<tag1>", "CyDex", "Brings", "the", "Following", "to", "us", "The", "CyDex", "acquisition", "brings", "numerous", "benefits", "to", "our", "business.", "<tag2>", "We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business.", "<tag3>"], "wordsA": ["CyDex", "Brings", "the", "Following", "to", "us", "The", "CyDex", "acquisition", "brings", "numerous", "benefits", "to", "our", "business."], "wordsB": ["We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p51_s0", "idA": "886163_11_item1_p54_s0", "sentA": "Topiramate IV in Preclinical development for seizures Technology Agreements In September 1993, CyDex obtained from the University of Kansas, or KU, an exclusive, worldwide license, with the right to sublicense, under the original Captisol patents, as well as intellectual property covering the results generated during specified CyDex-sponsored research activities at KU.", "sentB": "In September 1993, CyDex obtained from the University of Kansas, or KU, an exclusive, worldwide license, with the right to sublicense, under the original CAPTISOL patents, as well as intellectual property covering the results generated during specified CyDex-sponsored research activities at KU.", "type": 2, "words": ["<tag1>", "Topiramate", "IV", "in", "Preclinical", "development", "for", "seizures", "Technology", "Agreements", "In", "September", "1993,", "CyDex", "obtained", "from", "the", "University", "of", "Kansas,", "or", "KU,", "an", "exclusive,", "worldwide", "license,", "with", "the", "right", "to", "sublicense,", "under", "the", "original", "Captisol", "patents,", "as", "well", "as", "intellectual", "property", "covering", "the", "results", "generated", "during", "specified", "CyDex-sponsored", "research", "activities", "at", "KU.", "<tag2>", "In", "September", "1993,", "CyDex", "obtained", "from", "the", "University", "of", "Kansas,", "or", "KU,", "an", "exclusive,", "worldwide", "license,", "with", "the", "right", "to", "sublicense,", "under", "the", "original", "CAPTISOL", "patents,", "as", "well", "as", "intellectual", "property", "covering", "the", "results", "generated", "during", "specified", "CyDex-sponsored", "research", "activities", "at", "KU.", "<tag3>"], "wordsA": ["Topiramate", "IV", "in", "Preclinical", "development", "for", "seizures", "Technology", "Agreements", "In", "September", "1993,", "CyDex", "obtained", "from", "the", "University", "of", "Kansas,", "or", "KU,", "an", "exclusive,", "worldwide", "license,", "with", "the", "right", "to", "sublicense,", "under", "the", "original", "Captisol", "patents,", "as", "well", "as", "intellectual", "property", "covering", "the", "results", "generated", "during", "specified", "CyDex-sponsored", "research", "activities", "at", "KU."], "wordsB": ["In", "September", "1993,", "CyDex", "obtained", "from", "the", "University", "of", "Kansas,", "or", "KU,", "an", "exclusive,", "worldwide", "license,", "with", "the", "right", "to", "sublicense,", "under", "the", "original", "CAPTISOL", "patents,", "as", "well", "as", "intellectual", "property", "covering", "the", "results", "generated", "during", "specified", "CyDex-sponsored", "research", "activities", "at", "KU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p52_s0", "idA": "886163_11_item1_p55_s0", "sentA": "We are responsible for maintaining the DMF for Captisol.", "sentB": "We are responsible for maintaining the Drug Master File ( DMF ) for CAPTISOL.", "type": 2, "words": ["<tag1>", "We", "are", "responsible", "for", "maintaining", "the", "DMF", "for", "Captisol.", "<tag2>", "We", "are", "responsible", "for", "maintaining", "the", "Drug", "Master", "File", "(", "DMF", ")", "for", "CAPTISOL.", "<tag3>"], "wordsA": ["We", "are", "responsible", "for", "maintaining", "the", "DMF", "for", "Captisol."], "wordsB": ["We", "are", "responsible", "for", "maintaining", "the", "Drug", "Master", "File", "(", "DMF", ")", "for", "CAPTISOL."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p52_s2", "idA": "886163_11_item1_p55_s2", "sentA": "In August 2004, we amended the KU license agreement to replace all future payment terms under the agreement, including royalties, with a concurrent lump sum payment and issuance of CyDex stock to KU.", "sentB": "In August 2004, the KU license agreement was amended to replace all future payment terms under the agreement, including royalties, with a concurrent lump sum payment and issuance of CyDex stock to KU.", "type": 2, "words": ["<tag1>", "In", "August", "2004,", "we", "amended", "the", "KU", "license", "agreement", "to", "replace", "all", "future", "payment", "terms", "under", "the", "agreement,", "including", "royalties,", "with", "a", "concurrent", "lump", "sum", "payment", "and", "issuance", "of", "CyDex", "stock", "to", "KU.", "<tag2>", "In", "August", "2004,", "the", "KU", "license", "agreement", "was", "amended", "to", "replace", "all", "future", "payment", "terms", "under", "the", "agreement,", "including", "royalties,", "with", "a", "concurrent", "lump", "sum", "payment", "and", "issuance", "of", "CyDex", "stock", "to", "KU.", "<tag3>"], "wordsA": ["In", "August", "2004,", "we", "amended", "the", "KU", "license", "agreement", "to", "replace", "all", "future", "payment", "terms", "under", "the", "agreement,", "including", "royalties,", "with", "a", "concurrent", "lump", "sum", "payment", "and", "issuance", "of", "CyDex", "stock", "to", "KU."], "wordsB": ["In", "August", "2004,", "the", "KU", "license", "agreement", "was", "amended", "to", "replace", "all", "future", "payment", "terms", "under", "the", "agreement,", "including", "royalties,", "with", "a", "concurrent", "lump", "sum", "payment", "and", "issuance", "of", "CyDex", "stock", "to", "KU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s6", "idA": "886163_11_item1_p58_s5", "sentA": "Accordingly, BVF has paid us $1.375 million.", "sentB": "Lilly paid us a non-refundable license issuance fee of $1 million.", "type": 2, "words": ["<tag1>", "Accordingly,", "BVF", "has", "paid", "us", "$1.375", "million.", "<tag2>", "Lilly", "paid", "us", "a", "non-refundable", "license", "issuance", "fee", "of", "$1", "million.", "<tag3>"], "wordsA": ["Accordingly,", "BVF", "has", "paid", "us", "$1.375", "million."], "wordsB": ["Lilly", "paid", "us", "a", "non-refundable", "license", "issuance", "fee", "of", "$1", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p34_s1", "idA": "886163_11_item1_p59_s1", "sentA": "Several of these interleukin molecules, including IL-9, are thought to play an important role in the pathogenesis of asthma.", "sentB": "IRAK4 plays an important role in the innate immune system and may also be important for cross-talk between the innate and adaptive immune systems.", "type": 2, "words": ["<tag1>", "Several", "of", "these", "interleukin", "molecules,", "including", "IL-9,", "are", "thought", "to", "play", "an", "important", "role", "in", "the", "pathogenesis", "of", "asthma.", "<tag2>", "IRAK4", "plays", "an", "important", "role", "in", "the", "innate", "immune", "system", "and", "may", "also", "be", "important", "for", "cross-talk", "between", "the", "innate", "and", "adaptive", "immune", "systems.", "<tag3>"], "wordsA": ["Several", "of", "these", "interleukin", "molecules,", "including", "IL-9,", "are", "thought", "to", "play", "an", "important", "role", "in", "the", "pathogenesis", "of", "asthma."], "wordsB": ["IRAK4", "plays", "an", "important", "role", "in", "the", "innate", "immune", "system", "and", "may", "also", "be", "important", "for", "cross-talk", "between", "the", "innate", "and", "adaptive", "immune", "systems."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p5_s1", "idA": "886163_11_item1_p5_s0", "sentA": "These programs address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer s disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis, oncology and osteoporosis.", "sentB": "The therapies in our portfolio in development address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis.", "type": 2, "words": ["<tag1>", "These", "programs", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "COPD,", "asthma,", "rheumatoid", "arthritis,", "oncology", "and", "osteoporosis.", "<tag2>", "The", "therapies", "in", "our", "portfolio", "in", "development", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "asthma,", "rheumatoid", "arthritis", "and", "osteoporosis.", "<tag3>"], "wordsA": ["These", "programs", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "COPD,", "asthma,", "rheumatoid", "arthritis,", "oncology", "and", "osteoporosis."], "wordsB": ["The", "therapies", "in", "our", "portfolio", "in", "development", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "asthma,", "rheumatoid", "arthritis", "and", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s5", "idA": "886163_11_item1_p62_s0", "sentA": "In September 2010, we transferred exclusive license rights to Proximagen Limited for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system.", "sentB": "We have developed and are developing a number of policies and procedures to ensure our compliance with these state laws, in addition to the federal regulations described above.", "type": 2, "words": ["<tag1>", "In", "September", "2010,", "we", "transferred", "exclusive", "license", "rights", "to", "Proximagen", "Limited", "for", "a", "series", "of", "compound", "hits", "related", "to", "the", "CXCR4", "target", "with", "application", "for", "a", "number", "of", "indications", "including", "those", "related", "to", "the", "central", "nervous", "system.", "<tag2>", "We", "have", "developed", "and", "are", "developing", "a", "number", "of", "policies", "and", "procedures", "to", "ensure", "our", "compliance", "with", "these", "state", "laws,", "in", "addition", "to", "the", "federal", "regulations", "described", "above.", "<tag3>"], "wordsA": ["In", "September", "2010,", "we", "transferred", "exclusive", "license", "rights", "to", "Proximagen", "Limited", "for", "a", "series", "of", "compound", "hits", "related", "to", "the", "CXCR4", "target", "with", "application", "for", "a", "number", "of", "indications", "including", "those", "related", "to", "the", "central", "nervous", "system."], "wordsB": ["We", "have", "developed", "and", "are", "developing", "a", "number", "of", "policies", "and", "procedures", "to", "ensure", "our", "compliance", "with", "these", "state", "laws,", "in", "addition", "to", "the", "federal", "regulations", "described", "above."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p27_s2", "idA": "886163_11_item1_p63_s1", "sentA": "Under the terms of the agreement, we received $1 million at the close of the transaction.", "sentB": "We recognized $0.9 million of the upfront payment as revenue and under the terms of our CyDex contingent value rights agreement, remitted $0.9 million to CyDex shareholders.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "received", "$1", "million", "at", "the", "close", "of", "the", "transaction.", "<tag2>", "We", "recognized", "$0.9", "million", "of", "the", "upfront", "payment", "as", "revenue", "and", "under", "the", "terms", "of", "our", "CyDex", "contingent", "value", "rights", "agreement,", "remitted", "$0.9", "million", "to", "CyDex", "shareholders.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "received", "$1", "million", "at", "the", "close", "of", "the", "transaction."], "wordsB": ["We", "recognized", "$0.9", "million", "of", "the", "upfront", "payment", "as", "revenue", "and", "under", "the", "terms", "of", "our", "CyDex", "contingent", "value", "rights", "agreement,", "remitted", "$0.9", "million", "to", "CyDex", "shareholders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p27_s0", "idA": "886163_11_item1_p65_s1", "sentA": "As a result, we received an upfront payment of $1.0 million from Pfizer.", "sentB": "We received an upfront payment of $1.8 million, and are eligible to receive up to $22 million in milestones and up to double digit royalties on annual worldwide net sales.", "type": 2, "words": ["<tag1>", "As", "a", "result,", "we", "received", "an", "upfront", "payment", "of", "$1.0", "million", "from", "Pfizer.", "<tag2>", "We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "and", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "milestones", "and", "up", "to", "double", "digit", "royalties", "on", "annual", "worldwide", "net", "sales.", "<tag3>"], "wordsA": ["As", "a", "result,", "we", "received", "an", "upfront", "payment", "of", "$1.0", "million", "from", "Pfizer."], "wordsB": ["We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "and", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "milestones", "and", "up", "to", "double", "digit", "royalties", "on", "annual", "worldwide", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s8", "idA": "886163_11_item1_p65_s2", "sentA": "We are entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.", "sentB": "Under the Supply Agreement, Lilly agreed to purchase from us its CAPTISOL requirements for the development of the compounds contemplated by the License Agreement, as well as any CAPTISOL required for any product that is successfully commercialized.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "clinical", "and", "regulatory", "milestone", "payments", "from", "Pfizer", "as", "Tanaproget", "advances", "through", "the", "development", "process,", "as", "well", "as", "tiered", "royalties", "on", "net", "sales.", "<tag2>", "Under", "the", "Supply", "Agreement,", "Lilly", "agreed", "to", "purchase", "from", "us", "its", "CAPTISOL", "requirements", "for", "the", "development", "of", "the", "compounds", "contemplated", "by", "the", "License", "Agreement,", "as", "well", "as", "any", "CAPTISOL", "required", "for", "any", "product", "that", "is", "successfully", "commercialized.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "clinical", "and", "regulatory", "milestone", "payments", "from", "Pfizer", "as", "Tanaproget", "advances", "through", "the", "development", "process,", "as", "well", "as", "tiered", "royalties", "on", "net", "sales."], "wordsB": ["Under", "the", "Supply", "Agreement,", "Lilly", "agreed", "to", "purchase", "from", "us", "its", "CAPTISOL", "requirements", "for", "the", "development", "of", "the", "compounds", "contemplated", "by", "the", "License", "Agreement,", "as", "well", "as", "any", "CAPTISOL", "required", "for", "any", "product", "that", "is", "successfully", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p33_s1", "idA": "886163_11_item1_p66_s0", "sentA": "Tanaproget is a tissue-selective, non-steroidal contraceptive progesterone receptor agonist that has the potential for an improved side effect profile over current steroid containing contraceptives.", "sentB": "Data from current lead molecules suggest that directing these molecules to the liver using the HepDirect technology produces fewer side effects and the potential for an overall superior risk-benefit ratio compared to non HepDirect therapies.", "type": 2, "words": ["<tag1>", "Tanaproget", "is", "a", "tissue-selective,", "non-steroidal", "contraceptive", "progesterone", "receptor", "agonist", "that", "has", "the", "potential", "for", "an", "improved", "side", "effect", "profile", "over", "current", "steroid", "containing", "contraceptives.", "<tag2>", "Data", "from", "current", "lead", "molecules", "suggest", "that", "directing", "these", "molecules", "to", "the", "liver", "using", "the", "HepDirect", "technology", "produces", "fewer", "side", "effects", "and", "the", "potential", "for", "an", "overall", "superior", "risk-benefit", "ratio", "compared", "to", "non", "HepDirect", "therapies.", "<tag3>"], "wordsA": ["Tanaproget", "is", "a", "tissue-selective,", "non-steroidal", "contraceptive", "progesterone", "receptor", "agonist", "that", "has", "the", "potential", "for", "an", "improved", "side", "effect", "profile", "over", "current", "steroid", "containing", "contraceptives."], "wordsB": ["Data", "from", "current", "lead", "molecules", "suggest", "that", "directing", "these", "molecules", "to", "the", "liver", "using", "the", "HepDirect", "technology", "produces", "fewer", "side", "effects", "and", "the", "potential", "for", "an", "overall", "superior", "risk-benefit", "ratio", "compared", "to", "non", "HepDirect", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p42_s0", "idA": "886163_11_item1_p67_s0", "sentA": "In January 2011, we entered into a strategic relationship with Chiva Pharmaceuticals, Inc., or Chiva, to develop multiple of our assets and technology in China and potentially worldwide.", "sentB": "CAPTISOL License and Supply Agreement with The Medicines Company to Develop CAPTISOL-Enabled Clopidogrel In June 2011, we entered into a CAPTISOL License and Supply Agreement with The Medicines Company for development and commercialization of CAPTISOL-enabled clopidogrel for use as an intravenous drug.", "type": 2, "words": ["<tag1>", "In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide.", "<tag2>", "CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "to", "Develop", "CAPTISOL-Enabled", "Clopidogrel", "In", "June", "2011,", "we", "entered", "into", "a", "CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "for", "development", "and", "commercialization", "of", "CAPTISOL-enabled", "clopidogrel", "for", "use", "as", "an", "intravenous", "drug.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide."], "wordsB": ["CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "to", "Develop", "CAPTISOL-Enabled", "Clopidogrel", "In", "June", "2011,", "we", "entered", "into", "a", "CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "for", "development", "and", "commercialization", "of", "CAPTISOL-enabled", "clopidogrel", "for", "use", "as", "an", "intravenous", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p43_s0", "idA": "886163_11_item1_p67_s0", "sentA": "In January 2011, we entered into a strategic relationship with Chiva Pharmaceuticals, Inc., or Chiva, to develop multiple of our assets and technology in China and potentially worldwide.", "sentB": "CAPTISOL Supply Agreement with Merck for Undisclosed Program In June 2011, we entered into a commercial supply agreement to provide CAPTISOL to Merck.", "type": 2, "words": ["<tag1>", "In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide.", "<tag2>", "CAPTISOL", "Supply", "Agreement", "with", "Merck", "for", "Undisclosed", "Program", "In", "June", "2011,", "we", "entered", "into", "a", "commercial", "supply", "agreement", "to", "provide", "CAPTISOL", "to", "Merck.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide."], "wordsB": ["CAPTISOL", "Supply", "Agreement", "with", "Merck", "for", "Undisclosed", "Program", "In", "June", "2011,", "we", "entered", "into", "a", "commercial", "supply", "agreement", "to", "provide", "CAPTISOL", "to", "Merck."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p44_s0", "idA": "886163_11_item1_p67_s0", "sentA": "In January 2011, we entered into a strategic relationship with Chiva Pharmaceuticals, Inc., or Chiva, to develop multiple of our assets and technology in China and potentially worldwide.", "sentB": "Fablyn License Agreement with Chiva Pharmaceuticals In October 2011, we entered into a License Agreement with Chiva Pharmaceuticals, Inc.", "type": 2, "words": ["<tag1>", "In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide.", "<tag2>", "Fablyn", "License", "Agreement", "with", "Chiva", "Pharmaceuticals", "In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide."], "wordsB": ["Fablyn", "License", "Agreement", "with", "Chiva", "Pharmaceuticals", "In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "Chiva", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s4", "idA": "886163_11_item1_p67_s0", "sentA": "In January 2011, we entered into a strategic relationship with Chiva Pharmaceuticals, Inc., or Chiva, to develop multiple of our assets and technology in China and potentially worldwide.", "sentB": "In December 2011, we entered into a License and Supply Agreement with Eli Lilly ( Lilly ) and Company.", "type": 2, "words": ["<tag1>", "In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide.", "<tag2>", "In", "December", "2011,", "we", "entered", "into", "a", "License", "and", "Supply", "Agreement", "with", "Eli", "Lilly", "(", "Lilly", ")", "and", "Company.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide."], "wordsB": ["In", "December", "2011,", "we", "entered", "into", "a", "License", "and", "Supply", "Agreement", "with", "Eli", "Lilly", "(", "Lilly", ")", "and", "Company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s9", "idA": "886163_11_item1_p67_s0", "sentA": "In January 2011, we entered into a strategic relationship with Chiva Pharmaceuticals, Inc., or Chiva, to develop multiple of our assets and technology in China and potentially worldwide.", "sentB": "In December 2011, we entered into a License and Supply Agreement with Hospira, Inc.", "type": 2, "words": ["<tag1>", "In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide.", "<tag2>", "In", "December", "2011,", "we", "entered", "into", "a", "License", "and", "Supply", "Agreement", "with", "Hospira,", "Inc.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide."], "wordsB": ["In", "December", "2011,", "we", "entered", "into", "a", "License", "and", "Supply", "Agreement", "with", "Hospira,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p41_s3", "idA": "886163_11_item1_p68_s1", "sentA": "Chiva is developing these programs to address the high unmet medical need in China s fast growing pharmaceutical market.", "sentB": "Chiva is obligated to develop these programs to address the high unmet medical need in China s fast growing pharmaceutical market.", "type": 2, "words": ["<tag1>", "Chiva", "is", "developing", "these", "programs", "to", "address", "the", "high", "unmet", "medical", "need", "in", "China", "s", "fast", "growing", "pharmaceutical", "market.", "<tag2>", "Chiva", "is", "obligated", "to", "develop", "these", "programs", "to", "address", "the", "high", "unmet", "medical", "need", "in", "China", "s", "fast", "growing", "pharmaceutical", "market.", "<tag3>"], "wordsA": ["Chiva", "is", "developing", "these", "programs", "to", "address", "the", "high", "unmet", "medical", "need", "in", "China", "s", "fast", "growing", "pharmaceutical", "market."], "wordsB": ["Chiva", "is", "obligated", "to", "develop", "these", "programs", "to", "address", "the", "high", "unmet", "medical", "need", "in", "China", "s", "fast", "growing", "pharmaceutical", "market."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p5_s0", "idA": "886163_11_item1_p68_s3", "sentA": "Under the terms of the agreement, we have the potential to earn over $100 million in milestones and royalties on potential sales related to our assets.", "sentB": "In comparison to our peers, we believe we have assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate significant revenue in the future.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "potential", "to", "earn", "over", "$100", "million", "in", "milestones", "and", "royalties", "on", "potential", "sales", "related", "to", "our", "assets.", "<tag2>", "In", "comparison", "to", "our", "peers,", "we", "believe", "we", "have", "assembled", "one", "of", "the", "largest", "and", "most", "diversified", "asset", "portfolios", "in", "the", "industry", "with", "the", "potential", "to", "generate", "significant", "revenue", "in", "the", "future.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "potential", "to", "earn", "over", "$100", "million", "in", "milestones", "and", "royalties", "on", "potential", "sales", "related", "to", "our", "assets."], "wordsB": ["In", "comparison", "to", "our", "peers,", "we", "believe", "we", "have", "assembled", "one", "of", "the", "largest", "and", "most", "diversified", "asset", "portfolios", "in", "the", "industry", "with", "the", "potential", "to", "generate", "significant", "revenue", "in", "the", "future."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p41_s6", "idA": "886163_11_item1_p68_s4", "sentA": "In addition, we have the potential to receive a 10% equity position in Chiva and will also receive an undisclosed percentage of any sublicensing revenue generated from sublicensing of collaboration compounds to third parties in a major world market.", "sentB": "In August 2011, the contract was amended to increase the royalty rates we are eligible to receive on licensed products in return for relinquishing rights to a 10% equity position in Chiva that we were entitled to under the original agreement.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "have", "the", "potential", "to", "receive", "a", "10%", "equity", "position", "in", "Chiva", "and", "will", "also", "receive", "an", "undisclosed", "percentage", "of", "any", "sublicensing", "revenue", "generated", "from", "sublicensing", "of", "collaboration", "compounds", "to", "third", "parties", "in", "a", "major", "world", "market.", "<tag2>", "In", "August", "2011,", "the", "contract", "was", "amended", "to", "increase", "the", "royalty", "rates", "we", "are", "eligible", "to", "receive", "on", "licensed", "products", "in", "return", "for", "relinquishing", "rights", "to", "a", "10%", "equity", "position", "in", "Chiva", "that", "we", "were", "entitled", "to", "under", "the", "original", "agreement.", "<tag3>"], "wordsA": ["In", "addition,", "we", "have", "the", "potential", "to", "receive", "a", "10%", "equity", "position", "in", "Chiva", "and", "will", "also", "receive", "an", "undisclosed", "percentage", "of", "any", "sublicensing", "revenue", "generated", "from", "sublicensing", "of", "collaboration", "compounds", "to", "third", "parties", "in", "a", "major", "world", "market."], "wordsB": ["In", "August", "2011,", "the", "contract", "was", "amended", "to", "increase", "the", "royalty", "rates", "we", "are", "eligible", "to", "receive", "on", "licensed", "products", "in", "return", "for", "relinquishing", "rights", "to", "a", "10%", "equity", "position", "in", "Chiva", "that", "we", "were", "entitled", "to", "under", "the", "original", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s11", "idA": "886163_11_item1_p68_s5", "sentA": "We are entitled to receive initial 2011 license payments that total $1 million.", "sentB": "The terms of the Agreement call for us to receive a non-refundable license fee of $0.5 million.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "initial", "2011", "license", "payments", "that", "total", "$1", "million.", "<tag2>", "The", "terms", "of", "the", "Agreement", "call", "for", "us", "to", "receive", "a", "non-refundable", "license", "fee", "of", "$0.5", "million.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "initial", "2011", "license", "payments", "that", "total", "$1", "million."], "wordsB": ["The", "terms", "of", "the", "Agreement", "call", "for", "us", "to", "receive", "a", "non-refundable", "license", "fee", "of", "$0.5", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p5_s2", "idA": "886163_11_item1_p6_s0", "sentA": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Bristol-Myers Squibb, Onyx and AstraZeneca.", "sentB": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., Eli Lilly and Co., and The Medicines Company.", "type": 2, "words": ["<tag1>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Merck,", "Pfizer,", "Bristol-Myers", "Squibb,", "Onyx", "and", "AstraZeneca.", "<tag2>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Onyx", "Pharmaceuticals,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "The", "Medicines", "Company.", "<tag3>"], "wordsA": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Merck,", "Pfizer,", "Bristol-Myers", "Squibb,", "Onyx", "and", "AstraZeneca."], "wordsB": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Onyx", "Pharmaceuticals,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "The", "Medicines", "Company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p46_s0", "idA": "886163_11_item1_p74_s0", "sentA": "We employ various research laboratory methods to discover and conduct preclinical development of new chemical entities.", "sentB": "Technology We employ various research laboratory methods to discover and conduct preclinical development of new chemical entities.", "type": 2, "words": ["<tag1>", "We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities.", "<tag2>", "Technology", "We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities.", "<tag3>"], "wordsA": ["We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities."], "wordsB": ["Technology", "We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p20_s5", "idA": "886163_11_item1_p74_s1", "sentA": "These methods are performed either in our own laboratories or in those of contract research organizations under our direction.", "sentB": "We have multiple partnered programs in our portfolio that are either in or nearing the regulatory approval process.", "type": 2, "words": ["<tag1>", "These", "methods", "are", "performed", "either", "in", "our", "own", "laboratories", "or", "in", "those", "of", "contract", "research", "organizations", "under", "our", "direction.", "<tag2>", "We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process.", "<tag3>"], "wordsA": ["These", "methods", "are", "performed", "either", "in", "our", "own", "laboratories", "or", "in", "those", "of", "contract", "research", "organizations", "under", "our", "direction."], "wordsB": ["We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p25_s0", "idA": "886163_11_item1_p78_s5", "sentA": "In December 2002, we entered into a Captisol supply agreement with Hovione, under which Hovione is our exclusive supplier of Captisol and is restricted from supplying Captisol to third parties, so long as specified conditions are met.", "sentB": "Merck CAPTISOL Program, Molecule Undisclosed(Merck, Phase III, Undisclosed Indication) Ligand and Merck entered into a CAPTISOL supply agreement in June 2011 for an undisclosed Merck program.", "type": 2, "words": ["<tag1>", "In", "December", "2002,", "we", "entered", "into", "a", "Captisol", "supply", "agreement", "with", "Hovione,", "under", "which", "Hovione", "is", "our", "exclusive", "supplier", "of", "Captisol", "and", "is", "restricted", "from", "supplying", "Captisol", "to", "third", "parties,", "so", "long", "as", "specified", "conditions", "are", "met.", "<tag2>", "Merck", "CAPTISOL", "Program,", "Molecule", "Undisclosed(Merck,", "Phase", "III,", "Undisclosed", "Indication)", "Ligand", "and", "Merck", "entered", "into", "a", "CAPTISOL", "supply", "agreement", "in", "June", "2011", "for", "an", "undisclosed", "Merck", "program.", "<tag3>"], "wordsA": ["In", "December", "2002,", "we", "entered", "into", "a", "Captisol", "supply", "agreement", "with", "Hovione,", "under", "which", "Hovione", "is", "our", "exclusive", "supplier", "of", "Captisol", "and", "is", "restricted", "from", "supplying", "Captisol", "to", "third", "parties,", "so", "long", "as", "specified", "conditions", "are", "met."], "wordsB": ["Merck", "CAPTISOL", "Program,", "Molecule", "Undisclosed(Merck,", "Phase", "III,", "Undisclosed", "Indication)", "Ligand", "and", "Merck", "entered", "into", "a", "CAPTISOL", "supply", "agreement", "in", "June", "2011", "for", "an", "undisclosed", "Merck", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p54_s1", "idA": "886163_11_item1_p78_s5", "sentA": "In December 2002, we entered into a Captisol supply agreement with Hovione, under which Hovione is our exclusive supplier of Captisol and is restricted from supplying Captisol to third parties, so long as specified conditions are met.", "sentB": "In December 2002, CyDex entered into a CAPTISOL supply agreement with Hovione, under which Hovione is our exclusive supplier of CAPTISOL and is restricted from supplying CAPTISOL to third parties, so long as specified conditions are met.", "type": 2, "words": ["<tag1>", "In", "December", "2002,", "we", "entered", "into", "a", "Captisol", "supply", "agreement", "with", "Hovione,", "under", "which", "Hovione", "is", "our", "exclusive", "supplier", "of", "Captisol", "and", "is", "restricted", "from", "supplying", "Captisol", "to", "third", "parties,", "so", "long", "as", "specified", "conditions", "are", "met.", "<tag2>", "In", "December", "2002,", "CyDex", "entered", "into", "a", "CAPTISOL", "supply", "agreement", "with", "Hovione,", "under", "which", "Hovione", "is", "our", "exclusive", "supplier", "of", "CAPTISOL", "and", "is", "restricted", "from", "supplying", "CAPTISOL", "to", "third", "parties,", "so", "long", "as", "specified", "conditions", "are", "met.", "<tag3>"], "wordsA": ["In", "December", "2002,", "we", "entered", "into", "a", "Captisol", "supply", "agreement", "with", "Hovione,", "under", "which", "Hovione", "is", "our", "exclusive", "supplier", "of", "Captisol", "and", "is", "restricted", "from", "supplying", "Captisol", "to", "third", "parties,", "so", "long", "as", "specified", "conditions", "are", "met."], "wordsB": ["In", "December", "2002,", "CyDex", "entered", "into", "a", "CAPTISOL", "supply", "agreement", "with", "Hovione,", "under", "which", "Hovione", "is", "our", "exclusive", "supplier", "of", "CAPTISOL", "and", "is", "restricted", "from", "supplying", "CAPTISOL", "to", "third", "parties,", "so", "long", "as", "specified", "conditions", "are", "met."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s13", "idA": "886163_11_item1_p79_s2", "sentA": "In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione s assistance, qualify one or more alternate suppliers.", "sentB": "In the event of a termination prior to us supplying $2.5 million of CAPTISOL, we will refund the difference of the value of CAPTISOL supplied and the $2.5 million pre-payment.", "type": 2, "words": ["<tag1>", "In", "the", "event", "of", "a", "Captisol", "supply", "interruption,", "we", "are", "permitted", "to", "designate", "and,", "with", "Hovione", "s", "assistance,", "qualify", "one", "or", "more", "alternate", "suppliers.", "<tag2>", "In", "the", "event", "of", "a", "termination", "prior", "to", "us", "supplying", "$2.5", "million", "of", "CAPTISOL,", "we", "will", "refund", "the", "difference", "of", "the", "value", "of", "CAPTISOL", "supplied", "and", "the", "$2.5", "million", "pre-payment.", "<tag3>"], "wordsA": ["In", "the", "event", "of", "a", "Captisol", "supply", "interruption,", "we", "are", "permitted", "to", "designate", "and,", "with", "Hovione", "s", "assistance,", "qualify", "one", "or", "more", "alternate", "suppliers."], "wordsB": ["In", "the", "event", "of", "a", "termination", "prior", "to", "us", "supplying", "$2.5", "million", "of", "CAPTISOL,", "we", "will", "refund", "the", "difference", "of", "the", "value", "of", "CAPTISOL", "supplied", "and", "the", "$2.5", "million", "pre-payment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p55_s5", "idA": "886163_11_item1_p79_s6", "sentA": "Unless terminated earlier, the agreement will continue until the expiration in December 2019.", "sentB": "Unless terminated earlier, the agreement will continue until it expires in December 2019.", "type": 2, "words": ["<tag1>", "Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "the", "expiration", "in", "December", "2019.", "<tag2>", "Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019.", "<tag3>"], "wordsA": ["Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "the", "expiration", "in", "December", "2019."], "wordsB": ["Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p6_s1", "idA": "886163_11_item1_p7_s1", "sentA": "Our revenue consists mostly of license fees, milestones, royalties, and Captisol material sales from the partners that license our drugs and technologies.", "sentB": "Our revenue consists mostly of license fees, milestones, and royalties from the partners that license our drugs and technologies, and CAPTISOL material sales.", "type": 2, "words": ["<tag1>", "Our", "revenue", "consists", "mostly", "of", "license", "fees,", "milestones,", "royalties,", "and", "Captisol", "material", "sales", "from", "the", "partners", "that", "license", "our", "drugs", "and", "technologies.", "<tag2>", "Our", "revenue", "consists", "mostly", "of", "license", "fees,", "milestones,", "and", "royalties", "from", "the", "partners", "that", "license", "our", "drugs", "and", "technologies,", "and", "CAPTISOL", "material", "sales.", "<tag3>"], "wordsA": ["Our", "revenue", "consists", "mostly", "of", "license", "fees,", "milestones,", "royalties,", "and", "Captisol", "material", "sales", "from", "the", "partners", "that", "license", "our", "drugs", "and", "technologies."], "wordsB": ["Our", "revenue", "consists", "mostly", "of", "license", "fees,", "milestones,", "and", "royalties", "from", "the", "partners", "that", "license", "our", "drugs", "and", "technologies,", "and", "CAPTISOL", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p7_s1", "idA": "886163_11_item1_p8_s1", "sentA": "We have assembled a portfolio of over fifty fully-funded partner programs that are in all stages of development, from awaiting commercialization to preclinical research.", "sentB": "We have assembled a portfolio of over 50 fully-funded partner programs that are in all stages of development, from awaiting commercialization to preclinical research.", "type": 2, "words": ["<tag1>", "We", "have", "assembled", "a", "portfolio", "of", "over", "fifty", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "awaiting", "commercialization", "to", "preclinical", "research.", "<tag2>", "We", "have", "assembled", "a", "portfolio", "of", "over", "50", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "awaiting", "commercialization", "to", "preclinical", "research.", "<tag3>"], "wordsA": ["We", "have", "assembled", "a", "portfolio", "of", "over", "fifty", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "awaiting", "commercialization", "to", "preclinical", "research."], "wordsB": ["We", "have", "assembled", "a", "portfolio", "of", "over", "50", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "awaiting", "commercialization", "to", "preclinical", "research."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p58_s0", "idA": "886163_11_item1_p8_s6", "sentA": "We believe that focusing on discovery and early-stage drug development while benefiting from our partners proven development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.", "sentB": "A number of pharmaceutical and biotechnology companies are pursuing intracellular receptor-related approaches to drug discovery and development.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "focusing", "on", "discovery", "and", "early-stage", "drug", "development", "while", "benefiting", "from", "our", "partners", "proven", "development", "and", "commercialization", "expertise", "will", "reduce", "our", "internal", "expenses", "and", "allow", "us", "to", "have", "a", "larger", "number", "of", "drug", "candidates", "progress", "to", "later", "stages", "of", "drug", "development.", "<tag2>", "A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development.", "<tag3>"], "wordsA": ["We", "believe", "that", "focusing", "on", "discovery", "and", "early-stage", "drug", "development", "while", "benefiting", "from", "our", "partners", "proven", "development", "and", "commercialization", "expertise", "will", "reduce", "our", "internal", "expenses", "and", "allow", "us", "to", "have", "a", "larger", "number", "of", "drug", "candidates", "progress", "to", "later", "stages", "of", "drug", "development."], "wordsB": ["A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p12_s0", "idA": "886163_12_item1_p10_s0", "sentA": "PROMACTA (GSK) GSK s PROMACTA (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "Kyprolis is formulated with Ligand s Captisol and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "type": 2, "words": ["<tag1>", "PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag3>"], "wordsA": ["PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p42_s1", "idA": "886163_12_item1_p10_s0", "sentA": "PROMACTA (GSK) GSK s PROMACTA (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "In the first half of 2013, Rib-X plans to initiate the first of two planned Phase III clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "type": 2, "words": ["<tag1>", "PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "In", "the", "first", "half", "of", "2013,", "Rib-X", "plans", "to", "initiate", "the", "first", "of", "two", "planned", "Phase", "III", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag3>"], "wordsA": ["PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["In", "the", "first", "half", "of", "2013,", "Rib-X", "plans", "to", "initiate", "the", "first", "of", "two", "planned", "Phase", "III", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p6_s0", "idA": "886163_12_item1_p10_s0", "sentA": "PROMACTA (GSK) GSK s PROMACTA (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "Promacta (GSK) GSK s Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP.", "type": 2, "words": ["<tag1>", "PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "Promacta", "(GSK)", "GSK", "s", "Promacta", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP.", "<tag3>"], "wordsA": ["PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["Promacta", "(GSK)", "GSK", "s", "Promacta", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p8_s0", "idA": "886163_12_item1_p10_s0", "sentA": "PROMACTA (GSK) GSK s PROMACTA (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "In May 2012, GSK submitted a variation to the existing Marketing Authorization Application to the European Medicines Agency for Promacta/Revolade as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and during interferon-based therapy.", "type": 2, "words": ["<tag1>", "PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "In", "May", "2012,", "GSK", "submitted", "a", "variation", "to", "the", "existing", "Marketing", "Authorization", "Application", "to", "the", "European", "Medicines", "Agency", "for", "Promacta/Revolade", "as", "a", "treatment", "for", "thrombocytopenia", "in", "adult", "patients", "with", "chronic", "hepatitis", "C", "infection", "to", "enable", "the", "initiation", "of", "interferon-based", "therapy", "and", "during", "interferon-based", "therapy.", "<tag3>"], "wordsA": ["PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["In", "May", "2012,", "GSK", "submitted", "a", "variation", "to", "the", "existing", "Marketing", "Authorization", "Application", "to", "the", "European", "Medicines", "Agency", "for", "Promacta/Revolade", "as", "a", "treatment", "for", "thrombocytopenia", "in", "adult", "patients", "with", "chronic", "hepatitis", "C", "infection", "to", "enable", "the", "initiation", "of", "interferon-based", "therapy", "and", "during", "interferon-based", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p9_s0", "idA": "886163_12_item1_p10_s0", "sentA": "PROMACTA (GSK) GSK s PROMACTA (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "In November 2012, the FDA approved Promacta for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.", "type": 2, "words": ["<tag1>", "PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "In", "November", "2012,", "the", "FDA", "approved", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "(low", "blood", "platelet", "counts)", "in", "patients", "with", "chronic", "hepatitis", "C", "to", "allow", "them", "to", "initiate", "and", "maintain", "interferon-based", "therapy.", "<tag3>"], "wordsA": ["PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["In", "November", "2012,", "the", "FDA", "approved", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "(low", "blood", "platelet", "counts)", "in", "patients", "with", "chronic", "hepatitis", "C", "to", "allow", "them", "to", "initiate", "and", "maintain", "interferon-based", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p6_s1", "idA": "886163_12_item1_p11_s0", "sentA": "chronic immune (idiopathic) thrombocytopenic purpura, or ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "In late 2008, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of Promacta for the treatment of thrombocytopenia in patients with chronic ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "type": 2, "words": ["<tag1>", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag3>"], "wordsA": ["chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p7_s0", "idA": "886163_12_item1_p12_s0", "sentA": "In March 2010, GSK received approval for REVOLADE (eltrombopag/PROMACTA) from the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) and in November 2010 from the Japanese Ministry of Health, Labour and Welfare for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic ITP.", "sentB": "In 2010, GSK received approval for Revolade (eltrombopag/Promacta) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and from the Japanese Ministry of Health, Labour and Welfare for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic ITP.", "type": 2, "words": ["<tag1>", "In", "March", "2010,", "GSK", "received", "approval", "for", "REVOLADE", "(eltrombopag/PROMACTA)", "from", "the", "European", "Medicines", "Agency", "s", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "and", "in", "November", "2010", "from", "the", "Japanese", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "for", "the", "oral", "treatment", "of", "thrombocytopenia", "(reduced", "platelet", "count)", "in", "adults", "with", "the", "blood", "disorder", "chronic", "ITP.", "<tag2>", "In", "2010,", "GSK", "received", "approval", "for", "Revolade", "(eltrombopag/Promacta)", "from", "the", "European", "Medicines", "Agency's", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "and", "from", "the", "Japanese", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "for", "the", "oral", "treatment", "of", "thrombocytopenia", "(reduced", "platelet", "count)", "in", "adults", "with", "the", "blood", "disorder", "chronic", "ITP.", "<tag3>"], "wordsA": ["In", "March", "2010,", "GSK", "received", "approval", "for", "REVOLADE", "(eltrombopag/PROMACTA)", "from", "the", "European", "Medicines", "Agency", "s", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "and", "in", "November", "2010", "from", "the", "Japanese", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "for", "the", "oral", "treatment", "of", "thrombocytopenia", "(reduced", "platelet", "count)", "in", "adults", "with", "the", "blood", "disorder", "chronic", "ITP."], "wordsB": ["In", "2010,", "GSK", "received", "approval", "for", "Revolade", "(eltrombopag/Promacta)", "from", "the", "European", "Medicines", "Agency's", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "and", "from", "the", "Japanese", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "for", "the", "oral", "treatment", "of", "thrombocytopenia", "(reduced", "platelet", "count)", "in", "adults", "with", "the", "blood", "disorder", "chronic", "ITP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p10_s0", "idA": "886163_12_item1_p12_s1", "sentA": "Eltrombopag is also authorized for use in all 27 member states of the European Union, as well as India, Australia, Ireland, Japan, Taiwan, Turkey, Singapore, Kuwait, Chile, Russia and Bahrain under the trade name REVOLADE.", "sentB": "Promacta is authorized for use in 92 countries.", "type": 2, "words": ["<tag1>", "Eltrombopag", "is", "also", "authorized", "for", "use", "in", "all", "27", "member", "states", "of", "the", "European", "Union,", "as", "well", "as", "India,", "Australia,", "Ireland,", "Japan,", "Taiwan,", "Turkey,", "Singapore,", "Kuwait,", "Chile,", "Russia", "and", "Bahrain", "under", "the", "trade", "name", "REVOLADE.", "<tag2>", "Promacta", "is", "authorized", "for", "use", "in", "92", "countries.", "<tag3>"], "wordsA": ["Eltrombopag", "is", "also", "authorized", "for", "use", "in", "all", "27", "member", "states", "of", "the", "European", "Union,", "as", "well", "as", "India,", "Australia,", "Ireland,", "Japan,", "Taiwan,", "Turkey,", "Singapore,", "Kuwait,", "Chile,", "Russia", "and", "Bahrain", "under", "the", "trade", "name", "REVOLADE."], "wordsB": ["Promacta", "is", "authorized", "for", "use", "in", "92", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p31_s2", "idA": "886163_12_item1_p13_s0", "sentA": "As a result of the regulatory approvals of PROMACTA, pursuant to the terms of a license agreement with GSK, we are entitled to receive tiered royalties on annual net sales of PROMACTA.", "sentB": "Under our collaboration and license agreement with Merck, we are entitled to receive future milestones and royalties.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "the", "regulatory", "approvals", "of", "PROMACTA,", "pursuant", "to", "the", "terms", "of", "a", "license", "agreement", "with", "GSK,", "we", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "PROMACTA.", "<tag2>", "Under", "our", "collaboration", "and", "license", "agreement", "with", "Merck,", "we", "are", "entitled", "to", "receive", "future", "milestones", "and", "royalties.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "regulatory", "approvals", "of", "PROMACTA,", "pursuant", "to", "the", "terms", "of", "a", "license", "agreement", "with", "GSK,", "we", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "PROMACTA."], "wordsB": ["Under", "our", "collaboration", "and", "license", "agreement", "with", "Merck,", "we", "are", "entitled", "to", "receive", "future", "milestones", "and", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p14_s0", "idA": "886163_12_item1_p14_s0", "sentA": "We currently receive royalty revenues from Pfizer, Inc. for sales from the pain therapeutic AVINZA .", "sentB": "Avinza (Pfizer) We currently receive royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza .", "type": 2, "words": ["<tag1>", "We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.", "for", "sales", "from", "the", "pain", "therapeutic", "AVINZA", ".", "<tag2>", "Avinza", "(Pfizer)", "We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.,", "or", "Pfizer,", "for", "sales", "of", "the", "pain", "therapeutic", "Avinza", ".", "<tag3>"], "wordsA": ["We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.", "for", "sales", "from", "the", "pain", "therapeutic", "AVINZA", "."], "wordsB": ["Avinza", "(Pfizer)", "We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.,", "or", "Pfizer,", "for", "sales", "of", "the", "pain", "therapeutic", "Avinza", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p14_s1", "idA": "886163_12_item1_p14_s1", "sentA": "In February 2007, we completed the sale of our AVINZA product line to King.", "sentB": "In February 2007, we completed the sale of our Avinza product line to King Pharmaceuticals (or King).", "type": 2, "words": ["<tag1>", "In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "AVINZA", "product", "line", "to", "King.", "<tag2>", "In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "Avinza", "product", "line", "to", "King", "Pharmaceuticals", "(or", "King).", "<tag3>"], "wordsA": ["In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "AVINZA", "product", "line", "to", "King."], "wordsB": ["In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "Avinza", "product", "line", "to", "King", "Pharmaceuticals", "(or", "King)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p31_s1", "idA": "886163_12_item1_p14_s2", "sentA": "As a result of the sale, we receive royalties on the net sales of AVINZA through 2017.", "sentB": "As a result, we received a $2 million milestone payment upon initiation of the clinical study.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "the", "sale,", "we", "receive", "royalties", "on", "the", "net", "sales", "of", "AVINZA", "through", "2017.", "<tag2>", "As", "a", "result,", "we", "received", "a", "$2", "million", "milestone", "payment", "upon", "initiation", "of", "the", "clinical", "study.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "sale,", "we", "receive", "royalties", "on", "the", "net", "sales", "of", "AVINZA", "through", "2017."], "wordsB": ["As", "a", "result,", "we", "received", "a", "$2", "million", "milestone", "payment", "upon", "initiation", "of", "the", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p15_s0", "idA": "886163_12_item1_p15_s0", "sentA": "In October 2010, Pfizer announced the acquisition of King Pharmaceuticals.", "sentB": "In October 2010, Pfizer announced the acquisition of King.", "type": 2, "words": ["<tag1>", "In", "October", "2010,", "Pfizer", "announced", "the", "acquisition", "of", "King", "Pharmaceuticals.", "<tag2>", "In", "October", "2010,", "Pfizer", "announced", "the", "acquisition", "of", "King.", "<tag3>"], "wordsA": ["In", "October", "2010,", "Pfizer", "announced", "the", "acquisition", "of", "King", "Pharmaceuticals."], "wordsB": ["In", "October", "2010,", "Pfizer", "announced", "the", "acquisition", "of", "King."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p16_s0", "idA": "886163_12_item1_p16_s0", "sentA": "In October 2010, we announced that our partner Pfizer, Inc. launched VIVIANT (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "type": 2, "words": ["<tag1>", "In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag3>"], "wordsA": ["In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p20_s0", "idA": "886163_12_item1_p16_s0", "sentA": "In October 2010, we announced that our partner Pfizer, Inc. launched VIVIANT (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "type": 2, "words": ["<tag1>", "In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag3>"], "wordsA": ["In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p17_s0", "idA": "886163_12_item1_p17_s0", "sentA": "VIVIANT was approved in April 2009 by the European Commission (under the trade name CONBRIZA) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.", "sentB": "Viviant was approved in 2009 by the European Commission (under the trade name Conbriza) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.", "type": 2, "words": ["<tag1>", "VIVIANT", "was", "approved", "in", "April", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "CONBRIZA)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture.", "<tag2>", "Viviant", "was", "approved", "in", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "Conbriza)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture.", "<tag3>"], "wordsA": ["VIVIANT", "was", "approved", "in", "April", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "CONBRIZA)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture."], "wordsB": ["Viviant", "was", "approved", "in", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "Conbriza)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p8_s1", "idA": "886163_12_item1_p17_s0", "sentA": "VIVIANT was approved in April 2009 by the European Commission (under the trade name CONBRIZA) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.", "sentB": "That application is currently under review by the European Medicines Agency.", "type": 2, "words": ["<tag1>", "VIVIANT", "was", "approved", "in", "April", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "CONBRIZA)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture.", "<tag2>", "That", "application", "is", "currently", "under", "review", "by", "the", "European", "Medicines", "Agency.", "<tag3>"], "wordsA": ["VIVIANT", "was", "approved", "in", "April", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "CONBRIZA)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture."], "wordsB": ["That", "application", "is", "currently", "under", "review", "by", "the", "European", "Medicines", "Agency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p10_s1", "idA": "886163_12_item1_p19_s0", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "We are entitled to receive tiered royalties on annual net sales of Promacta.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "Promacta.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "Promacta."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p30_s0", "idA": "886163_12_item1_p19_s0", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "Former license holders are entitled to receive 15% of the proceeds received upon sale of the securities.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "Former", "license", "holders", "are", "entitled", "to", "receive", "15%", "of", "the", "proceeds", "received", "upon", "sale", "of", "the", "securities.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["Former", "license", "holders", "are", "entitled", "to", "receive", "15%", "of", "the", "proceeds", "received", "upon", "sale", "of", "the", "securities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p18_s3", "idA": "886163_12_item1_p19_s1", "sentA": "Any such royalties may be subject to reduction or offset for past milestone payments and/or may be subject to other terms and conditions set forth in our agreement.", "sentB": "Any such royalties may be subject to reduction or offset for past milestone payments and/or may be subject to other terms and conditions set forth in our agreement with Pfizer.", "type": 2, "words": ["<tag1>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement.", "<tag2>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer.", "<tag3>"], "wordsA": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement."], "wordsB": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p19_s0", "idA": "886163_12_item1_p20_s0", "sentA": "In 2006, CyDex outlicensed Nexterone , an injectable formulation combining amiodarone and CAPTISOL , to Baxter International Baxter (formerly Prism Pharmaceuticals, Inc.).", "sentB": "In 2006, Ligand outlicensed Nexterone, an injectable formulation combining amiodarone and Captisol, to Baxter International, or Baxter (formerly Prism Pharmaceuticals, Inc.).", "type": 2, "words": ["<tag1>", "In", "2006,", "CyDex", "outlicensed", "Nexterone", ",", "an", "injectable", "formulation", "combining", "amiodarone", "and", "CAPTISOL", ",", "to", "Baxter", "International", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.).", "<tag2>", "In", "2006,", "Ligand", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "or", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.).", "<tag3>"], "wordsA": ["In", "2006,", "CyDex", "outlicensed", "Nexterone", ",", "an", "injectable", "formulation", "combining", "amiodarone", "and", "CAPTISOL", ",", "to", "Baxter", "International", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.)."], "wordsB": ["In", "2006,", "Ligand", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "or", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p19_s4", "idA": "886163_12_item1_p20_s3", "sentA": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through March 2029.", "sentB": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through early 2029.", "type": 2, "words": ["<tag1>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029.", "<tag2>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029.", "<tag3>"], "wordsA": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "March", "2029."], "wordsB": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p11_s1", "idA": "886163_12_item1_p20_s4", "sentA": "On November 19, 2010, Prism, who was subsequently acquired by Baxter, received marketing approval from the FDA for Nexterone and launched Nexterone in the United States in 2011.", "sentB": "In July 2012, Onyx received accelerated approval from the FDA for Kyprolis (Carfilzomib) for injection.", "type": 2, "words": ["<tag1>", "On", "November", "19,", "2010,", "Prism,", "who", "was", "subsequently", "acquired", "by", "Baxter,", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "launched", "Nexterone", "in", "the", "United", "States", "in", "2011.", "<tag2>", "In", "July", "2012,", "Onyx", "received", "accelerated", "approval", "from", "the", "FDA", "for", "Kyprolis", "(Carfilzomib)", "for", "injection.", "<tag3>"], "wordsA": ["On", "November", "19,", "2010,", "Prism,", "who", "was", "subsequently", "acquired", "by", "Baxter,", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "launched", "Nexterone", "in", "the", "United", "States", "in", "2011."], "wordsB": ["In", "July", "2012,", "Onyx", "received", "accelerated", "approval", "from", "the", "FDA", "for", "Kyprolis", "(Carfilzomib)", "for", "injection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p19_s2", "idA": "886163_12_item1_p20_s4", "sentA": "On November 19, 2010, Prism, who was subsequently acquired by Baxter, received marketing approval from the FDA for Nexterone and launched Nexterone in the United States in 2011.", "sentB": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "type": 2, "words": ["<tag1>", "On", "November", "19,", "2010,", "Prism,", "who", "was", "subsequently", "acquired", "by", "Baxter,", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "launched", "Nexterone", "in", "the", "United", "States", "in", "2011.", "<tag2>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag3>"], "wordsA": ["On", "November", "19,", "2010,", "Prism,", "who", "was", "subsequently", "acquired", "by", "Baxter,", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "launched", "Nexterone", "in", "the", "United", "States", "in", "2011."], "wordsB": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p21_s0", "idA": "886163_12_item1_p22_s0", "sentA": "GSK is also conducting Phase II clinical studies for oncology-related thrombocytopenia in patients with solid tumors, sarcoma and advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS.", "sentB": "Promacta (GSK, Oncology) GSK is conducting Phase II clinical studies of Promacta for oncology-related thrombocytopenia in patients with solid tumors, Myelodysplastic Syndrome (MDS), or Secondary Acute Myeloid Leukemia (AML) after MDS.", "type": 2, "words": ["<tag1>", "GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS.", "<tag2>", "Promacta", "(GSK,", "Oncology)", "GSK", "is", "conducting", "Phase", "II", "clinical", "studies", "of", "Promacta", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "Myelodysplastic", "Syndrome", "(MDS),", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "(AML)", "after", "MDS.", "<tag3>"], "wordsA": ["GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS."], "wordsB": ["Promacta", "(GSK,", "Oncology)", "GSK", "is", "conducting", "Phase", "II", "clinical", "studies", "of", "Promacta", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "Myelodysplastic", "Syndrome", "(MDS),", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "(AML)", "after", "MDS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p21_s1", "idA": "886163_12_item1_p22_s0", "sentA": "GSK is also conducting Phase II clinical studies for oncology-related thrombocytopenia in patients with solid tumors, sarcoma and advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS.", "sentB": "Promacta is also in Phase II studies for patients with Aplastic Anemia.", "type": 2, "words": ["<tag1>", "GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS.", "<tag2>", "Promacta", "is", "also", "in", "Phase", "II", "studies", "for", "patients", "with", "Aplastic", "Anemia.", "<tag3>"], "wordsA": ["GSK", "is", "also", "conducting", "Phase", "II", "clinical", "studies", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "sarcoma", "and", "advanced", "Myelodysplastic", "Syndrome", "(MDS)", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "after", "MDS."], "wordsB": ["Promacta", "is", "also", "in", "Phase", "II", "studies", "for", "patients", "with", "Aplastic", "Anemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p11_s0", "idA": "886163_12_item1_p23_s0", "sentA": "Carfilzomib (Onyx, Phase III/NDA, Multiple Myeloma) CyDex and Onyx Pharmaceuticals (formerly Proteolix) entered into a collaboration in 2005 to develop the CAPTISOL-enabled IV formulation of carfilzomib for refractory multiple myeloma.", "sentB": "Kyprolis (Onyx, Phase III/NDA, Multiple Myeloma) Ligand (formerly CyDex) and Onyx Pharmaceuticals (formerly Proteolix) entered into a collaboration in 2005 to develop the Captisol-enabled IV formulation of Carfilzomib for refractory multiple myeloma.", "type": 2, "words": ["<tag1>", "Carfilzomib", "(Onyx,", "Phase", "III/NDA,", "Multiple", "Myeloma)", "CyDex", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix)", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "CAPTISOL-enabled", "IV", "formulation", "of", "carfilzomib", "for", "refractory", "multiple", "myeloma.", "<tag2>", "Kyprolis", "(Onyx,", "Phase", "III/NDA,", "Multiple", "Myeloma)", "Ligand", "(formerly", "CyDex)", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix)", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "Captisol-enabled", "IV", "formulation", "of", "Carfilzomib", "for", "refractory", "multiple", "myeloma.", "<tag3>"], "wordsA": ["Carfilzomib", "(Onyx,", "Phase", "III/NDA,", "Multiple", "Myeloma)", "CyDex", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix)", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "CAPTISOL-enabled", "IV", "formulation", "of", "carfilzomib", "for", "refractory", "multiple", "myeloma."], "wordsB": ["Kyprolis", "(Onyx,", "Phase", "III/NDA,", "Multiple", "Myeloma)", "Ligand", "(formerly", "CyDex)", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix)", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "Captisol-enabled", "IV", "formulation", "of", "Carfilzomib", "for", "refractory", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p52_s4", "idA": "886163_12_item1_p23_s3", "sentA": "We are eligible to receive milestones, royalties and CAPTISOL material sales revenue from this program.", "sentB": "We are preparing to file an IND for this program.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "milestones,", "royalties", "and", "CAPTISOL", "material", "sales", "revenue", "from", "this", "program.", "<tag2>", "We", "are", "preparing", "to", "file", "an", "IND", "for", "this", "program.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "milestones,", "royalties", "and", "CAPTISOL", "material", "sales", "revenue", "from", "this", "program."], "wordsB": ["We", "are", "preparing", "to", "file", "an", "IND", "for", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p31_s0", "idA": "886163_12_item1_p24_s0", "sentA": "In October 2010, we announced that our partner Pfizer, Inc. launched VIVIANT (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "In October 2012, our licensee, Merck, initiated a Phase IIb/III adaptive clinical trial for Dinaciclib for the treatment of patients with refractory chronic lymphocytic leukemia (CLL).", "type": 2, "words": ["<tag1>", "In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "In", "October", "2012,", "our", "licensee,", "Merck,", "initiated", "a", "Phase", "IIb/III", "adaptive", "clinical", "trial", "for", "Dinaciclib", "for", "the", "treatment", "of", "patients", "with", "refractory", "chronic", "lymphocytic", "leukemia", "(CLL).", "<tag3>"], "wordsA": ["In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["In", "October", "2012,", "our", "licensee,", "Merck,", "initiated", "a", "Phase", "IIb/III", "adaptive", "clinical", "trial", "for", "Dinaciclib", "for", "the", "treatment", "of", "patients", "with", "refractory", "chronic", "lymphocytic", "leukemia", "(CLL)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p20_s1", "idA": "886163_12_item1_p24_s1", "sentA": "Pfizer is now combining VIVIANT with Premarin to create a combination therapy called Aprela for the treatment of post-menopausal symptoms in women.", "sentB": "Pfizer has combined Viviant with Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women.", "type": 2, "words": ["<tag1>", "Pfizer", "is", "now", "combining", "VIVIANT", "with", "Premarin", "to", "create", "a", "combination", "therapy", "called", "Aprela", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag2>", "Pfizer", "has", "combined", "Viviant", "with", "Premarin", "to", "create", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag3>"], "wordsA": ["Pfizer", "is", "now", "combining", "VIVIANT", "with", "Premarin", "to", "create", "a", "combination", "therapy", "called", "Aprela", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "wordsB": ["Pfizer", "has", "combined", "Viviant", "with", "Premarin", "to", "create", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p20_s2", "idA": "886163_12_item1_p24_s2", "sentA": "Pfizer has completed PIII studies of Aprela and we expect an NDA filing in 2012.", "sentB": "Pfizer has completed Phase III studies of bazedoxifene and filed an approval submission with the FDA and EMA in 2012.", "type": 2, "words": ["<tag1>", "Pfizer", "has", "completed", "PIII", "studies", "of", "Aprela", "and", "we", "expect", "an", "NDA", "filing", "in", "2012.", "<tag2>", "Pfizer", "has", "completed", "Phase", "III", "studies", "of", "bazedoxifene", "and", "filed", "an", "approval", "submission", "with", "the", "FDA", "and", "EMA", "in", "2012.", "<tag3>"], "wordsA": ["Pfizer", "has", "completed", "PIII", "studies", "of", "Aprela", "and", "we", "expect", "an", "NDA", "filing", "in", "2012."], "wordsB": ["Pfizer", "has", "completed", "Phase", "III", "studies", "of", "bazedoxifene", "and", "filed", "an", "approval", "submission", "with", "the", "FDA", "and", "EMA", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p9_s2", "idA": "886163_12_item1_p24_s3", "sentA": "We are entitled to receive tiered royalties on all net sales of bazedoxifene, whether alone or in combination with other products.", "sentB": "Promacta in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "all", "net", "sales", "of", "bazedoxifene,", "whether", "alone", "or", "in", "combination", "with", "other", "products.", "<tag2>", "Promacta", "in", "combination", "with", "interferon-based", "therapy", "has", "been", "shown", "to", "improve", "a", "patient's", "chance", "of", "achieving", "a", "sustained", "virologic", "response", "(SVR)", "or", "viral", "cure.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "all", "net", "sales", "of", "bazedoxifene,", "whether", "alone", "or", "in", "combination", "with", "other", "products."], "wordsB": ["Promacta", "in", "combination", "with", "interferon-based", "therapy", "has", "been", "shown", "to", "improve", "a", "patient's", "chance", "of", "achieving", "a", "sustained", "virologic", "response", "(SVR)", "or", "viral", "cure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p20_s5", "idA": "886163_12_item1_p24_s4", "sentA": "Any such royalties may be subject to reduction or offset against past milestone payments and/or may be subject to other terms and conditions set forth in our agreement.", "sentB": "Any such royalties may be subject to reduction or offset against past milestone payments and/or may be subject to other terms and conditions set forth in our agreement with Pfizer.", "type": 2, "words": ["<tag1>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement.", "<tag2>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer.", "<tag3>"], "wordsA": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement."], "wordsB": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p24_s2", "idA": "886163_12_item1_p25_s2", "sentA": "Financial terms of the relationship remain undisclosed, but we expect to generate substantial material sales revenue through the supply of CAPTISOL for this program.", "sentB": "Financial terms of the relationship remain undisclosed, but we expect to generate revenue through the supply of Captisol for this program.", "type": 2, "words": ["<tag1>", "Financial", "terms", "of", "the", "relationship", "remain", "undisclosed,", "but", "we", "expect", "to", "generate", "substantial", "material", "sales", "revenue", "through", "the", "supply", "of", "CAPTISOL", "for", "this", "program.", "<tag2>", "Financial", "terms", "of", "the", "relationship", "remain", "undisclosed,", "but", "we", "expect", "to", "generate", "revenue", "through", "the", "supply", "of", "Captisol", "for", "this", "program.", "<tag3>"], "wordsA": ["Financial", "terms", "of", "the", "relationship", "remain", "undisclosed,", "but", "we", "expect", "to", "generate", "substantial", "material", "sales", "revenue", "through", "the", "supply", "of", "CAPTISOL", "for", "this", "program."], "wordsB": ["Financial", "terms", "of", "the", "relationship", "remain", "undisclosed,", "but", "we", "expect", "to", "generate", "revenue", "through", "the", "supply", "of", "Captisol", "for", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p22_s0", "idA": "886163_12_item1_p25_s3", "sentA": "We announced in June 2011 that we had licensed the full world-wide rights to our CAPTISOL -enabled clopidogrel program to The Medicines Company.", "sentB": "In March 2013, we licensed the full world-wide rights to Captisol-enabled melphalan IV to Spectrum Pharmaceuticals, Inc.", "type": 2, "words": ["<tag1>", "We", "announced", "in", "June", "2011", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "our", "CAPTISOL", "-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company.", "<tag2>", "In", "March", "2013,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "Captisol-enabled", "melphalan", "IV", "to", "Spectrum", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["We", "announced", "in", "June", "2011", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "our", "CAPTISOL", "-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company."], "wordsB": ["In", "March", "2013,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "Captisol-enabled", "melphalan", "IV", "to", "Spectrum", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p24_s3", "idA": "886163_12_item1_p25_s3", "sentA": "We announced in June 2011 that we had licensed the full world-wide rights to our CAPTISOL -enabled clopidogrel program to The Medicines Company.", "sentB": "In June 2011, we licensed the full world-wide rights to our Captisol-enabled clopidogrel program to The Medicines Company.", "type": 2, "words": ["<tag1>", "We", "announced", "in", "June", "2011", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "our", "CAPTISOL", "-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company.", "<tag2>", "In", "June", "2011,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "our", "Captisol-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company.", "<tag3>"], "wordsA": ["We", "announced", "in", "June", "2011", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "our", "CAPTISOL", "-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company."], "wordsB": ["In", "June", "2011,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "our", "Captisol-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p49_s0", "idA": "886163_12_item1_p26_s0", "sentA": "Clopidogrel is the active ingredient in PLAVIX , the world s leading anti-platelet medication which is currently only available in an oral formulation.", "sentB": "Topiramate is sold under the trade name Topamax and is currently only available in an oral formulation.", "type": 2, "words": ["<tag1>", "Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", ",", "the", "world", "s", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation.", "<tag2>", "Topiramate", "is", "sold", "under", "the", "trade", "name", "Topamax", "and", "is", "currently", "only", "available", "in", "an", "oral", "formulation.", "<tag3>"], "wordsA": ["Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", ",", "the", "world", "s", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation."], "wordsB": ["Topiramate", "is", "sold", "under", "the", "trade", "name", "Topamax", "and", "is", "currently", "only", "available", "in", "an", "oral", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p49_s1", "idA": "886163_12_item1_p26_s1", "sentA": "The CAPTISOL-enabled clopidogrel formulation is designed to provide an intravenous option in situations where the administration of oral platelet inhibitors is not feasible or desirable.", "sentB": "The Captisol-enabled topiramate formulation is designed to provide an intravenous or intramuscular option for hospitalized epilepsy patients where oral topiramate is not an option.", "type": 2, "words": ["<tag1>", "The", "CAPTISOL-enabled", "clopidogrel", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "option", "in", "situations", "where", "the", "administration", "of", "oral", "platelet", "inhibitors", "is", "not", "feasible", "or", "desirable.", "<tag2>", "The", "Captisol-enabled", "topiramate", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "or", "intramuscular", "option", "for", "hospitalized", "epilepsy", "patients", "where", "oral", "topiramate", "is", "not", "an", "option.", "<tag3>"], "wordsA": ["The", "CAPTISOL-enabled", "clopidogrel", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "option", "in", "situations", "where", "the", "administration", "of", "oral", "platelet", "inhibitors", "is", "not", "feasible", "or", "desirable."], "wordsB": ["The", "Captisol-enabled", "topiramate", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "or", "intramuscular", "option", "for", "hospitalized", "epilepsy", "patients", "where", "oral", "topiramate", "is", "not", "an", "option."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p26_s0", "idA": "886163_12_item1_p27_s0", "sentA": "We received an upfront payment of $1.8 million, and are eligible to receive up to $22 million in milestones and up to double digit royalties on annual worldwide net sales.", "sentB": "We received an upfront payment of $1.8 million, $0.9 million of which was remitted to the former CyDex shareholders.", "type": 2, "words": ["<tag1>", "We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "and", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "milestones", "and", "up", "to", "double", "digit", "royalties", "on", "annual", "worldwide", "net", "sales.", "<tag2>", "We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "$0.9", "million", "of", "which", "was", "remitted", "to", "the", "former", "CyDex", "shareholders.", "<tag3>"], "wordsA": ["We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "and", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "milestones", "and", "up", "to", "double", "digit", "royalties", "on", "annual", "worldwide", "net", "sales."], "wordsB": ["We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "$0.9", "million", "of", "which", "was", "remitted", "to", "the", "former", "CyDex", "shareholders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p26_s1", "idA": "886163_12_item1_p27_s0", "sentA": "We received an upfront payment of $1.8 million, and are eligible to receive up to $22 million in milestones and up to double digit royalties on annual worldwide net sales.", "sentB": "We are eligible to receive up to $8 million in milestones, net of amounts owed and royalties on annual worldwide net sales.", "type": 2, "words": ["<tag1>", "We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "and", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "milestones", "and", "up", "to", "double", "digit", "royalties", "on", "annual", "worldwide", "net", "sales.", "<tag2>", "We", "are", "eligible", "to", "receive", "up", "to", "$8", "million", "in", "milestones,", "net", "of", "amounts", "owed", "and", "royalties", "on", "annual", "worldwide", "net", "sales.", "<tag3>"], "wordsA": ["We", "received", "an", "upfront", "payment", "of", "$1.8", "million,", "and", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "milestones", "and", "up", "to", "double", "digit", "royalties", "on", "annual", "worldwide", "net", "sales."], "wordsB": ["We", "are", "eligible", "to", "receive", "up", "to", "$8", "million", "in", "milestones,", "net", "of", "amounts", "owed", "and", "royalties", "on", "annual", "worldwide", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p26_s2", "idA": "886163_12_item1_p27_s1", "sentA": "In addition, we will also supply both the clinical and commercial requirements of CAPTISOL for this program, and if the intravenous formulation is approved for commercialization, we will be the exclusive supplier of the product.", "sentB": "In addition, we will also supply both the clinical and commercial requirements of Captisol for this program, now known as MDCO-157, and if the intravenous formulation is approved for commercialization, we will be the exclusive supplier of Captisol for the product.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "will", "also", "supply", "both", "the", "clinical", "and", "commercial", "requirements", "of", "CAPTISOL", "for", "this", "program,", "and", "if", "the", "intravenous", "formulation", "is", "approved", "for", "commercialization,", "we", "will", "be", "the", "exclusive", "supplier", "of", "the", "product.", "<tag2>", "In", "addition,", "we", "will", "also", "supply", "both", "the", "clinical", "and", "commercial", "requirements", "of", "Captisol", "for", "this", "program,", "now", "known", "as", "MDCO-157,", "and", "if", "the", "intravenous", "formulation", "is", "approved", "for", "commercialization,", "we", "will", "be", "the", "exclusive", "supplier", "of", "Captisol", "for", "the", "product.", "<tag3>"], "wordsA": ["In", "addition,", "we", "will", "also", "supply", "both", "the", "clinical", "and", "commercial", "requirements", "of", "CAPTISOL", "for", "this", "program,", "and", "if", "the", "intravenous", "formulation", "is", "approved", "for", "commercialization,", "we", "will", "be", "the", "exclusive", "supplier", "of", "the", "product."], "wordsB": ["In", "addition,", "we", "will", "also", "supply", "both", "the", "clinical", "and", "commercial", "requirements", "of", "Captisol", "for", "this", "program,", "now", "known", "as", "MDCO-157,", "and", "if", "the", "intravenous", "formulation", "is", "approved", "for", "commercialization,", "we", "will", "be", "the", "exclusive", "supplier", "of", "Captisol", "for", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p30_s3", "idA": "886163_12_item1_p27_s2", "sentA": "We recognized $0.9 million of the upfront payment as revenue and under the terms of our CyDex contingent value rights agreement, remitted $0.9 million to CyDex shareholders.", "sentB": "We will remit $0.2 million to former license holders under the terms of a previous license agreement for RE-021.", "type": 2, "words": ["<tag1>", "We", "recognized", "$0.9", "million", "of", "the", "upfront", "payment", "as", "revenue", "and", "under", "the", "terms", "of", "our", "CyDex", "contingent", "value", "rights", "agreement,", "remitted", "$0.9", "million", "to", "CyDex", "shareholders.", "<tag2>", "We", "will", "remit", "$0.2", "million", "to", "former", "license", "holders", "under", "the", "terms", "of", "a", "previous", "license", "agreement", "for", "RE-021.", "<tag3>"], "wordsA": ["We", "recognized", "$0.9", "million", "of", "the", "upfront", "payment", "as", "revenue", "and", "under", "the", "terms", "of", "our", "CyDex", "contingent", "value", "rights", "agreement,", "remitted", "$0.9", "million", "to", "CyDex", "shareholders."], "wordsB": ["We", "will", "remit", "$0.2", "million", "to", "former", "license", "holders", "under", "the", "terms", "of", "a", "previous", "license", "agreement", "for", "RE-021."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p27_s0", "idA": "886163_12_item1_p27_s3", "sentA": "In February 2012, we announced that we had licensed the full world-wide rights to DARA (a Dual Acting Receptor Antagonist of Angiotension and Endothelin receptors).", "sentB": "In early 2012, we licensed the world-wide rights to RE-021 (formerly known as DARA-a Dual Acting Receptor Antagonist of Angiotension and Endothelin receptors) to Retrophin, Inc., or Retrophin.", "type": 2, "words": ["<tag1>", "In", "February", "2012,", "we", "announced", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "DARA", "(a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors).", "<tag2>", "In", "early", "2012,", "we", "licensed", "the", "world-wide", "rights", "to", "RE-021", "(formerly", "known", "as", "DARA-a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)", "to", "Retrophin,", "Inc.,", "or", "Retrophin.", "<tag3>"], "wordsA": ["In", "February", "2012,", "we", "announced", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "DARA", "(a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)."], "wordsB": ["In", "early", "2012,", "we", "licensed", "the", "world-wide", "rights", "to", "RE-021", "(formerly", "known", "as", "DARA-a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)", "to", "Retrophin,", "Inc.,", "or", "Retrophin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p27_s1", "idA": "886163_12_item1_p27_s4", "sentA": "Retrophin intends to develop DARA for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy.", "sentB": "Retrophin intends to develop RE-021 for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy.", "type": 2, "words": ["<tag1>", "Retrophin", "intends", "to", "develop", "DARA", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy.", "<tag2>", "Retrophin", "intends", "to", "develop", "RE-021", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy.", "<tag3>"], "wordsA": ["Retrophin", "intends", "to", "develop", "DARA", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy."], "wordsB": ["Retrophin", "intends", "to", "develop", "RE-021", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p28_s1", "idA": "886163_12_item1_p28_s1", "sentA": "DARA, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.", "sentB": "RE-021, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.", "type": 2, "words": ["<tag1>", "DARA,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies.", "<tag2>", "RE-021,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies.", "<tag3>"], "wordsA": ["DARA,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies."], "wordsB": ["RE-021,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p37_s1", "idA": "886163_12_item1_p28_s1", "sentA": "DARA, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.", "sentB": "A beta-secretase inhibitor is expected to reduce amyloid-beta generation in Alzheimer's disease patients.", "type": 2, "words": ["<tag1>", "DARA,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies.", "<tag2>", "A", "beta-secretase", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer's", "disease", "patients.", "<tag3>"], "wordsA": ["DARA,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies."], "wordsB": ["A", "beta-secretase", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer's", "disease", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p29_s0", "idA": "886163_12_item1_p29_s0", "sentA": "We are entitled to receive a net up front payment of $1 million, and may receive, net of amounts owed to third parties, over $75 million in milestones as well as 9% in royalties on potential future worldwide sales by Retrophin.", "sentB": "We received an upfront payment of $1 million, net of amounts owed to third parties.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin.", "<tag2>", "We", "received", "an", "upfront", "payment", "of", "$1", "million,", "net", "of", "amounts", "owed", "to", "third", "parties.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin."], "wordsB": ["We", "received", "an", "upfront", "payment", "of", "$1", "million,", "net", "of", "amounts", "owed", "to", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p30_s1", "idA": "886163_12_item1_p29_s0", "sentA": "We are entitled to receive a net up front payment of $1 million, and may receive, net of amounts owed to third parties, over $75 million in milestones as well as 9% in royalties on potential future worldwide sales by Retrophin.", "sentB": "We may receive over $75 million in milestones as well as 9% in royalties on potential future worldwide sales by Retrophin.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin.", "<tag2>", "We", "may", "receive", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin."], "wordsB": ["We", "may", "receive", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p39_s0", "idA": "886163_12_item1_p29_s0", "sentA": "We are entitled to receive a net up front payment of $1 million, and may receive, net of amounts owed to third parties, over $75 million in milestones as well as 9% in royalties on potential future worldwide sales by Retrophin.", "sentB": "Ligand is entitled to royalties on potential future sales by Merck.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin.", "<tag2>", "Ligand", "is", "entitled", "to", "royalties", "on", "potential", "future", "sales", "by", "Merck.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "a", "net", "up", "front", "payment", "of", "$1", "million,", "and", "may", "receive,", "net", "of", "amounts", "owed", "to", "third", "parties,", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin."], "wordsB": ["Ligand", "is", "entitled", "to", "royalties", "on", "potential", "future", "sales", "by", "Merck."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p48_s0", "idA": "886163_12_item1_p31_s0", "sentA": "CAPTISOL-Enabled Melphalan IV We are developing a proprietary CAPTISOL-enabled formulation of melphalan as an injectable, palliative treatment for patients with multiple myeloma.", "sentB": "Captisol-enabled Topiramate IV We are developing a proprietary Captisol-enabled formulation of topiramate for the treatment of acute epileptic seizures.", "type": 2, "words": ["<tag1>", "CAPTISOL-Enabled", "Melphalan", "IV", "We", "are", "developing", "a", "proprietary", "CAPTISOL-enabled", "formulation", "of", "melphalan", "as", "an", "injectable,", "palliative", "treatment", "for", "patients", "with", "multiple", "myeloma.", "<tag2>", "Captisol-enabled", "Topiramate", "IV", "We", "are", "developing", "a", "proprietary", "Captisol-enabled", "formulation", "of", "topiramate", "for", "the", "treatment", "of", "acute", "epileptic", "seizures.", "<tag3>"], "wordsA": ["CAPTISOL-Enabled", "Melphalan", "IV", "We", "are", "developing", "a", "proprietary", "CAPTISOL-enabled", "formulation", "of", "melphalan", "as", "an", "injectable,", "palliative", "treatment", "for", "patients", "with", "multiple", "myeloma."], "wordsB": ["Captisol-enabled", "Topiramate", "IV", "We", "are", "developing", "a", "proprietary", "Captisol-enabled", "formulation", "of", "topiramate", "for", "the", "treatment", "of", "acute", "epileptic", "seizures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p22_s3", "idA": "886163_12_item1_p32_s1", "sentA": "This allows for longer administration durations and slower infusion rates, enabling doctors to safely achieve a higher dose intensity of pre-transplant chemotherapy.", "sentB": "The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.", "type": 2, "words": ["<tag1>", "This", "allows", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "enabling", "doctors", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy.", "<tag2>", "The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy.", "<tag3>"], "wordsA": ["This", "allows", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "enabling", "doctors", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy."], "wordsB": ["The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p22_s1", "idA": "886163_12_item1_p32_s2", "sentA": "The CAPTISOL-enabled melphalan program has also obtained orphan drug designation from the FDA.", "sentB": "The Captisol-enabled, PG-free melphalan program uses a new intravenous formulation of melphalan for the multiple myeloma transplant setting, and has been granted Orphan designation by the FDA.", "type": 2, "words": ["<tag1>", "The", "CAPTISOL-enabled", "melphalan", "program", "has", "also", "obtained", "orphan", "drug", "designation", "from", "the", "FDA.", "<tag2>", "The", "Captisol-enabled,", "PG-free", "melphalan", "program", "uses", "a", "new", "intravenous", "formulation", "of", "melphalan", "for", "the", "multiple", "myeloma", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "designation", "by", "the", "FDA.", "<tag3>"], "wordsA": ["The", "CAPTISOL-enabled", "melphalan", "program", "has", "also", "obtained", "orphan", "drug", "designation", "from", "the", "FDA."], "wordsB": ["The", "Captisol-enabled,", "PG-free", "melphalan", "program", "uses", "a", "new", "intravenous", "formulation", "of", "melphalan", "for", "the", "multiple", "myeloma", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "designation", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p26_s3", "idA": "886163_12_item1_p32_s3", "sentA": "In December 2011, we reported final phase II bioequivalence data from this program and expect to initiate a pivotal study in 2012 to support a US 505(b)(2) filing with the FDA in 2013.", "sentB": "The Medicines Company is planning to initiate a pivotal study for the program in 2013 and is developing the product for global markets.", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "reported", "final", "phase", "II", "bioequivalence", "data", "from", "this", "program", "and", "expect", "to", "initiate", "a", "pivotal", "study", "in", "2012", "to", "support", "a", "US", "505(b)(2)", "filing", "with", "the", "FDA", "in", "2013.", "<tag2>", "The", "Medicines", "Company", "is", "planning", "to", "initiate", "a", "pivotal", "study", "for", "the", "program", "in", "2013", "and", "is", "developing", "the", "product", "for", "global", "markets.", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "reported", "final", "phase", "II", "bioequivalence", "data", "from", "this", "program", "and", "expect", "to", "initiate", "a", "pivotal", "study", "in", "2012", "to", "support", "a", "US", "505(b)(2)", "filing", "with", "the", "FDA", "in", "2013."], "wordsB": ["The", "Medicines", "Company", "is", "planning", "to", "initiate", "a", "pivotal", "study", "for", "the", "program", "in", "2013", "and", "is", "developing", "the", "product", "for", "global", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p53_s1", "idA": "886163_12_item1_p33_s1", "sentA": "Data from current lead molecules suggest that directing these molecules to the liver using the HepDirect technology produces fewer side effects and the potential for an overall superior risk-benefit ratio compared to non HepDirect therapies.", "sentB": "Data from current lead molecules suggest that directing these molecules to the liver using the HepDirect technology could produce fewer side effects and has the potential for an overall superior risk-benefit ratio compared to non HepDirect therapies.", "type": 2, "words": ["<tag1>", "Data", "from", "current", "lead", "molecules", "suggest", "that", "directing", "these", "molecules", "to", "the", "liver", "using", "the", "HepDirect", "technology", "produces", "fewer", "side", "effects", "and", "the", "potential", "for", "an", "overall", "superior", "risk-benefit", "ratio", "compared", "to", "non", "HepDirect", "therapies.", "<tag2>", "Data", "from", "current", "lead", "molecules", "suggest", "that", "directing", "these", "molecules", "to", "the", "liver", "using", "the", "HepDirect", "technology", "could", "produce", "fewer", "side", "effects", "and", "has", "the", "potential", "for", "an", "overall", "superior", "risk-benefit", "ratio", "compared", "to", "non", "HepDirect", "therapies.", "<tag3>"], "wordsA": ["Data", "from", "current", "lead", "molecules", "suggest", "that", "directing", "these", "molecules", "to", "the", "liver", "using", "the", "HepDirect", "technology", "produces", "fewer", "side", "effects", "and", "the", "potential", "for", "an", "overall", "superior", "risk-benefit", "ratio", "compared", "to", "non", "HepDirect", "therapies."], "wordsB": ["Data", "from", "current", "lead", "molecules", "suggest", "that", "directing", "these", "molecules", "to", "the", "liver", "using", "the", "HepDirect", "technology", "could", "produce", "fewer", "side", "effects", "and", "has", "the", "potential", "for", "an", "overall", "superior", "risk-benefit", "ratio", "compared", "to", "non", "HepDirect", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p34_s0", "idA": "886163_12_item1_p34_s0", "sentA": "(IRAK4) inhibitors for the treatment of inflammatory and immune disorders.", "sentB": "The development agreement for the beta-secretase inhibitor program (or BACE) was entered into in 2009 between Ligand (formerly Pharmacopeia) and Merck (formerly Schering-Plough), under a 1998 agreement, for the treatment of Alzheimer's disease.", "type": 2, "words": ["<tag1>", "(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders.", "<tag2>", "The", "development", "agreement", "for", "the", "beta-secretase", "inhibitor", "program", "(or", "BACE)", "was", "entered", "into", "in", "2009", "between", "Ligand", "(formerly", "Pharmacopeia)", "and", "Merck", "(formerly", "Schering-Plough),", "under", "a", "1998", "agreement,", "for", "the", "treatment", "of", "Alzheimer's", "disease.", "<tag3>"], "wordsA": ["(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders."], "wordsB": ["The", "development", "agreement", "for", "the", "beta-secretase", "inhibitor", "program", "(or", "BACE)", "was", "entered", "into", "in", "2009", "between", "Ligand", "(formerly", "Pharmacopeia)", "and", "Merck", "(formerly", "Schering-Plough),", "under", "a", "1998", "agreement,", "for", "the", "treatment", "of", "Alzheimer's", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p54_s1", "idA": "886163_12_item1_p34_s0", "sentA": "(IRAK4) inhibitors for the treatment of inflammatory and immune disorders.", "sentB": "The goal of our GCSFR agonist program is to develop a non-peptide, small molecule, oral GCSFR agonist that is a convenient, cost-effective alternative as compared to recombinant human GCSF for the treatment of neutropenia and other related indications.", "type": 2, "words": ["<tag1>", "(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders.", "<tag2>", "The", "goal", "of", "our", "GCSFR", "agonist", "program", "is", "to", "develop", "a", "non-peptide,", "small", "molecule,", "oral", "GCSFR", "agonist", "that", "is", "a", "convenient,", "cost-effective", "alternative", "as", "compared", "to", "recombinant", "human", "GCSF", "for", "the", "treatment", "of", "neutropenia", "and", "other", "related", "indications.", "<tag3>"], "wordsA": ["(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders."], "wordsB": ["The", "goal", "of", "our", "GCSFR", "agonist", "program", "is", "to", "develop", "a", "non-peptide,", "small", "molecule,", "oral", "GCSFR", "agonist", "that", "is", "a", "convenient,", "cost-effective", "alternative", "as", "compared", "to", "recombinant", "human", "GCSF", "for", "the", "treatment", "of", "neutropenia", "and", "other", "related", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p55_s1", "idA": "886163_12_item1_p34_s0", "sentA": "(IRAK4) inhibitors for the treatment of inflammatory and immune disorders.", "sentB": "Further optimization of the LG7455 structure series could lead to a first-in-class, once-daily, oral medication for the treatment of congenital, chronic or chemotherapy-induced neutropenia.", "type": 2, "words": ["<tag1>", "(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders.", "<tag2>", "Further", "optimization", "of", "the", "LG7455", "structure", "series", "could", "lead", "to", "a", "first-in-class,", "once-daily,", "oral", "medication", "for", "the", "treatment", "of", "congenital,", "chronic", "or", "chemotherapy-induced", "neutropenia.", "<tag3>"], "wordsA": ["(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders."], "wordsB": ["Further", "optimization", "of", "the", "LG7455", "structure", "series", "could", "lead", "to", "a", "first-in-class,", "once-daily,", "oral", "medication", "for", "the", "treatment", "of", "congenital,", "chronic", "or", "chemotherapy-induced", "neutropenia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p56_s1", "idA": "886163_12_item1_p34_s0", "sentA": "(IRAK4) inhibitors for the treatment of inflammatory and immune disorders.", "sentB": "Various recombinant human EPO derivatives are marketed as erythropoiesis-stimulating agents (ESAs) for the treatment of anemia due to renal failure or cancer chemotherapy.", "type": 2, "words": ["<tag1>", "(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders.", "<tag2>", "Various", "recombinant", "human", "EPO", "derivatives", "are", "marketed", "as", "erythropoiesis-stimulating", "agents", "(ESAs)", "for", "the", "treatment", "of", "anemia", "due", "to", "renal", "failure", "or", "cancer", "chemotherapy.", "<tag3>"], "wordsA": ["(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders."], "wordsB": ["Various", "recombinant", "human", "EPO", "derivatives", "are", "marketed", "as", "erythropoiesis-stimulating", "agents", "(ESAs)", "for", "the", "treatment", "of", "anemia", "due", "to", "renal", "failure", "or", "cancer", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p50_s0", "idA": "886163_12_item1_p36_s0", "sentA": "Glucagon Receptor Antagonist Research Program We are developing small molecule glucagon receptor antagonists for the treatment of Type 2 diabetes mellitus.", "sentB": "We are currently developing small molecule glucagon receptor antagonists for the treatment of Type II diabetes mellitus.", "type": 2, "words": ["<tag1>", "Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus.", "<tag3>"], "wordsA": ["Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p52_s2", "idA": "886163_12_item1_p36_s0", "sentA": "Glucagon Receptor Antagonist Research Program We are developing small molecule glucagon receptor antagonists for the treatment of Type 2 diabetes mellitus.", "sentB": "Clinical proof of concept studies with glucagon receptor antagonists in Type 2 diabetic patients were reported at the American Diabetes Association Annual Meeting in 2011 and 2012, supporting the potential benefit of this therapeutic target.", "type": 2, "words": ["<tag1>", "Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "Clinical", "proof", "of", "concept", "studies", "with", "glucagon", "receptor", "antagonists", "in", "Type", "2", "diabetic", "patients", "were", "reported", "at", "the", "American", "Diabetes", "Association", "Annual", "Meeting", "in", "2011", "and", "2012,", "supporting", "the", "potential", "benefit", "of", "this", "therapeutic", "target.", "<tag3>"], "wordsA": ["Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["Clinical", "proof", "of", "concept", "studies", "with", "glucagon", "receptor", "antagonists", "in", "Type", "2", "diabetic", "patients", "were", "reported", "at", "the", "American", "Diabetes", "Association", "Annual", "Meeting", "in", "2011", "and", "2012,", "supporting", "the", "potential", "benefit", "of", "this", "therapeutic", "target."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p36_s0", "idA": "886163_12_item1_p38_s0", "sentA": "Glucagon stimulates the production of glucose by the liver and its release into the blood stream.", "sentB": "Beta secretase is believed to be a key enzyme in the production of amyloid-beta protein.", "type": 2, "words": ["<tag1>", "Glucagon", "stimulates", "the", "production", "of", "glucose", "by", "the", "liver", "and", "its", "release", "into", "the", "blood", "stream.", "<tag2>", "Beta", "secretase", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein.", "<tag3>"], "wordsA": ["Glucagon", "stimulates", "the", "production", "of", "glucose", "by", "the", "liver", "and", "its", "release", "into", "the", "blood", "stream."], "wordsB": ["Beta", "secretase", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p52_s3", "idA": "886163_12_item1_p39_s1", "sentA": "Our advanced glucagon antagonist compounds demonstrate oral bioavailability in rodents.", "sentB": "Our advanced glucagon antagonist compound blocks glucagon action in human hepatocytes in vitro, reduces blood glucose in animal models of Type 1 and Type 2 diabetes, has demonstrated good oral bioavailability in rodents, and has a safety profile in preclinical studies suitable for further clinical development.", "type": 2, "words": ["<tag1>", "Our", "advanced", "glucagon", "antagonist", "compounds", "demonstrate", "oral", "bioavailability", "in", "rodents.", "<tag2>", "Our", "advanced", "glucagon", "antagonist", "compound", "blocks", "glucagon", "action", "in", "human", "hepatocytes", "in", "vitro,", "reduces", "blood", "glucose", "in", "animal", "models", "of", "Type", "1", "and", "Type", "2", "diabetes,", "has", "demonstrated", "good", "oral", "bioavailability", "in", "rodents,", "and", "has", "a", "safety", "profile", "in", "preclinical", "studies", "suitable", "for", "further", "clinical", "development.", "<tag3>"], "wordsA": ["Our", "advanced", "glucagon", "antagonist", "compounds", "demonstrate", "oral", "bioavailability", "in", "rodents."], "wordsB": ["Our", "advanced", "glucagon", "antagonist", "compound", "blocks", "glucagon", "action", "in", "human", "hepatocytes", "in", "vitro,", "reduces", "blood", "glucose", "in", "animal", "models", "of", "Type", "1", "and", "Type", "2", "diabetes,", "has", "demonstrated", "good", "oral", "bioavailability", "in", "rodents,", "and", "has", "a", "safety", "profile", "in", "preclinical", "studies", "suitable", "for", "further", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p56_s3", "idA": "886163_12_item1_p39_s1", "sentA": "Our advanced glucagon antagonist compounds demonstrate oral bioavailability in rodents.", "sentB": "The lead compound, LG5640, has demonstrated high potency and oral bioavailability in the mouse, rat and monkey.", "type": 2, "words": ["<tag1>", "Our", "advanced", "glucagon", "antagonist", "compounds", "demonstrate", "oral", "bioavailability", "in", "rodents.", "<tag2>", "The", "lead", "compound,", "LG5640,", "has", "demonstrated", "high", "potency", "and", "oral", "bioavailability", "in", "the", "mouse,", "rat", "and", "monkey.", "<tag3>"], "wordsA": ["Our", "advanced", "glucagon", "antagonist", "compounds", "demonstrate", "oral", "bioavailability", "in", "rodents."], "wordsB": ["The", "lead", "compound,", "LG5640,", "has", "demonstrated", "high", "potency", "and", "oral", "bioavailability", "in", "the", "mouse,", "rat", "and", "monkey."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p22_s4", "idA": "886163_12_item1_p41_s5", "sentA": "Under the terms of the agreement, we have the potential to earn over $100 million in milestones and royalties on potential sales related to our assets.", "sentB": "Under the terms of the license agreement, we will receive a $3 million license fee and are eligible to receive more than $50 million in potential milestone payments.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "potential", "to", "earn", "over", "$100", "million", "in", "milestones", "and", "royalties", "on", "potential", "sales", "related", "to", "our", "assets.", "<tag2>", "Under", "the", "terms", "of", "the", "license", "agreement,", "we", "will", "receive", "a", "$3", "million", "license", "fee", "and", "are", "eligible", "to", "receive", "more", "than", "$50", "million", "in", "potential", "milestone", "payments.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "potential", "to", "earn", "over", "$100", "million", "in", "milestones", "and", "royalties", "on", "potential", "sales", "related", "to", "our", "assets."], "wordsB": ["Under", "the", "terms", "of", "the", "license", "agreement,", "we", "will", "receive", "a", "$3", "million", "license", "fee", "and", "are", "eligible", "to", "receive", "more", "than", "$50", "million", "in", "potential", "milestone", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p44_s5", "idA": "886163_12_item1_p41_s5", "sentA": "Under the terms of the agreement, we have the potential to earn over $100 million in milestones and royalties on potential sales related to our assets.", "sentB": "Under the Fablyn license agreement, we have been paid and will retain $2.5 million in license fees.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "potential", "to", "earn", "over", "$100", "million", "in", "milestones", "and", "royalties", "on", "potential", "sales", "related", "to", "our", "assets.", "<tag2>", "Under", "the", "Fablyn", "license", "agreement,", "we", "have", "been", "paid", "and", "will", "retain", "$2.5", "million", "in", "license", "fees.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "potential", "to", "earn", "over", "$100", "million", "in", "milestones", "and", "royalties", "on", "potential", "sales", "related", "to", "our", "assets."], "wordsB": ["Under", "the", "Fablyn", "license", "agreement,", "we", "have", "been", "paid", "and", "will", "retain", "$2.5", "million", "in", "license", "fees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p29_s1", "idA": "886163_12_item1_p42_s1", "sentA": "Under this License Agreement, we received a $1.8 million upfront payment, of which $0.9 million was remitted to the CyDex CVR holders.", "sentB": "In late 2012, we received a milestone payment of 620,000 shares of common stock in partner Retrophin, Inc.", "type": 2, "words": ["<tag1>", "Under", "this", "License", "Agreement,", "we", "received", "a", "$1.8", "million", "upfront", "payment,", "of", "which", "$0.9", "million", "was", "remitted", "to", "the", "CyDex", "CVR", "holders.", "<tag2>", "In", "late", "2012,", "we", "received", "a", "milestone", "payment", "of", "620,000", "shares", "of", "common", "stock", "in", "partner", "Retrophin,", "Inc.", "<tag3>"], "wordsA": ["Under", "this", "License", "Agreement,", "we", "received", "a", "$1.8", "million", "upfront", "payment,", "of", "which", "$0.9", "million", "was", "remitted", "to", "the", "CyDex", "CVR", "holders."], "wordsB": ["In", "late", "2012,", "we", "received", "a", "milestone", "payment", "of", "620,000", "shares", "of", "common", "stock", "in", "partner", "Retrophin,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p30_s2", "idA": "886163_12_item1_p42_s1", "sentA": "Under this License Agreement, we received a $1.8 million upfront payment, of which $0.9 million was remitted to the CyDex CVR holders.", "sentB": "In early 2013 we received a $1.4 million milestone payment from Retrophin, Inc.", "type": 2, "words": ["<tag1>", "Under", "this", "License", "Agreement,", "we", "received", "a", "$1.8", "million", "upfront", "payment,", "of", "which", "$0.9", "million", "was", "remitted", "to", "the", "CyDex", "CVR", "holders.", "<tag2>", "In", "early", "2013", "we", "received", "a", "$1.4", "million", "milestone", "payment", "from", "Retrophin,", "Inc.", "<tag3>"], "wordsA": ["Under", "this", "License", "Agreement,", "we", "received", "a", "$1.8", "million", "upfront", "payment,", "of", "which", "$0.9", "million", "was", "remitted", "to", "the", "CyDex", "CVR", "holders."], "wordsB": ["In", "early", "2013", "we", "received", "a", "$1.4", "million", "milestone", "payment", "from", "Retrophin,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p44_s0", "idA": "886163_12_item1_p44_s0", "sentA": "Fablyn License Agreement with Chiva Pharmaceuticals In October 2011, we entered into a License Agreement with Chiva Pharmaceuticals, Inc.", "sentB": "In October 2011, we entered into a license agreement with Chiva Pharmaceuticals, Inc., or Chiva.", "type": 2, "words": ["<tag1>", "Fablyn", "License", "Agreement", "with", "Chiva", "Pharmaceuticals", "In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.", "<tag2>", "In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva.", "<tag3>"], "wordsA": ["Fablyn", "License", "Agreement", "with", "Chiva", "Pharmaceuticals", "In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "Chiva", "Pharmaceuticals,", "Inc."], "wordsB": ["In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p44_s2", "idA": "886163_12_item1_p44_s0", "sentA": "Fablyn License Agreement with Chiva Pharmaceuticals In October 2011, we entered into a License Agreement with Chiva Pharmaceuticals, Inc.", "sentB": "In October 2012, we entered into a settlement agreement and mutual release with Chiva, pursuant to which we resolved all disputes, including our primary claim in arbitration relating to payments due under the License Agreement.", "type": 2, "words": ["<tag1>", "Fablyn", "License", "Agreement", "with", "Chiva", "Pharmaceuticals", "In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.", "<tag2>", "In", "October", "2012,", "we", "entered", "into", "a", "settlement", "agreement", "and", "mutual", "release", "with", "Chiva,", "pursuant", "to", "which", "we", "resolved", "all", "disputes,", "including", "our", "primary", "claim", "in", "arbitration", "relating", "to", "payments", "due", "under", "the", "License", "Agreement.", "<tag3>"], "wordsA": ["Fablyn", "License", "Agreement", "with", "Chiva", "Pharmaceuticals", "In", "October", "2011,", "we", "entered", "into", "a", "License", "Agreement", "with", "Chiva", "Pharmaceuticals,", "Inc."], "wordsB": ["In", "October", "2012,", "we", "entered", "into", "a", "settlement", "agreement", "and", "mutual", "release", "with", "Chiva,", "pursuant", "to", "which", "we", "resolved", "all", "disputes,", "including", "our", "primary", "claim", "in", "arbitration", "relating", "to", "payments", "due", "under", "the", "License", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p44_s1", "idA": "886163_12_item1_p44_s1", "sentA": "Under the License Agreement, we granted to Chiva an exclusive worldwide license, with sub-license rights, to our intellectual property rights related to Fablyn, a selective estrogen receptor modulator.", "sentB": "We granted to Chiva an exclusive worldwide license, with sub-license rights, to our intellectual property rights related to Fablyn, a selective estrogen receptor modulator.", "type": 2, "words": ["<tag1>", "Under", "the", "License", "Agreement,", "we", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator.", "<tag2>", "We", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator.", "<tag3>"], "wordsA": ["Under", "the", "License", "Agreement,", "we", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator."], "wordsB": ["We", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p13_s1", "idA": "886163_12_item1_p45_s3", "sentA": "We are also eligible to receive material sales revenue from the shipment of CAPTISOL to SAGE for clinical and commercial activities.", "sentB": "Under our agreement with Onyx, we are entitled to receive milestones, tiered royalties ranging between 1.5% and 3% as shown in the table below, and revenue from clinical and commercial Captisol material sales.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "material", "sales", "revenue", "from", "the", "shipment", "of", "CAPTISOL", "to", "SAGE", "for", "clinical", "and", "commercial", "activities.", "<tag2>", "Under", "our", "agreement", "with", "Onyx,", "we", "are", "entitled", "to", "receive", "milestones,", "tiered", "royalties", "ranging", "between", "1.5%", "and", "3%", "as", "shown", "in", "the", "table", "below,", "and", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "material", "sales", "revenue", "from", "the", "shipment", "of", "CAPTISOL", "to", "SAGE", "for", "clinical", "and", "commercial", "activities."], "wordsB": ["Under", "our", "agreement", "with", "Onyx,", "we", "are", "entitled", "to", "receive", "milestones,", "tiered", "royalties", "ranging", "between", "1.5%", "and", "3%", "as", "shown", "in", "the", "table", "below,", "and", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p22_s5", "idA": "886163_12_item1_p45_s7", "sentA": "We are also eligible to receive royalty payments on worldwide net sales of any products that are successfully commercialized.", "sentB": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "any", "products", "that", "are", "successfully", "commercialized.", "<tag2>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "any", "products", "that", "are", "successfully", "commercialized."], "wordsB": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p57_s0", "idA": "886163_12_item1_p46_s0", "sentA": "Technology We employ various research laboratory methods to discover and conduct preclinical development of new chemical entities.", "sentB": "Others Technology We employ various research laboratory methods to discover and conduct preclinical development of new chemical entities.", "type": 2, "words": ["<tag1>", "Technology", "We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities.", "<tag2>", "Others", "Technology", "We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities.", "<tag3>"], "wordsA": ["Technology", "We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities."], "wordsB": ["Others", "Technology", "We", "employ", "various", "research", "laboratory", "methods", "to", "discover", "and", "conduct", "preclinical", "development", "of", "new", "chemical", "entities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p57_s2", "idA": "886163_12_item1_p46_s2", "sentA": "In our efforts to discover new and important medicines, we have concentrated on certain technologies and acquired special expertise related to intracellular receptors and the receptors for hematopoietic growth factors.", "sentB": "Our discovery work is based on certain technologies and acquired special expertise related to intracellular receptors and the receptors for hematopoietic growth factors.", "type": 2, "words": ["<tag1>", "In", "our", "efforts", "to", "discover", "new", "and", "important", "medicines,", "we", "have", "concentrated", "on", "certain", "technologies", "and", "acquired", "special", "expertise", "related", "to", "intracellular", "receptors", "and", "the", "receptors", "for", "hematopoietic", "growth", "factors.", "<tag2>", "Our", "discovery", "work", "is", "based", "on", "certain", "technologies", "and", "acquired", "special", "expertise", "related", "to", "intracellular", "receptors", "and", "the", "receptors", "for", "hematopoietic", "growth", "factors.", "<tag3>"], "wordsA": ["In", "our", "efforts", "to", "discover", "new", "and", "important", "medicines,", "we", "have", "concentrated", "on", "certain", "technologies", "and", "acquired", "special", "expertise", "related", "to", "intracellular", "receptors", "and", "the", "receptors", "for", "hematopoietic", "growth", "factors."], "wordsB": ["Our", "discovery", "work", "is", "based", "on", "certain", "technologies", "and", "acquired", "special", "expertise", "related", "to", "intracellular", "receptors", "and", "the", "receptors", "for", "hematopoietic", "growth", "factors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p41_s0", "idA": "886163_12_item1_p47_s1", "sentA": "Hematopoietic growth factor receptors are involved in the differentiation and proliferation of blood cell progenitors, the formation of new blood cells, and the action of drugs such as PROMACTA, Epogen and Neumega.", "sentB": "The development and commercialization agreement for Captisol-enabled delafloxacin began in 2008 between Rib-X Pharmaceuticals and us for the use of Captisol in the formation of delafloxacin.", "type": 2, "words": ["<tag1>", "Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "PROMACTA,", "Epogen", "and", "Neumega.", "<tag2>", "The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin", "began", "in", "2008", "between", "Rib-X", "Pharmaceuticals", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formation", "of", "delafloxacin.", "<tag3>"], "wordsA": ["Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "PROMACTA,", "Epogen", "and", "Neumega."], "wordsB": ["The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin", "began", "in", "2008", "between", "Rib-X", "Pharmaceuticals", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formation", "of", "delafloxacin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p59_s1", "idA": "886163_12_item1_p48_s1", "sentA": "Some of these methods are covered by patents issued to or licensed by us, are trade secrets, or are methods that are in the public domain, but that we may use in novel ways to improve our efficiency in identifying promising leads and developing new chemical entities.", "sentB": "Some of these methods are covered by patents issued to or licensed by us, some are trade secrets, and some are methods that are in the public domain, but that we may use in novel ways to improve our efficiency in identifying promising leads and developing new chemical entities.", "type": 2, "words": ["<tag1>", "Some", "of", "these", "methods", "are", "covered", "by", "patents", "issued", "to", "or", "licensed", "by", "us,", "are", "trade", "secrets,", "or", "are", "methods", "that", "are", "in", "the", "public", "domain,", "but", "that", "we", "may", "use", "in", "novel", "ways", "to", "improve", "our", "efficiency", "in", "identifying", "promising", "leads", "and", "developing", "new", "chemical", "entities.", "<tag2>", "Some", "of", "these", "methods", "are", "covered", "by", "patents", "issued", "to", "or", "licensed", "by", "us,", "some", "are", "trade", "secrets,", "and", "some", "are", "methods", "that", "are", "in", "the", "public", "domain,", "but", "that", "we", "may", "use", "in", "novel", "ways", "to", "improve", "our", "efficiency", "in", "identifying", "promising", "leads", "and", "developing", "new", "chemical", "entities.", "<tag3>"], "wordsA": ["Some", "of", "these", "methods", "are", "covered", "by", "patents", "issued", "to", "or", "licensed", "by", "us,", "are", "trade", "secrets,", "or", "are", "methods", "that", "are", "in", "the", "public", "domain,", "but", "that", "we", "may", "use", "in", "novel", "ways", "to", "improve", "our", "efficiency", "in", "identifying", "promising", "leads", "and", "developing", "new", "chemical", "entities."], "wordsB": ["Some", "of", "these", "methods", "are", "covered", "by", "patents", "issued", "to", "or", "licensed", "by", "us,", "some", "are", "trade", "secrets,", "and", "some", "are", "methods", "that", "are", "in", "the", "public", "domain,", "but", "that", "we", "may", "use", "in", "novel", "ways", "to", "improve", "our", "efficiency", "in", "identifying", "promising", "leads", "and", "developing", "new", "chemical", "entities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p0_s0", "idA": "886163_12_item1_p4_s0", "sentA": "We are a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them to a lean corporate cost structure.", "sentB": "Overview We are a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them to a lean corporate cost structure.", "type": 2, "words": ["<tag1>", "We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure.", "<tag2>", "Overview", "We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure.", "<tag3>"], "wordsA": ["We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure."], "wordsB": ["Overview", "We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "to", "a", "lean", "corporate", "cost", "structure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p0_s4", "idA": "886163_12_item1_p4_s4", "sentA": "CAPTISOL is a powerful formulation technology that has enabled five FDA approved products, including Pfizer s VFEND IV and Baxter International s Nexterone and is currently being used in a number of clinical-stage partner programs.", "sentB": "Captisol is a powerful formulation technology that has enabled six FDA approved products, including Onyx s Kyprolis and Baxter International s Nexterone and is currently being developed in a number of clinical-stage partner programs.", "type": 2, "words": ["<tag1>", "CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag2>", "Captisol", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx", "s", "Kyprolis", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag3>"], "wordsA": ["CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "wordsB": ["Captisol", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx", "s", "Kyprolis", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p40_s2", "idA": "886163_12_item1_p4_s4", "sentA": "CAPTISOL is a powerful formulation technology that has enabled five FDA approved products, including Pfizer s VFEND IV and Baxter International s Nexterone and is currently being used in a number of clinical-stage partner programs.", "sentB": "CE carbamazepine-IV is currently being evaluated in a Phase III clinical trial.", "type": 2, "words": ["<tag1>", "CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag2>", "CE", "carbamazepine-IV", "is", "currently", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial.", "<tag3>"], "wordsA": ["CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "wordsB": ["CE", "carbamazepine-IV", "is", "currently", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p62_s5", "idA": "886163_12_item1_p52_s5", "sentA": "To date, we have not exercised our right of first refusal to acquire any such improvements.", "sentB": "To date, we have not qualified any alternate suppliers.", "type": 2, "words": ["<tag1>", "To", "date,", "we", "have", "not", "exercised", "our", "right", "of", "first", "refusal", "to", "acquire", "any", "such", "improvements.", "<tag2>", "To", "date,", "we", "have", "not", "qualified", "any", "alternate", "suppliers.", "<tag3>"], "wordsA": ["To", "date,", "we", "have", "not", "exercised", "our", "right", "of", "first", "refusal", "to", "acquire", "any", "such", "improvements."], "wordsB": ["To", "date,", "we", "have", "not", "qualified", "any", "alternate", "suppliers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p43_s0", "idA": "886163_12_item1_p53_s0", "sentA": "In December 1993, as contemplated by our license agreement with KU, KU entered into an option agreement with Pfizer, simultaneously transferring to us all of KU s rights and obligations under that agreement.", "sentB": "In September 2012, Ligand entered into an option agreement with an undisclosed partner for the clinical development of an undisclosed novel inhibitor of the fructose-1,6-bisphosphatase (FBPase) enzyme for the treatment of type 2 diabetes.", "type": 2, "words": ["<tag1>", "In", "December", "1993,", "as", "contemplated", "by", "our", "license", "agreement", "with", "KU,", "KU", "entered", "into", "an", "option", "agreement", "with", "Pfizer,", "simultaneously", "transferring", "to", "us", "all", "of", "KU", "s", "rights", "and", "obligations", "under", "that", "agreement.", "<tag2>", "In", "September", "2012,", "Ligand", "entered", "into", "an", "option", "agreement", "with", "an", "undisclosed", "partner", "for", "the", "clinical", "development", "of", "an", "undisclosed", "novel", "inhibitor", "of", "the", "fructose-1,6-bisphosphatase", "(FBPase)", "enzyme", "for", "the", "treatment", "of", "type", "2", "diabetes.", "<tag3>"], "wordsA": ["In", "December", "1993,", "as", "contemplated", "by", "our", "license", "agreement", "with", "KU,", "KU", "entered", "into", "an", "option", "agreement", "with", "Pfizer,", "simultaneously", "transferring", "to", "us", "all", "of", "KU", "s", "rights", "and", "obligations", "under", "that", "agreement."], "wordsB": ["In", "September", "2012,", "Ligand", "entered", "into", "an", "option", "agreement", "with", "an", "undisclosed", "partner", "for", "the", "clinical", "development", "of", "an", "undisclosed", "novel", "inhibitor", "of", "the", "fructose-1,6-bisphosphatase", "(FBPase)", "enzyme", "for", "the", "treatment", "of", "type", "2", "diabetes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p61_s3", "idA": "886163_12_item1_p53_s1", "sentA": "Manufacturing We currently have no manufacturing facilities and, accordingly, rely on third parties, including our collaborative partners, for clinical production of any products or compounds.", "sentB": "Manufacturing We currently have no manufacturing facilities and rely on third parties, including our collaborative partners, for clinical production of any products or compounds.", "type": 2, "words": ["<tag1>", "Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and,", "accordingly,", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production", "of", "any", "products", "or", "compounds.", "<tag2>", "Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production", "of", "any", "products", "or", "compounds.", "<tag3>"], "wordsA": ["Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and,", "accordingly,", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production", "of", "any", "products", "or", "compounds."], "wordsB": ["Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production", "of", "any", "products", "or", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p61_s4", "idA": "886163_12_item1_p54_s0", "sentA": "We currently outsource the production of CAPTISOL to Hovione FarmaCiencia SA, or Hovione, a major supplier of APIs and API intermediates located in Lisbon, Portugal.", "sentB": "We currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a major supplier of APIs and API intermediates located in Portugal.", "type": 2, "words": ["<tag1>", "We", "currently", "outsource", "the", "production", "of", "CAPTISOL", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "APIs", "and", "API", "intermediates", "located", "in", "Lisbon,", "Portugal.", "<tag2>", "We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "APIs", "and", "API", "intermediates", "located", "in", "Portugal.", "<tag3>"], "wordsA": ["We", "currently", "outsource", "the", "production", "of", "CAPTISOL", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "APIs", "and", "API", "intermediates", "located", "in", "Lisbon,", "Portugal."], "wordsB": ["We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "APIs", "and", "API", "intermediates", "located", "in", "Portugal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p62_s7", "idA": "886163_12_item1_p54_s2", "sentA": "In addition to its main manufacturing site in Loures, Portugal, Hovione will qualify a second site in Macau if our forecast requirements for CAPTISOL exceed the capabilities of the Loures site.", "sentB": "Additionally, in 2012, we qualified a Hovione site in Cork, Ireland to perform certain manufacturing steps to provide back-up and increased capacity to the Loures site.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "a", "second", "site", "in", "Macau", "if", "our", "forecast", "requirements", "for", "CAPTISOL", "exceed", "the", "capabilities", "of", "the", "Loures", "site.", "<tag2>", "Additionally,", "in", "2012,", "we", "qualified", "a", "Hovione", "site", "in", "Cork,", "Ireland", "to", "perform", "certain", "manufacturing", "steps", "to", "provide", "back-up", "and", "increased", "capacity", "to", "the", "Loures", "site.", "<tag3>"], "wordsA": ["In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "a", "second", "site", "in", "Macau", "if", "our", "forecast", "requirements", "for", "CAPTISOL", "exceed", "the", "capabilities", "of", "the", "Loures", "site."], "wordsB": ["Additionally,", "in", "2012,", "we", "qualified", "a", "Hovione", "site", "in", "Cork,", "Ireland", "to", "perform", "certain", "manufacturing", "steps", "to", "provide", "back-up", "and", "increased", "capacity", "to", "the", "Loures", "site."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p61_s9", "idA": "886163_12_item1_p54_s5", "sentA": "In January 2008, we entered into an amendment to the supply agreement, under which we and Hovione agreed to reduce our minimum annual purchase requirement of CAPTISOL and to extend the term of the agreement.", "sentB": "In 2008, we entered into an amendment to the supply agreement, under which we and Hovione agreed to reduce our minimum annual purchase requirement of Captisol and to extend the term of the agreement.", "type": 2, "words": ["<tag1>", "In", "January", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "CAPTISOL", "and", "to", "extend", "the", "term", "of", "the", "agreement.", "<tag2>", "In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement.", "<tag3>"], "wordsA": ["In", "January", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "CAPTISOL", "and", "to", "extend", "the", "term", "of", "the", "agreement."], "wordsB": ["In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p62_s0", "idA": "886163_12_item1_p54_s6", "sentA": "We pay Hovione unit prices, in U.S. dollars, for all CAPTISOL supplied after the commercial production date, which prices may be adjusted based on the following:", "sentB": "We pay Hovione unit prices, in U.S. dollars, for all Captisol supplied after the commercial production date, which prices may be adjusted for fluctuation in currency exchange rates, change in raw material prices and change in the Portuguese consumer price index.", "type": 2, "words": ["<tag1>", "We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "CAPTISOL", "supplied", "after", "the", "commercial", "production", "date,", "which", "prices", "may", "be", "adjusted", "based", "on", "the", "following:", "<tag2>", "We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied", "after", "the", "commercial", "production", "date,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index.", "<tag3>"], "wordsA": ["We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "CAPTISOL", "supplied", "after", "the", "commercial", "production", "date,", "which", "prices", "may", "be", "adjusted", "based", "on", "the", "following:"], "wordsB": ["We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied", "after", "the", "commercial", "production", "date,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p62_s1", "idA": "886163_12_item1_p55_s0", "sentA": "our requested changes to the CAPTISOL manufacturing process or specifications.", "sentB": "Additionally, prices may be adjusted based on requested changes to the Captisol manufacturing process or specifications.", "type": 2, "words": ["<tag1>", "our", "requested", "changes", "to", "the", "CAPTISOL", "manufacturing", "process", "or", "specifications.", "<tag2>", "Additionally,", "prices", "may", "be", "adjusted", "based", "on", "requested", "changes", "to", "the", "Captisol", "manufacturing", "process", "or", "specifications.", "<tag3>"], "wordsA": ["our", "requested", "changes", "to", "the", "CAPTISOL", "manufacturing", "process", "or", "specifications."], "wordsB": ["Additionally,", "prices", "may", "be", "adjusted", "based", "on", "requested", "changes", "to", "the", "Captisol", "manufacturing", "process", "or", "specifications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p63_s1", "idA": "886163_12_item1_p56_s1", "sentA": "Research and Development Expenses Research and development expenses from continuing operations were $10.3 million, $22.1 million, and $39.9 million in 2011, 2010, and 2009, respectively, of which 99%, 61%, and 47%, respectively, were sponsored by us.", "sentB": "Research and Development Expenses Research and development expenses from continuing operations were $10.8 million, $10.3 million, and $22.1 million in 2012, 2011 and 2010, respectively, of which 100%, 99%, and 61%, respectively, were sponsored by us.", "type": 2, "words": ["<tag1>", "Research", "and", "Development", "Expenses", "Research", "and", "development", "expenses", "from", "continuing", "operations", "were", "$10.3", "million,", "$22.1", "million,", "and", "$39.9", "million", "in", "2011,", "2010,", "and", "2009,", "respectively,", "of", "which", "99%,", "61%,", "and", "47%,", "respectively,", "were", "sponsored", "by", "us.", "<tag2>", "Research", "and", "Development", "Expenses", "Research", "and", "development", "expenses", "from", "continuing", "operations", "were", "$10.8", "million,", "$10.3", "million,", "and", "$22.1", "million", "in", "2012,", "2011", "and", "2010,", "respectively,", "of", "which", "100%,", "99%,", "and", "61%,", "respectively,", "were", "sponsored", "by", "us.", "<tag3>"], "wordsA": ["Research", "and", "Development", "Expenses", "Research", "and", "development", "expenses", "from", "continuing", "operations", "were", "$10.3", "million,", "$22.1", "million,", "and", "$39.9", "million", "in", "2011,", "2010,", "and", "2009,", "respectively,", "of", "which", "99%,", "61%,", "and", "47%,", "respectively,", "were", "sponsored", "by", "us."], "wordsB": ["Research", "and", "Development", "Expenses", "Research", "and", "development", "expenses", "from", "continuing", "operations", "were", "$10.8", "million,", "$10.3", "million,", "and", "$22.1", "million", "in", "2012,", "2011", "and", "2010,", "respectively,", "of", "which", "100%,", "99%,", "and", "61%,", "respectively,", "were", "sponsored", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p63_s2", "idA": "886163_12_item1_p56_s2", "sentA": "There were no research and development expenses from discontinued operations in 2011, 2010, and 2009.", "sentB": "There were no research and development expenses from discontinued operations in 2012, 2011 and 2010.", "type": 2, "words": ["<tag1>", "There", "were", "no", "research", "and", "development", "expenses", "from", "discontinued", "operations", "in", "2011,", "2010,", "and", "2009.", "<tag2>", "There", "were", "no", "research", "and", "development", "expenses", "from", "discontinued", "operations", "in", "2012,", "2011", "and", "2010.", "<tag3>"], "wordsA": ["There", "were", "no", "research", "and", "development", "expenses", "from", "discontinued", "operations", "in", "2011,", "2010,", "and", "2009."], "wordsB": ["There", "were", "no", "research", "and", "development", "expenses", "from", "discontinued", "operations", "in", "2012,", "2011", "and", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p64_s0", "idA": "886163_12_item1_p57_s0", "sentA": "Competition Some of the drugs we are developing may compete with existing therapies or other drugs in development by other companies.", "sentB": "Competition Some of the drugs we and our collaborative partners are developing may compete with existing therapies or other drugs in development by other companies.", "type": 2, "words": ["<tag1>", "Competition", "Some", "of", "the", "drugs", "we", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag2>", "Competition", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag3>"], "wordsA": ["Competition", "Some", "of", "the", "drugs", "we", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "wordsB": ["Competition", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p1_s1", "idA": "886163_12_item1_p5_s1", "sentA": "The therapies in our portfolio in development address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis.", "sentB": "The therapies in our development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, multiple myeloma, Alzheimer s disease, dyslipidemia, diabetes, anemia, epilepsy, FSGS and osteoporosis.", "type": 2, "words": ["<tag1>", "The", "therapies", "in", "our", "portfolio", "in", "development", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "asthma,", "rheumatoid", "arthritis", "and", "osteoporosis.", "<tag2>", "The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "FSGS", "and", "osteoporosis.", "<tag3>"], "wordsA": ["The", "therapies", "in", "our", "portfolio", "in", "development", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "asthma,", "rheumatoid", "arthritis", "and", "osteoporosis."], "wordsB": ["The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "FSGS", "and", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p1_s2", "idA": "886163_12_item1_p5_s2", "sentA": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., Eli Lilly and Co., and The Medicines Company.", "sentB": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals and The Medicines Company.", "type": 2, "words": ["<tag1>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Onyx", "Pharmaceuticals,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "The", "Medicines", "Company.", "<tag2>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "Spectrum", "Pharmaceuticals", "and", "The", "Medicines", "Company.", "<tag3>"], "wordsA": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Onyx", "Pharmaceuticals,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "The", "Medicines", "Company."], "wordsB": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "Spectrum", "Pharmaceuticals", "and", "The", "Medicines", "Company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p1_s3", "idA": "886163_12_item1_p5_s3", "sentA": "Our business model is designed to create value for stockholders by assembling a diversified portfolio of biotech and pharmaceutical revenue streams and operating that business with an efficient and low cost structure.", "sentB": "Our business model is designed to create value for stockholders by assembling a diversified portfolio of biotech and pharmaceutical revenue streams and operating that business with an efficient and low corporate cost structure.", "type": 2, "words": ["<tag1>", "Our", "business", "model", "is", "designed", "to", "create", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "cost", "structure.", "<tag2>", "Our", "business", "model", "is", "designed", "to", "create", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure.", "<tag3>"], "wordsA": ["Our", "business", "model", "is", "designed", "to", "create", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "cost", "structure."], "wordsB": ["Our", "business", "model", "is", "designed", "to", "create", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p1_s4", "idA": "886163_12_item1_p5_s4", "sentA": "Our goal is to become a sustainably profitable company that offers investors an opportunity to invest in the ever more complicated and unpredictable pharmaceutical industry.", "sentB": "Our goal is to become a sustainably profitable company that offers investors an opportunity to participate in the promise of the biotech industry in a diversified, lower-risk business than a typical biotech.", "type": 2, "words": ["<tag1>", "Our", "goal", "is", "to", "become", "a", "sustainably", "profitable", "company", "that", "offers", "investors", "an", "opportunity", "to", "invest", "in", "the", "ever", "more", "complicated", "and", "unpredictable", "pharmaceutical", "industry.", "<tag2>", "Our", "goal", "is", "to", "become", "a", "sustainably", "profitable", "company", "that", "offers", "investors", "an", "opportunity", "to", "participate", "in", "the", "promise", "of", "the", "biotech", "industry", "in", "a", "diversified,", "lower-risk", "business", "than", "a", "typical", "biotech.", "<tag3>"], "wordsA": ["Our", "goal", "is", "to", "become", "a", "sustainably", "profitable", "company", "that", "offers", "investors", "an", "opportunity", "to", "invest", "in", "the", "ever", "more", "complicated", "and", "unpredictable", "pharmaceutical", "industry."], "wordsB": ["Our", "goal", "is", "to", "become", "a", "sustainably", "profitable", "company", "that", "offers", "investors", "an", "opportunity", "to", "participate", "in", "the", "promise", "of", "the", "biotech", "industry", "in", "a", "diversified,", "lower-risk", "business", "than", "a", "typical", "biotech."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p70_s3", "idA": "886163_12_item1_p64_s3", "sentA": "Royalties we currently receive from Pfizer, as successor to King on AVINZA represent a portion of our ongoing revenue.", "sentB": "Royalties we currently receive from Pfizer on Avinza represent a portion of our ongoing revenue.", "type": 2, "words": ["<tag1>", "Royalties", "we", "currently", "receive", "from", "Pfizer,", "as", "successor", "to", "King", "on", "AVINZA", "represent", "a", "portion", "of", "our", "ongoing", "revenue.", "<tag2>", "Royalties", "we", "currently", "receive", "from", "Pfizer", "on", "Avinza", "represent", "a", "portion", "of", "our", "ongoing", "revenue.", "<tag3>"], "wordsA": ["Royalties", "we", "currently", "receive", "from", "Pfizer,", "as", "successor", "to", "King", "on", "AVINZA", "represent", "a", "portion", "of", "our", "ongoing", "revenue."], "wordsB": ["Royalties", "we", "currently", "receive", "from", "Pfizer", "on", "Avinza", "represent", "a", "portion", "of", "our", "ongoing", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p70_s5", "idA": "886163_12_item1_p64_s5", "sentA": "The last to expire United States patents relating to PROMACTA is not expected to expire until December 2024.", "sentB": "The last to expire United States patents relating to Promacta is not expected to expire until August 2027.", "type": 2, "words": ["<tag1>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "PROMACTA", "is", "not", "expected", "to", "expire", "until", "December", "2024.", "<tag2>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027.", "<tag3>"], "wordsA": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "PROMACTA", "is", "not", "expected", "to", "expire", "until", "December", "2024."], "wordsB": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p70_s7", "idA": "886163_12_item1_p64_s7", "sentA": "Subject to compliance with the terms of the respective agreements, our rights under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "sentB": "Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "type": 2, "words": ["<tag1>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag2>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag3>"], "wordsA": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "wordsB": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p71_s0", "idA": "886163_12_item1_p65_s0", "sentA": "Human Resources As of February 1, 2012, we had 21 full-time employees, of whom 7 are involved directly in scientific research and development activities.", "sentB": "Human Resources As of February 1, 2013, we had 21 full-time employees, of whom 6 are involved directly in scientific research and development activities.", "type": 2, "words": ["<tag1>", "Human", "Resources", "As", "of", "February", "1,", "2012,", "we", "had", "21", "full-time", "employees,", "of", "whom", "7", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag2>", "Human", "Resources", "As", "of", "February", "1,", "2013,", "we", "had", "21", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["Human", "Resources", "As", "of", "February", "1,", "2012,", "we", "had", "21", "full-time", "employees,", "of", "whom", "7", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "wordsB": ["Human", "Resources", "As", "of", "February", "1,", "2013,", "we", "had", "21", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p71_s1", "idA": "886163_12_item1_p65_s1", "sentA": "Of these employees, 6 hold Ph.D. or M.D. degrees.", "sentB": "Of these employees, 5 hold Ph.D. or M.D. degrees.", "type": 2, "words": ["<tag1>", "Of", "these", "employees,", "6", "hold", "Ph.D.", "or", "M.D.", "degrees.", "<tag2>", "Of", "these", "employees,", "5", "hold", "Ph.D.", "or", "M.D.", "degrees.", "<tag3>"], "wordsA": ["Of", "these", "employees,", "6", "hold", "Ph.D.", "or", "M.D.", "degrees."], "wordsB": ["Of", "these", "employees,", "5", "hold", "Ph.D.", "or", "M.D.", "degrees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p1_s5", "idA": "886163_12_item1_p6_s0", "sentA": "doing what we do best; drug discovery, reformulation and partnering with other pharmaceutical companies to leverage what they do best (late stage development, regulatory management and commercialization) to ultimately generate our revenue.", "sentB": "Our business model is based on the concept of doing what we do best; drug discovery, reformulation and partnering with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.", "type": 2, "words": ["<tag1>", "doing", "what", "we", "do", "best;", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late", "stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue.", "<tag2>", "Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best;", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue.", "<tag3>"], "wordsA": ["doing", "what", "we", "do", "best;", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late", "stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue."], "wordsB": ["Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best;", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p2_s1", "idA": "886163_12_item1_p7_s1", "sentA": "We have assembled a portfolio of over 50 fully-funded partner programs that are in all stages of development, from awaiting commercialization to preclinical research.", "sentB": "We have assembled a portfolio of over 70 fully-funded partner programs that are in all stages of development, from preclinical research to awaiting commercialization.", "type": 2, "words": ["<tag1>", "We", "have", "assembled", "a", "portfolio", "of", "over", "50", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "awaiting", "commercialization", "to", "preclinical", "research.", "<tag2>", "We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization.", "<tag3>"], "wordsA": ["We", "have", "assembled", "a", "portfolio", "of", "over", "50", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "awaiting", "commercialization", "to", "preclinical", "research."], "wordsB": ["We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p2_s3", "idA": "886163_12_item1_p7_s3", "sentA": "We assemble this portfolio by either licensing out our own proprietary drug development programs or acquiring in partnered programs from other companies.", "sentB": "We assemble this portfolio by either licensing out our own proprietary drug development programs or acquiring existing partnered programs from other companies.", "type": 2, "words": ["<tag1>", "We", "assemble", "this", "portfolio", "by", "either", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs", "or", "acquiring", "in", "partnered", "programs", "from", "other", "companies.", "<tag2>", "We", "assemble", "this", "portfolio", "by", "either", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies.", "<tag3>"], "wordsA": ["We", "assemble", "this", "portfolio", "by", "either", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs", "or", "acquiring", "in", "partnered", "programs", "from", "other", "companies."], "wordsB": ["We", "assemble", "this", "portfolio", "by", "either", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p2_s5", "idA": "886163_12_item1_p7_s5", "sentA": "We believe partnerships are not only a source of research funding, license fees, future milestone payments and royalties, but they also deliver our assets into the hands of companies that have the expertise to obtain regulatory approval and successfully launch and commercialize these assets.", "sentB": "We believe partnerships are not only a source of research funding, license fees, future milestone payments and royalties, but they also position our assets with companies that have the expertise to obtain regulatory approval and successfully launch and commercialize these assets.", "type": 2, "words": ["<tag1>", "We", "believe", "partnerships", "are", "not", "only", "a", "source", "of", "research", "funding,", "license", "fees,", "future", "milestone", "payments", "and", "royalties,", "but", "they", "also", "deliver", "our", "assets", "into", "the", "hands", "of", "companies", "that", "have", "the", "expertise", "to", "obtain", "regulatory", "approval", "and", "successfully", "launch", "and", "commercialize", "these", "assets.", "<tag2>", "We", "believe", "partnerships", "are", "not", "only", "a", "source", "of", "research", "funding,", "license", "fees,", "future", "milestone", "payments", "and", "royalties,", "but", "they", "also", "position", "our", "assets", "with", "companies", "that", "have", "the", "expertise", "to", "obtain", "regulatory", "approval", "and", "successfully", "launch", "and", "commercialize", "these", "assets.", "<tag3>"], "wordsA": ["We", "believe", "partnerships", "are", "not", "only", "a", "source", "of", "research", "funding,", "license", "fees,", "future", "milestone", "payments", "and", "royalties,", "but", "they", "also", "deliver", "our", "assets", "into", "the", "hands", "of", "companies", "that", "have", "the", "expertise", "to", "obtain", "regulatory", "approval", "and", "successfully", "launch", "and", "commercialize", "these", "assets."], "wordsB": ["We", "believe", "partnerships", "are", "not", "only", "a", "source", "of", "research", "funding,", "license", "fees,", "future", "milestone", "payments", "and", "royalties,", "but", "they", "also", "position", "our", "assets", "with", "companies", "that", "have", "the", "expertise", "to", "obtain", "regulatory", "approval", "and", "successfully", "launch", "and", "commercialize", "these", "assets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p3_s0", "idA": "886163_12_item1_p8_s0", "sentA": "We are selling CAPTISOL material to various customers.", "sentB": "We sell Captisol material to a broad range of customers.", "type": 2, "words": ["<tag1>", "We", "are", "selling", "CAPTISOL", "material", "to", "various", "customers.", "<tag2>", "We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers.", "<tag3>"], "wordsA": ["We", "are", "selling", "CAPTISOL", "material", "to", "various", "customers."], "wordsB": ["We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p4_s0", "idA": "886163_12_item1_p8_s1", "sentA": "We are the sole provider of a proprietary formulation reagent known as CAPTISOL.", "sentB": "We are the sole provider of a proprietary formulation technology known as Captisol.", "type": 2, "words": ["<tag1>", "We", "are", "the", "sole", "provider", "of", "a", "proprietary", "formulation", "reagent", "known", "as", "CAPTISOL.", "<tag2>", "We", "are", "the", "sole", "provider", "of", "a", "proprietary", "formulation", "technology", "known", "as", "Captisol.", "<tag3>"], "wordsA": ["We", "are", "the", "sole", "provider", "of", "a", "proprietary", "formulation", "reagent", "known", "as", "CAPTISOL."], "wordsB": ["We", "are", "the", "sole", "provider", "of", "a", "proprietary", "formulation", "technology", "known", "as", "Captisol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p4_s1", "idA": "886163_12_item1_p8_s2", "sentA": "CAPTISOL is a well validated chemically-modified cyclodextrin molecule that improves the solubility, stability, and pharmicokinetics of many drugs.", "sentB": "Captisol is a well validated chemically-modified cyclodextrin that improves the solubility, stability, and pharmicokinetics of many drugs.", "type": 2, "words": ["<tag1>", "CAPTISOL", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "molecule", "that", "improves", "the", "solubility,", "stability,", "and", "pharmicokinetics", "of", "many", "drugs.", "<tag2>", "Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmicokinetics", "of", "many", "drugs.", "<tag3>"], "wordsA": ["CAPTISOL", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "molecule", "that", "improves", "the", "solubility,", "stability,", "and", "pharmicokinetics", "of", "many", "drugs."], "wordsB": ["Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmicokinetics", "of", "many", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p4_s2", "idA": "886163_12_item1_p8_s3", "sentA": "We receive revenue from the selling of CAPTISOL to our partners that have either licensed our proprietary CAPTISOL-enabled drugs or have taken a license to use CAPTISOL with their own internal programs.", "sentB": "We receive revenue from the selling of Captisol material to our partners that have either licensed our proprietary Captisol-enabled drugs or have taken a license to use Captisol with their own internal programs.", "type": 2, "words": ["<tag1>", "We", "receive", "revenue", "from", "the", "selling", "of", "CAPTISOL", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "CAPTISOL-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "CAPTISOL", "with", "their", "own", "internal", "programs.", "<tag2>", "We", "receive", "revenue", "from", "the", "selling", "of", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs.", "<tag3>"], "wordsA": ["We", "receive", "revenue", "from", "the", "selling", "of", "CAPTISOL", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "CAPTISOL-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "CAPTISOL", "with", "their", "own", "internal", "programs."], "wordsB": ["We", "receive", "revenue", "from", "the", "selling", "of", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p40_s0", "idA": "886163_12_item1_p9_s4", "sentA": "Our goal is to partner our programs early in the development and regulatory life-cycle.", "sentB": "The development and commercialization agreement for Captisol-enabled carbamazepine-IV began in 2004 between Lundbeck (formerly Ovation Pharmaceuticals) and us for the use of Captisol in the formulation of CE carbamazepine-IV.", "type": 2, "words": ["<tag1>", "Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle.", "<tag2>", "The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "began", "in", "2004", "between", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV.", "<tag3>"], "wordsA": ["Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle."], "wordsB": ["The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "began", "in", "2004", "between", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p5_s5", "idA": "886163_12_item1_p9_s5", "sentA": "Our Asset Portfolio We have a portfolio of over 60 current and future potential revenue generating programs, over 50 of which are fully funded by our partners.", "sentB": "Our Asset Portfolio We have a portfolio of over 80 current and future potential revenue generating programs, over 70 of which are fully funded by our partners.", "type": 2, "words": ["<tag1>", "Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "60", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "50", "of", "which", "are", "fully", "funded", "by", "our", "partners.", "<tag2>", "Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "80", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "70", "of", "which", "are", "fully", "funded", "by", "our", "partners.", "<tag3>"], "wordsA": ["Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "60", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "50", "of", "which", "are", "fully", "funded", "by", "our", "partners."], "wordsB": ["Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "80", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "70", "of", "which", "are", "fully", "funded", "by", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p5_s6", "idA": "886163_12_item1_p9_s6", "sentA": "We expect to receive royalties from eight marketed products in 2012 and have multiple programs at Phase IIb through NDA submission which represent our future upcoming potential revenue generating programs.", "sentB": "We expect to receive royalties from seven marketed products in 2013 and have multiple partnered programs at Phase IIb through NDA submission which represent our future upcoming potential revenue generating programs.", "type": 2, "words": ["<tag1>", "We", "expect", "to", "receive", "royalties", "from", "eight", "marketed", "products", "in", "2012", "and", "have", "multiple", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs.", "<tag2>", "We", "expect", "to", "receive", "royalties", "from", "seven", "marketed", "products", "in", "2013", "and", "have", "multiple", "partnered", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs.", "<tag3>"], "wordsA": ["We", "expect", "to", "receive", "royalties", "from", "eight", "marketed", "products", "in", "2012", "and", "have", "multiple", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs."], "wordsB": ["We", "expect", "to", "receive", "royalties", "from", "seven", "marketed", "products", "in", "2013", "and", "have", "multiple", "partnered", "programs", "at", "Phase", "IIb", "through", "NDA", "submission", "which", "represent", "our", "future", "upcoming", "potential", "revenue", "generating", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p0_s4", "idA": "886163_13_item1_p0_s4", "sentA": "Captisol is a powerful formulation technology that has enabled six FDA approved products, including Onyx s Kyprolis and Baxter International s Nexterone and is currently being developed in a number of clinical-stage partner programs.", "sentB": "Captisol is a formulation technology that has enabled six FDA approved products, including Onyx's Kyprolis and Baxter International's Nexterone and is currently being developed in a number of clinical-stage partner programs.", "type": 2, "words": ["<tag1>", "Captisol", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx", "s", "Kyprolis", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag2>", "Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx's", "Kyprolis", "and", "Baxter", "International's", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag3>"], "wordsA": ["Captisol", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx", "s", "Kyprolis", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "wordsB": ["Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx's", "Kyprolis", "and", "Baxter", "International's", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p12_s0", "idA": "886163_13_item1_p10_s0", "sentA": "Promacta is authorized for use in 92 countries.", "sentB": "Promacta is authorized for use in 95 countries.", "type": 2, "words": ["<tag1>", "Promacta", "is", "authorized", "for", "use", "in", "92", "countries.", "<tag2>", "Promacta", "is", "authorized", "for", "use", "in", "95", "countries.", "<tag3>"], "wordsA": ["Promacta", "is", "authorized", "for", "use", "in", "92", "countries."], "wordsB": ["Promacta", "is", "authorized", "for", "use", "in", "95", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p14_s0", "idA": "886163_13_item1_p10_s1", "sentA": "We are entitled to receive tiered royalties on annual net sales of Promacta.", "sentB": "We are entitled to receive royalties on annual net sales of Promacta as set forth in the following table:", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "Promacta.", "<tag2>", "We", "are", "entitled", "to", "receive", "royalties", "on", "annual", "net", "sales", "of", "Promacta", "as", "set", "forth", "in", "the", "following", "table:", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "Promacta."], "wordsB": ["We", "are", "entitled", "to", "receive", "royalties", "on", "annual", "net", "sales", "of", "Promacta", "as", "set", "forth", "in", "the", "following", "table:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p28_s5", "idA": "886163_13_item1_p10_s1", "sentA": "We are entitled to receive tiered royalties on annual net sales of Promacta.", "sentB": "Net royalties on annual net sales of Viviant and Duavee are each payable to us at a rate shown in the table below and are payable through the life of the relevant patents.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "Promacta.", "<tag2>", "Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "annual", "net", "sales", "of", "Promacta."], "wordsB": ["Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s3", "idA": "886163_13_item1_p10_s2", "sentA": "GSK has listed a patent in the FDA s Orange Book for Promacta with an expiration date in 2027.", "sentB": "GSK has listed a patent in the FDA s Orange Book for Promacta with an expiration date in 2027, and we are entitled to receive royalties related to Promacta under this license as set forth below.", "type": 2, "words": ["<tag1>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027.", "<tag2>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "we", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "under", "this", "license", "as", "set", "forth", "below.", "<tag3>"], "wordsA": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027."], "wordsB": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "we", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "under", "this", "license", "as", "set", "forth", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p83_s3", "idA": "886163_13_item1_p10_s2", "sentA": "GSK has listed a patent in the FDA s Orange Book for Promacta with an expiration date in 2027.", "sentB": "The type of patent protection ( e.g ., composition of matter or use) for each patent listed in the Orange Book and the expiration date for each patent listed in the Orange Book are provided in the following table.", "type": 2, "words": ["<tag1>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027.", "<tag2>", "The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "date", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027."], "wordsB": ["The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "date", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p87_s1", "idA": "886163_13_item1_p10_s2", "sentA": "GSK has listed a patent in the FDA s Orange Book for Promacta with an expiration date in 2027.", "sentB": "The type of patent protection ( e.g ., composition of matter or use) for the patent listed in the Orange Book and the expiration date for the patent is provided in the following table.", "type": 2, "words": ["<tag1>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027.", "<tag2>", "The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "the", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "date", "for", "the", "patent", "is", "provided", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027."], "wordsB": ["The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "the", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "date", "for", "the", "patent", "is", "provided", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p17_s0", "idA": "886163_13_item1_p11_s0", "sentA": "Kyprolis (Onyx, Phase III/NDA, Multiple Myeloma) Ligand (formerly CyDex) and Onyx Pharmaceuticals (formerly Proteolix) entered into a collaboration in 2005 to develop the Captisol-enabled IV formulation of Carfilzomib for refractory multiple myeloma.", "sentB": "Kyprolis (Onyx Pharmaceuticals, a subsidiary of Amgen) Ligand and Onyx Pharmaceuticals (formerly Proteolix, and now a subsidiary of Amgen, Inc.), entered into a collaboration in 2005 to develop the Captisol-enabled IV formulation of the active ingredient carfilzomib for refractory multiple myeloma.", "type": 2, "words": ["<tag1>", "Kyprolis", "(Onyx,", "Phase", "III/NDA,", "Multiple", "Myeloma)", "Ligand", "(formerly", "CyDex)", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix)", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "Captisol-enabled", "IV", "formulation", "of", "Carfilzomib", "for", "refractory", "multiple", "myeloma.", "<tag2>", "Kyprolis", "(Onyx", "Pharmaceuticals,", "a", "subsidiary", "of", "Amgen)", "Ligand", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix,", "and", "now", "a", "subsidiary", "of", "Amgen,", "Inc.),", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "Captisol-enabled", "IV", "formulation", "of", "the", "active", "ingredient", "carfilzomib", "for", "refractory", "multiple", "myeloma.", "<tag3>"], "wordsA": ["Kyprolis", "(Onyx,", "Phase", "III/NDA,", "Multiple", "Myeloma)", "Ligand", "(formerly", "CyDex)", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix)", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "Captisol-enabled", "IV", "formulation", "of", "Carfilzomib", "for", "refractory", "multiple", "myeloma."], "wordsB": ["Kyprolis", "(Onyx", "Pharmaceuticals,", "a", "subsidiary", "of", "Amgen)", "Ligand", "and", "Onyx", "Pharmaceuticals", "(formerly", "Proteolix,", "and", "now", "a", "subsidiary", "of", "Amgen,", "Inc.),", "entered", "into", "a", "collaboration", "in", "2005", "to", "develop", "the", "Captisol-enabled", "IV", "formulation", "of", "the", "active", "ingredient", "carfilzomib", "for", "refractory", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p18_s1", "idA": "886163_13_item1_p12_s0", "sentA": "Kyprolis is formulated with Ligand s Captisol and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p19_s5", "idA": "886163_13_item1_p13_s1", "sentA": "Under our agreement with Onyx, we are entitled to receive milestones, tiered royalties ranging between 1.5% and 3% as shown in the table below, and revenue from clinical and commercial Captisol material sales.", "sentB": "Under this agreement, we are entitled to receive remaining milestones of up to $2.5 million, revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis as set forth in the following table:", "type": 2, "words": ["<tag1>", "Under", "our", "agreement", "with", "Onyx,", "we", "are", "entitled", "to", "receive", "milestones,", "tiered", "royalties", "ranging", "between", "1.5%", "and", "3%", "as", "shown", "in", "the", "table", "below,", "and", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales.", "<tag2>", "Under", "this", "agreement,", "we", "are", "entitled", "to", "receive", "remaining", "milestones", "of", "up", "to", "$2.5", "million,", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales", "and", "royalties", "on", "annual", "net", "sales", "of", "Kyprolis", "as", "set", "forth", "in", "the", "following", "table:", "<tag3>"], "wordsA": ["Under", "our", "agreement", "with", "Onyx,", "we", "are", "entitled", "to", "receive", "milestones,", "tiered", "royalties", "ranging", "between", "1.5%", "and", "3%", "as", "shown", "in", "the", "table", "below,", "and", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales."], "wordsB": ["Under", "this", "agreement,", "we", "are", "entitled", "to", "receive", "remaining", "milestones", "of", "up", "to", "$2.5", "million,", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales", "and", "royalties", "on", "annual", "net", "sales", "of", "Kyprolis", "as", "set", "forth", "in", "the", "following", "table:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p20_s1", "idA": "886163_13_item1_p14_s1", "sentA": "In February 2007, we completed the sale of our Avinza product line to King Pharmaceuticals (or King).", "sentB": "In February 2007, we completed the sale of our Avinza product line, together with all patent rights and licenses related to Avinza, to King Pharmaceuticals, which was acquired by Pfizer in February 2011.", "type": 2, "words": ["<tag1>", "In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "Avinza", "product", "line", "to", "King", "Pharmaceuticals", "(or", "King).", "<tag2>", "In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "Avinza", "product", "line,", "together", "with", "all", "patent", "rights", "and", "licenses", "related", "to", "Avinza,", "to", "King", "Pharmaceuticals,", "which", "was", "acquired", "by", "Pfizer", "in", "February", "2011.", "<tag3>"], "wordsA": ["In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "Avinza", "product", "line", "to", "King", "Pharmaceuticals", "(or", "King)."], "wordsB": ["In", "February", "2007,", "we", "completed", "the", "sale", "of", "our", "Avinza", "product", "line,", "together", "with", "all", "patent", "rights", "and", "licenses", "related", "to", "Avinza,", "to", "King", "Pharmaceuticals,", "which", "was", "acquired", "by", "Pfizer", "in", "February", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p20_s2", "idA": "886163_13_item1_p14_s2", "sentA": "As a result of the sale, we receive royalties on the net sales of Avinza through 2017.", "sentB": "As a result of the sale, we are entitled to receive royalties from Prizer on net sales of Avinza through the term of the relevant patent, which we currently expect to expire on November 25, 2017.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "the", "sale,", "we", "receive", "royalties", "on", "the", "net", "sales", "of", "Avinza", "through", "2017.", "<tag2>", "As", "a", "result", "of", "the", "sale,", "we", "are", "entitled", "to", "receive", "royalties", "from", "Prizer", "on", "net", "sales", "of", "Avinza", "through", "the", "term", "of", "the", "relevant", "patent,", "which", "we", "currently", "expect", "to", "expire", "on", "November", "25,", "2017.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "sale,", "we", "receive", "royalties", "on", "the", "net", "sales", "of", "Avinza", "through", "2017."], "wordsB": ["As", "a", "result", "of", "the", "sale,", "we", "are", "entitled", "to", "receive", "royalties", "from", "Prizer", "on", "net", "sales", "of", "Avinza", "through", "the", "term", "of", "the", "relevant", "patent,", "which", "we", "currently", "expect", "to", "expire", "on", "November", "25,", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p20_s3", "idA": "886163_13_item1_p14_s3", "sentA": "Royalties are paid at a rate of 5% on sales up to $200 million and a higher rate above $200 million.", "sentB": "Royalties on annual net sales are paid at a rate of 5% on sales up to $200 million, 10% on sales above $200 million and 15% on sales above $250 million.", "type": 2, "words": ["<tag1>", "Royalties", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million", "and", "a", "higher", "rate", "above", "$200", "million.", "<tag2>", "Royalties", "on", "annual", "net", "sales", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million,", "10%", "on", "sales", "above", "$200", "million", "and", "15%", "on", "sales", "above", "$250", "million.", "<tag3>"], "wordsA": ["Royalties", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million", "and", "a", "higher", "rate", "above", "$200", "million."], "wordsB": ["Royalties", "on", "annual", "net", "sales", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million,", "10%", "on", "sales", "above", "$200", "million", "and", "15%", "on", "sales", "above", "$250", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p28_s0", "idA": "886163_13_item1_p18_s0", "sentA": "Viviant, a selective estrogen receptor modulator (SERM), is a result of the successful research collaboration between Wyeth (now a subsidiary of Pfizer) and us that began in 1994.", "sentB": "Viviant, a selective estrogen receptor modulator, or SERM, is a result of the successful research collaboration between Wyeth (now a subsidiary of Pfizer) and us that began in 1994.", "type": 2, "words": ["<tag1>", "Viviant,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994.", "<tag2>", "Viviant,", "a", "selective", "estrogen", "receptor", "modulator,", "or", "SERM,", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994.", "<tag3>"], "wordsA": ["Viviant,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994."], "wordsB": ["Viviant,", "a", "selective", "estrogen", "receptor", "modulator,", "or", "SERM,", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p51_s1", "idA": "886163_13_item1_p18_s2", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "Additionally, we are owed net tiered royalties on future sales of 6.0% to 7.5%.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "Additionally,", "we", "are", "owed", "net", "tiered", "royalties", "on", "future", "sales", "of", "6.0%", "to", "7.5%.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["Additionally,", "we", "are", "owed", "net", "tiered", "royalties", "on", "future", "sales", "of", "6.0%", "to", "7.5%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p30_s0", "idA": "886163_13_item1_p18_s3", "sentA": "Any such royalties may be subject to reduction or offset for past milestone payments and/or may be subject to other terms and conditions set forth in our agreement with Pfizer.", "sentB": "Any such royalties may be subject to reduction or offset for past milestone payments and/or may be subject to other terms and conditions set forth in our license agreement with Pfizer.", "type": 2, "words": ["<tag1>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer.", "<tag2>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "license", "agreement", "with", "Pfizer.", "<tag3>"], "wordsA": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer."], "wordsB": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "for", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "license", "agreement", "with", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p31_s0", "idA": "886163_13_item1_p19_s0", "sentA": "In 2006, Ligand outlicensed Nexterone, an injectable formulation combining amiodarone and Captisol, to Baxter International, or Baxter (formerly Prism Pharmaceuticals, Inc.).", "sentB": "In 2006, we outlicensed Nexterone, an injectable formulation combining amiodarone and Captisol, to Baxter International, Inc. or Baxter (which acquired Prism Pharmaceuticals, Inc., the original licensee, in 2011).", "type": 2, "words": ["<tag1>", "In", "2006,", "Ligand", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "or", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.).", "<tag2>", "In", "2006,", "we", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "Inc.", "or", "Baxter", "(which", "acquired", "Prism", "Pharmaceuticals,", "Inc.,", "the", "original", "licensee,", "in", "2011).", "<tag3>"], "wordsA": ["In", "2006,", "Ligand", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "or", "Baxter", "(formerly", "Prism", "Pharmaceuticals,", "Inc.)."], "wordsB": ["In", "2006,", "we", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "Inc.", "or", "Baxter", "(which", "acquired", "Prism", "Pharmaceuticals,", "Inc.,", "the", "original", "licensee,", "in", "2011)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p42_s1", "idA": "886163_13_item1_p19_s1", "sentA": "Under the terms of the agreement, Baxter is responsible, under an exclusive worldwide license, for all development and commercialization of Nexterone at its sole expense.", "sentB": "Under the agreement, we granted to Azure an exclusive worldwide license to develop and market a novel formulation of lasofoxifene.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "Under", "the", "agreement,", "we", "granted", "to", "Azure", "an", "exclusive", "worldwide", "license", "to", "develop", "and", "market", "a", "novel", "formulation", "of", "lasofoxifene.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["Under", "the", "agreement,", "we", "granted", "to", "Azure", "an", "exclusive", "worldwide", "license", "to", "develop", "and", "market", "a", "novel", "formulation", "of", "lasofoxifene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p5_s2", "idA": "886163_13_item1_p19_s1", "sentA": "Under the terms of the agreement, Baxter is responsible, under an exclusive worldwide license, for all development and commercialization of Nexterone at its sole expense.", "sentB": "Fully funded programs are those for which our partners pay all of the development and commercialization costs.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "Fully", "funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["Fully", "funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p28_s4", "idA": "886163_13_item1_p19_s2", "sentA": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "sentB": "Pfizer launched Duavee in the United States in the first quarter of 2014.", "type": 2, "words": ["<tag1>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag2>", "Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014.", "<tag3>"], "wordsA": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "wordsB": ["Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p82_s1", "idA": "886163_13_item1_p19_s2", "sentA": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "sentB": "The scope and type of patent protection provided by each patent family is defined by the claims in the various patents.", "type": 2, "words": ["<tag1>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag2>", "The", "scope", "and", "type", "of", "patent", "protection", "provided", "by", "each", "patent", "family", "is", "defined", "by", "the", "claims", "in", "the", "various", "patents.", "<tag3>"], "wordsA": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "wordsB": ["The", "scope", "and", "type", "of", "patent", "protection", "provided", "by", "each", "patent", "family", "is", "defined", "by", "the", "claims", "in", "the", "various", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p87_s2", "idA": "886163_13_item1_p19_s2", "sentA": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "sentB": "Certain related patents in other jurisdictions are not identified in the following table, as our royalties are based on sales in the United States.", "type": 2, "words": ["<tag1>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag2>", "Certain", "related", "patents", "in", "other", "jurisdictions", "are", "not", "identified", "in", "the", "following", "table,", "as", "our", "royalties", "are", "based", "on", "sales", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "wordsB": ["Certain", "related", "patents", "in", "other", "jurisdictions", "are", "not", "identified", "in", "the", "following", "table,", "as", "our", "royalties", "are", "based", "on", "sales", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p43_s1", "idA": "886163_13_item1_p19_s3", "sentA": "We are supplying Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "Under the terms of the license agreement with Azure, we retain the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "type": 2, "words": ["<tag1>", "We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retain", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag3>"], "wordsA": ["We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retain", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p31_s4", "idA": "886163_13_item1_p19_s4", "sentA": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through early 2029.", "sentB": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through early 2033.", "type": 2, "words": ["<tag1>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029.", "<tag2>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2033.", "<tag3>"], "wordsA": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029."], "wordsB": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2033."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p49_s0", "idA": "886163_13_item1_p19_s4", "sentA": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through early 2029.", "sentB": "Melinta has made certain milestone payments to us already and may be required to pay us an aggregate of an additional $3.6 million upon the achievement of specified development and regulatory approval milestones.", "type": 2, "words": ["<tag1>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029.", "<tag2>", "Melinta", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$3.6", "million", "upon", "the", "achievement", "of", "specified", "development", "and", "regulatory", "approval", "milestones.", "<tag3>"], "wordsA": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029."], "wordsB": ["Melinta", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$3.6", "million", "upon", "the", "achievement", "of", "specified", "development", "and", "regulatory", "approval", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p1_s1", "idA": "886163_13_item1_p1_s1", "sentA": "The therapies in our development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, multiple myeloma, Alzheimer s disease, dyslipidemia, diabetes, anemia, epilepsy, FSGS and osteoporosis.", "sentB": "The therapies in our development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, immune (idiopathic) thrombocytopenic purpura, or ITP, muscle wasting, multiple myeloma, Alzheimer s disease, dyslipidemia, diabetes, anemia, epilepsy, Focal Segmental Glomerulosclerosis, or FSGS, and osteoporosis.", "type": 2, "words": ["<tag1>", "The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "FSGS", "and", "osteoporosis.", "<tag2>", "The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "Focal", "Segmental", "Glomerulosclerosis,", "or", "FSGS,", "and", "osteoporosis.", "<tag3>"], "wordsA": ["The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "FSGS", "and", "osteoporosis."], "wordsB": ["The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "Focal", "Segmental", "Glomerulosclerosis,", "or", "FSGS,", "and", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p2_s0", "idA": "886163_13_item1_p1_s2", "sentA": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals and The Medicines Company.", "sentB": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen, Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly and Co., and Spectrum Pharmaceuticals, Inc.", "type": 2, "words": ["<tag1>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "Spectrum", "Pharmaceuticals", "and", "The", "Medicines", "Company.", "<tag2>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals", "(a", "subsidiary", "of", "Amgen,", "Inc.),", "Merck,", "Pfizer,", "Baxter", "International,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "Spectrum", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals,", "Merck,", "Pfizer,", "Baxter", "International,", "Bristol-Myers", "Squibb,", "Celgene,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "Spectrum", "Pharmaceuticals", "and", "The", "Medicines", "Company."], "wordsB": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals", "(a", "subsidiary", "of", "Amgen,", "Inc.),", "Merck,", "Pfizer,", "Baxter", "International,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "Spectrum", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p4_s2", "idA": "886163_13_item1_p1_s5", "sentA": "Our business model is based on the concept of doing what we do best; drug discovery, reformulation and partnering with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.", "sentB": "Our business model is based on the concept of doing what we do best: drug discovery, reformulation and partnering with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.", "type": 2, "words": ["<tag1>", "Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best;", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue.", "<tag2>", "Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue.", "<tag3>"], "wordsA": ["Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best;", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue."], "wordsB": ["Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p57_s1", "idA": "886163_13_item1_p20_s0", "sentA": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "Inhibitors of IRAK4 may also be useful for the treatment of certain leukemias and lymphomas.", "type": 2, "words": ["<tag1>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas.", "<tag3>"], "wordsA": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p28_s2", "idA": "886163_13_item1_p20_s1", "sentA": "Pfizer has combined Viviant with Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women.", "sentB": "Pfizer has combined bazedoxifene (discussed above) with the active ingredient in Premarin to create Duavee , a combination therapy for the treatment of post-menopausal symptoms in women.", "type": 2, "words": ["<tag1>", "Pfizer", "has", "combined", "Viviant", "with", "Premarin", "to", "create", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag2>", "Pfizer", "has", "combined", "bazedoxifene", "(discussed", "above)", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee", ",", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag3>"], "wordsA": ["Pfizer", "has", "combined", "Viviant", "with", "Premarin", "to", "create", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "wordsB": ["Pfizer", "has", "combined", "bazedoxifene", "(discussed", "above)", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee", ",", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p28_s3", "idA": "886163_13_item1_p20_s2", "sentA": "Pfizer has completed Phase III studies of bazedoxifene and filed an approval submission with the FDA and EMA in 2012.", "sentB": "Pfizer obtained FDA approval for Duavee in the United States in October 2013 and filed an approval submission with the EMA in 2012.", "type": 2, "words": ["<tag1>", "Pfizer", "has", "completed", "Phase", "III", "studies", "of", "bazedoxifene", "and", "filed", "an", "approval", "submission", "with", "the", "FDA", "and", "EMA", "in", "2012.", "<tag2>", "Pfizer", "obtained", "FDA", "approval", "for", "Duavee", "in", "the", "United", "States", "in", "October", "2013", "and", "filed", "an", "approval", "submission", "with", "the", "EMA", "in", "2012.", "<tag3>"], "wordsA": ["Pfizer", "has", "completed", "Phase", "III", "studies", "of", "bazedoxifene", "and", "filed", "an", "approval", "submission", "with", "the", "FDA", "and", "EMA", "in", "2012."], "wordsB": ["Pfizer", "obtained", "FDA", "approval", "for", "Duavee", "in", "the", "United", "States", "in", "October", "2013", "and", "filed", "an", "approval", "submission", "with", "the", "EMA", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p16_s0", "idA": "886163_13_item1_p20_s5", "sentA": "Any such royalties may be subject to reduction or offset against past milestone payments and/or may be subject to other terms and conditions set forth in our agreement with Pfizer.", "sentB": "Any such royalties may be subject to reduction (e.g., in the event of no patent coverage for the product) and/or may be subject to other terms and conditions set forth in our license agreement with GSK.", "type": 2, "words": ["<tag1>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer.", "<tag2>", "Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "(e.g.,", "in", "the", "event", "of", "no", "patent", "coverage", "for", "the", "product)", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "license", "agreement", "with", "GSK.", "<tag3>"], "wordsA": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "or", "offset", "against", "past", "milestone", "payments", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "agreement", "with", "Pfizer."], "wordsB": ["Any", "such", "royalties", "may", "be", "subject", "to", "reduction", "(e.g.,", "in", "the", "event", "of", "no", "patent", "coverage", "for", "the", "product)", "and/or", "may", "be", "subject", "to", "other", "terms", "and", "conditions", "set", "forth", "in", "our", "license", "agreement", "with", "GSK."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p11_s4", "idA": "886163_13_item1_p21_s0", "sentA": "Promacta (GSK, Oncology) GSK is conducting Phase II clinical studies of Promacta for oncology-related thrombocytopenia in patients with solid tumors, Myelodysplastic Syndrome (MDS), or Secondary Acute Myeloid Leukemia (AML) after MDS.", "sentB": "GSK is conducting clinical studies of Promacta for various indications, including oncology-related indications.", "type": 2, "words": ["<tag1>", "Promacta", "(GSK,", "Oncology)", "GSK", "is", "conducting", "Phase", "II", "clinical", "studies", "of", "Promacta", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "Myelodysplastic", "Syndrome", "(MDS),", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "(AML)", "after", "MDS.", "<tag2>", "GSK", "is", "conducting", "clinical", "studies", "of", "Promacta", "for", "various", "indications,", "including", "oncology-related", "indications.", "<tag3>"], "wordsA": ["Promacta", "(GSK,", "Oncology)", "GSK", "is", "conducting", "Phase", "II", "clinical", "studies", "of", "Promacta", "for", "oncology-related", "thrombocytopenia", "in", "patients", "with", "solid", "tumors,", "Myelodysplastic", "Syndrome", "(MDS),", "or", "Secondary", "Acute", "Myeloid", "Leukemia", "(AML)", "after", "MDS."], "wordsB": ["GSK", "is", "conducting", "clinical", "studies", "of", "Promacta", "for", "various", "indications,", "including", "oncology-related", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p22_s0", "idA": "886163_13_item1_p22_s0", "sentA": "In March 2013, we licensed the full world-wide rights to Captisol-enabled melphalan IV to Spectrum Pharmaceuticals, Inc.", "sentB": "In March 2013, we licensed the full world-wide rights to Captisol-enabled melphalan IV to Spectrum Pharmaceuticals, Inc., or Spectrum.", "type": 2, "words": ["<tag1>", "In", "March", "2013,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "Captisol-enabled", "melphalan", "IV", "to", "Spectrum", "Pharmaceuticals,", "Inc.", "<tag2>", "In", "March", "2013,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "Captisol-enabled", "melphalan", "IV", "to", "Spectrum", "Pharmaceuticals,", "Inc.,", "or", "Spectrum.", "<tag3>"], "wordsA": ["In", "March", "2013,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "Captisol-enabled", "melphalan", "IV", "to", "Spectrum", "Pharmaceuticals,", "Inc."], "wordsB": ["In", "March", "2013,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "Captisol-enabled", "melphalan", "IV", "to", "Spectrum", "Pharmaceuticals,", "Inc.,", "or", "Spectrum."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p24_s0", "idA": "886163_13_item1_p22_s4", "sentA": "Under the terms of the license agreement, we will receive a $3 million license fee and are eligible to receive more than $50 million in potential milestone payments.", "sentB": "Under the terms of the license agreement, we granted an exclusive license to Spectrum under our patent rights to Captisol relating to the melphalan product.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement,", "we", "will", "receive", "a", "$3", "million", "license", "fee", "and", "are", "eligible", "to", "receive", "more", "than", "$50", "million", "in", "potential", "milestone", "payments.", "<tag2>", "Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "melphalan", "product.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement,", "we", "will", "receive", "a", "$3", "million", "license", "fee", "and", "are", "eligible", "to", "receive", "more", "than", "$50", "million", "in", "potential", "milestone", "payments."], "wordsB": ["Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "melphalan", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s2", "idA": "886163_13_item1_p22_s4", "sentA": "Under the terms of the license agreement, we will receive a $3 million license fee and are eligible to receive more than $50 million in potential milestone payments.", "sentB": "Under the terms of our Royalty Stream and Milestone Payments Purchase Agreement with Selexis, we are eligible to receive approximately $17 million in milestones and potentially over $40 million in estimated annual royalties from these assets.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement,", "we", "will", "receive", "a", "$3", "million", "license", "fee", "and", "are", "eligible", "to", "receive", "more", "than", "$50", "million", "in", "potential", "milestone", "payments.", "<tag2>", "Under", "the", "terms", "of", "our", "Royalty", "Stream", "and", "Milestone", "Payments", "Purchase", "Agreement", "with", "Selexis,", "we", "are", "eligible", "to", "receive", "approximately", "$17", "million", "in", "milestones", "and", "potentially", "over", "$40", "million", "in", "estimated", "annual", "royalties", "from", "these", "assets.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement,", "we", "will", "receive", "a", "$3", "million", "license", "fee", "and", "are", "eligible", "to", "receive", "more", "than", "$50", "million", "in", "potential", "milestone", "payments."], "wordsB": ["Under", "the", "terms", "of", "our", "Royalty", "Stream", "and", "Milestone", "Payments", "Purchase", "Agreement", "with", "Selexis,", "we", "are", "eligible", "to", "receive", "approximately", "$17", "million", "in", "milestones", "and", "potentially", "over", "$40", "million", "in", "estimated", "annual", "royalties", "from", "these", "assets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p24_s1", "idA": "886163_13_item1_p22_s5", "sentA": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate in the range of 15% to 25%.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p42_s2", "idA": "886163_13_item1_p22_s5", "sentA": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "We are entitled to receive up to $2.6 million in potential development and regulatory milestones as well as a 5% royalty on future net sales through the later of the life of the relevant patents (currently expected to be at least until 2027) or 10 years after regulatory approval.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "We", "are", "entitled", "to", "receive", "up", "to", "$2.6", "million", "in", "potential", "development", "and", "regulatory", "milestones", "as", "well", "as", "a", "5%", "royalty", "on", "future", "net", "sales", "through", "the", "later", "of", "the", "life", "of", "the", "relevant", "patents", "(currently", "expected", "to", "be", "at", "least", "until", "2027)", "or", "10", "years", "after", "regulatory", "approval.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["We", "are", "entitled", "to", "receive", "up", "to", "$2.6", "million", "in", "potential", "development", "and", "regulatory", "milestones", "as", "well", "as", "a", "5%", "royalty", "on", "future", "net", "sales", "through", "the", "later", "of", "the", "life", "of", "the", "relevant", "patents", "(currently", "expected", "to", "be", "at", "least", "until", "2027)", "or", "10", "years", "after", "regulatory", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p43_s3", "idA": "886163_13_item1_p22_s5", "sentA": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s0", "idA": "886163_13_item1_p23_s0", "sentA": "This program is currently enrolling patients in a pivotal clinical trial.", "sentB": "This program has completed enrollment in a pivotal clinical trial.", "type": 2, "words": ["<tag1>", "This", "program", "is", "currently", "enrolling", "patients", "in", "a", "pivotal", "clinical", "trial.", "<tag2>", "This", "program", "has", "completed", "enrollment", "in", "a", "pivotal", "clinical", "trial.", "<tag3>"], "wordsA": ["This", "program", "is", "currently", "enrolling", "patients", "in", "a", "pivotal", "clinical", "trial."], "wordsB": ["This", "program", "has", "completed", "enrollment", "in", "a", "pivotal", "clinical", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p32_s0", "idA": "886163_13_item1_p24_s0", "sentA": "Merck Captisol Program, Molecule Undisclosed(Merck, Phase III, Undisclosed Indication) Ligand and Merck entered into a Captisol supply agreement in June 2011 for an undisclosed Merck program.", "sentB": "We and Merck entered into a Captisol supply agreement in June 2011 for Captisol-enabled Noxafil-IV.", "type": 2, "words": ["<tag1>", "Merck", "Captisol", "Program,", "Molecule", "Undisclosed(Merck,", "Phase", "III,", "Undisclosed", "Indication)", "Ligand", "and", "Merck", "entered", "into", "a", "Captisol", "supply", "agreement", "in", "June", "2011", "for", "an", "undisclosed", "Merck", "program.", "<tag2>", "We", "and", "Merck", "entered", "into", "a", "Captisol", "supply", "agreement", "in", "June", "2011", "for", "Captisol-enabled", "Noxafil-IV.", "<tag3>"], "wordsA": ["Merck", "Captisol", "Program,", "Molecule", "Undisclosed(Merck,", "Phase", "III,", "Undisclosed", "Indication)", "Ligand", "and", "Merck", "entered", "into", "a", "Captisol", "supply", "agreement", "in", "June", "2011", "for", "an", "undisclosed", "Merck", "program."], "wordsB": ["We", "and", "Merck", "entered", "into", "a", "Captisol", "supply", "agreement", "in", "June", "2011", "for", "Captisol-enabled", "Noxafil-IV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p32_s1", "idA": "886163_13_item1_p24_s1", "sentA": "Merck is currently conducting a pivitol study for this program and we expect Merck to potentially file a 505(b)(2) in 2013 for approval to market this Captisol program.", "sentB": "Merck has completed a Phase 3 study for this program and it filed a 505(b)(2) in 2013 for approval in the United States and European Union to market the drug.", "type": 2, "words": ["<tag1>", "Merck", "is", "currently", "conducting", "a", "pivitol", "study", "for", "this", "program", "and", "we", "expect", "Merck", "to", "potentially", "file", "a", "505(b)(2)", "in", "2013", "for", "approval", "to", "market", "this", "Captisol", "program.", "<tag2>", "Merck", "has", "completed", "a", "Phase", "3", "study", "for", "this", "program", "and", "it", "filed", "a", "505(b)(2)", "in", "2013", "for", "approval", "in", "the", "United", "States", "and", "European", "Union", "to", "market", "the", "drug.", "<tag3>"], "wordsA": ["Merck", "is", "currently", "conducting", "a", "pivitol", "study", "for", "this", "program", "and", "we", "expect", "Merck", "to", "potentially", "file", "a", "505(b)(2)", "in", "2013", "for", "approval", "to", "market", "this", "Captisol", "program."], "wordsB": ["Merck", "has", "completed", "a", "Phase", "3", "study", "for", "this", "program", "and", "it", "filed", "a", "505(b)(2)", "in", "2013", "for", "approval", "in", "the", "United", "States", "and", "European", "Union", "to", "market", "the", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p66_s0", "idA": "886163_13_item1_p24_s3", "sentA": "In June 2011, we licensed the full world-wide rights to our Captisol-enabled clopidogrel program to The Medicines Company.", "sentB": "We licensed the full worldwide rights to The Medicines Company, or MedCo, in June 2011.", "type": 2, "words": ["<tag1>", "In", "June", "2011,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "our", "Captisol-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company.", "<tag2>", "We", "licensed", "the", "full", "worldwide", "rights", "to", "The", "Medicines", "Company,", "or", "MedCo,", "in", "June", "2011.", "<tag3>"], "wordsA": ["In", "June", "2011,", "we", "licensed", "the", "full", "world-wide", "rights", "to", "our", "Captisol-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company."], "wordsB": ["We", "licensed", "the", "full", "worldwide", "rights", "to", "The", "Medicines", "Company,", "or", "MedCo,", "in", "June", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p65_s0", "idA": "886163_13_item1_p25_s0", "sentA": "Clopidogrel is the active ingredient in Plavix , the world s leading anti-platelet medication which is currently only available in an oral formulation.", "sentB": "Clopidogrel is the active ingredient in PLAVIX , a leading anti-platelet medication which is currently only available in an oral formulation.", "type": 2, "words": ["<tag1>", "Clopidogrel", "is", "the", "active", "ingredient", "in", "Plavix", ",", "the", "world", "s", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation.", "<tag2>", "Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", ",", "a", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation.", "<tag3>"], "wordsA": ["Clopidogrel", "is", "the", "active", "ingredient", "in", "Plavix", ",", "the", "world", "s", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation."], "wordsB": ["Clopidogrel", "is", "the", "active", "ingredient", "in", "PLAVIX", ",", "a", "leading", "anti-platelet", "medication", "which", "is", "currently", "only", "available", "in", "an", "oral", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p32_s4", "idA": "886163_13_item1_p26_s3", "sentA": "The Medicines Company is planning to initiate a pivotal study for the program in 2013 and is developing the product for global markets.", "sentB": "Action is expected for both the NDA and MAA in 2014, which may lead to commercial sale of Captisol for the program in multiple markets.", "type": 2, "words": ["<tag1>", "The", "Medicines", "Company", "is", "planning", "to", "initiate", "a", "pivotal", "study", "for", "the", "program", "in", "2013", "and", "is", "developing", "the", "product", "for", "global", "markets.", "<tag2>", "Action", "is", "expected", "for", "both", "the", "NDA", "and", "MAA", "in", "2014,", "which", "may", "lead", "to", "commercial", "sale", "of", "Captisol", "for", "the", "program", "in", "multiple", "markets.", "<tag3>"], "wordsA": ["The", "Medicines", "Company", "is", "planning", "to", "initiate", "a", "pivotal", "study", "for", "the", "program", "in", "2013", "and", "is", "developing", "the", "product", "for", "global", "markets."], "wordsB": ["Action", "is", "expected", "for", "both", "the", "NDA", "and", "MAA", "in", "2014,", "which", "may", "lead", "to", "commercial", "sale", "of", "Captisol", "for", "the", "program", "in", "multiple", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p37_s0", "idA": "886163_13_item1_p27_s0", "sentA": "In early 2012, we licensed the world-wide rights to RE-021 (formerly known as DARA-a Dual Acting Receptor Antagonist of Angiotension and Endothelin receptors) to Retrophin, Inc., or Retrophin.", "sentB": "In early 2012, we licensed the world-wide rights to Sparsentan (formerly known as RE-021 and DARA-a Dual Acting Receptor Antagonist of Angiotension and Endothelin receptors) to Retrophin, Inc., or Retrophin.", "type": 2, "words": ["<tag1>", "In", "early", "2012,", "we", "licensed", "the", "world-wide", "rights", "to", "RE-021", "(formerly", "known", "as", "DARA-a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)", "to", "Retrophin,", "Inc.,", "or", "Retrophin.", "<tag2>", "In", "early", "2012,", "we", "licensed", "the", "world-wide", "rights", "to", "Sparsentan", "(formerly", "known", "as", "RE-021", "and", "DARA-a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)", "to", "Retrophin,", "Inc.,", "or", "Retrophin.", "<tag3>"], "wordsA": ["In", "early", "2012,", "we", "licensed", "the", "world-wide", "rights", "to", "RE-021", "(formerly", "known", "as", "DARA-a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)", "to", "Retrophin,", "Inc.,", "or", "Retrophin."], "wordsB": ["In", "early", "2012,", "we", "licensed", "the", "world-wide", "rights", "to", "Sparsentan", "(formerly", "known", "as", "RE-021", "and", "DARA-a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)", "to", "Retrophin,", "Inc.,", "or", "Retrophin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p37_s1", "idA": "886163_13_item1_p27_s1", "sentA": "Retrophin intends to develop RE-021 for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy.", "sentB": "Retrophin is developing Sparsentan for orphan indications of severe kidney diseases including FSGS as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy.", "type": 2, "words": ["<tag1>", "Retrophin", "intends", "to", "develop", "RE-021", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy.", "<tag2>", "Retrophin", "is", "developing", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy.", "<tag3>"], "wordsA": ["Retrophin", "intends", "to", "develop", "RE-021", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy."], "wordsB": ["Retrophin", "is", "developing", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p38_s1", "idA": "886163_13_item1_p28_s1", "sentA": "RE-021, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.", "sentB": "Sparsentan, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.", "type": 2, "words": ["<tag1>", "RE-021,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies.", "<tag2>", "Sparsentan,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies.", "<tag3>"], "wordsA": ["RE-021,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies."], "wordsB": ["Sparsentan,", "with", "its", "unique", "dual", "blockade", "of", "angiotensin", "and", "endothelin", "receptors,", "is", "expected", "to", "provide", "meaningful", "clinical", "benefits", "in", "mitigating", "proteinuria", "in", "indications", "where", "there", "are", "no", "approved", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p51_s0", "idA": "886163_13_item1_p29_s0", "sentA": "We received an upfront payment of $1 million, net of amounts owed to third parties.", "sentB": "CurX has made certain milestone payments to us already and may be required to pay us an aggregate of an additional $19.6 million, net of amounts owed to third parties upon the achievement of specified milestones.", "type": 2, "words": ["<tag1>", "We", "received", "an", "upfront", "payment", "of", "$1", "million,", "net", "of", "amounts", "owed", "to", "third", "parties.", "<tag2>", "CurX", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones.", "<tag3>"], "wordsA": ["We", "received", "an", "upfront", "payment", "of", "$1", "million,", "net", "of", "amounts", "owed", "to", "third", "parties."], "wordsB": ["CurX", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p40_s0", "idA": "886163_13_item1_p29_s1", "sentA": "In late 2012, we received a milestone payment of 620,000 shares of common stock in partner Retrophin, Inc.", "sentB": "In late 2012, we received a milestone payment of 620,000 shares of common stock in Retrophin.", "type": 2, "words": ["<tag1>", "In", "late", "2012,", "we", "received", "a", "milestone", "payment", "of", "620,000", "shares", "of", "common", "stock", "in", "partner", "Retrophin,", "Inc.", "<tag2>", "In", "late", "2012,", "we", "received", "a", "milestone", "payment", "of", "620,000", "shares", "of", "common", "stock", "in", "Retrophin.", "<tag3>"], "wordsA": ["In", "late", "2012,", "we", "received", "a", "milestone", "payment", "of", "620,000", "shares", "of", "common", "stock", "in", "partner", "Retrophin,", "Inc."], "wordsB": ["In", "late", "2012,", "we", "received", "a", "milestone", "payment", "of", "620,000", "shares", "of", "common", "stock", "in", "Retrophin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p5_s1", "idA": "886163_13_item1_p2_s1", "sentA": "We have assembled a portfolio of over 70 fully-funded partner programs that are in all stages of development, from preclinical research to awaiting commercialization.", "sentB": "We have assembled a portfolio of over 90 fully funded partner programs that are in all stages of development, from preclinical research to awaiting commercialization.", "type": 2, "words": ["<tag1>", "We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization.", "<tag2>", "We", "have", "assembled", "a", "portfolio", "of", "over", "90", "fully", "funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization.", "<tag3>"], "wordsA": ["We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization."], "wordsB": ["We", "have", "assembled", "a", "portfolio", "of", "over", "90", "fully", "funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p41_s0", "idA": "886163_13_item1_p30_s1", "sentA": "We may receive over $75 million in milestones as well as 9% in royalties on potential future worldwide sales by Retrophin.", "sentB": "Under our license agreement with Retrophin we are entitled to receive over $75 million in milestones, as well as 9% in royalties on future worldwide sales by Retrophin through the life of the relevant patents, which we currently expect to be through at least 2019 and may be extended until 2024.", "type": 2, "words": ["<tag1>", "We", "may", "receive", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin.", "<tag2>", "Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "milestones,", "as", "well", "as", "9%", "in", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024.", "<tag3>"], "wordsA": ["We", "may", "receive", "over", "$75", "million", "in", "milestones", "as", "well", "as", "9%", "in", "royalties", "on", "potential", "future", "worldwide", "sales", "by", "Retrophin."], "wordsB": ["Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "milestones,", "as", "well", "as", "9%", "in", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p41_s1", "idA": "886163_13_item1_p30_s2", "sentA": "In early 2013 we received a $1.4 million milestone payment from Retrophin, Inc.", "sentB": "In 2013 we received a net $1.2 million milestone payment from Retrophin.", "type": 2, "words": ["<tag1>", "In", "early", "2013", "we", "received", "a", "$1.4", "million", "milestone", "payment", "from", "Retrophin,", "Inc.", "<tag2>", "In", "2013", "we", "received", "a", "net", "$1.2", "million", "milestone", "payment", "from", "Retrophin.", "<tag3>"], "wordsA": ["In", "early", "2013", "we", "received", "a", "$1.4", "million", "milestone", "payment", "from", "Retrophin,", "Inc."], "wordsB": ["In", "2013", "we", "received", "a", "net", "$1.2", "million", "milestone", "payment", "from", "Retrophin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p39_s0", "idA": "886163_13_item1_p31_s0", "sentA": "In October 2012, our licensee, Merck, initiated a Phase IIb/III adaptive clinical trial for Dinaciclib for the treatment of patients with refractory chronic lymphocytic leukemia (CLL).", "sentB": "Retrophin announced initiation of a potentially pivotal Phase 2 clinical trial for Sparsentan on January 2, 2014.", "type": 2, "words": ["<tag1>", "In", "October", "2012,", "our", "licensee,", "Merck,", "initiated", "a", "Phase", "IIb/III", "adaptive", "clinical", "trial", "for", "Dinaciclib", "for", "the", "treatment", "of", "patients", "with", "refractory", "chronic", "lymphocytic", "leukemia", "(CLL).", "<tag2>", "Retrophin", "announced", "initiation", "of", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "on", "January", "2,", "2014.", "<tag3>"], "wordsA": ["In", "October", "2012,", "our", "licensee,", "Merck,", "initiated", "a", "Phase", "IIb/III", "adaptive", "clinical", "trial", "for", "Dinaciclib", "for", "the", "treatment", "of", "patients", "with", "refractory", "chronic", "lymphocytic", "leukemia", "(CLL)."], "wordsB": ["Retrophin", "announced", "initiation", "of", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "on", "January", "2,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p61_s0", "idA": "886163_13_item1_p31_s0", "sentA": "In October 2012, our licensee, Merck, initiated a Phase IIb/III adaptive clinical trial for Dinaciclib for the treatment of patients with refractory chronic lymphocytic leukemia (CLL).", "sentB": "In October 2013, the FDA accepted our Investigational New Drug, or IND, application for our proprietary Glucagon receptor antagonist product (LGD-6972) candidate for the treatment of diabetes.", "type": 2, "words": ["<tag1>", "In", "October", "2012,", "our", "licensee,", "Merck,", "initiated", "a", "Phase", "IIb/III", "adaptive", "clinical", "trial", "for", "Dinaciclib", "for", "the", "treatment", "of", "patients", "with", "refractory", "chronic", "lymphocytic", "leukemia", "(CLL).", "<tag2>", "In", "October", "2013,", "the", "FDA", "accepted", "our", "Investigational", "New", "Drug,", "or", "IND,", "application", "for", "our", "proprietary", "Glucagon", "receptor", "antagonist", "product", "(LGD-6972)", "candidate", "for", "the", "treatment", "of", "diabetes.", "<tag3>"], "wordsA": ["In", "October", "2012,", "our", "licensee,", "Merck,", "initiated", "a", "Phase", "IIb/III", "adaptive", "clinical", "trial", "for", "Dinaciclib", "for", "the", "treatment", "of", "patients", "with", "refractory", "chronic", "lymphocytic", "leukemia", "(CLL)."], "wordsB": ["In", "October", "2013,", "the", "FDA", "accepted", "our", "Investigational", "New", "Drug,", "or", "IND,", "application", "for", "our", "proprietary", "Glucagon", "receptor", "antagonist", "product", "(LGD-6972)", "candidate", "for", "the", "treatment", "of", "diabetes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p9_s3", "idA": "886163_13_item1_p33_s0", "sentA": "Dinaciclib is derived from a collaboration initiated in 1998 by Pharmacopeia (now a wholly owned subsidiary of Ligand).", "sentB": "Over 70% of our 2013 revenue is derived from our Promacta , Kyprolis, and Captisol programs (including Captisol material sales).", "type": 2, "words": ["<tag1>", "Dinaciclib", "is", "derived", "from", "a", "collaboration", "initiated", "in", "1998", "by", "Pharmacopeia", "(now", "a", "wholly", "owned", "subsidiary", "of", "Ligand).", "<tag2>", "Over", "70%", "of", "our", "2013", "revenue", "is", "derived", "from", "our", "Promacta", ",", "Kyprolis,", "and", "Captisol", "programs", "(including", "Captisol", "material", "sales).", "<tag3>"], "wordsA": ["Dinaciclib", "is", "derived", "from", "a", "collaboration", "initiated", "in", "1998", "by", "Pharmacopeia", "(now", "a", "wholly", "owned", "subsidiary", "of", "Ligand)."], "wordsB": ["Over", "70%", "of", "our", "2013", "revenue", "is", "derived", "from", "our", "Promacta", ",", "Kyprolis,", "and", "Captisol", "programs", "(including", "Captisol", "material", "sales)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p33_s0", "idA": "886163_13_item1_p34_s0", "sentA": "The development agreement for the beta-secretase inhibitor program (or BACE) was entered into in 2009 between Ligand (formerly Pharmacopeia) and Merck (formerly Schering-Plough), under a 1998 agreement, for the treatment of Alzheimer's disease.", "sentB": "We have a development agreement with Merck (formerly Schering-Plough) for a beta-secretase, or BACE, inhibitor program for the treatment of Alzheimer s disease.", "type": 2, "words": ["<tag1>", "The", "development", "agreement", "for", "the", "beta-secretase", "inhibitor", "program", "(or", "BACE)", "was", "entered", "into", "in", "2009", "between", "Ligand", "(formerly", "Pharmacopeia)", "and", "Merck", "(formerly", "Schering-Plough),", "under", "a", "1998", "agreement,", "for", "the", "treatment", "of", "Alzheimer's", "disease.", "<tag2>", "We", "have", "a", "development", "agreement", "with", "Merck", "(formerly", "Schering-Plough)", "for", "a", "beta-secretase,", "or", "BACE,", "inhibitor", "program", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag3>"], "wordsA": ["The", "development", "agreement", "for", "the", "beta-secretase", "inhibitor", "program", "(or", "BACE)", "was", "entered", "into", "in", "2009", "between", "Ligand", "(formerly", "Pharmacopeia)", "and", "Merck", "(formerly", "Schering-Plough),", "under", "a", "1998", "agreement,", "for", "the", "treatment", "of", "Alzheimer's", "disease."], "wordsB": ["We", "have", "a", "development", "agreement", "with", "Merck", "(formerly", "Schering-Plough)", "for", "a", "beta-secretase,", "or", "BACE,", "inhibitor", "program", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p35_s0", "idA": "886163_13_item1_p36_s0", "sentA": "Beta secretase is believed to be a key enzyme in the production of amyloid-beta protein.", "sentB": "BACE is believed to be a key enzyme in the production of amyloid-beta protein.", "type": 2, "words": ["<tag1>", "Beta", "secretase", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein.", "<tag2>", "BACE", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein.", "<tag3>"], "wordsA": ["Beta", "secretase", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein."], "wordsB": ["BACE", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p35_s1", "idA": "886163_13_item1_p37_s0", "sentA": "Amyloid-beta is formed when the larger amyloid precursor protein (APP) is cleaved by two enzymes, beta-secretase and gamma-secretase, which releases the amyloid-beta fragment.", "sentB": "Amyloid-beta is formed when the larger amyloid precursor protein (APP) is cleaved by two enzymes, BACE and gamma-secretase, which releases the amyloid-beta fragment.", "type": 2, "words": ["<tag1>", "Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "beta-secretase", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment.", "<tag2>", "Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "BACE", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment.", "<tag3>"], "wordsA": ["Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "beta-secretase", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment."], "wordsB": ["Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "BACE", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p35_s2", "idA": "886163_13_item1_p37_s1", "sentA": "A beta-secretase inhibitor is expected to reduce amyloid-beta generation in Alzheimer's disease patients.", "sentB": "A BACE inhibitor is expected to reduce amyloid-beta generation in Alzheimer s disease patients.", "type": 2, "words": ["<tag1>", "A", "beta-secretase", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer's", "disease", "patients.", "<tag2>", "A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients.", "<tag3>"], "wordsA": ["A", "beta-secretase", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer's", "disease", "patients."], "wordsB": ["A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p35_s3", "idA": "886163_13_item1_p38_s0", "sentA": "In December 2012, Merck initiated a Phase II/III clinical trial for its lead BACE inhibitor product candidate, MK-8931, evaluating its safety and efficacy in patients with mild-to-moderate Alzheimer's disease.", "sentB": "In December 2012, Merck initiated a Phase 2/3 clinical trial for its lead BACE inhibitor product candidate, MK-8931, evaluating its safety and efficacy in patients with mild-to-moderate Alzheimer s disease.", "type": 2, "words": ["<tag1>", "In", "December", "2012,", "Merck", "initiated", "a", "Phase", "II/III", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer's", "disease.", "<tag2>", "In", "December", "2012,", "Merck", "initiated", "a", "Phase", "2/3", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer", "s", "disease.", "<tag3>"], "wordsA": ["In", "December", "2012,", "Merck", "initiated", "a", "Phase", "II/III", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer's", "disease."], "wordsB": ["In", "December", "2012,", "Merck", "initiated", "a", "Phase", "2/3", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer", "s", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p36_s0", "idA": "886163_13_item1_p39_s0", "sentA": "Ligand is entitled to royalties on potential future sales by Merck.", "sentB": "We are entitled to a royalty on potential future sales by Merck.", "type": 2, "words": ["<tag1>", "Ligand", "is", "entitled", "to", "royalties", "on", "potential", "future", "sales", "by", "Merck.", "<tag2>", "We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck.", "<tag3>"], "wordsA": ["Ligand", "is", "entitled", "to", "royalties", "on", "potential", "future", "sales", "by", "Merck."], "wordsB": ["We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p49_s1", "idA": "886163_13_item1_p39_s0", "sentA": "Ligand is entitled to royalties on potential future sales by Merck.", "sentB": "We are entitled to a royalty on potential future sales by Melinta.", "type": 2, "words": ["<tag1>", "Ligand", "is", "entitled", "to", "royalties", "on", "potential", "future", "sales", "by", "Merck.", "<tag2>", "We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta.", "<tag3>"], "wordsA": ["Ligand", "is", "entitled", "to", "royalties", "on", "potential", "future", "sales", "by", "Merck."], "wordsB": ["We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p89_s1", "idA": "886163_13_item1_p3_s0", "sentA": "We sell Captisol material to a broad range of customers.", "sentB": "*Expiration date is subject to a terminal disclaimer.", "type": 2, "words": ["<tag1>", "We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers.", "<tag2>", "*Expiration", "date", "is", "subject", "to", "a", "terminal", "disclaimer.", "<tag3>"], "wordsA": ["We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers."], "wordsB": ["*Expiration", "date", "is", "subject", "to", "a", "terminal", "disclaimer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p46_s0", "idA": "886163_13_item1_p40_s0", "sentA": "The development and commercialization agreement for Captisol-enabled carbamazepine-IV began in 2004 between Lundbeck (formerly Ovation Pharmaceuticals) and us for the use of Captisol in the formulation of CE carbamazepine-IV.", "sentB": "We have a development and commercialization agreement for Captisol-enabled carbamazepine-IV with Lundbeck (formerly Ovation Pharmaceuticals) for the use of Captisol in the formulation of CE carbamazepine-IV.", "type": 2, "words": ["<tag1>", "The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "began", "in", "2004", "between", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV.", "<tag2>", "We", "have", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "with", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV.", "<tag3>"], "wordsA": ["The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "began", "in", "2004", "between", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV."], "wordsB": ["We", "have", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "with", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p46_s1", "idA": "886163_13_item1_p40_s1", "sentA": "Lundbeck is developing CE carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings.", "sentB": "Lundbeck is developing CE carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings and announced plans to submit an NDA prior to the end of 2013.", "type": 2, "words": ["<tag1>", "Lundbeck", "is", "developing", "CE", "carbamazepine-IV", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings.", "<tag2>", "Lundbeck", "is", "developing", "CE", "carbamazepine-IV", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings", "and", "announced", "plans", "to", "submit", "an", "NDA", "prior", "to", "the", "end", "of", "2013.", "<tag3>"], "wordsA": ["Lundbeck", "is", "developing", "CE", "carbamazepine-IV", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings."], "wordsB": ["Lundbeck", "is", "developing", "CE", "carbamazepine-IV", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings", "and", "announced", "plans", "to", "submit", "an", "NDA", "prior", "to", "the", "end", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p62_s0", "idA": "886163_13_item1_p40_s2", "sentA": "CE carbamazepine-IV is currently being evaluated in a Phase III clinical trial.", "sentB": "We initiated a Phase 1 clinical trial in the fourth quarter of 2013.", "type": 2, "words": ["<tag1>", "CE", "carbamazepine-IV", "is", "currently", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial.", "<tag2>", "We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013.", "<tag3>"], "wordsA": ["CE", "carbamazepine-IV", "is", "currently", "being", "evaluated", "in", "a", "Phase", "III", "clinical", "trial."], "wordsB": ["We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p47_s0", "idA": "886163_13_item1_p41_s0", "sentA": "The development and commercialization agreement for Captisol-enabled delafloxacin began in 2008 between Rib-X Pharmaceuticals and us for the use of Captisol in the formation of delafloxacin.", "sentB": "We entered into a development and commercialization agreement for Captisol-enabled delafloxacin-IV in 2008 with Melinta Therapeutics, Inc. (formerly Rib-X Pharmaceuticals), or Melinta, for the use of Captisol in the intravenous formulation of delafloxacin.", "type": 2, "words": ["<tag1>", "The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin", "began", "in", "2008", "between", "Rib-X", "Pharmaceuticals", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formation", "of", "delafloxacin.", "<tag2>", "We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin.", "<tag3>"], "wordsA": ["The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin", "began", "in", "2008", "between", "Rib-X", "Pharmaceuticals", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formation", "of", "delafloxacin."], "wordsB": ["We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p48_s0", "idA": "886163_13_item1_p42_s0", "sentA": "Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of quinolone-resistant Gram-positive and Gram-negative bacteria, including quinolone-resistant, methicillin-resistant Staphylococcus aureus (MRSA).", "sentB": "Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of quinolone-resistant Gram-positive and Gram-negative bacteria, including quinolone-resistant, methicillin-resistant Staphylococcus aureu, or MRSA.", "type": 2, "words": ["<tag1>", "Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureus", "(MRSA).", "<tag2>", "Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureu,", "or", "MRSA.", "<tag3>"], "wordsA": ["Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureus", "(MRSA)."], "wordsB": ["Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureu,", "or", "MRSA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p48_s1", "idA": "886163_13_item1_p42_s1", "sentA": "In the first half of 2013, Rib-X plans to initiate the first of two planned Phase III clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "sentB": "In 2013 Melinta initiated the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "Rib-X", "plans", "to", "initiate", "the", "first", "of", "two", "planned", "Phase", "III", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag2>", "In", "2013", "Melinta", "initiated", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "Rib-X", "plans", "to", "initiate", "the", "first", "of", "two", "planned", "Phase", "III", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "wordsB": ["In", "2013", "Melinta", "initiated", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s0", "idA": "886163_13_item1_p44_s0", "sentA": "In October 2011, we entered into a license agreement with Chiva Pharmaceuticals, Inc., or Chiva.", "sentB": "We entered into a Research, Development and License Agreement with SmithKline Beecham Corporation (now GSK) on December 29, 1994.", "type": 2, "words": ["<tag1>", "In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva.", "<tag2>", "We", "entered", "into", "a", "Research,", "Development", "and", "License", "Agreement", "with", "SmithKline", "Beecham", "Corporation", "(now", "GSK)", "on", "December", "29,", "1994.", "<tag3>"], "wordsA": ["In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva."], "wordsB": ["We", "entered", "into", "a", "Research,", "Development", "and", "License", "Agreement", "with", "SmithKline", "Beecham", "Corporation", "(now", "GSK)", "on", "December", "29,", "1994."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p42_s0", "idA": "886163_13_item1_p44_s0", "sentA": "In October 2011, we entered into a license agreement with Chiva Pharmaceuticals, Inc., or Chiva.", "sentB": "On July 17, 2013, we entered into a license agreement with Azure Biotech, Inc., or Azure.", "type": 2, "words": ["<tag1>", "In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva.", "<tag2>", "On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure.", "<tag3>"], "wordsA": ["In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva."], "wordsB": ["On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p43_s2", "idA": "886163_13_item1_p44_s0", "sentA": "In October 2011, we entered into a license agreement with Chiva Pharmaceuticals, Inc., or Chiva.", "sentB": "In July 2013, we also entered into a license agreement with Ethicor for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.", "type": 2, "words": ["<tag1>", "In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva.", "<tag2>", "In", "July", "2013,", "we", "also", "entered", "into", "a", "license", "agreement", "with", "Ethicor", "for", "the", "manufacture", "and", "distribution", "of", "the", "oral", "formulation", "of", "lasofoxifene", "in", "the", "European", "Economic", "Area,", "Switzerland", "and", "the", "Indian", "Subcontinent.", "<tag3>"], "wordsA": ["In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva."], "wordsB": ["In", "July", "2013,", "we", "also", "entered", "into", "a", "license", "agreement", "with", "Ethicor", "for", "the", "manufacture", "and", "distribution", "of", "the", "oral", "formulation", "of", "lasofoxifene", "in", "the", "European", "Economic", "Area,", "Switzerland", "and", "the", "Indian", "Subcontinent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p50_s1", "idA": "886163_13_item1_p44_s0", "sentA": "In October 2011, we entered into a license agreement with Chiva Pharmaceuticals, Inc., or Chiva.", "sentB": "In August 2013, we entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Topiramate.", "type": 2, "words": ["<tag1>", "In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva.", "<tag2>", "In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate.", "<tag3>"], "wordsA": ["In", "October", "2011,", "we", "entered", "into", "a", "license", "agreement", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva."], "wordsB": ["In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s2", "idA": "886163_13_item1_p44_s1", "sentA": "We granted to Chiva an exclusive worldwide license, with sub-license rights, to our intellectual property rights related to Fablyn, a selective estrogen receptor modulator.", "sentB": "We granted an exclusive license under our patent rights to any product developed from the joint research.", "type": 2, "words": ["<tag1>", "We", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator.", "<tag2>", "We", "granted", "an", "exclusive", "license", "under", "our", "patent", "rights", "to", "any", "product", "developed", "from", "the", "joint", "research.", "<tag3>"], "wordsA": ["We", "granted", "to", "Chiva", "an", "exclusive", "worldwide", "license,", "with", "sub-license", "rights,", "to", "our", "intellectual", "property", "rights", "related", "to", "Fablyn,", "a", "selective", "estrogen", "receptor", "modulator."], "wordsB": ["We", "granted", "an", "exclusive", "license", "under", "our", "patent", "rights", "to", "any", "product", "developed", "from", "the", "joint", "research."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p66_s2", "idA": "886163_13_item1_p44_s3", "sentA": "We also agreed to terminate the Fablyn license agreement and all assets related to Fablyn, including all relevant patents, know-how, properties, rights, interests and other tangible and intangible assets owned or controlled by Chiva were returned to us.", "sentB": "Upon termination, the licensed rights relating to the compound were returned to us.", "type": 2, "words": ["<tag1>", "We", "also", "agreed", "to", "terminate", "the", "Fablyn", "license", "agreement", "and", "all", "assets", "related", "to", "Fablyn,", "including", "all", "relevant", "patents,", "know-how,", "properties,", "rights,", "interests", "and", "other", "tangible", "and", "intangible", "assets", "owned", "or", "controlled", "by", "Chiva", "were", "returned", "to", "us.", "<tag2>", "Upon", "termination,", "the", "licensed", "rights", "relating", "to", "the", "compound", "were", "returned", "to", "us.", "<tag3>"], "wordsA": ["We", "also", "agreed", "to", "terminate", "the", "Fablyn", "license", "agreement", "and", "all", "assets", "related", "to", "Fablyn,", "including", "all", "relevant", "patents,", "know-how,", "properties,", "rights,", "interests", "and", "other", "tangible", "and", "intangible", "assets", "owned", "or", "controlled", "by", "Chiva", "were", "returned", "to", "us."], "wordsB": ["Upon", "termination,", "the", "licensed", "rights", "relating", "to", "the", "compound", "were", "returned", "to", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p63_s0", "idA": "886163_13_item1_p46_s0", "sentA": "Our LGD-4033 is a non-steroidal selective androgen receptor modulator (SARM) that is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration.", "sentB": "Our LGD-4033 is a non-steroidal selective androgen receptor modulator, or SARM, that is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration.", "type": 2, "words": ["<tag1>", "Our", "LGD-4033", "is", "a", "non-steroidal", "selective", "androgen", "receptor", "modulator", "(SARM)", "that", "is", "expected", "to", "produce", "the", "therapeutic", "benefits", "of", "testosterone", "with", "improved", "safety,", "tolerability", "and", "patient", "acceptance", "due", "to", "a", "tissue-selective", "mechanism", "of", "action", "and", "an", "oral", "route", "of", "administration.", "<tag2>", "Our", "LGD-4033", "is", "a", "non-steroidal", "selective", "androgen", "receptor", "modulator,", "or", "SARM,", "that", "is", "expected", "to", "produce", "the", "therapeutic", "benefits", "of", "testosterone", "with", "improved", "safety,", "tolerability", "and", "patient", "acceptance", "due", "to", "a", "tissue-selective", "mechanism", "of", "action", "and", "an", "oral", "route", "of", "administration.", "<tag3>"], "wordsA": ["Our", "LGD-4033", "is", "a", "non-steroidal", "selective", "androgen", "receptor", "modulator", "(SARM)", "that", "is", "expected", "to", "produce", "the", "therapeutic", "benefits", "of", "testosterone", "with", "improved", "safety,", "tolerability", "and", "patient", "acceptance", "due", "to", "a", "tissue-selective", "mechanism", "of", "action", "and", "an", "oral", "route", "of", "administration."], "wordsB": ["Our", "LGD-4033", "is", "a", "non-steroidal", "selective", "androgen", "receptor", "modulator,", "or", "SARM,", "that", "is", "expected", "to", "produce", "the", "therapeutic", "benefits", "of", "testosterone", "with", "improved", "safety,", "tolerability", "and", "patient", "acceptance", "due", "to", "a", "tissue-selective", "mechanism", "of", "action", "and", "an", "oral", "route", "of", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p64_s0", "idA": "886163_13_item1_p47_s0", "sentA": "Phase I single and multiple dose escalation studies of LGD-4033 were conducted in a total of 116 healthy male subjects.", "sentB": "Phase 1 single and multiple dose escalation studies of LGD-4033 were conducted in a total of 116 healthy male subjects.", "type": 2, "words": ["<tag1>", "Phase", "I", "single", "and", "multiple", "dose", "escalation", "studies", "of", "LGD-4033", "were", "conducted", "in", "a", "total", "of", "116", "healthy", "male", "subjects.", "<tag2>", "Phase", "1", "single", "and", "multiple", "dose", "escalation", "studies", "of", "LGD-4033", "were", "conducted", "in", "a", "total", "of", "116", "healthy", "male", "subjects.", "<tag3>"], "wordsA": ["Phase", "I", "single", "and", "multiple", "dose", "escalation", "studies", "of", "LGD-4033", "were", "conducted", "in", "a", "total", "of", "116", "healthy", "male", "subjects."], "wordsB": ["Phase", "1", "single", "and", "multiple", "dose", "escalation", "studies", "of", "LGD-4033", "were", "conducted", "in", "a", "total", "of", "116", "healthy", "male", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p64_s1", "idA": "886163_13_item1_p47_s1", "sentA": "The safety, tolerability and preliminary efficacy of LGD-4033 was evaluated in the double-blind, placebo-controlled Phase I multiple ascending dose study.", "sentB": "The safety, tolerability and preliminary efficacy of LGD-4033 was evaluated in the double-blind, placebo-controlled Phase 1 multiple ending dose study.", "type": 2, "words": ["<tag1>", "The", "safety,", "tolerability", "and", "preliminary", "efficacy", "of", "LGD-4033", "was", "evaluated", "in", "the", "double-blind,", "placebo-controlled", "Phase", "I", "multiple", "ascending", "dose", "study.", "<tag2>", "The", "safety,", "tolerability", "and", "preliminary", "efficacy", "of", "LGD-4033", "was", "evaluated", "in", "the", "double-blind,", "placebo-controlled", "Phase", "1", "multiple", "ending", "dose", "study.", "<tag3>"], "wordsA": ["The", "safety,", "tolerability", "and", "preliminary", "efficacy", "of", "LGD-4033", "was", "evaluated", "in", "the", "double-blind,", "placebo-controlled", "Phase", "I", "multiple", "ascending", "dose", "study."], "wordsB": ["The", "safety,", "tolerability", "and", "preliminary", "efficacy", "of", "LGD-4033", "was", "evaluated", "in", "the", "double-blind,", "placebo-controlled", "Phase", "1", "multiple", "ending", "dose", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p64_s4", "idA": "886163_13_item1_p47_s4", "sentA": "LGD-4033 is positioned to enter into Phase II development, and potential studies include evaluation of LGD-4033 in conditions such as muscle wasting associated with cancer (cachexia), acute rehabilitation (e.g. hip fracture), and acute illness.", "sentB": "LGD-4033 is positioned to enter into Phase 2 development, and potential studies include evaluation of LGD-4033 in conditions such as muscle wasting associated with cancer (cachexia), acute rehabilitation (e.g. hip fracture), and acute illness.", "type": 2, "words": ["<tag1>", "LGD-4033", "is", "positioned", "to", "enter", "into", "Phase", "II", "development,", "and", "potential", "studies", "include", "evaluation", "of", "LGD-4033", "in", "conditions", "such", "as", "muscle", "wasting", "associated", "with", "cancer", "(cachexia),", "acute", "rehabilitation", "(e.g.", "hip", "fracture),", "and", "acute", "illness.", "<tag2>", "LGD-4033", "is", "positioned", "to", "enter", "into", "Phase", "2", "development,", "and", "potential", "studies", "include", "evaluation", "of", "LGD-4033", "in", "conditions", "such", "as", "muscle", "wasting", "associated", "with", "cancer", "(cachexia),", "acute", "rehabilitation", "(e.g.", "hip", "fracture),", "and", "acute", "illness.", "<tag3>"], "wordsA": ["LGD-4033", "is", "positioned", "to", "enter", "into", "Phase", "II", "development,", "and", "potential", "studies", "include", "evaluation", "of", "LGD-4033", "in", "conditions", "such", "as", "muscle", "wasting", "associated", "with", "cancer", "(cachexia),", "acute", "rehabilitation", "(e.g.", "hip", "fracture),", "and", "acute", "illness."], "wordsB": ["LGD-4033", "is", "positioned", "to", "enter", "into", "Phase", "2", "development,", "and", "potential", "studies", "include", "evaluation", "of", "LGD-4033", "in", "conditions", "such", "as", "muscle", "wasting", "associated", "with", "cancer", "(cachexia),", "acute", "rehabilitation", "(e.g.", "hip", "fracture),", "and", "acute", "illness."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p50_s0", "idA": "886163_13_item1_p48_s0", "sentA": "Captisol-enabled Topiramate IV We are developing a proprietary Captisol-enabled formulation of topiramate for the treatment of acute epileptic seizures.", "sentB": "In July 2013, the FDA granted orphan-drug designation for our proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.", "type": 2, "words": ["<tag1>", "Captisol-enabled", "Topiramate", "IV", "We", "are", "developing", "a", "proprietary", "Captisol-enabled", "formulation", "of", "topiramate", "for", "the", "treatment", "of", "acute", "epileptic", "seizures.", "<tag2>", "In", "July", "2013,", "the", "FDA", "granted", "orphan-drug", "designation", "for", "our", "proprietary", "Captisol-enabled", "Topiramate", "Injection", "for", "the", "treatment", "of", "partial", "onset", "or", "primary", "generalized", "tonic-clonic", "seizures", "in", "hospitalized", "epilepsy", "patients", "who", "are", "unable", "to", "take", "oral", "topiramate.", "<tag3>"], "wordsA": ["Captisol-enabled", "Topiramate", "IV", "We", "are", "developing", "a", "proprietary", "Captisol-enabled", "formulation", "of", "topiramate", "for", "the", "treatment", "of", "acute", "epileptic", "seizures."], "wordsB": ["In", "July", "2013,", "the", "FDA", "granted", "orphan-drug", "designation", "for", "our", "proprietary", "Captisol-enabled", "Topiramate", "Injection", "for", "the", "treatment", "of", "partial", "onset", "or", "primary", "generalized", "tonic-clonic", "seizures", "in", "hospitalized", "epilepsy", "patients", "who", "are", "unable", "to", "take", "oral", "topiramate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p7_s1", "idA": "886163_13_item1_p4_s1", "sentA": "Captisol is a well validated chemically-modified cyclodextrin that improves the solubility, stability, and pharmicokinetics of many drugs.", "sentB": "Captisol is a well validated chemically-modified cyclodextrin that improves the solubility, stability, and pharmacokinetics of many drugs.", "type": 2, "words": ["<tag1>", "Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmicokinetics", "of", "many", "drugs.", "<tag2>", "Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs.", "<tag3>"], "wordsA": ["Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmicokinetics", "of", "many", "drugs."], "wordsB": ["Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p7_s2", "idA": "886163_13_item1_p4_s2", "sentA": "We receive revenue from the selling of Captisol material to our partners that have either licensed our proprietary Captisol-enabled drugs or have taken a license to use Captisol with their own internal programs.", "sentB": "We generate revenue by selling Captisol material to our partners that have either licensed our proprietary Captisol-enabled drugs or have taken a license to use Captisol with their own internal programs.", "type": 2, "words": ["<tag1>", "We", "receive", "revenue", "from", "the", "selling", "of", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs.", "<tag2>", "We", "generate", "revenue", "by", "selling", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs.", "<tag3>"], "wordsA": ["We", "receive", "revenue", "from", "the", "selling", "of", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs."], "wordsB": ["We", "generate", "revenue", "by", "selling", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p56_s0", "idA": "886163_13_item1_p50_s0", "sentA": "We are currently developing small molecule glucagon receptor antagonists for the treatment of Type II diabetes mellitus.", "sentB": "IRAK4 Inhibitor Program We are developing small molecule Interleukin-1 Receptor Associated Kinase-4, or IRAK4, inhibitors for the treatment of inflammatory and immune disorders.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus.", "<tag2>", "IRAK4", "Inhibitor", "Program", "We", "are", "developing", "small", "molecule", "Interleukin-1", "Receptor", "Associated", "Kinase-4,", "or", "IRAK4,", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders.", "<tag3>"], "wordsA": ["We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus."], "wordsB": ["IRAK4", "Inhibitor", "Program", "We", "are", "developing", "small", "molecule", "Interleukin-1", "Receptor", "Associated", "Kinase-4,", "or", "IRAK4,", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p32_s5", "idA": "886163_13_item1_p52_s4", "sentA": "We are preparing to file an IND for this program.", "sentB": "We will receive our commercial compensation for this program through the sale of Captisol, and we will not receive a royalty on this program.", "type": 2, "words": ["<tag1>", "We", "are", "preparing", "to", "file", "an", "IND", "for", "this", "program.", "<tag2>", "We", "will", "receive", "our", "commercial", "compensation", "for", "this", "program", "through", "the", "sale", "of", "Captisol,", "and", "we", "will", "not", "receive", "a", "royalty", "on", "this", "program.", "<tag3>"], "wordsA": ["We", "are", "preparing", "to", "file", "an", "IND", "for", "this", "program."], "wordsB": ["We", "will", "receive", "our", "commercial", "compensation", "for", "this", "program", "through", "the", "sale", "of", "Captisol,", "and", "we", "will", "not", "receive", "a", "royalty", "on", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p57_s2", "idA": "886163_13_item1_p53_s0", "sentA": "HepDirect HCV Inhibitor Program We are developing novel small molecule inhibitors of the Hepatitis C virus using our HepDirect technology platform.", "sentB": "We have identified orally available small molecule inhibitors of IRAK4 which are under investigation for use in cancer and autoimmune diseases.", "type": 2, "words": ["<tag1>", "HepDirect", "HCV", "Inhibitor", "Program", "We", "are", "developing", "novel", "small", "molecule", "inhibitors", "of", "the", "Hepatitis", "C", "virus", "using", "our", "HepDirect", "technology", "platform.", "<tag2>", "We", "have", "identified", "orally", "available", "small", "molecule", "inhibitors", "of", "IRAK4", "which", "are", "under", "investigation", "for", "use", "in", "cancer", "and", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["HepDirect", "HCV", "Inhibitor", "Program", "We", "are", "developing", "novel", "small", "molecule", "inhibitors", "of", "the", "Hepatitis", "C", "virus", "using", "our", "HepDirect", "technology", "platform."], "wordsB": ["We", "have", "identified", "orally", "available", "small", "molecule", "inhibitors", "of", "IRAK4", "which", "are", "under", "investigation", "for", "use", "in", "cancer", "and", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p69_s0", "idA": "886163_13_item1_p58_s0", "sentA": "Intracellular receptors are involved in the actions of non-peptide hormones and drugs such as selective estrogen receptor modulators, or SERMs, and SARMs.", "sentB": "Intracellular receptors are involved in the actions of non-peptide hormones and drugs such as SERMs and SARMs.", "type": 2, "words": ["<tag1>", "Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "selective", "estrogen", "receptor", "modulators,", "or", "SERMs,", "and", "SARMs.", "<tag2>", "Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "SERMs", "and", "SARMs.", "<tag3>"], "wordsA": ["Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "selective", "estrogen", "receptor", "modulators,", "or", "SERMs,", "and", "SARMs."], "wordsB": ["Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "SERMs", "and", "SARMs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p9_s0", "idA": "886163_13_item1_p5_s3", "sentA": "We believe that this focused strategy allows us to eliminate unpromising candidates from consideration sooner without incurring substantial clinical costs.", "sentB": "from consideration sooner without incurring substantial clinical costs.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "this", "focused", "strategy", "allows", "us", "to", "eliminate", "unpromising", "candidates", "from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs.", "<tag2>", "from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "focused", "strategy", "allows", "us", "to", "eliminate", "unpromising", "candidates", "from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs."], "wordsB": ["from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p9_s2", "idA": "886163_13_item1_p5_s5", "sentA": "Our Asset Portfolio We have a portfolio of over 80 current and future potential revenue generating programs, over 70 of which are fully funded by our partners.", "sentB": "Our Asset Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 90 of which are fully-funded by our partners.", "type": 2, "words": ["<tag1>", "Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "80", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "70", "of", "which", "are", "fully", "funded", "by", "our", "partners.", "<tag2>", "Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "90", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag3>"], "wordsA": ["Our", "Asset", "Portfolio", "We", "have", "a", "portfolio", "of", "over", "80", "current", "and", "future", "potential", "revenue", "generating", "programs,", "over", "70", "of", "which", "are", "fully", "funded", "by", "our", "partners."], "wordsB": ["Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "90", "of", "which", "are", "fully-funded", "by", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s7", "idA": "886163_13_item1_p5_s7", "sentA": "While many of these programs have been disclosed publicly, a significant number of our partners and their programs remain undisclosed to protect competitive and proprietary information about these programs.", "sentB": "Selexis retained ownership of the underlying intellectual property for each of these programs.", "type": 2, "words": ["<tag1>", "While", "many", "of", "these", "programs", "have", "been", "disclosed", "publicly,", "a", "significant", "number", "of", "our", "partners", "and", "their", "programs", "remain", "undisclosed", "to", "protect", "competitive", "and", "proprietary", "information", "about", "these", "programs.", "<tag2>", "Selexis", "retained", "ownership", "of", "the", "underlying", "intellectual", "property", "for", "each", "of", "these", "programs.", "<tag3>"], "wordsA": ["While", "many", "of", "these", "programs", "have", "been", "disclosed", "publicly,", "a", "significant", "number", "of", "our", "partners", "and", "their", "programs", "remain", "undisclosed", "to", "protect", "competitive", "and", "proprietary", "information", "about", "these", "programs."], "wordsB": ["Selexis", "retained", "ownership", "of", "the", "underlying", "intellectual", "property", "for", "each", "of", "these", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p61_s1", "idA": "886163_13_item1_p61_s1", "sentA": "In connection with our acquisition of CyDex, we acquired the Captisol drug formulation platform technology.", "sentB": "LGD-6972 was acquired in connection with our acquisition of Metabasis and we may be required to remit payment to the contingent value right, or CVR, holders upon the sale or partnering of the asset.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "our", "acquisition", "of", "CyDex,", "we", "acquired", "the", "Captisol", "drug", "formulation", "platform", "technology.", "<tag2>", "LGD-6972", "was", "acquired", "in", "connection", "with", "our", "acquisition", "of", "Metabasis", "and", "we", "may", "be", "required", "to", "remit", "payment", "to", "the", "contingent", "value", "right,", "or", "CVR,", "holders", "upon", "the", "sale", "or", "partnering", "of", "the", "asset.", "<tag3>"], "wordsA": ["In", "connection", "with", "our", "acquisition", "of", "CyDex,", "we", "acquired", "the", "Captisol", "drug", "formulation", "platform", "technology."], "wordsB": ["LGD-6972", "was", "acquired", "in", "connection", "with", "our", "acquisition", "of", "Metabasis", "and", "we", "may", "be", "required", "to", "remit", "payment", "to", "the", "contingent", "value", "right,", "or", "CVR,", "holders", "upon", "the", "sale", "or", "partnering", "of", "the", "asset."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p72_s4", "idA": "886163_13_item1_p61_s4", "sentA": "We currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a major supplier of APIs and API intermediates located in Portugal.", "sentB": "We currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a major supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal.", "type": 2, "words": ["<tag1>", "We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "APIs", "and", "API", "intermediates", "located", "in", "Portugal.", "<tag2>", "We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "active", "pharmaceutical", "ingredients,", "or", "APIs", "and", "API", "intermediates", "located", "in", "Portugal.", "<tag3>"], "wordsA": ["We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "APIs", "and", "API", "intermediates", "located", "in", "Portugal."], "wordsB": ["We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "active", "pharmaceutical", "ingredients,", "or", "APIs", "and", "API", "intermediates", "located", "in", "Portugal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p72_s6", "idA": "886163_13_item1_p61_s6", "sentA": "In addition to its main manufacturing site in Loures, Portugal, Hovione will qualify a second site in Macau if our forecast requirements for Captisol exceed the capabilities of the Loures site.", "sentB": "In addition to its main manufacturing site in Loures, Portugal, Hovione will qualify additional sites if our forecast requirements for Captisol exceed the capabilities of the Loures site.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "a", "second", "site", "in", "Macau", "if", "our", "forecast", "requirements", "for", "Captisol", "exceed", "the", "capabilities", "of", "the", "Loures", "site.", "<tag2>", "In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "additional", "sites", "if", "our", "forecast", "requirements", "for", "Captisol", "exceed", "the", "capabilities", "of", "the", "Loures", "site.", "<tag3>"], "wordsA": ["In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "a", "second", "site", "in", "Macau", "if", "our", "forecast", "requirements", "for", "Captisol", "exceed", "the", "capabilities", "of", "the", "Loures", "site."], "wordsB": ["In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "additional", "sites", "if", "our", "forecast", "requirements", "for", "Captisol", "exceed", "the", "capabilities", "of", "the", "Loures", "site."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p73_s0", "idA": "886163_13_item1_p61_s7", "sentA": "We have ongoing minimum purchase commitments under the agreement and are required to pay Hovione an aggregate minimum amount during the agreement term.", "sentB": "to pay Hovione an aggregate minimum amount during the agreement term.", "type": 2, "words": ["<tag1>", "We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement", "and", "are", "required", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term.", "<tag2>", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term.", "<tag3>"], "wordsA": ["We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement", "and", "are", "required", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term."], "wordsB": ["to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s5", "idA": "886163_13_item1_p61_s9", "sentA": "In 2008, we entered into an amendment to the supply agreement, under which we and Hovione agreed to reduce our minimum annual purchase requirement of Captisol and to extend the term of the agreement.", "sentB": "Absent early termination for bankruptcy or material breach, the term of the agreement expires upon expiration of the obligation to pay royalties.", "type": 2, "words": ["<tag1>", "In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement.", "<tag2>", "Absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties.", "<tag3>"], "wordsA": ["In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement."], "wordsB": ["Absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p20_s4", "idA": "886163_13_item1_p61_s9", "sentA": "In 2008, we entered into an amendment to the supply agreement, under which we and Hovione agreed to reduce our minimum annual purchase requirement of Captisol and to extend the term of the agreement.", "sentB": "Neither party to the agreement has any ongoing termination rights.", "type": 2, "words": ["<tag1>", "In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement.", "<tag2>", "Neither", "party", "to", "the", "agreement", "has", "any", "ongoing", "termination", "rights.", "<tag3>"], "wordsA": ["In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement."], "wordsB": ["Neither", "party", "to", "the", "agreement", "has", "any", "ongoing", "termination", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p73_s2", "idA": "886163_13_item1_p62_s0", "sentA": "We pay Hovione unit prices, in U.S. dollars, for all Captisol supplied after the commercial production date, which prices may be adjusted for fluctuation in currency exchange rates, change in raw material prices and change in the Portuguese consumer price index.", "sentB": "We pay Hovione unit prices, in U.S. dollars, for all Captisol supplied, which prices may be adjusted for fluctuation in currency exchange rates, change in raw material prices and change in the Portuguese consumer price index.", "type": 2, "words": ["<tag1>", "We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied", "after", "the", "commercial", "production", "date,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index.", "<tag2>", "We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index.", "<tag3>"], "wordsA": ["We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied", "after", "the", "commercial", "production", "date,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index."], "wordsB": ["We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s6", "idA": "886163_13_item1_p62_s10", "sentA": "In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event.", "sentB": "Either party may terminate the agreement in the event of bankruptcy or material breach.", "type": 2, "words": ["<tag1>", "In", "addition,", "either", "party", "may", "terminate", "the", "agreement", "for", "the", "uncured", "material", "breach", "or", "bankruptcy", "of", "the", "other", "party", "or", "an", "extended", "force", "majeure", "event.", "<tag2>", "Either", "party", "may", "terminate", "the", "agreement", "in", "the", "event", "of", "bankruptcy", "or", "material", "breach.", "<tag3>"], "wordsA": ["In", "addition,", "either", "party", "may", "terminate", "the", "agreement", "for", "the", "uncured", "material", "breach", "or", "bankruptcy", "of", "the", "other", "party", "or", "an", "extended", "force", "majeure", "event."], "wordsB": ["Either", "party", "may", "terminate", "the", "agreement", "in", "the", "event", "of", "bankruptcy", "or", "material", "breach."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p19_s3", "idA": "886163_13_item1_p62_s10", "sentA": "In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event.", "sentB": "Our agreement with Onyx may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Onyx with prior written notice, subject to certain surviving obligations such as placing orders under any binding forecasts.", "type": 2, "words": ["<tag1>", "In", "addition,", "either", "party", "may", "terminate", "the", "agreement", "for", "the", "uncured", "material", "breach", "or", "bankruptcy", "of", "the", "other", "party", "or", "an", "extended", "force", "majeure", "event.", "<tag2>", "Our", "agreement", "with", "Onyx", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Onyx", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts.", "<tag3>"], "wordsA": ["In", "addition,", "either", "party", "may", "terminate", "the", "agreement", "for", "the", "uncured", "material", "breach", "or", "bankruptcy", "of", "the", "other", "party", "or", "an", "extended", "force", "majeure", "event."], "wordsB": ["Our", "agreement", "with", "Onyx", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Onyx", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p24_s5", "idA": "886163_13_item1_p62_s10", "sentA": "In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event.", "sentB": "The agreement may be terminated by either party for an uncured material breach or unilaterally by Spectrum by prior written notice.", "type": 2, "words": ["<tag1>", "In", "addition,", "either", "party", "may", "terminate", "the", "agreement", "for", "the", "uncured", "material", "breach", "or", "bankruptcy", "of", "the", "other", "party", "or", "an", "extended", "force", "majeure", "event.", "<tag2>", "The", "agreement", "may", "be", "terminated", "by", "either", "party", "for", "an", "uncured", "material", "breach", "or", "unilaterally", "by", "Spectrum", "by", "prior", "written", "notice.", "<tag3>"], "wordsA": ["In", "addition,", "either", "party", "may", "terminate", "the", "agreement", "for", "the", "uncured", "material", "breach", "or", "bankruptcy", "of", "the", "other", "party", "or", "an", "extended", "force", "majeure", "event."], "wordsB": ["The", "agreement", "may", "be", "terminated", "by", "either", "party", "for", "an", "uncured", "material", "breach", "or", "unilaterally", "by", "Spectrum", "by", "prior", "written", "notice."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s7", "idA": "886163_13_item1_p62_s3", "sentA": "If the supply interruption continues beyond a designated period, we may terminate the agreement.", "sentB": "There are no remaining milestones to be paid under the agreement.", "type": 2, "words": ["<tag1>", "If", "the", "supply", "interruption", "continues", "beyond", "a", "designated", "period,", "we", "may", "terminate", "the", "agreement.", "<tag2>", "There", "are", "no", "remaining", "milestones", "to", "be", "paid", "under", "the", "agreement.", "<tag3>"], "wordsA": ["If", "the", "supply", "interruption", "continues", "beyond", "a", "designated", "period,", "we", "may", "terminate", "the", "agreement."], "wordsB": ["There", "are", "no", "remaining", "milestones", "to", "be", "paid", "under", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p42_s3", "idA": "886163_13_item1_p62_s3", "sentA": "If the supply interruption continues beyond a designated period, we may terminate the agreement.", "sentB": "Azure may terminate the license agreement at any time upon six months prior notice.", "type": 2, "words": ["<tag1>", "If", "the", "supply", "interruption", "continues", "beyond", "a", "designated", "period,", "we", "may", "terminate", "the", "agreement.", "<tag2>", "Azure", "may", "terminate", "the", "license", "agreement", "at", "any", "time", "upon", "six", "months", "prior", "notice.", "<tag3>"], "wordsA": ["If", "the", "supply", "interruption", "continues", "beyond", "a", "designated", "period,", "we", "may", "terminate", "the", "agreement."], "wordsB": ["Azure", "may", "terminate", "the", "license", "agreement", "at", "any", "time", "upon", "six", "months", "prior", "notice."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p19_s4", "idA": "886163_13_item1_p62_s8", "sentA": "Unless terminated earlier, the agreement will continue until it expires in December 2019.", "sentB": "Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties.", "type": 2, "words": ["<tag1>", "Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019.", "<tag2>", "Absent", "early", "termination,", "the", "agreement", "will", "terminate", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties.", "<tag3>"], "wordsA": ["Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019."], "wordsB": ["Absent", "early", "termination,", "the", "agreement", "will", "terminate", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p24_s4", "idA": "886163_13_item1_p62_s8", "sentA": "Unless terminated earlier, the agreement will continue until it expires in December 2019.", "sentB": "Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties.", "type": 2, "words": ["<tag1>", "Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019.", "<tag2>", "Absent", "early", "termination,", "the", "agreement", "will", "terminate", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties.", "<tag3>"], "wordsA": ["Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019."], "wordsB": ["Absent", "early", "termination,", "the", "agreement", "will", "terminate", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p73_s9", "idA": "886163_13_item1_p62_s8", "sentA": "Unless terminated earlier, the agreement will continue until it expires in December 2019.", "sentB": "The initial term of the agreement expires in December 2019.", "type": 2, "words": ["<tag1>", "Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019.", "<tag2>", "The", "initial", "term", "of", "the", "agreement", "expires", "in", "December", "2019.", "<tag3>"], "wordsA": ["Unless", "terminated", "earlier,", "the", "agreement", "will", "continue", "until", "it", "expires", "in", "December", "2019."], "wordsB": ["The", "initial", "term", "of", "the", "agreement", "expires", "in", "December", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p19_s1", "idA": "886163_13_item1_p62_s9", "sentA": "The term will automatically continue after the initial term for successive two year renewal terms, unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term.", "sentB": "Onyx s obligation to pay royalties does not expire until four years after the expiration of the last-to-expire patent covering Captisol.", "type": 2, "words": ["<tag1>", "The", "term", "will", "automatically", "continue", "after", "the", "initial", "term", "for", "successive", "two", "year", "renewal", "terms,", "unless", "either", "party", "gives", "written", "notice", "of", "its", "intention", "to", "terminate", "the", "agreement", "no", "less", "than", "two", "years", "prior", "to", "the", "expiration", "of", "the", "initial", "term", "or", "renewal", "term.", "<tag2>", "Onyx", "s", "obligation", "to", "pay", "royalties", "does", "not", "expire", "until", "four", "years", "after", "the", "expiration", "of", "the", "last-to-expire", "patent", "covering", "Captisol.", "<tag3>"], "wordsA": ["The", "term", "will", "automatically", "continue", "after", "the", "initial", "term", "for", "successive", "two", "year", "renewal", "terms,", "unless", "either", "party", "gives", "written", "notice", "of", "its", "intention", "to", "terminate", "the", "agreement", "no", "less", "than", "two", "years", "prior", "to", "the", "expiration", "of", "the", "initial", "term", "or", "renewal", "term."], "wordsB": ["Onyx", "s", "obligation", "to", "pay", "royalties", "does", "not", "expire", "until", "four", "years", "after", "the", "expiration", "of", "the", "last-to-expire", "patent", "covering", "Captisol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p73_s10", "idA": "886163_13_item1_p62_s9", "sentA": "The term will automatically continue after the initial term for successive two year renewal terms, unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term.", "sentB": "The agreement will automatically renew for successive two year renewal terms unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term.", "type": 2, "words": ["<tag1>", "The", "term", "will", "automatically", "continue", "after", "the", "initial", "term", "for", "successive", "two", "year", "renewal", "terms,", "unless", "either", "party", "gives", "written", "notice", "of", "its", "intention", "to", "terminate", "the", "agreement", "no", "less", "than", "two", "years", "prior", "to", "the", "expiration", "of", "the", "initial", "term", "or", "renewal", "term.", "<tag2>", "The", "agreement", "will", "automatically", "renew", "for", "successive", "two", "year", "renewal", "terms", "unless", "either", "party", "gives", "written", "notice", "of", "its", "intention", "to", "terminate", "the", "agreement", "no", "less", "than", "two", "years", "prior", "to", "the", "expiration", "of", "the", "initial", "term", "or", "renewal", "term.", "<tag3>"], "wordsA": ["The", "term", "will", "automatically", "continue", "after", "the", "initial", "term", "for", "successive", "two", "year", "renewal", "terms,", "unless", "either", "party", "gives", "written", "notice", "of", "its", "intention", "to", "terminate", "the", "agreement", "no", "less", "than", "two", "years", "prior", "to", "the", "expiration", "of", "the", "initial", "term", "or", "renewal", "term."], "wordsB": ["The", "agreement", "will", "automatically", "renew", "for", "successive", "two", "year", "renewal", "terms", "unless", "either", "party", "gives", "written", "notice", "of", "its", "intention", "to", "terminate", "the", "agreement", "no", "less", "than", "two", "years", "prior", "to", "the", "expiration", "of", "the", "initial", "term", "or", "renewal", "term."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p75_s0", "idA": "886163_13_item1_p64_s0", "sentA": "Competition Some of the drugs we and our collaborative partners are developing may compete with existing therapies or other drugs in development by other companies.", "sentB": "Some of the drugs we and our collaborative partners are developing may compete with existing therapies or other drugs in development by other companies.", "type": 2, "words": ["<tag1>", "Competition", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag2>", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag3>"], "wordsA": ["Competition", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "wordsB": ["Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p32_s2", "idA": "886163_13_item1_p67_s0", "sentA": "In the United States, pharmaceuticals are subject to rigorous regulation by federal and various state authorities, including the FDA.", "sentB": "In the United States, the New Drug Application, or NDA, for Noxafil-IV was filed and received FDA Priority Review in November 2013.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag2>", "In", "the", "United", "States,", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "Noxafil-IV", "was", "filed", "and", "received", "FDA", "Priority", "Review", "in", "November", "2013.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "wordsB": ["In", "the", "United", "States,", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "Noxafil-IV", "was", "filed", "and", "received", "FDA", "Priority", "Review", "in", "November", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p82_s3", "idA": "886163_13_item1_p68_s0", "sentA": "Product development and approval within this regulatory framework takes a number of years and involves the expenditure of substantial resources.", "sentB": "The actual patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and terminal disclaimers.", "type": 2, "words": ["<tag1>", "Product", "development", "and", "approval", "within", "this", "regulatory", "framework", "takes", "a", "number", "of", "years", "and", "involves", "the", "expenditure", "of", "substantial", "resources.", "<tag2>", "The", "actual", "patent", "term", "may", "vary", "by", "jurisdiction", "and", "depend", "on", "a", "number", "of", "factors", "including", "potential", "patent", "term", "adjustments,", "patent", "term", "extensions,", "and", "terminal", "disclaimers.", "<tag3>"], "wordsA": ["Product", "development", "and", "approval", "within", "this", "regulatory", "framework", "takes", "a", "number", "of", "years", "and", "involves", "the", "expenditure", "of", "substantial", "resources."], "wordsB": ["The", "actual", "patent", "term", "may", "vary", "by", "jurisdiction", "and", "depend", "on", "a", "number", "of", "factors", "including", "potential", "patent", "term", "adjustments,", "patent", "term", "extensions,", "and", "terminal", "disclaimers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p87_s0", "idA": "886163_13_item1_p70_s4", "sentA": "The United States patent on Avinza is not expected to expire until November 2017; however, applications for generic forms of Avinza have been submitted to the FDA.", "sentB": "Avinza The United States patent listed in the Orange Book relating to the Avinza formulation with the latest expiration date is not expected to expire until 2017; however, applications for generic forms of Avinza have been submitted to the FDA.", "type": 2, "words": ["<tag1>", "The", "United", "States", "patent", "on", "Avinza", "is", "not", "expected", "to", "expire", "until", "November", "2017;", "however,", "applications", "for", "generic", "forms", "of", "Avinza", "have", "been", "submitted", "to", "the", "FDA.", "<tag2>", "Avinza", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "the", "Avinza", "formulation", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2017;", "however,", "applications", "for", "generic", "forms", "of", "Avinza", "have", "been", "submitted", "to", "the", "FDA.", "<tag3>"], "wordsA": ["The", "United", "States", "patent", "on", "Avinza", "is", "not", "expected", "to", "expire", "until", "November", "2017;", "however,", "applications", "for", "generic", "forms", "of", "Avinza", "have", "been", "submitted", "to", "the", "FDA."], "wordsB": ["Avinza", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "the", "Avinza", "formulation", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2017;", "however,", "applications", "for", "generic", "forms", "of", "Avinza", "have", "been", "submitted", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p19_s2", "idA": "886163_13_item1_p70_s5", "sentA": "The last to expire United States patents relating to Promacta is not expected to expire until August 2027.", "sentB": "Our patents and applications relating to the Captisol component of Kyprolis are not expected to expire until 2033.", "type": 2, "words": ["<tag1>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027.", "<tag2>", "Our", "patents", "and", "applications", "relating", "to", "the", "Captisol", "component", "of", "Kyprolis", "are", "not", "expected", "to", "expire", "until", "2033.", "<tag3>"], "wordsA": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027."], "wordsB": ["Our", "patents", "and", "applications", "relating", "to", "the", "Captisol", "component", "of", "Kyprolis", "are", "not", "expected", "to", "expire", "until", "2033."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p24_s3", "idA": "886163_13_item1_p70_s5", "sentA": "The last to expire United States patents relating to Promacta is not expected to expire until August 2027.", "sentB": "Our patents and applications relating to the Captisol component of melphalan are not expected to expire until 2033.", "type": 2, "words": ["<tag1>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027.", "<tag2>", "Our", "patents", "and", "applications", "relating", "to", "the", "Captisol", "component", "of", "melphalan", "are", "not", "expected", "to", "expire", "until", "2033.", "<tag3>"], "wordsA": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027."], "wordsB": ["Our", "patents", "and", "applications", "relating", "to", "the", "Captisol", "component", "of", "melphalan", "are", "not", "expected", "to", "expire", "until", "2033."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p83_s2", "idA": "886163_13_item1_p70_s5", "sentA": "The last to expire United States patents relating to Promacta is not expected to expire until August 2027.", "sentB": "The United States patent listed in the FDA s listing of Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book ) relating to Promacta with the latest expiration date is not expected to expire until 2027.", "type": 2, "words": ["<tag1>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027.", "<tag2>", "The", "United", "States", "patent", "listed", "in", "the", "FDA", "s", "listing", "of", "Approved", "Drug", "Products", "with", "Therapeutic", "Equivalence", "Evaluations", "(the", "Orange", "Book", ")", "relating", "to", "Promacta", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027.", "<tag3>"], "wordsA": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027."], "wordsB": ["The", "United", "States", "patent", "listed", "in", "the", "FDA", "s", "listing", "of", "Approved", "Drug", "Products", "with", "Therapeutic", "Equivalence", "Evaluations", "(the", "Orange", "Book", ")", "relating", "to", "Promacta", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p85_s1", "idA": "886163_13_item1_p70_s5", "sentA": "The last to expire United States patents relating to Promacta is not expected to expire until August 2027.", "sentB": "The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2027.", "type": 2, "words": ["<tag1>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027.", "<tag2>", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027.", "<tag3>"], "wordsA": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027."], "wordsB": ["The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p85_s2", "idA": "886163_13_item1_p70_s5", "sentA": "The last to expire United States patents relating to Promacta is not expected to expire until August 2027.", "sentB": "Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033.", "type": 2, "words": ["<tag1>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027.", "<tag2>", "Patents", "and", "applications", "owned", "by", "Ligand", "relating", "to", "the", "Captisol", "component", "of", "Kyprolis", "are", "not", "expected", "to", "expire", "until", "2033.", "<tag3>"], "wordsA": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "Promacta", "is", "not", "expected", "to", "expire", "until", "August", "2027."], "wordsB": ["Patents", "and", "applications", "owned", "by", "Ligand", "relating", "to", "the", "Captisol", "component", "of", "Kyprolis", "are", "not", "expected", "to", "expire", "until", "2033."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s3", "idA": "886163_13_item1_p70_s7", "sentA": "Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "sentB": "The payment obligations for the particular programs are set forth in the various underlying commercial license agreements between Selexis and various third parties, which have remaining terms tied to the life of the underlying patents, which we currently expect to be maintained until at least 2026.", "type": 2, "words": ["<tag1>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag2>", "The", "payment", "obligations", "for", "the", "particular", "programs", "are", "set", "forth", "in", "the", "various", "underlying", "commercial", "license", "agreements", "between", "Selexis", "and", "various", "third", "parties,", "which", "have", "remaining", "terms", "tied", "to", "the", "life", "of", "the", "underlying", "patents,", "which", "we", "currently", "expect", "to", "be", "maintained", "until", "at", "least", "2026.", "<tag3>"], "wordsA": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "wordsB": ["The", "payment", "obligations", "for", "the", "particular", "programs", "are", "set", "forth", "in", "the", "various", "underlying", "commercial", "license", "agreements", "between", "Selexis", "and", "various", "third", "parties,", "which", "have", "remaining", "terms", "tied", "to", "the", "life", "of", "the", "underlying", "patents,", "which", "we", "currently", "expect", "to", "be", "maintained", "until", "at", "least", "2026."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p89_s2", "idA": "886163_13_item1_p70_s7", "sentA": "Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "sentB": "Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments.", "type": 2, "words": ["<tag1>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag2>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "typically", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag3>"], "wordsA": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "wordsB": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "typically", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p91_s0", "idA": "886163_13_item1_p71_s0", "sentA": "Human Resources As of February 1, 2013, we had 21 full-time employees, of whom 6 are involved directly in scientific research and development activities.", "sentB": "Human Resources As of February 1, 2014, we had 20 full-time employees, of whom 6 are involved directly in scientific research and development activities.", "type": 2, "words": ["<tag1>", "Human", "Resources", "As", "of", "February", "1,", "2013,", "we", "had", "21", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag2>", "Human", "Resources", "As", "of", "February", "1,", "2014,", "we", "had", "20", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["Human", "Resources", "As", "of", "February", "1,", "2013,", "we", "had", "21", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "wordsB": ["Human", "Resources", "As", "of", "February", "1,", "2014,", "we", "had", "20", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p91_s1", "idA": "886163_13_item1_p71_s1", "sentA": "Of these employees, 5 hold Ph.D. or M.D. degrees.", "sentB": "Of these employees, 6 hold Ph.D. or M.D. degrees.", "type": 2, "words": ["<tag1>", "Of", "these", "employees,", "5", "hold", "Ph.D.", "or", "M.D.", "degrees.", "<tag2>", "Of", "these", "employees,", "6", "hold", "Ph.D.", "or", "M.D.", "degrees.", "<tag3>"], "wordsA": ["Of", "these", "employees,", "5", "hold", "Ph.D.", "or", "M.D.", "degrees."], "wordsB": ["Of", "these", "employees,", "6", "hold", "Ph.D.", "or", "M.D.", "degrees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p11_s3", "idA": "886163_13_item1_p7_s0", "sentA": "In 2010, GSK received approval for Revolade (eltrombopag/Promacta) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and from the Japanese Ministry of Health, Labour and Welfare for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic ITP.", "sentB": "In September 2013, GSK received Marketing Authorization from the European Commission for an additional Revolade (eltrombopag/Promacta) indication as the first approved treatment for chronic Hepatitis C-associated thrombocytopenia.", "type": 2, "words": ["<tag1>", "In", "2010,", "GSK", "received", "approval", "for", "Revolade", "(eltrombopag/Promacta)", "from", "the", "European", "Medicines", "Agency's", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "and", "from", "the", "Japanese", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "for", "the", "oral", "treatment", "of", "thrombocytopenia", "(reduced", "platelet", "count)", "in", "adults", "with", "the", "blood", "disorder", "chronic", "ITP.", "<tag2>", "In", "September", "2013,", "GSK", "received", "Marketing", "Authorization", "from", "the", "European", "Commission", "for", "an", "additional", "Revolade", "(eltrombopag/Promacta)", "indication", "as", "the", "first", "approved", "treatment", "for", "chronic", "Hepatitis", "C-associated", "thrombocytopenia.", "<tag3>"], "wordsA": ["In", "2010,", "GSK", "received", "approval", "for", "Revolade", "(eltrombopag/Promacta)", "from", "the", "European", "Medicines", "Agency's", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "and", "from", "the", "Japanese", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "for", "the", "oral", "treatment", "of", "thrombocytopenia", "(reduced", "platelet", "count)", "in", "adults", "with", "the", "blood", "disorder", "chronic", "ITP."], "wordsB": ["In", "September", "2013,", "GSK", "received", "Marketing", "Authorization", "from", "the", "European", "Commission", "for", "an", "additional", "Revolade", "(eltrombopag/Promacta)", "indication", "as", "the", "first", "approved", "treatment", "for", "chronic", "Hepatitis", "C-associated", "thrombocytopenia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p10_s3", "idA": "886163_13_item1_p7_s1", "sentA": "In February 2011, the FDA granted GSK full approval status for Promacta in the US following the submission of long- term safety data from post-marketing clinical studies, as well as the completion of other commitments that verify the clinical benefit to patients.", "sentB": "In February 2011, the FDA granted GSK full approval status for Promacta for ITP in the United States following the submission of long-term safety data from post-marketing clinical studies, as well as the completion of other commitments that verify the clinical benefit to patients.", "type": 2, "words": ["<tag1>", "In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "Promacta", "in", "the", "US", "following", "the", "submission", "of", "long-", "term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients.", "<tag2>", "In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "Promacta", "for", "ITP", "in", "the", "United", "States", "following", "the", "submission", "of", "long-term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients.", "<tag3>"], "wordsA": ["In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "Promacta", "in", "the", "US", "following", "the", "submission", "of", "long-", "term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients."], "wordsB": ["In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "Promacta", "for", "ITP", "in", "the", "United", "States", "following", "the", "submission", "of", "long-term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p10_s4", "idA": "886163_13_item1_p7_s2", "sentA": "Additionally, it was reported in November 2011 that the Risk Evaluation and Mitgation Strategies (REMS) program that Promacta had been operating under in the US was being significantly reduced in scope by the FDA due to data that had been submitted by GSK demonstrating the long term safety of Promacta.", "sentB": "Additionally, it was reported in November 2011 that the Risk Evaluation and Mitigation Strategies (REMS) program that Promacta had been operating under in the United States was being significantly reduced in scope by the FDA due to data that had been submitted by GSK demonstrating the long-term safety of Promacta.", "type": 2, "words": ["<tag1>", "Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitgation", "Strategies", "(REMS)", "program", "that", "Promacta", "had", "been", "operating", "under", "in", "the", "US", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long", "term", "safety", "of", "Promacta.", "<tag2>", "Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitigation", "Strategies", "(REMS)", "program", "that", "Promacta", "had", "been", "operating", "under", "in", "the", "United", "States", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long-term", "safety", "of", "Promacta.", "<tag3>"], "wordsA": ["Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitgation", "Strategies", "(REMS)", "program", "that", "Promacta", "had", "been", "operating", "under", "in", "the", "US", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long", "term", "safety", "of", "Promacta."], "wordsB": ["Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitigation", "Strategies", "(REMS)", "program", "that", "Promacta", "had", "been", "operating", "under", "in", "the", "United", "States", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long-term", "safety", "of", "Promacta."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p32_s3", "idA": "886163_13_item1_p8_s1", "sentA": "That application is currently under review by the European Medicines Agency.", "sentB": "In the European Union, the Marketing Authorization Application, or MAA, is filed with the European Medicines Agency.", "type": 2, "words": ["<tag1>", "That", "application", "is", "currently", "under", "review", "by", "the", "European", "Medicines", "Agency.", "<tag2>", "In", "the", "European", "Union,", "the", "Marketing", "Authorization", "Application,", "or", "MAA,", "is", "filed", "with", "the", "European", "Medicines", "Agency.", "<tag3>"], "wordsA": ["That", "application", "is", "currently", "under", "review", "by", "the", "European", "Medicines", "Agency."], "wordsB": ["In", "the", "European", "Union,", "the", "Marketing", "Authorization", "Application,", "or", "MAA,", "is", "filed", "with", "the", "European", "Medicines", "Agency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p0_s0", "idA": "886163_14_item1_p0_s0", "sentA": "Overview We are a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure.", "sentB": "Overview We are a biotechnology company that develops and acquires revenue generating assets and couples them with a lean corporate cost structure.", "type": 2, "words": ["<tag1>", "Overview", "We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "with", "a", "lean", "corporate", "cost", "structure.", "<tag2>", "Overview", "We", "are", "a", "biotechnology", "company", "that", "develops", "and", "acquires", "revenue", "generating", "assets", "and", "couples", "them", "with", "a", "lean", "corporate", "cost", "structure.", "<tag3>"], "wordsA": ["Overview", "We", "are", "a", "biotechnology", "company", "that", "operates", "with", "a", "business", "model", "focused", "on", "developing", "or", "acquiring", "revenue", "generating", "assets", "and", "coupling", "them", "with", "a", "lean", "corporate", "cost", "structure."], "wordsB": ["Overview", "We", "are", "a", "biotechnology", "company", "that", "develops", "and", "acquires", "revenue", "generating", "assets", "and", "couples", "them", "with", "a", "lean", "corporate", "cost", "structure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p0_s4", "idA": "886163_14_item1_p0_s4", "sentA": "Captisol is a formulation technology that has enabled six FDA approved products, including Onyx's Kyprolis and Baxter International's Nexterone and is currently being developed in a number of clinical-stage partner programs.", "sentB": "Captisol is a formulation technology that has enabled seven FDA approved products, including Amgen, Inc.'s Kyprolis and Merck's Noxafil-IV and is currently being developed in a number of clinical-stage partner programs.", "type": 2, "words": ["<tag1>", "Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx's", "Kyprolis", "and", "Baxter", "International's", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag2>", "Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "seven", "FDA", "approved", "products,", "including", "Amgen,", "Inc.'s", "Kyprolis", "and", "Merck's", "Noxafil-IV", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag3>"], "wordsA": ["Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx's", "Kyprolis", "and", "Baxter", "International's", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "wordsB": ["Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "seven", "FDA", "approved", "products,", "including", "Amgen,", "Inc.'s", "Kyprolis", "and", "Merck's", "Noxafil-IV", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p12_s4", "idA": "886163_14_item1_p0_s4", "sentA": "Captisol is a formulation technology that has enabled six FDA approved products, including Onyx's Kyprolis and Baxter International's Nexterone and is currently being developed in a number of clinical-stage partner programs.", "sentB": "Promacta is currently in clinical development for a number of additional indications in oncology including myelodysplastiuc syndromes (MDS), acute myeloid leukemia (AML) and chemotherapy-induced thrombocytopenia (CIT).", "type": 2, "words": ["<tag1>", "Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx's", "Kyprolis", "and", "Baxter", "International's", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag2>", "Promacta", "is", "currently", "in", "clinical", "development", "for", "a", "number", "of", "additional", "indications", "in", "oncology", "including", "myelodysplastiuc", "syndromes", "(MDS),", "acute", "myeloid", "leukemia", "(AML)", "and", "chemotherapy-induced", "thrombocytopenia", "(CIT).", "<tag3>"], "wordsA": ["Captisol", "is", "a", "formulation", "technology", "that", "has", "enabled", "six", "FDA", "approved", "products,", "including", "Onyx's", "Kyprolis", "and", "Baxter", "International's", "Nexterone", "and", "is", "currently", "being", "developed", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "wordsB": ["Promacta", "is", "currently", "in", "clinical", "development", "for", "a", "number", "of", "additional", "indications", "in", "oncology", "including", "myelodysplastiuc", "syndromes", "(MDS),", "acute", "myeloid", "leukemia", "(AML)", "and", "chemotherapy-induced", "thrombocytopenia", "(CIT)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p7_s0", "idA": "886163_14_item1_p10_s0", "sentA": "Promacta (GSK) GSK s Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP.", "sentB": "Promacta (GSK) GSK s Promacta (eltrombopag) is an oral medicine that increases the number of platelets in the blood.", "type": 2, "words": ["<tag1>", "Promacta", "(GSK)", "GSK", "s", "Promacta", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP.", "<tag2>", "Promacta", "(GSK)", "GSK", "s", "Promacta", "(eltrombopag)", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood.", "<tag3>"], "wordsA": ["Promacta", "(GSK)", "GSK", "s", "Promacta", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP."], "wordsB": ["Promacta", "(GSK)", "GSK", "s", "Promacta", "(eltrombopag)", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p12_s2", "idA": "886163_14_item1_p10_s1", "sentA": "In late 2008, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of Promacta for the treatment of thrombocytopenia in patients with chronic ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "In December 2014, GSK reported the submission of a sNDA to the FDA for Promacta, seeking an additional indication in pediatric patients six years old and older with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "type": 2, "words": ["<tag1>", "In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "In", "December", "2014,", "GSK", "reported", "the", "submission", "of", "a", "sNDA", "to", "the", "FDA", "for", "Promacta,", "seeking", "an", "additional", "indication", "in", "pediatric", "patients", "six", "years", "old", "and", "older", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag3>"], "wordsA": ["In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["In", "December", "2014,", "GSK", "reported", "the", "submission", "of", "a", "sNDA", "to", "the", "FDA", "for", "Promacta,", "seeking", "an", "additional", "indication", "in", "pediatric", "patients", "six", "years", "old", "and", "older", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p12_s3", "idA": "886163_14_item1_p10_s1", "sentA": "In late 2008, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of Promacta for the treatment of thrombocytopenia in patients with chronic ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "In February of 2015, GSK announced submission to the European Medicines Agency, or EMA, of a variation to the Marketing Authorization for Revolade , seeking an additional indication for the treatment of pediatric patients (age 1 year and above) with chronic ITP who have had an insufficient response to corticosteroids or immunoglobulins.", "type": 2, "words": ["<tag1>", "In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "In", "February", "of", "2015,", "GSK", "announced", "submission", "to", "the", "European", "Medicines", "Agency,", "or", "EMA,", "of", "a", "variation", "to", "the", "Marketing", "Authorization", "for", "Revolade", ",", "seeking", "an", "additional", "indication", "for", "the", "treatment", "of", "pediatric", "patients", "(age", "1", "year", "and", "above)", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids", "or", "immunoglobulins.", "<tag3>"], "wordsA": ["In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["In", "February", "of", "2015,", "GSK", "announced", "submission", "to", "the", "European", "Medicines", "Agency,", "or", "EMA,", "of", "a", "variation", "to", "the", "Marketing", "Authorization", "for", "Revolade", ",", "seeking", "an", "additional", "indication", "for", "the", "treatment", "of", "pediatric", "patients", "(age", "1", "year", "and", "above)", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids", "or", "immunoglobulins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p20_s2", "idA": "886163_14_item1_p10_s1", "sentA": "In late 2008, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of Promacta for the treatment of thrombocytopenia in patients with chronic ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "The U.S. submission is designed to support conversion from accelerated approval to full FDA approval and also expand the current approved indication for the drug.", "type": 2, "words": ["<tag1>", "In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "The", "U.S.", "submission", "is", "designed", "to", "support", "conversion", "from", "accelerated", "approval", "to", "full", "FDA", "approval", "and", "also", "expand", "the", "current", "approved", "indication", "for", "the", "drug.", "<tag3>"], "wordsA": ["In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["The", "U.S.", "submission", "is", "designed", "to", "support", "conversion", "from", "accelerated", "approval", "to", "full", "FDA", "approval", "and", "also", "expand", "the", "current", "approved", "indication", "for", "the", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p9_s0", "idA": "886163_14_item1_p10_s1", "sentA": "In late 2008, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of Promacta for the treatment of thrombocytopenia in patients with chronic ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "Promacta was first approved by the U.S. Food and Drug Administration, or FDA, in 2008 under an accelerated approval for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "type": 2, "words": ["<tag1>", "In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "Promacta", "was", "first", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "in", "2008", "under", "an", "accelerated", "approval", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag3>"], "wordsA": ["In", "late", "2008,", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "granted", "accelerated", "approval", "of", "Promacta", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["Promacta", "was", "first", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "in", "2008", "under", "an", "accelerated", "approval", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p11_s2", "idA": "886163_14_item1_p11_s4", "sentA": "GSK is conducting clinical studies of Promacta for various indications, including oncology-related indications.", "sentB": "Beyond the currently approved indications, GSK is also performing development activities to expand the brand into new indications, including pediatric ITP and a number of oncology-related indications.", "type": 2, "words": ["<tag1>", "GSK", "is", "conducting", "clinical", "studies", "of", "Promacta", "for", "various", "indications,", "including", "oncology-related", "indications.", "<tag2>", "Beyond", "the", "currently", "approved", "indications,", "GSK", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "pediatric", "ITP", "and", "a", "number", "of", "oncology-related", "indications.", "<tag3>"], "wordsA": ["GSK", "is", "conducting", "clinical", "studies", "of", "Promacta", "for", "various", "indications,", "including", "oncology-related", "indications."], "wordsB": ["Beyond", "the", "currently", "approved", "indications,", "GSK", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "pediatric", "ITP", "and", "a", "number", "of", "oncology-related", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p10_s0", "idA": "886163_14_item1_p12_s0", "sentA": "Promacta is authorized for use in 95 countries.", "sentB": "Promacta is known as Revolade in the EU.", "type": 2, "words": ["<tag1>", "Promacta", "is", "authorized", "for", "use", "in", "95", "countries.", "<tag2>", "Promacta", "is", "known", "as", "Revolade", "in", "the", "EU.", "<tag3>"], "wordsA": ["Promacta", "is", "authorized", "for", "use", "in", "95", "countries."], "wordsB": ["Promacta", "is", "known", "as", "Revolade", "in", "the", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p19_s2", "idA": "886163_14_item1_p12_s0", "sentA": "Promacta is authorized for use in 95 countries.", "sentB": "ASPIRE enrolled 792 relapsed or refractory multiple myeloma patients from 20 countries.", "type": 2, "words": ["<tag1>", "Promacta", "is", "authorized", "for", "use", "in", "95", "countries.", "<tag2>", "ASPIRE", "enrolled", "792", "relapsed", "or", "refractory", "multiple", "myeloma", "patients", "from", "20", "countries.", "<tag3>"], "wordsA": ["Promacta", "is", "authorized", "for", "use", "in", "95", "countries."], "wordsB": ["ASPIRE", "enrolled", "792", "relapsed", "or", "refractory", "multiple", "myeloma", "patients", "from", "20", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p14_s0", "idA": "886163_14_item1_p13_s1", "sentA": "The purpose of the agreement was to engage in a joint research and development effort to discover and/or design small molecule compounds which act as modulators of certain signal transducers and activators of transcription, or STATS, to develop pharmaceutical products from such compounds and to commercialize products resulting from the joint research and development.", "sentB": "We entered into a Research, Development and License Agreement with SmithKline Beecham Corporation (now GSK) in 1994 to discover and/or design small molecule compounds which act as modulators of certain signal transducers and activators of transcription, or STATS, to develop pharmaceutical products from such compounds and to commercialize products resulting from the joint research and development.", "type": 2, "words": ["<tag1>", "The", "purpose", "of", "the", "agreement", "was", "to", "engage", "in", "a", "joint", "research", "and", "development", "effort", "to", "discover", "and/or", "design", "small", "molecule", "compounds", "which", "act", "as", "modulators", "of", "certain", "signal", "transducers", "and", "activators", "of", "transcription,", "or", "STATS,", "to", "develop", "pharmaceutical", "products", "from", "such", "compounds", "and", "to", "commercialize", "products", "resulting", "from", "the", "joint", "research", "and", "development.", "<tag2>", "We", "entered", "into", "a", "Research,", "Development", "and", "License", "Agreement", "with", "SmithKline", "Beecham", "Corporation", "(now", "GSK)", "in", "1994", "to", "discover", "and/or", "design", "small", "molecule", "compounds", "which", "act", "as", "modulators", "of", "certain", "signal", "transducers", "and", "activators", "of", "transcription,", "or", "STATS,", "to", "develop", "pharmaceutical", "products", "from", "such", "compounds", "and", "to", "commercialize", "products", "resulting", "from", "the", "joint", "research", "and", "development.", "<tag3>"], "wordsA": ["The", "purpose", "of", "the", "agreement", "was", "to", "engage", "in", "a", "joint", "research", "and", "development", "effort", "to", "discover", "and/or", "design", "small", "molecule", "compounds", "which", "act", "as", "modulators", "of", "certain", "signal", "transducers", "and", "activators", "of", "transcription,", "or", "STATS,", "to", "develop", "pharmaceutical", "products", "from", "such", "compounds", "and", "to", "commercialize", "products", "resulting", "from", "the", "joint", "research", "and", "development."], "wordsB": ["We", "entered", "into", "a", "Research,", "Development", "and", "License", "Agreement", "with", "SmithKline", "Beecham", "Corporation", "(now", "GSK)", "in", "1994", "to", "discover", "and/or", "design", "small", "molecule", "compounds", "which", "act", "as", "modulators", "of", "certain", "signal", "transducers", "and", "activators", "of", "transcription,", "or", "STATS,", "to", "develop", "pharmaceutical", "products", "from", "such", "compounds", "and", "to", "commercialize", "products", "resulting", "from", "the", "joint", "research", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p14_s2", "idA": "886163_14_item1_p13_s4", "sentA": "The obligation to pay royalties lasts during the life or the relevant patents or at a reduced rate for ten years from the first commercial sale, whichever is longer, on a country-by-country basis.", "sentB": "We are entitled to receive royalties related to Promacta during the life of the relevant patents or at a reduced rate for ten years from the first commercial sale, whichever is longer, on a country-by-country basis.", "type": 2, "words": ["<tag1>", "The", "obligation", "to", "pay", "royalties", "lasts", "during", "the", "life", "or", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis.", "<tag2>", "We", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "during", "the", "life", "of", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["The", "obligation", "to", "pay", "royalties", "lasts", "during", "the", "life", "or", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis."], "wordsB": ["We", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "during", "the", "life", "of", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p14_s3", "idA": "886163_14_item1_p13_s5", "sentA": "Absent early termination for bankruptcy or material breach, the term of the agreement expires upon expiration of the obligation to pay royalties.", "sentB": "GSK has listed a patent in the FDA s Orange Book for Promacta with an expiration date in 2027, and absent early termination for bankruptcy or material breach, the term of the agreement expires upon expiration of the obligation to pay royalties.", "type": 2, "words": ["<tag1>", "Absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties.", "<tag2>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties.", "<tag3>"], "wordsA": ["Absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties."], "wordsB": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p60_s2", "idA": "886163_14_item1_p13_s6", "sentA": "Either party may terminate the agreement in the event of bankruptcy or material breach.", "sentB": "We also have the right to terminate the license agreement in the event of insolvency or bankruptcy of Viking.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "agreement", "in", "the", "event", "of", "bankruptcy", "or", "material", "breach.", "<tag2>", "We", "also", "have", "the", "right", "to", "terminate", "the", "license", "agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "Viking.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "agreement", "in", "the", "event", "of", "bankruptcy", "or", "material", "breach."], "wordsB": ["We", "also", "have", "the", "right", "to", "terminate", "the", "license", "agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "Viking."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p17_s0", "idA": "886163_14_item1_p17_s1", "sentA": "Under this agreement we agreed to sell Captisol to Onyx for use with carfilzomib, and granted an exclusive product-specific license under our patent rights with respect to Captisol.", "sentB": "Kyprolis (Amgen) Ligand supplies Captisol to Amgen, Inc. under a 2005 agreement pursuant to an agreement whereby we sell Captisol for use with carfilzomib, and granted an exclusive product-specific license under our patent rights with respect to Captisol.", "type": 2, "words": ["<tag1>", "Under", "this", "agreement", "we", "agreed", "to", "sell", "Captisol", "to", "Onyx", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol.", "<tag2>", "Kyprolis", "(Amgen)", "Ligand", "supplies", "Captisol", "to", "Amgen,", "Inc.", "under", "a", "2005", "agreement", "pursuant", "to", "an", "agreement", "whereby", "we", "sell", "Captisol", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol.", "<tag3>"], "wordsA": ["Under", "this", "agreement", "we", "agreed", "to", "sell", "Captisol", "to", "Onyx", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol."], "wordsB": ["Kyprolis", "(Amgen)", "Ligand", "supplies", "Captisol", "to", "Amgen,", "Inc.", "under", "a", "2005", "agreement", "pursuant", "to", "an", "agreement", "whereby", "we", "sell", "Captisol", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p39_s3", "idA": "886163_14_item1_p18_s0", "sentA": "In July 2012, Onyx received accelerated approval from the FDA for Kyprolis (carfilzomib) for injection.", "sentB": "SAGE-547 also received orphan drug designation, which is intended to facilitate drug development for rare diseases, from the FDA in April 2014.", "type": 2, "words": ["<tag1>", "In", "July", "2012,", "Onyx", "received", "accelerated", "approval", "from", "the", "FDA", "for", "Kyprolis", "(carfilzomib)", "for", "injection.", "<tag2>", "SAGE-547", "also", "received", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "from", "the", "FDA", "in", "April", "2014.", "<tag3>"], "wordsA": ["In", "July", "2012,", "Onyx", "received", "accelerated", "approval", "from", "the", "FDA", "for", "Kyprolis", "(carfilzomib)", "for", "injection."], "wordsB": ["SAGE-547", "also", "received", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "from", "the", "FDA", "in", "April", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p19_s0", "idA": "886163_14_item1_p19_s0", "sentA": "The indication for Kyprolis is based on response rate.", "sentB": "This indication for Kyprolis is based on response rate.", "type": 2, "words": ["<tag1>", "The", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate.", "<tag2>", "This", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate.", "<tag3>"], "wordsA": ["The", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate."], "wordsB": ["This", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p21_s0", "idA": "886163_14_item1_p19_s1", "sentA": "Onyx s obligation to pay royalties does not expire until four years after the expiration of the last-to-expire patent covering Captisol.", "sentB": "Amgen s obligation to pay royalties does not expire until four years after the expiration of the last-to-expire patent covering Captisol.", "type": 2, "words": ["<tag1>", "Onyx", "s", "obligation", "to", "pay", "royalties", "does", "not", "expire", "until", "four", "years", "after", "the", "expiration", "of", "the", "last-to-expire", "patent", "covering", "Captisol.", "<tag2>", "Amgen", "s", "obligation", "to", "pay", "royalties", "does", "not", "expire", "until", "four", "years", "after", "the", "expiration", "of", "the", "last-to-expire", "patent", "covering", "Captisol.", "<tag3>"], "wordsA": ["Onyx", "s", "obligation", "to", "pay", "royalties", "does", "not", "expire", "until", "four", "years", "after", "the", "expiration", "of", "the", "last-to-expire", "patent", "covering", "Captisol."], "wordsB": ["Amgen", "s", "obligation", "to", "pay", "royalties", "does", "not", "expire", "until", "four", "years", "after", "the", "expiration", "of", "the", "last-to-expire", "patent", "covering", "Captisol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p21_s2", "idA": "886163_14_item1_p19_s3", "sentA": "Our agreement with Onyx may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Onyx with prior written notice, subject to certain surviving obligations such as placing orders under any binding forecasts.", "sentB": "Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations such as placing orders under any binding forecasts.", "type": 2, "words": ["<tag1>", "Our", "agreement", "with", "Onyx", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Onyx", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts.", "<tag2>", "Our", "agreement", "with", "Amgen", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Amgen", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts.", "<tag3>"], "wordsA": ["Our", "agreement", "with", "Onyx", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Onyx", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts."], "wordsB": ["Our", "agreement", "with", "Amgen", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Amgen", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p7_s1", "idA": "886163_14_item1_p1_s0", "sentA": "In comparison to our peers, we believe we have assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate significant revenue in the future.", "sentB": "Platelets are one of the three components of blood and facilitate clotting in the blood.", "type": 2, "words": ["<tag1>", "In", "comparison", "to", "our", "peers,", "we", "believe", "we", "have", "assembled", "one", "of", "the", "largest", "and", "most", "diversified", "asset", "portfolios", "in", "the", "industry", "with", "the", "potential", "to", "generate", "significant", "revenue", "in", "the", "future.", "<tag2>", "Platelets", "are", "one", "of", "the", "three", "components", "of", "blood", "and", "facilitate", "clotting", "in", "the", "blood.", "<tag3>"], "wordsA": ["In", "comparison", "to", "our", "peers,", "we", "believe", "we", "have", "assembled", "one", "of", "the", "largest", "and", "most", "diversified", "asset", "portfolios", "in", "the", "industry", "with", "the", "potential", "to", "generate", "significant", "revenue", "in", "the", "future."], "wordsB": ["Platelets", "are", "one", "of", "the", "three", "components", "of", "blood", "and", "facilitate", "clotting", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p1_s1", "idA": "886163_14_item1_p1_s1", "sentA": "The therapies in our development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, immune (idiopathic) thrombocytopenic purpura, or ITP, muscle wasting, multiple myeloma, Alzheimer s disease, dyslipidemia, diabetes, anemia, epilepsy, Focal Segmental Glomerulosclerosis, or FSGS, and osteoporosis.", "sentB": "The therapies in our development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, multiple myeloma, muscle wasting, Alzheimer s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, or FSGS and osteoporosis.", "type": 2, "words": ["<tag1>", "The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "Focal", "Segmental", "Glomerulosclerosis,", "or", "FSGS,", "and", "osteoporosis.", "<tag2>", "The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "multiple", "myeloma,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "focal", "segmental", "glomerulosclerosis,", "or", "FSGS", "and", "osteoporosis.", "<tag3>"], "wordsA": ["The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "Focal", "Segmental", "Glomerulosclerosis,", "or", "FSGS,", "and", "osteoporosis."], "wordsB": ["The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "multiple", "myeloma,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "focal", "segmental", "glomerulosclerosis,", "or", "FSGS", "and", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p29_s5", "idA": "886163_14_item1_p20_s0", "sentA": "Avinza (Pfizer) We currently receive royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza .", "sentB": "Avinza (Pfizer) We have received royalties of 5% from Pfizer on sales of the pain therapeutic Avinza .", "type": 2, "words": ["<tag1>", "Avinza", "(Pfizer)", "We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.,", "or", "Pfizer,", "for", "sales", "of", "the", "pain", "therapeutic", "Avinza", ".", "<tag2>", "Avinza", "(Pfizer)", "We", "have", "received", "royalties", "of", "5%", "from", "Pfizer", "on", "sales", "of", "the", "pain", "therapeutic", "Avinza", ".", "<tag3>"], "wordsA": ["Avinza", "(Pfizer)", "We", "currently", "receive", "royalty", "revenues", "from", "Pfizer,", "Inc.,", "or", "Pfizer,", "for", "sales", "of", "the", "pain", "therapeutic", "Avinza", "."], "wordsB": ["Avinza", "(Pfizer)", "We", "have", "received", "royalties", "of", "5%", "from", "Pfizer", "on", "sales", "of", "the", "pain", "therapeutic", "Avinza", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s8", "idA": "886163_14_item1_p21_s0", "sentA": "We have multiple partnered programs in our portfolio that are either in or nearing the regulatory approval process.", "sentB": "We have multiple partnered programs in our portfolio that have products that are already being commercialized.", "type": 2, "words": ["<tag1>", "We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process.", "<tag2>", "We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "have", "products", "that", "are", "already", "being", "commercialized.", "<tag3>"], "wordsA": ["We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process."], "wordsB": ["We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "have", "products", "that", "are", "already", "being", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p46_s2", "idA": "886163_14_item1_p24_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate in the range of 15% to 25%.", "sentB": "Under the terms of the agreement, we received 125,000 shares of TG Therapeutics common stock, valued at approximately $1.2 million at date of signing, and we are eligible to receive $207.0 million in potential milestone payments.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "received", "125,000", "shares", "of", "TG", "Therapeutics", "common", "stock,", "valued", "at", "approximately", "$1.2", "million", "at", "date", "of", "signing,", "and", "we", "are", "eligible", "to", "receive", "$207.0", "million", "in", "potential", "milestone", "payments.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "received", "125,000", "shares", "of", "TG", "Therapeutics", "common", "stock,", "valued", "at", "approximately", "$1.2", "million", "at", "date", "of", "signing,", "and", "we", "are", "eligible", "to", "receive", "$207.0", "million", "in", "potential", "milestone", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p46_s3", "idA": "886163_14_item1_p24_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate in the range of 15% to 25%.", "sentB": "We are also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%.", "<tag2>", "We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%."], "wordsB": ["We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p57_s1", "idA": "886163_14_item1_p24_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate in the range of 15% to 25%.", "sentB": "Under the terms of the expanded license, we are eligible to receive up to $22 million in potential milestone payments, revenue from the sales of Captisol, and tiered royalties on future net sales in the range of 4% to 7% for Captisol-enabled Lamotrigine.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%.", "<tag2>", "Under", "the", "terms", "of", "the", "expanded", "license,", "we", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "potential", "milestone", "payments,", "revenue", "from", "the", "sales", "of", "Captisol,", "and", "tiered", "royalties", "on", "future", "net", "sales", "in", "the", "range", "of", "4%", "to", "7%", "for", "Captisol-enabled", "Lamotrigine.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%."], "wordsB": ["Under", "the", "terms", "of", "the", "expanded", "license,", "we", "are", "eligible", "to", "receive", "up", "to", "$22", "million", "in", "potential", "milestone", "payments,", "revenue", "from", "the", "sales", "of", "Captisol,", "and", "tiered", "royalties", "on", "future", "net", "sales", "in", "the", "range", "of", "4%", "to", "7%", "for", "Captisol-enabled", "Lamotrigine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p59_s1", "idA": "886163_14_item1_p24_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate in the range of 15% to 25%.", "sentB": "Each licensed program includes a fee to be paid to us in Viking equity at the time of a private or public financing, milestone payments and royalties on future net sales.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%.", "<tag2>", "Each", "licensed", "program", "includes", "a", "fee", "to", "be", "paid", "to", "us", "in", "Viking", "equity", "at", "the", "time", "of", "a", "private", "or", "public", "financing,", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "in", "the", "range", "of", "15%", "to", "25%."], "wordsB": ["Each", "licensed", "program", "includes", "a", "fee", "to", "be", "paid", "to", "us", "in", "Viking", "equity", "at", "the", "time", "of", "a", "private", "or", "public", "financing,", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p49_s3", "idA": "886163_14_item1_p25_s4", "sentA": "In return for the rights to these payment streams, we paid Selexis $3.5 million in an upfront cash payment, and expect to make a $1 million cash payment in April 2014 on the first anniversary of the acquisition.", "sentB": "In return for the rights to these payment streams, we paid Selexis $4.5 million.", "type": 2, "words": ["<tag1>", "In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$3.5", "million", "in", "an", "upfront", "cash", "payment,", "and", "expect", "to", "make", "a", "$1", "million", "cash", "payment", "in", "April", "2014", "on", "the", "first", "anniversary", "of", "the", "acquisition.", "<tag2>", "In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$4.5", "million.", "<tag3>"], "wordsA": ["In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$3.5", "million", "in", "an", "upfront", "cash", "payment,", "and", "expect", "to", "make", "a", "$1", "million", "cash", "payment", "in", "April", "2014", "on", "the", "first", "anniversary", "of", "the", "acquisition."], "wordsB": ["In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$4.5", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p49_s5", "idA": "886163_14_item1_p25_s6", "sentA": "The programs that we acquired in this transaction are based on Selexis technology platform for cell line development and scale-up to manufacturing of therapeutic proteins, and relate to pre-commercialized drugs that are currently being developed; the programs should thus require no funding or technological support from Ligand.", "sentB": "The programs that we acquired in this transaction are based on Selexis technology platform for cell line development and scale-up to manufacturing of therapeutic proteins, and relate to pre-commercialized drugs that are currently being developed; the programs should thus require no funding or technological support from us.", "type": 2, "words": ["<tag1>", "The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "Ligand.", "<tag2>", "The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us.", "<tag3>"], "wordsA": ["The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "Ligand."], "wordsB": ["The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p58_s2", "idA": "886163_14_item1_p28_s3", "sentA": "Pfizer obtained FDA approval for Duavee in the United States in October 2013 and filed an approval submission with the EMA in 2012.", "sentB": "The FBPase Inhibitor program was the subject of an option originally granted to Viking in 2012.", "type": 2, "words": ["<tag1>", "Pfizer", "obtained", "FDA", "approval", "for", "Duavee", "in", "the", "United", "States", "in", "October", "2013", "and", "filed", "an", "approval", "submission", "with", "the", "EMA", "in", "2012.", "<tag2>", "The", "FBPase", "Inhibitor", "program", "was", "the", "subject", "of", "an", "option", "originally", "granted", "to", "Viking", "in", "2012.", "<tag3>"], "wordsA": ["Pfizer", "obtained", "FDA", "approval", "for", "Duavee", "in", "the", "United", "States", "in", "October", "2013", "and", "filed", "an", "approval", "submission", "with", "the", "EMA", "in", "2012."], "wordsB": ["The", "FBPase", "Inhibitor", "program", "was", "the", "subject", "of", "an", "option", "originally", "granted", "to", "Viking", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p13_s1", "idA": "886163_14_item1_p28_s4", "sentA": "Pfizer launched Duavee in the United States in the first quarter of 2014.", "sentB": "Subject to regulatory reviews, it is expected that the transaction will complete in the first half of 2015 and Promacta will transition to Novartis.", "type": 2, "words": ["<tag1>", "Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "Subject", "to", "regulatory", "reviews,", "it", "is", "expected", "that", "the", "transaction", "will", "complete", "in", "the", "first", "half", "of", "2015", "and", "Promacta", "will", "transition", "to", "Novartis.", "<tag3>"], "wordsA": ["Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["Subject", "to", "regulatory", "reviews,", "it", "is", "expected", "that", "the", "transaction", "will", "complete", "in", "the", "first", "half", "of", "2015", "and", "Promacta", "will", "transition", "to", "Novartis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p24_s5", "idA": "886163_14_item1_p28_s4", "sentA": "Pfizer launched Duavee in the United States in the first quarter of 2014.", "sentB": "Pfizer received EMA approval for Duavive in December of 2014.", "type": 2, "words": ["<tag1>", "Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "Pfizer", "received", "EMA", "approval", "for", "Duavive", "in", "December", "of", "2014.", "<tag3>"], "wordsA": ["Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["Pfizer", "received", "EMA", "approval", "for", "Duavive", "in", "December", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p29_s8", "idA": "886163_14_item1_p28_s4", "sentA": "Pfizer launched Duavee in the United States in the first quarter of 2014.", "sentB": "We expect future royalties from Avinza to stop in the second quarter of 2015 and that any remaining royalty payments for Avinza will be minimal.", "type": 2, "words": ["<tag1>", "Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "We", "expect", "future", "royalties", "from", "Avinza", "to", "stop", "in", "the", "second", "quarter", "of", "2015", "and", "that", "any", "remaining", "royalty", "payments", "for", "Avinza", "will", "be", "minimal.", "<tag3>"], "wordsA": ["Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["We", "expect", "future", "royalties", "from", "Avinza", "to", "stop", "in", "the", "second", "quarter", "of", "2015", "and", "that", "any", "remaining", "royalty", "payments", "for", "Avinza", "will", "be", "minimal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p45_s1", "idA": "886163_14_item1_p28_s4", "sentA": "Pfizer launched Duavee in the United States in the first quarter of 2014.", "sentB": "Lundbeck is in the process of responding to a request of Chemistry, Manufacturing and Controls, or CMC, data from the FDA s Complete Response Letter received in late 2014.", "type": 2, "words": ["<tag1>", "Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "Lundbeck", "is", "in", "the", "process", "of", "responding", "to", "a", "request", "of", "Chemistry,", "Manufacturing", "and", "Controls,", "or", "CMC,", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014.", "<tag3>"], "wordsA": ["Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["Lundbeck", "is", "in", "the", "process", "of", "responding", "to", "a", "request", "of", "Chemistry,", "Manufacturing", "and", "Controls,", "or", "CMC,", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p77_s0", "idA": "886163_14_item1_p28_s4", "sentA": "Pfizer launched Duavee in the United States in the first quarter of 2014.", "sentB": "Hovione operates FDA-inspected sites in the US, Ireland and Portugal.", "type": 2, "words": ["<tag1>", "Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "Hovione", "operates", "FDA-inspected", "sites", "in", "the", "US,", "Ireland", "and", "Portugal.", "<tag3>"], "wordsA": ["Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["Hovione", "operates", "FDA-inspected", "sites", "in", "the", "US,", "Ireland", "and", "Portugal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p25_s0", "idA": "886163_14_item1_p28_s5", "sentA": "Net royalties on annual net sales of Viviant and Duavee are each payable to us at a rate shown in the table below and are payable through the life of the relevant patents.", "sentB": "Net royalties on annual net sales of Viviant and Duavee are each payable to us at a rate shown in the table below and are payable through the life of the relevant patents or ten years from the first commercial sale, whichever is longer, on a country by country basis.", "type": 2, "words": ["<tag1>", "Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents.", "<tag2>", "Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents", "or", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country", "by", "country", "basis.", "<tag3>"], "wordsA": ["Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents."], "wordsB": ["Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents", "or", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country", "by", "country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p9_s3", "idA": "886163_14_item1_p28_s5", "sentA": "Net royalties on annual net sales of Viviant and Duavee are each payable to us at a rate shown in the table below and are payable through the life of the relevant patents.", "sentB": "The timing of the approvals for Promacta in the US and Europe is summarized in the table below.", "type": 2, "words": ["<tag1>", "Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents.", "<tag2>", "The", "timing", "of", "the", "approvals", "for", "Promacta", "in", "the", "US", "and", "Europe", "is", "summarized", "in", "the", "table", "below.", "<tag3>"], "wordsA": ["Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents."], "wordsB": ["The", "timing", "of", "the", "approvals", "for", "Promacta", "in", "the", "US", "and", "Europe", "is", "summarized", "in", "the", "table", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p1_s2", "idA": "886163_14_item1_p2_s0", "sentA": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen, Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly and Co., and Spectrum Pharmaceuticals, Inc.", "sentB": "We have established multiple alliances with the world s leading pharmaceutical companies including GlaxoSmithKline (GSK), Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co.", "type": 2, "words": ["<tag1>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals", "(a", "subsidiary", "of", "Amgen,", "Inc.),", "Merck,", "Pfizer,", "Baxter", "International,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "Spectrum", "Pharmaceuticals,", "Inc.", "<tag2>", "We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline", "(GSK),", "Amgen,", "Inc.,", "Merck,", "Pfizer,", "Baxter", "International,", "and", "Eli", "Lilly", "and", "Co.", "<tag3>"], "wordsA": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline,", "Onyx", "Pharmaceuticals", "(a", "subsidiary", "of", "Amgen,", "Inc.),", "Merck,", "Pfizer,", "Baxter", "International,", "Lundbeck", "Inc.,", "Eli", "Lilly", "and", "Co.,", "and", "Spectrum", "Pharmaceuticals,", "Inc."], "wordsB": ["We", "have", "established", "multiple", "alliances", "with", "the", "world", "s", "leading", "pharmaceutical", "companies", "including", "GlaxoSmithKline", "(GSK),", "Amgen,", "Inc.,", "Merck,", "Pfizer,", "Baxter", "International,", "and", "Eli", "Lilly", "and", "Co."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p29_s0", "idA": "886163_14_item1_p31_s0", "sentA": "In 2006, we outlicensed Nexterone, an injectable formulation combining amiodarone and Captisol, to Baxter International, Inc. or Baxter (which acquired Prism Pharmaceuticals, Inc., the original licensee, in 2011).", "sentB": "In 2006, we out-licensed Nexterone, an injectable formulation combining amiodarone and Captisol, to Baxter International, Inc. or Baxter (which acquired Prism Pharmaceuticals, Inc., the original licensee, in 2011).", "type": 2, "words": ["<tag1>", "In", "2006,", "we", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "Inc.", "or", "Baxter", "(which", "acquired", "Prism", "Pharmaceuticals,", "Inc.,", "the", "original", "licensee,", "in", "2011).", "<tag2>", "In", "2006,", "we", "out-licensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "Inc.", "or", "Baxter", "(which", "acquired", "Prism", "Pharmaceuticals,", "Inc.,", "the", "original", "licensee,", "in", "2011).", "<tag3>"], "wordsA": ["In", "2006,", "we", "outlicensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "Inc.", "or", "Baxter", "(which", "acquired", "Prism", "Pharmaceuticals,", "Inc.,", "the", "original", "licensee,", "in", "2011)."], "wordsB": ["In", "2006,", "we", "out-licensed", "Nexterone,", "an", "injectable", "formulation", "combining", "amiodarone", "and", "Captisol,", "to", "Baxter", "International,", "Inc.", "or", "Baxter", "(which", "acquired", "Prism", "Pharmaceuticals,", "Inc.,", "the", "original", "licensee,", "in", "2011)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p57_s2", "idA": "886163_14_item1_p31_s1", "sentA": "Under the terms of the agreement, Baxter is responsible, under an exclusive worldwide license, for all development and commercialization of Nexterone at its sole expense.", "sentB": "CURx will be responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p60_s0", "idA": "886163_14_item1_p31_s1", "sentA": "Under the terms of the agreement, Baxter is responsible, under an exclusive worldwide license, for all development and commercialization of Nexterone at its sole expense.", "sentB": "Viking is responsible for all development activities under the license.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "Viking", "is", "responsible", "for", "all", "development", "activities", "under", "the", "license.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "Baxter", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["Viking", "is", "responsible", "for", "all", "development", "activities", "under", "the", "license."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p17_s1", "idA": "886163_14_item1_p31_s2", "sentA": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "sentB": "In July 2012, Kyprolis was approved by the FDA under accelerated review.", "type": 2, "words": ["<tag1>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag2>", "In", "July", "2012,", "Kyprolis", "was", "approved", "by", "the", "FDA", "under", "accelerated", "review.", "<tag3>"], "wordsA": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "wordsB": ["In", "July", "2012,", "Kyprolis", "was", "approved", "by", "the", "FDA", "under", "accelerated", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p28_s1", "idA": "886163_14_item1_p31_s2", "sentA": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "sentB": "Merck s NOXAFIL -IV, which is a new Captisol-enabled formulation of posaconazole for intravenous (IV) use, was approved by the FDA, EMA and Health Canada in 2014.", "type": 2, "words": ["<tag1>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag2>", "Merck", "s", "NOXAFIL", "-IV,", "which", "is", "a", "new", "Captisol-enabled", "formulation", "of", "posaconazole", "for", "intravenous", "(IV)", "use,", "was", "approved", "by", "the", "FDA,", "EMA", "and", "Health", "Canada", "in", "2014.", "<tag3>"], "wordsA": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "wordsB": ["Merck", "s", "NOXAFIL", "-IV,", "which", "is", "a", "new", "Captisol-enabled", "formulation", "of", "posaconazole", "for", "intravenous", "(IV)", "use,", "was", "approved", "by", "the", "FDA,", "EMA", "and", "Health", "Canada", "in", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p39_s1", "idA": "886163_14_item1_p31_s2", "sentA": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "sentB": "SAGE-547 was granted Fast Track designation by the FDA in July 2014 for SRSE.", "type": 2, "words": ["<tag1>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag2>", "SAGE-547", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA", "in", "July", "2014", "for", "SRSE.", "<tag3>"], "wordsA": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "wordsB": ["SAGE-547", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA", "in", "July", "2014", "for", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p32_s0", "idA": "886163_14_item1_p32_s2", "sentA": "In the United States, the New Drug Application, or NDA, for Noxafil-IV was filed and received FDA Priority Review in November 2013.", "sentB": "Spectrum Pharmaceuticals submitted a New Drug Application, or NDA, under a 505 (b)-(2) application for the program in December 2014.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "Noxafil-IV", "was", "filed", "and", "received", "FDA", "Priority", "Review", "in", "November", "2013.", "<tag2>", "Spectrum", "Pharmaceuticals", "submitted", "a", "New", "Drug", "Application,", "or", "NDA,", "under", "a", "505", "(b)-(2)", "application", "for", "the", "program", "in", "December", "2014.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "Noxafil-IV", "was", "filed", "and", "received", "FDA", "Priority", "Review", "in", "November", "2013."], "wordsB": ["Spectrum", "Pharmaceuticals", "submitted", "a", "New", "Drug", "Application,", "or", "NDA,", "under", "a", "505", "(b)-(2)", "application", "for", "the", "program", "in", "December", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p39_s4", "idA": "886163_14_item1_p35_s3", "sentA": "In December 2012, Merck initiated a Phase 2/3 clinical trial for its lead BACE inhibitor product candidate, MK-8931, evaluating its safety and efficacy in patients with mild-to-moderate Alzheimer s disease.", "sentB": "In January of 2015, SAGE reported updated data from an ongoing Phase 1/2 clinical trial and its emergency use program of SAGE-547 in patients with SRSE.", "type": 2, "words": ["<tag1>", "In", "December", "2012,", "Merck", "initiated", "a", "Phase", "2/3", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer", "s", "disease.", "<tag2>", "In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag3>"], "wordsA": ["In", "December", "2012,", "Merck", "initiated", "a", "Phase", "2/3", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer", "s", "disease."], "wordsB": ["In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p19_s1", "idA": "886163_14_item1_p35_s4", "sentA": "In December 2013, Merck announced progression of the program to Phase 3 by advancing the Phase 2/3 trial to Phase 3 and by initiating a second Phase 3 trial.", "sentB": "In 2014, Amgen announced positive results from the Phase 3 ASPIRE trial.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "by", "initiating", "a", "second", "Phase", "3", "trial.", "<tag2>", "In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial.", "<tag3>"], "wordsA": ["In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "by", "initiating", "a", "second", "Phase", "3", "trial."], "wordsB": ["In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p36_s1", "idA": "886163_14_item1_p35_s4", "sentA": "In December 2013, Merck announced progression of the program to Phase 3 by advancing the Phase 2/3 trial to Phase 3 and by initiating a second Phase 3 trial.", "sentB": "In December 2013, Merck announced progression of the program to Phase 3 by advancing the Phase 2/3 trial to Phase 3 and also initiated a second Phase 3 trial in earlier-stage or prodromal patients.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "by", "initiating", "a", "second", "Phase", "3", "trial.", "<tag2>", "In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "also", "initiated", "a", "second", "Phase", "3", "trial", "in", "earlier-stage", "or", "prodromal", "patients.", "<tag3>"], "wordsA": ["In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "by", "initiating", "a", "second", "Phase", "3", "trial."], "wordsB": ["In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "also", "initiated", "a", "second", "Phase", "3", "trial", "in", "earlier-stage", "or", "prodromal", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p48_s1", "idA": "886163_14_item1_p36_s0", "sentA": "We are entitled to a royalty on potential future sales by Merck.", "sentB": "The agreement includes over $44.5 million in potential milestones to us and tiered mid- to high- single digit royalties on potential future sales.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck.", "<tag2>", "The", "agreement", "includes", "over", "$44.5", "million", "in", "potential", "milestones", "to", "us", "and", "tiered", "mid-", "to", "high-", "single", "digit", "royalties", "on", "potential", "future", "sales.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck."], "wordsB": ["The", "agreement", "includes", "over", "$44.5", "million", "in", "potential", "milestones", "to", "us", "and", "tiered", "mid-", "to", "high-", "single", "digit", "royalties", "on", "potential", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p41_s2", "idA": "886163_14_item1_p39_s0", "sentA": "Retrophin announced initiation of a potentially pivotal Phase 2 clinical trial for Sparsentan on January 2, 2014.", "sentB": "Retrophin is currently conducting a potentially pivotal Phase 2 clinical trial for Sparsentan and has received orphan drug designation.", "type": 2, "words": ["<tag1>", "Retrophin", "announced", "initiation", "of", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "on", "January", "2,", "2014.", "<tag2>", "Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation.", "<tag3>"], "wordsA": ["Retrophin", "announced", "initiation", "of", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "on", "January", "2,", "2014."], "wordsB": ["Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p41_s5", "idA": "886163_14_item1_p41_s0", "sentA": "Under our license agreement with Retrophin we are entitled to receive over $75 million in milestones, as well as 9% in royalties on future worldwide sales by Retrophin through the life of the relevant patents, which we currently expect to be through at least 2019 and may be extended until 2024.", "sentB": "Under our license agreement with Retrophin we are entitled to receive over $75 million in net milestones, as well as 9% in net royalties on future worldwide sales by Retrophin through the life of the relevant patents, which we currently expect to be through at least 2019 and may be extended until 2024.", "type": 2, "words": ["<tag1>", "Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "milestones,", "as", "well", "as", "9%", "in", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024.", "<tag2>", "Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "net", "milestones,", "as", "well", "as", "9%", "in", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024.", "<tag3>"], "wordsA": ["Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "milestones,", "as", "well", "as", "9%", "in", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024."], "wordsB": ["Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "net", "milestones,", "as", "well", "as", "9%", "in", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p47_s0", "idA": "886163_14_item1_p42_s0", "sentA": "On July 17, 2013, we entered into a license agreement with Azure Biotech, Inc., or Azure.", "sentB": "In 2014, we entered into a partnership with Omthera, a division of AstraZeneca focused on LTP therapies for dyslipidemia.", "type": 2, "words": ["<tag1>", "On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure.", "<tag2>", "In", "2014,", "we", "entered", "into", "a", "partnership", "with", "Omthera,", "a", "division", "of", "AstraZeneca", "focused", "on", "LTP", "therapies", "for", "dyslipidemia.", "<tag3>"], "wordsA": ["On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure."], "wordsB": ["In", "2014,", "we", "entered", "into", "a", "partnership", "with", "Omthera,", "a", "division", "of", "AstraZeneca", "focused", "on", "LTP", "therapies", "for", "dyslipidemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p51_s0", "idA": "886163_14_item1_p42_s0", "sentA": "On July 17, 2013, we entered into a license agreement with Azure Biotech, Inc., or Azure.", "sentB": "In July 2013, we entered into a license agreement with Azure Biotech, Inc., or Azure.", "type": 2, "words": ["<tag1>", "On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure.", "<tag2>", "In", "July", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure.", "<tag3>"], "wordsA": ["On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure."], "wordsB": ["In", "July", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p56_s0", "idA": "886163_14_item1_p42_s0", "sentA": "On July 17, 2013, we entered into a license agreement with Azure Biotech, Inc., or Azure.", "sentB": "In February 2015, we entered into a license agreement with Sermonix for oral lasofoxifene for the United States and additional territories.", "type": 2, "words": ["<tag1>", "On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure.", "<tag2>", "In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories.", "<tag3>"], "wordsA": ["On", "July", "17,", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure."], "wordsB": ["In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p60_s1", "idA": "886163_14_item1_p42_s3", "sentA": "Azure may terminate the license agreement at any time upon six months prior notice.", "sentB": "We have the right to terminate the license agreement on or after April 30, 2015 if Viking has neither completed an IPO nor received aggregate net proceeds of at least $20.0 million in one or more private financings.", "type": 2, "words": ["<tag1>", "Azure", "may", "terminate", "the", "license", "agreement", "at", "any", "time", "upon", "six", "months", "prior", "notice.", "<tag2>", "We", "have", "the", "right", "to", "terminate", "the", "license", "agreement", "on", "or", "after", "April", "30,", "2015", "if", "Viking", "has", "neither", "completed", "an", "IPO", "nor", "received", "aggregate", "net", "proceeds", "of", "at", "least", "$20.0", "million", "in", "one", "or", "more", "private", "financings.", "<tag3>"], "wordsA": ["Azure", "may", "terminate", "the", "license", "agreement", "at", "any", "time", "upon", "six", "months", "prior", "notice."], "wordsB": ["We", "have", "the", "right", "to", "terminate", "the", "license", "agreement", "on", "or", "after", "April", "30,", "2015", "if", "Viking", "has", "neither", "completed", "an", "IPO", "nor", "received", "aggregate", "net", "proceeds", "of", "at", "least", "$20.0", "million", "in", "one", "or", "more", "private", "financings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p52_s1", "idA": "886163_14_item1_p43_s1", "sentA": "Under the terms of the license agreement with Azure, we retain the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retain", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retain", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p38_s1", "idA": "886163_14_item1_p43_s3", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the agreement, Ligand has received upfront and research support payments and has the potential to receive milestone payments and royalties for Captisol-enabled programs.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "agreement,", "Ligand", "has", "received", "upfront", "and", "research", "support", "payments", "and", "has", "the", "potential", "to", "receive", "milestone", "payments", "and", "royalties", "for", "Captisol-enabled", "programs.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "agreement,", "Ligand", "has", "received", "upfront", "and", "research", "support", "payments", "and", "has", "the", "potential", "to", "receive", "milestone", "payments", "and", "royalties", "for", "Captisol-enabled", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p41_s4", "idA": "886163_14_item1_p43_s3", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Bristol Myers Squibb is entitled to receive 15% of the proceeds received upon sale of this stock.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Bristol", "Myers", "Squibb", "is", "entitled", "to", "receive", "15%", "of", "the", "proceeds", "received", "upon", "sale", "of", "this", "stock.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Bristol", "Myers", "Squibb", "is", "entitled", "to", "receive", "15%", "of", "the", "proceeds", "received", "upon", "sale", "of", "this", "stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p56_s1", "idA": "886163_14_item1_p43_s3", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p30_s1", "idA": "886163_14_item1_p47_s0", "sentA": "We entered into a development and commercialization agreement for Captisol-enabled delafloxacin-IV in 2008 with Melinta Therapeutics, Inc. (formerly Rib-X Pharmaceuticals), or Melinta, for the use of Captisol in the intravenous formulation of delafloxacin.", "sentB": "The Captisol-enabled, PG-free melphalan program uses a new intravenous formulation of melphalan for the multiple myeloma transplant setting, and has been granted Orphan Designation by the FDA.", "type": 2, "words": ["<tag1>", "We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin.", "<tag2>", "The", "Captisol-enabled,", "PG-free", "melphalan", "program", "uses", "a", "new", "intravenous", "formulation", "of", "melphalan", "for", "the", "multiple", "myeloma", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA.", "<tag3>"], "wordsA": ["We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin."], "wordsB": ["The", "Captisol-enabled,", "PG-free", "melphalan", "program", "uses", "a", "new", "intravenous", "formulation", "of", "melphalan", "for", "the", "multiple", "myeloma", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p42_s0", "idA": "886163_14_item1_p47_s0", "sentA": "We entered into a development and commercialization agreement for Captisol-enabled delafloxacin-IV in 2008 with Melinta Therapeutics, Inc. (formerly Rib-X Pharmaceuticals), or Melinta, for the use of Captisol in the intravenous formulation of delafloxacin.", "sentB": "We supply Captisol to Melinta Therapeutics, Inc. (formerly Rib-X Pharmaceuticals), or Melinta, under a 2008 development and commercialization agreement for Captisol-enabled delafloxacin-IV.", "type": 2, "words": ["<tag1>", "We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin.", "<tag2>", "We", "supply", "Captisol", "to", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "under", "a", "2008", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV.", "<tag3>"], "wordsA": ["We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin."], "wordsB": ["We", "supply", "Captisol", "to", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "under", "a", "2008", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p42_s1", "idA": "886163_14_item1_p47_s0", "sentA": "We entered into a development and commercialization agreement for Captisol-enabled delafloxacin-IV in 2008 with Melinta Therapeutics, Inc. (formerly Rib-X Pharmaceuticals), or Melinta, for the use of Captisol in the intravenous formulation of delafloxacin.", "sentB": "The agreement permits the use of Captisol in the intravenous formulation of delafloxacin.", "type": 2, "words": ["<tag1>", "We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin.", "<tag2>", "The", "agreement", "permits", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin.", "<tag3>"], "wordsA": ["We", "entered", "into", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin-IV", "in", "2008", "with", "Melinta", "Therapeutics,", "Inc.", "(formerly", "Rib-X", "Pharmaceuticals),", "or", "Melinta,", "for", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin."], "wordsB": ["The", "agreement", "permits", "the", "use", "of", "Captisol", "in", "the", "intravenous", "formulation", "of", "delafloxacin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p43_s1", "idA": "886163_14_item1_p48_s1", "sentA": "In 2013 Melinta initiated the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "sentB": "In 2015, Melinta reported positive top-line results on the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "type": 2, "words": ["<tag1>", "In", "2013", "Melinta", "initiated", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag2>", "In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag3>"], "wordsA": ["In", "2013", "Melinta", "initiated", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "wordsB": ["In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p3_s0", "idA": "886163_14_item1_p4_s0", "sentA": "Our business model is designed to create value for stockholders by assembling a diversified portfolio of biotech and pharmaceutical revenue streams and operating that business with an efficient and low corporate cost structure.", "sentB": "Our business model creates value for stockholders by assembling a diversified portfolio of biotech and pharmaceutical revenue streams and operating that business with an efficient and low corporate cost structure.", "type": 2, "words": ["<tag1>", "Our", "business", "model", "is", "designed", "to", "create", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure.", "<tag2>", "Our", "business", "model", "creates", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure.", "<tag3>"], "wordsA": ["Our", "business", "model", "is", "designed", "to", "create", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure."], "wordsB": ["Our", "business", "model", "creates", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p3_s1", "idA": "886163_14_item1_p4_s1", "sentA": "Our goal is to become a sustainably profitable company that offers investors an opportunity to participate in the promise of the biotech industry in a diversified, lower-risk business than a typical biotech company.", "sentB": "Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.", "type": 2, "words": ["<tag1>", "Our", "goal", "is", "to", "become", "a", "sustainably", "profitable", "company", "that", "offers", "investors", "an", "opportunity", "to", "participate", "in", "the", "promise", "of", "the", "biotech", "industry", "in", "a", "diversified,", "lower-risk", "business", "than", "a", "typical", "biotech", "company.", "<tag2>", "Our", "goal", "is", "to", "offer", "investors", "an", "opportunity", "to", "participate", "in", "the", "promise", "of", "the", "biotech", "industry", "in", "a", "profitable,", "diversified", "and", "lower-risk", "business", "than", "a", "typical", "biotech", "company.", "<tag3>"], "wordsA": ["Our", "goal", "is", "to", "become", "a", "sustainably", "profitable", "company", "that", "offers", "investors", "an", "opportunity", "to", "participate", "in", "the", "promise", "of", "the", "biotech", "industry", "in", "a", "diversified,", "lower-risk", "business", "than", "a", "typical", "biotech", "company."], "wordsB": ["Our", "goal", "is", "to", "offer", "investors", "an", "opportunity", "to", "participate", "in", "the", "promise", "of", "the", "biotech", "industry", "in", "a", "profitable,", "diversified", "and", "lower-risk", "business", "than", "a", "typical", "biotech", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p3_s2", "idA": "886163_14_item1_p4_s2", "sentA": "Our business model is based on the concept of doing what we do best: drug discovery, reformulation and partnering with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.", "sentB": "Our business model is based on the concept of doing what we do best: drug discovery, reformulation and partnering.", "type": 2, "words": ["<tag1>", "Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue.", "<tag2>", "Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering.", "<tag3>"], "wordsA": ["Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue."], "wordsB": ["Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p3_s3", "idA": "886163_14_item1_p4_s2", "sentA": "Our business model is based on the concept of doing what we do best: drug discovery, reformulation and partnering with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.", "sentB": "We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.", "type": 2, "words": ["<tag1>", "Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue.", "<tag2>", "We", "partner", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue.", "<tag3>"], "wordsA": ["Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue."], "wordsB": ["We", "partner", "with", "other", "pharmaceutical", "companies", "to", "leverage", "what", "they", "do", "best", "(late-stage", "development,", "regulatory", "management", "and", "commercialization)", "to", "ultimately", "generate", "our", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p38_s0", "idA": "886163_14_item1_p50_s1", "sentA": "In August 2013, we entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Topiramate.", "sentB": "In 2011, we entered into a Captisol license agreement with SAGE Therapeutics, Inc. (SAGE) for the development and commercialization of Captisol-enabled(R) therapeutics for a broad range of debilitating central nervous system (CNS) conditions.", "type": 2, "words": ["<tag1>", "In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate.", "<tag2>", "In", "2011,", "we", "entered", "into", "a", "Captisol", "license", "agreement", "with", "SAGE", "Therapeutics,", "Inc.", "(SAGE)", "for", "the", "development", "and", "commercialization", "of", "Captisol-enabled(R)", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "(CNS)", "conditions.", "<tag3>"], "wordsA": ["In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate."], "wordsB": ["In", "2011,", "we", "entered", "into", "a", "Captisol", "license", "agreement", "with", "SAGE", "Therapeutics,", "Inc.", "(SAGE)", "for", "the", "development", "and", "commercialization", "of", "Captisol-enabled(R)", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "(CNS)", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p46_s0", "idA": "886163_14_item1_p50_s1", "sentA": "In August 2013, we entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Topiramate.", "sentB": "We entered into an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of our Interleukin-1 Receptor Associated Kinase-4 or IRAK-4 inhibitors.", "type": 2, "words": ["<tag1>", "In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate.", "<tag2>", "We", "entered", "into", "an", "exclusive", "global", "license", "agreement", "with", "TG", "Therapeutics,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "our", "Interleukin-1", "Receptor", "Associated", "Kinase-4", "or", "IRAK-4", "inhibitors.", "<tag3>"], "wordsA": ["In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate."], "wordsB": ["We", "entered", "into", "an", "exclusive", "global", "license", "agreement", "with", "TG", "Therapeutics,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "our", "Interleukin-1", "Receptor", "Associated", "Kinase-4", "or", "IRAK-4", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p50_s1", "idA": "886163_14_item1_p50_s1", "sentA": "In August 2013, we entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Topiramate.", "sentB": "In August 2013, we entered a global license agreement with CURx Pharmaceuticals, Inc., or CURx, for the development and commercialization of Topiramate.", "type": 2, "words": ["<tag1>", "In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate.", "<tag2>", "In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.,", "or", "CURx,", "for", "the", "development", "and", "commercialization", "of", "Topiramate.", "<tag3>"], "wordsA": ["In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate."], "wordsB": ["In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.,", "or", "CURx,", "for", "the", "development", "and", "commercialization", "of", "Topiramate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p57_s0", "idA": "886163_14_item1_p50_s1", "sentA": "In August 2013, we entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Topiramate.", "sentB": "In September 2014, we expanded our global license agreement with CURx to also include the development and commercialization of our Captisol-enabled Lamotrigine program.", "type": 2, "words": ["<tag1>", "In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate.", "<tag2>", "In", "September", "2014,", "we", "expanded", "our", "global", "license", "agreement", "with", "CURx", "to", "also", "include", "the", "development", "and", "commercialization", "of", "our", "Captisol-enabled", "Lamotrigine", "program.", "<tag3>"], "wordsA": ["In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate."], "wordsB": ["In", "September", "2014,", "we", "expanded", "our", "global", "license", "agreement", "with", "CURx", "to", "also", "include", "the", "development", "and", "commercialization", "of", "our", "Captisol-enabled", "Lamotrigine", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p58_s0", "idA": "886163_14_item1_p50_s1", "sentA": "In August 2013, we entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Topiramate.", "sentB": "In May 2014, we entered into an exclusive global license agreement with Viking Therapeutics Inc. or Viking for the rights to five programs.", "type": 2, "words": ["<tag1>", "In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate.", "<tag2>", "In", "May", "2014,", "we", "entered", "into", "an", "exclusive", "global", "license", "agreement", "with", "Viking", "Therapeutics", "Inc.", "or", "Viking", "for", "the", "rights", "to", "five", "programs.", "<tag3>"], "wordsA": ["In", "August", "2013,", "we", "entered", "a", "global", "license", "agreement", "with", "CURx", "Pharmaceuticals,", "Inc.", "for", "the", "development", "and", "commercialization", "of", "Topiramate."], "wordsB": ["In", "May", "2014,", "we", "entered", "into", "an", "exclusive", "global", "license", "agreement", "with", "Viking", "Therapeutics", "Inc.", "or", "Viking", "for", "the", "rights", "to", "five", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s9", "idA": "886163_14_item1_p52_s1", "sentA": "These programs represent our future licensing opportunities to expand our partnered asset portfolio.", "sentB": "These programs represent key components of our current portfolio of revenue-generating assets and potential for near-term growth in royalty and other revenue.", "type": 2, "words": ["<tag1>", "These", "programs", "represent", "our", "future", "licensing", "opportunities", "to", "expand", "our", "partnered", "asset", "portfolio.", "<tag2>", "These", "programs", "represent", "key", "components", "of", "our", "current", "portfolio", "of", "revenue-generating", "assets", "and", "potential", "for", "near-term", "growth", "in", "royalty", "and", "other", "revenue.", "<tag3>"], "wordsA": ["These", "programs", "represent", "our", "future", "licensing", "opportunities", "to", "expand", "our", "partnered", "asset", "portfolio."], "wordsB": ["These", "programs", "represent", "key", "components", "of", "our", "current", "portfolio", "of", "revenue-generating", "assets", "and", "potential", "for", "near-term", "growth", "in", "royalty", "and", "other", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p69_s0", "idA": "886163_14_item1_p57_s0", "sentA": "Inhibition of IRAK4 activity has been implicated in multiple diseases including rheumatoid arthritis, systemic lupus erythematosus, gout, inflammatory bowel disease, asthma, and allergic rhinitis.", "sentB": "Kinase Inhibitors (Unpartnered, Preclinical, Multiple) Ligand is pursuing a series of Kinase Inhibitors preclinically that may have the potential for broad therapeutic applications in areas such as oncology or inflammatory conditions potentially including diseases like arthritis, gout, inflammatory bowel disease, and asthma.", "type": 2, "words": ["<tag1>", "Inhibition", "of", "IRAK4", "activity", "has", "been", "implicated", "in", "multiple", "diseases", "including", "rheumatoid", "arthritis,", "systemic", "lupus", "erythematosus,", "gout,", "inflammatory", "bowel", "disease,", "asthma,", "and", "allergic", "rhinitis.", "<tag2>", "Kinase", "Inhibitors", "(Unpartnered,", "Preclinical,", "Multiple)", "Ligand", "is", "pursuing", "a", "series", "of", "Kinase", "Inhibitors", "preclinically", "that", "may", "have", "the", "potential", "for", "broad", "therapeutic", "applications", "in", "areas", "such", "as", "oncology", "or", "inflammatory", "conditions", "potentially", "including", "diseases", "like", "arthritis,", "gout,", "inflammatory", "bowel", "disease,", "and", "asthma.", "<tag3>"], "wordsA": ["Inhibition", "of", "IRAK4", "activity", "has", "been", "implicated", "in", "multiple", "diseases", "including", "rheumatoid", "arthritis,", "systemic", "lupus", "erythematosus,", "gout,", "inflammatory", "bowel", "disease,", "asthma,", "and", "allergic", "rhinitis."], "wordsB": ["Kinase", "Inhibitors", "(Unpartnered,", "Preclinical,", "Multiple)", "Ligand", "is", "pursuing", "a", "series", "of", "Kinase", "Inhibitors", "preclinically", "that", "may", "have", "the", "potential", "for", "broad", "therapeutic", "applications", "in", "areas", "such", "as", "oncology", "or", "inflammatory", "conditions", "potentially", "including", "diseases", "like", "arthritis,", "gout,", "inflammatory", "bowel", "disease,", "and", "asthma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p39_s0", "idA": "886163_14_item1_p57_s1", "sentA": "Inhibitors of IRAK4 may also be useful for the treatment of certain leukemias and lymphomas.", "sentB": "SAGE s lead clinical program, Captisol-enabled SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of super-refractory status epilepticus, or SRSE.", "type": 2, "words": ["<tag1>", "Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas.", "<tag2>", "SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABAA", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "super-refractory", "status", "epilepticus,", "or", "SRSE.", "<tag3>"], "wordsA": ["Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas."], "wordsB": ["SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABAA", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "super-refractory", "status", "epilepticus,", "or", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p39_s6", "idA": "886163_14_item1_p57_s1", "sentA": "Inhibitors of IRAK4 may also be useful for the treatment of certain leukemias and lymphomas.", "sentB": "Also in January of 2015, SAGE announced the initiation of an exploratory Phase 2a trial of SAGE-547 in severe postpartum depression, in addition to its ongoing exploratory trial of SAGE-547 for the treatment of essential tremor.", "type": 2, "words": ["<tag1>", "Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas.", "<tag2>", "Also", "in", "January", "of", "2015,", "SAGE", "announced", "the", "initiation", "of", "an", "exploratory", "Phase", "2a", "trial", "of", "SAGE-547", "in", "severe", "postpartum", "depression,", "in", "addition", "to", "its", "ongoing", "exploratory", "trial", "of", "SAGE-547", "for", "the", "treatment", "of", "essential", "tremor.", "<tag3>"], "wordsA": ["Inhibitors", "of", "IRAK4", "may", "also", "be", "useful", "for", "the", "treatment", "of", "certain", "leukemias", "and", "lymphomas."], "wordsB": ["Also", "in", "January", "of", "2015,", "SAGE", "announced", "the", "initiation", "of", "an", "exploratory", "Phase", "2a", "trial", "of", "SAGE-547", "in", "severe", "postpartum", "depression,", "in", "addition", "to", "its", "ongoing", "exploratory", "trial", "of", "SAGE-547", "for", "the", "treatment", "of", "essential", "tremor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p46_s1", "idA": "886163_14_item1_p57_s2", "sentA": "We have identified orally available small molecule inhibitors of IRAK4 which are under investigation for use in cancer and autoimmune diseases.", "sentB": "The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases.", "type": 2, "words": ["<tag1>", "We", "have", "identified", "orally", "available", "small", "molecule", "inhibitors", "of", "IRAK4", "which", "are", "under", "investigation", "for", "use", "in", "cancer", "and", "autoimmune", "diseases.", "<tag2>", "The", "IRAK-4", "program", "is", "in", "preclinical", "development", "for", "potential", "use", "in", "certain", "cancers", "and", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["We", "have", "identified", "orally", "available", "small", "molecule", "inhibitors", "of", "IRAK4", "which", "are", "under", "investigation", "for", "use", "in", "cancer", "and", "autoimmune", "diseases."], "wordsB": ["The", "IRAK-4", "program", "is", "in", "preclinical", "development", "for", "potential", "use", "in", "certain", "cancers", "and", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p62_s0", "idA": "886163_14_item1_p58_s0", "sentA": "We are currently developing small molecule glucagon receptor antagonists for the treatment of Type II diabetes mellitus.", "sentB": "Glucagon Receptor Antagonist Program We are currently developing small molecule glucagon receptor antagonists for the treatment of Type II diabetes mellitus.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus.", "<tag2>", "Glucagon", "Receptor", "Antagonist", "Program", "We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus.", "<tag3>"], "wordsA": ["We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus."], "wordsB": ["Glucagon", "Receptor", "Antagonist", "Program", "We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p4_s1", "idA": "886163_14_item1_p5_s1", "sentA": "We have assembled a portfolio of over 90 fully funded partner programs that are in all stages of development, from preclinical research to awaiting commercialization.", "sentB": "We have assembled a portfolio of over 100 fully-funded partner programs that are in all stages of development, from preclinical research to commercialization.", "type": 2, "words": ["<tag1>", "We", "have", "assembled", "a", "portfolio", "of", "over", "90", "fully", "funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization.", "<tag2>", "We", "have", "assembled", "a", "portfolio", "of", "over", "100", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "commercialization.", "<tag3>"], "wordsA": ["We", "have", "assembled", "a", "portfolio", "of", "over", "90", "fully", "funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization."], "wordsB": ["We", "have", "assembled", "a", "portfolio", "of", "over", "100", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p4_s2", "idA": "886163_14_item1_p5_s2", "sentA": "Fully funded programs are those for which our partners pay all of the development and commercialization costs.", "sentB": "Fully-funded programs are those for which our partners pay all of the development and commercialization costs.", "type": 2, "words": ["<tag1>", "Fully", "funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs.", "<tag2>", "Fully-funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs.", "<tag3>"], "wordsA": ["Fully", "funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs."], "wordsB": ["Fully-funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p4_s3", "idA": "886163_14_item1_p5_s4", "sentA": "We assemble this portfolio by either licensing out our own proprietary drug development programs or acquiring existing partnered programs from other companies.", "sentB": "We assemble this portfolio either by licensing out our own proprietary drug development programs, licensing our Captisol technology to partners for use with their proprietary programs or acquiring existing partnered programs from other companies.", "type": 2, "words": ["<tag1>", "We", "assemble", "this", "portfolio", "by", "either", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies.", "<tag2>", "We", "assemble", "this", "portfolio", "either", "by", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs,", "licensing", "our", "Captisol", "technology", "to", "partners", "for", "use", "with", "their", "proprietary", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies.", "<tag3>"], "wordsA": ["We", "assemble", "this", "portfolio", "by", "either", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies."], "wordsB": ["We", "assemble", "this", "portfolio", "either", "by", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs,", "licensing", "our", "Captisol", "technology", "to", "partners", "for", "use", "with", "their", "proprietary", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p68_s1", "idA": "886163_14_item1_p60_s0", "sentA": "Glucagon stimulates the production of glucose by the liver and its release into the blood stream.", "sentB": "The LTP technology is designed to improve the activity and/or safety of existing drugs, develop new agents to treat certain liver disease, and treat diseases caused by homeostasis imbalance of circulating molecules controlled by the liver and is especially applicable to metabolic and cardiovascular indications, among others.", "type": 2, "words": ["<tag1>", "Glucagon", "stimulates", "the", "production", "of", "glucose", "by", "the", "liver", "and", "its", "release", "into", "the", "blood", "stream.", "<tag2>", "The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others.", "<tag3>"], "wordsA": ["Glucagon", "stimulates", "the", "production", "of", "glucose", "by", "the", "liver", "and", "its", "release", "into", "the", "blood", "stream."], "wordsB": ["The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p45_s0", "idA": "886163_14_item1_p61_s0", "sentA": "In October 2013, the FDA accepted our Investigational New Drug, or IND, application for our proprietary Glucagon receptor antagonist product (LGD-6972) candidate for the treatment of diabetes.", "sentB": "the FDA accepted the NDA submission in 2014.", "type": 2, "words": ["<tag1>", "In", "October", "2013,", "the", "FDA", "accepted", "our", "Investigational", "New", "Drug,", "or", "IND,", "application", "for", "our", "proprietary", "Glucagon", "receptor", "antagonist", "product", "(LGD-6972)", "candidate", "for", "the", "treatment", "of", "diabetes.", "<tag2>", "the", "FDA", "accepted", "the", "NDA", "submission", "in", "2014.", "<tag3>"], "wordsA": ["In", "October", "2013,", "the", "FDA", "accepted", "our", "Investigational", "New", "Drug,", "or", "IND,", "application", "for", "our", "proprietary", "Glucagon", "receptor", "antagonist", "product", "(LGD-6972)", "candidate", "for", "the", "treatment", "of", "diabetes."], "wordsB": ["the", "FDA", "accepted", "the", "NDA", "submission", "in", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p65_s2", "idA": "886163_14_item1_p62_s0", "sentA": "We initiated a Phase 1 clinical trial in the fourth quarter of 2013.", "sentB": "We initiated a Phase 1 clinical trial in the fourth quarter of 2013 and announced positive results from that trial in June of 2014.", "type": 2, "words": ["<tag1>", "We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013.", "<tag2>", "We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013", "and", "announced", "positive", "results", "from", "that", "trial", "in", "June", "of", "2014.", "<tag3>"], "wordsA": ["We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013."], "wordsB": ["We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013", "and", "announced", "positive", "results", "from", "that", "trial", "in", "June", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p65_s3", "idA": "886163_14_item1_p62_s0", "sentA": "We initiated a Phase 1 clinical trial in the fourth quarter of 2013.", "sentB": "In the fourth quarter of 2014, we initiated a Phase 1b trial, and expect results in the second quarter of 2015.", "type": 2, "words": ["<tag1>", "We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013.", "<tag2>", "In", "the", "fourth", "quarter", "of", "2014,", "we", "initiated", "a", "Phase", "1b", "trial,", "and", "expect", "results", "in", "the", "second", "quarter", "of", "2015.", "<tag3>"], "wordsA": ["We", "initiated", "a", "Phase", "1", "clinical", "trial", "in", "the", "fourth", "quarter", "of", "2013."], "wordsB": ["In", "the", "fourth", "quarter", "of", "2014,", "we", "initiated", "a", "Phase", "1b", "trial,", "and", "expect", "results", "in", "the", "second", "quarter", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p68_s0", "idA": "886163_14_item1_p6_s0", "sentA": "We sell Captisol material to a broad range of customers.", "sentB": "LTP Platform (Unpartnered, Preclinical, Metabolic and Cardiovascular) Ligand scientists developed a novel pro-drug technology designed to selectively deliver a broad range of pharmaceutical agents to the liver.", "type": 2, "words": ["<tag1>", "We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers.", "<tag2>", "LTP", "Platform", "(Unpartnered,", "Preclinical,", "Metabolic", "and", "Cardiovascular)", "Ligand", "scientists", "developed", "a", "novel", "pro-drug", "technology", "designed", "to", "selectively", "deliver", "a", "broad", "range", "of", "pharmaceutical", "agents", "to", "the", "liver.", "<tag3>"], "wordsA": ["We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers."], "wordsB": ["LTP", "Platform", "(Unpartnered,", "Preclinical,", "Metabolic", "and", "Cardiovascular)", "Ligand", "scientists", "developed", "a", "novel", "pro-drug", "technology", "designed", "to", "selectively", "deliver", "a", "broad", "range", "of", "pharmaceutical", "agents", "to", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p75_s3", "idA": "886163_14_item1_p72_s3", "sentA": "Manufacturing We currently have no manufacturing facilities and rely on third parties, including our collaborative partners, for clinical production of any products or compounds.", "sentB": "Manufacturing We currently have no manufacturing facilities and rely on third parties, including our collaborative partners, for clinical production.", "type": 2, "words": ["<tag1>", "Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production", "of", "any", "products", "or", "compounds.", "<tag2>", "Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production.", "<tag3>"], "wordsA": ["Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production", "of", "any", "products", "or", "compounds."], "wordsB": ["Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p76_s0", "idA": "886163_14_item1_p72_s4", "sentA": "We currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a major supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal.", "sentB": "We currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a major global supplier with over 50 years of experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates.", "type": 2, "words": ["<tag1>", "We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "active", "pharmaceutical", "ingredients,", "or", "APIs", "and", "API", "intermediates", "located", "in", "Portugal.", "<tag2>", "We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "global", "supplier", "with", "over", "50", "years", "of", "experience", "in", "the", "development", "and", "compliant", "manufacture", "of", "Active", "Pharmaceutical", "Ingredients", "and", "Drug", "Product", "Intermediates.", "<tag3>"], "wordsA": ["We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "supplier", "of", "active", "pharmaceutical", "ingredients,", "or", "APIs", "and", "API", "intermediates", "located", "in", "Portugal."], "wordsB": ["We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "global", "supplier", "with", "over", "50", "years", "of", "experience", "in", "the", "development", "and", "compliant", "manufacture", "of", "Active", "Pharmaceutical", "Ingredients", "and", "Drug", "Product", "Intermediates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p77_s3", "idA": "886163_14_item1_p73_s0", "sentA": "to pay Hovione an aggregate minimum amount during the agreement term.", "sentB": "We have ongoing minimum purchase commitments under the agreement and are required to pay Hovione an aggregate minimum amount during the agreement term.", "type": 2, "words": ["<tag1>", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term.", "<tag2>", "We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement", "and", "are", "required", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term.", "<tag3>"], "wordsA": ["to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term."], "wordsB": ["We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement", "and", "are", "required", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p78_s3", "idA": "886163_14_item1_p73_s6", "sentA": "In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event or if the unit price of Captisol exceeds a set figure, we may obtain Captisol from a third party.", "sentB": "In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event or if the unit price of Captisol exceeds a set figure, we may obtain Captisol from an additional third party.", "type": 2, "words": ["<tag1>", "In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party.", "<tag2>", "In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "an", "additional", "third", "party.", "<tag3>"], "wordsA": ["In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party."], "wordsB": ["In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "an", "additional", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p78_s4", "idA": "886163_14_item1_p73_s7", "sentA": "In December 2011, the contract was amended to allow certain bulk quantities of Captisol to be distributed directly from Hovione.", "sentB": "In 2011, the contract was amended to allow storage of bulk Captisol and to allow Captisol to be distributed from Hovione's US, Portugal and Ireland sites directly to our customers, under our instruction.", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "Captisol", "to", "be", "distributed", "directly", "from", "Hovione.", "<tag2>", "In", "2011,", "the", "contract", "was", "amended", "to", "allow", "storage", "of", "bulk", "Captisol", "and", "to", "allow", "Captisol", "to", "be", "distributed", "from", "Hovione's", "US,", "Portugal", "and", "Ireland", "sites", "directly", "to", "our", "customers,", "under", "our", "instruction.", "<tag3>"], "wordsA": ["In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "Captisol", "to", "be", "distributed", "directly", "from", "Hovione."], "wordsB": ["In", "2011,", "the", "contract", "was", "amended", "to", "allow", "storage", "of", "bulk", "Captisol", "and", "to", "allow", "Captisol", "to", "be", "distributed", "from", "Hovione's", "US,", "Portugal", "and", "Ireland", "sites", "directly", "to", "our", "customers,", "under", "our", "instruction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p78_s5", "idA": "886163_14_item1_p73_s7", "sentA": "In December 2011, the contract was amended to allow certain bulk quantities of Captisol to be distributed directly from Hovione.", "sentB": "In addition, we also distribute and store bulk quantities of Captisol ourselves, utilizing subterranean warehouse space located in Lenexa, Kansas.", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "Captisol", "to", "be", "distributed", "directly", "from", "Hovione.", "<tag2>", "In", "addition,", "we", "also", "distribute", "and", "store", "bulk", "quantities", "of", "Captisol", "ourselves,", "utilizing", "subterranean", "warehouse", "space", "located", "in", "Lenexa,", "Kansas.", "<tag3>"], "wordsA": ["In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "Captisol", "to", "be", "distributed", "directly", "from", "Hovione."], "wordsB": ["In", "addition,", "we", "also", "distribute", "and", "store", "bulk", "quantities", "of", "Captisol", "ourselves,", "utilizing", "subterranean", "warehouse", "space", "located", "in", "Lenexa,", "Kansas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p78_s6", "idA": "886163_14_item1_p73_s9", "sentA": "The initial term of the agreement expires in December 2019.", "sentB": "The initial term of the agreement with Hovione expires in December 2019.", "type": 2, "words": ["<tag1>", "The", "initial", "term", "of", "the", "agreement", "expires", "in", "December", "2019.", "<tag2>", "The", "initial", "term", "of", "the", "agreement", "with", "Hovione", "expires", "in", "December", "2019.", "<tag3>"], "wordsA": ["The", "initial", "term", "of", "the", "agreement", "expires", "in", "December", "2019."], "wordsB": ["The", "initial", "term", "of", "the", "agreement", "with", "Hovione", "expires", "in", "December", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p84_s0", "idA": "886163_14_item1_p78_s1", "sentA": "The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products.", "sentB": "Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products.", "type": 2, "words": ["<tag1>", "The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products.", "<tag2>", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products.", "<tag3>"], "wordsA": ["The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products."], "wordsB": ["Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p8_s0", "idA": "886163_14_item1_p79_s0", "sentA": "Product development and approval within this regulatory framework takes a number of years and involves the expenditure of substantial resources.", "sentB": "Because of the importance of having a sufficient number of platelets, Promacta has broad potential applicability to a number of medical situations where low platelets exist.", "type": 2, "words": ["<tag1>", "Product", "development", "and", "approval", "within", "this", "regulatory", "framework", "takes", "a", "number", "of", "years", "and", "involves", "the", "expenditure", "of", "substantial", "resources.", "<tag2>", "Because", "of", "the", "importance", "of", "having", "a", "sufficient", "number", "of", "platelets,", "Promacta", "has", "broad", "potential", "applicability", "to", "a", "number", "of", "medical", "situations", "where", "low", "platelets", "exist.", "<tag3>"], "wordsA": ["Product", "development", "and", "approval", "within", "this", "regulatory", "framework", "takes", "a", "number", "of", "years", "and", "involves", "the", "expenditure", "of", "substantial", "resources."], "wordsB": ["Because", "of", "the", "importance", "of", "having", "a", "sufficient", "number", "of", "platelets,", "Promacta", "has", "broad", "potential", "applicability", "to", "a", "number", "of", "medical", "situations", "where", "low", "platelets", "exist."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p5_s1", "idA": "886163_14_item1_p7_s0", "sentA": "We are the sole provider of a proprietary formulation technology known as Captisol.", "sentB": "We provide our proprietary formulation technology known as Captisol to our customers.", "type": 2, "words": ["<tag1>", "We", "are", "the", "sole", "provider", "of", "a", "proprietary", "formulation", "technology", "known", "as", "Captisol.", "<tag2>", "We", "provide", "our", "proprietary", "formulation", "technology", "known", "as", "Captisol", "to", "our", "customers.", "<tag3>"], "wordsA": ["We", "are", "the", "sole", "provider", "of", "a", "proprietary", "formulation", "technology", "known", "as", "Captisol."], "wordsB": ["We", "provide", "our", "proprietary", "formulation", "technology", "known", "as", "Captisol", "to", "our", "customers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p90_s0", "idA": "886163_14_item1_p85_s0", "sentA": "Kyprolis Patents protecting Kyprolis include those owned by Onyx Pharmaceuticals and those owned by Ligand.", "sentB": "Kyprolis Patents protecting Kyprolis include those owned by Amgen and those owned by Ligand.", "type": 2, "words": ["<tag1>", "Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Onyx", "Pharmaceuticals", "and", "those", "owned", "by", "Ligand.", "<tag2>", "Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Amgen", "and", "those", "owned", "by", "Ligand.", "<tag3>"], "wordsA": ["Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Onyx", "Pharmaceuticals", "and", "those", "owned", "by", "Ligand."], "wordsB": ["Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Amgen", "and", "those", "owned", "by", "Ligand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p20_s1", "idA": "886163_14_item1_p87_s2", "sentA": "Certain related patents in other jurisdictions are not identified in the following table, as our royalties are based on sales in the United States.", "sentB": "In 2015, based on the results from the ASPIRE trial, Amgen announced submissions in the United States and EU for Kyprolis for relapsed multiple myeloma.", "type": 2, "words": ["<tag1>", "Certain", "related", "patents", "in", "other", "jurisdictions", "are", "not", "identified", "in", "the", "following", "table,", "as", "our", "royalties", "are", "based", "on", "sales", "in", "the", "United", "States.", "<tag2>", "In", "2015,", "based", "on", "the", "results", "from", "the", "ASPIRE", "trial,", "Amgen", "announced", "submissions", "in", "the", "United", "States", "and", "EU", "for", "Kyprolis", "for", "relapsed", "multiple", "myeloma.", "<tag3>"], "wordsA": ["Certain", "related", "patents", "in", "other", "jurisdictions", "are", "not", "identified", "in", "the", "following", "table,", "as", "our", "royalties", "are", "based", "on", "sales", "in", "the", "United", "States."], "wordsB": ["In", "2015,", "based", "on", "the", "results", "from", "the", "ASPIRE", "trial,", "Amgen", "announced", "submissions", "in", "the", "United", "States", "and", "EU", "for", "Kyprolis", "for", "relapsed", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s1", "idA": "886163_14_item1_p8_s1", "sentA": "We discover, synthesize and test numerous compounds to identify those that are most promising for clinical development.", "sentB": "We discover, synthesize and test numerous compounds to identify and focus upon those that are most promising for clinical development.", "type": 2, "words": ["<tag1>", "We", "discover,", "synthesize", "and", "test", "numerous", "compounds", "to", "identify", "those", "that", "are", "most", "promising", "for", "clinical", "development.", "<tag2>", "We", "discover,", "synthesize", "and", "test", "numerous", "compounds", "to", "identify", "and", "focus", "upon", "those", "that", "are", "most", "promising", "for", "clinical", "development.", "<tag3>"], "wordsA": ["We", "discover,", "synthesize", "and", "test", "numerous", "compounds", "to", "identify", "those", "that", "are", "most", "promising", "for", "clinical", "development."], "wordsB": ["We", "discover,", "synthesize", "and", "test", "numerous", "compounds", "to", "identify", "and", "focus", "upon", "those", "that", "are", "most", "promising", "for", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p96_s0", "idA": "886163_14_item1_p91_s0", "sentA": "Human Resources As of February 1, 2014, we had 20 full-time employees, of whom 6 are involved directly in scientific research and development activities.", "sentB": "Human Resources As of February 1, 2015, we had 19 full-time employees, of whom six are involved directly in scientific research and development activities.", "type": 2, "words": ["<tag1>", "Human", "Resources", "As", "of", "February", "1,", "2014,", "we", "had", "20", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag2>", "Human", "Resources", "As", "of", "February", "1,", "2015,", "we", "had", "19", "full-time", "employees,", "of", "whom", "six", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["Human", "Resources", "As", "of", "February", "1,", "2014,", "we", "had", "20", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "wordsB": ["Human", "Resources", "As", "of", "February", "1,", "2015,", "we", "had", "19", "full-time", "employees,", "of", "whom", "six", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s3", "idA": "886163_14_item1_p9_s0", "sentA": "from consideration sooner without incurring substantial clinical costs.", "sentB": "We seek to eliminate unpromising candidates from consideration sooner without incurring substantial clinical costs.", "type": 2, "words": ["<tag1>", "from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs.", "<tag2>", "We", "seek", "to", "eliminate", "unpromising", "candidates", "from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs.", "<tag3>"], "wordsA": ["from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs."], "wordsB": ["We", "seek", "to", "eliminate", "unpromising", "candidates", "from", "consideration", "sooner", "without", "incurring", "substantial", "clinical", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p0_s1", "idA": "886163_14_item1_p9_s1", "sentA": "Our goal is to partner our programs early in the development and regulatory life-cycle.", "sentB": "Our goal is to generate substantial cash flow and profits.", "type": 2, "words": ["<tag1>", "Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle.", "<tag2>", "Our", "goal", "is", "to", "generate", "substantial", "cash", "flow", "and", "profits.", "<tag3>"], "wordsA": ["Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle."], "wordsB": ["Our", "goal", "is", "to", "generate", "substantial", "cash", "flow", "and", "profits."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s4", "idA": "886163_14_item1_p9_s1", "sentA": "Our goal is to partner our programs early in the development and regulatory life-cycle.", "sentB": "Our goal and strategy is to partner our programs early in the development and regulatory life-cycle.", "type": 2, "words": ["<tag1>", "Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle.", "<tag2>", "Our", "goal", "and", "strategy", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle.", "<tag3>"], "wordsA": ["Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle."], "wordsB": ["Our", "goal", "and", "strategy", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s5", "idA": "886163_14_item1_p9_s2", "sentA": "Our Asset Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 90 of which are fully-funded by our partners.", "sentB": "Our Asset Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 100 of which are fully-funded by our partners.", "type": 2, "words": ["<tag1>", "Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "90", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag2>", "Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "100", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag3>"], "wordsA": ["Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "90", "of", "which", "are", "fully-funded", "by", "our", "partners."], "wordsB": ["Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "100", "of", "which", "are", "fully-funded", "by", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s6", "idA": "886163_14_item1_p9_s3", "sentA": "Over 70% of our 2013 revenue is derived from our Promacta , Kyprolis, and Captisol programs (including Captisol material sales).", "sentB": "Approximately 43% of our 2014 revenue was derived from our Promacta and Kyprolis royalties.", "type": 2, "words": ["<tag1>", "Over", "70%", "of", "our", "2013", "revenue", "is", "derived", "from", "our", "Promacta", ",", "Kyprolis,", "and", "Captisol", "programs", "(including", "Captisol", "material", "sales).", "<tag2>", "Approximately", "43%", "of", "our", "2014", "revenue", "was", "derived", "from", "our", "Promacta", "and", "Kyprolis", "royalties.", "<tag3>"], "wordsA": ["Over", "70%", "of", "our", "2013", "revenue", "is", "derived", "from", "our", "Promacta", ",", "Kyprolis,", "and", "Captisol", "programs", "(including", "Captisol", "material", "sales)."], "wordsB": ["Approximately", "43%", "of", "our", "2014", "revenue", "was", "derived", "from", "our", "Promacta", "and", "Kyprolis", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p6_s7", "idA": "886163_14_item1_p9_s3", "sentA": "Over 70% of our 2013 revenue is derived from our Promacta , Kyprolis, and Captisol programs (including Captisol material sales).", "sentB": "In addition, approximately 44% of our revenue was derived from selling Captisol material to over 100 companies.", "type": 2, "words": ["<tag1>", "Over", "70%", "of", "our", "2013", "revenue", "is", "derived", "from", "our", "Promacta", ",", "Kyprolis,", "and", "Captisol", "programs", "(including", "Captisol", "material", "sales).", "<tag2>", "In", "addition,", "approximately", "44%", "of", "our", "revenue", "was", "derived", "from", "selling", "Captisol", "material", "to", "over", "100", "companies.", "<tag3>"], "wordsA": ["Over", "70%", "of", "our", "2013", "revenue", "is", "derived", "from", "our", "Promacta", ",", "Kyprolis,", "and", "Captisol", "programs", "(including", "Captisol", "material", "sales)."], "wordsB": ["In", "addition,", "approximately", "44%", "of", "our", "revenue", "was", "derived", "from", "selling", "Captisol", "material", "to", "over", "100", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p37_s2", "idA": "886163_15_item1_p10_s0", "sentA": "Promacta is known as Revolade in the EU.", "sentB": "Promacta is known as Revolade in the EU and other non-US markets.", "type": 2, "words": ["<tag1>", "Promacta", "is", "known", "as", "Revolade", "in", "the", "EU.", "<tag2>", "Promacta", "is", "known", "as", "Revolade", "in", "the", "EU", "and", "other", "non-US", "markets.", "<tag3>"], "wordsA": ["Promacta", "is", "known", "as", "Revolade", "in", "the", "EU."], "wordsB": ["Promacta", "is", "known", "as", "Revolade", "in", "the", "EU", "and", "other", "non-US", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s3", "idA": "886163_15_item1_p10_s0", "sentA": "Promacta is known as Revolade in the EU.", "sentB": "Duavee is approved in the United States and it is anticipated that it will be marketed under the brand name Duavive in the EU.", "type": 2, "words": ["<tag1>", "Promacta", "is", "known", "as", "Revolade", "in", "the", "EU.", "<tag2>", "Duavee", "is", "approved", "in", "the", "United", "States", "and", "it", "is", "anticipated", "that", "it", "will", "be", "marketed", "under", "the", "brand", "name", "Duavive", "in", "the", "EU.", "<tag3>"], "wordsA": ["Promacta", "is", "known", "as", "Revolade", "in", "the", "EU."], "wordsB": ["Duavee", "is", "approved", "in", "the", "United", "States", "and", "it", "is", "anticipated", "that", "it", "will", "be", "marketed", "under", "the", "brand", "name", "Duavive", "in", "the", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p37_s3", "idA": "886163_15_item1_p11_s0", "sentA": "GSK has been and continues to pursue globalization of the brand and currently markets Promacta in multiple countries for the three approved indications.", "sentB": "Novartis has been and continues to pursue globalization of the brand and currently markets Promacta in multiple countries for the three approved indications.", "type": 2, "words": ["<tag1>", "GSK", "has", "been", "and", "continues", "to", "pursue", "globalization", "of", "the", "brand", "and", "currently", "markets", "Promacta", "in", "multiple", "countries", "for", "the", "three", "approved", "indications.", "<tag2>", "Novartis", "has", "been", "and", "continues", "to", "pursue", "globalization", "of", "the", "brand", "and", "currently", "markets", "Promacta", "in", "multiple", "countries", "for", "the", "three", "approved", "indications.", "<tag3>"], "wordsA": ["GSK", "has", "been", "and", "continues", "to", "pursue", "globalization", "of", "the", "brand", "and", "currently", "markets", "Promacta", "in", "multiple", "countries", "for", "the", "three", "approved", "indications."], "wordsB": ["Novartis", "has", "been", "and", "continues", "to", "pursue", "globalization", "of", "the", "brand", "and", "currently", "markets", "Promacta", "in", "multiple", "countries", "for", "the", "three", "approved", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p37_s1", "idA": "886163_15_item1_p11_s1", "sentA": "Specifically, ITP is currently approved in 95 countries, the Hepatitic C-related indication is currently approved in 53 countries, and the severe aplastic anemia indication is approved in 3 counties.", "sentB": "Promacta was initially approved in 2008, and the product has been generating royalty revenue for Ligand since 2009.", "type": 2, "words": ["<tag1>", "Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties.", "<tag2>", "Promacta", "was", "initially", "approved", "in", "2008,", "and", "the", "product", "has", "been", "generating", "royalty", "revenue", "for", "Ligand", "since", "2009.", "<tag3>"], "wordsA": ["Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties."], "wordsB": ["Promacta", "was", "initially", "approved", "in", "2008,", "and", "the", "product", "has", "been", "generating", "royalty", "revenue", "for", "Ligand", "since", "2009."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p37_s4", "idA": "886163_15_item1_p11_s1", "sentA": "Specifically, ITP is currently approved in 95 countries, the Hepatitic C-related indication is currently approved in 53 countries, and the severe aplastic anemia indication is approved in 3 counties.", "sentB": "Specifically, ITP is currently approved in more than 100 countries, the Hepatitis C-related indication is currently approved in more than 50 countries, and the SAA indication is approved in more than 30 counties.", "type": 2, "words": ["<tag1>", "Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties.", "<tag2>", "Specifically,", "ITP", "is", "currently", "approved", "in", "more", "than", "100", "countries,", "the", "Hepatitis", "C-related", "indication", "is", "currently", "approved", "in", "more", "than", "50", "countries,", "and", "the", "SAA", "indication", "is", "approved", "in", "more", "than", "30", "counties.", "<tag3>"], "wordsA": ["Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties."], "wordsB": ["Specifically,", "ITP", "is", "currently", "approved", "in", "more", "than", "100", "countries,", "the", "Hepatitis", "C-related", "indication", "is", "currently", "approved", "in", "more", "than", "50", "countries,", "and", "the", "SAA", "indication", "is", "approved", "in", "more", "than", "30", "counties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p43_s0", "idA": "886163_15_item1_p11_s1", "sentA": "Specifically, ITP is currently approved in 95 countries, the Hepatitic C-related indication is currently approved in 53 countries, and the severe aplastic anemia indication is approved in 3 counties.", "sentB": "Kyprolis is also approved in Argentina, Israel, Kuwait, Mexico, Thailand, Columbia, Korea, Canada and the European Union.", "type": 2, "words": ["<tag1>", "Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties.", "<tag2>", "Kyprolis", "is", "also", "approved", "in", "Argentina,", "Israel,", "Kuwait,", "Mexico,", "Thailand,", "Columbia,", "Korea,", "Canada", "and", "the", "European", "Union.", "<tag3>"], "wordsA": ["Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties."], "wordsB": ["Kyprolis", "is", "also", "approved", "in", "Argentina,", "Israel,", "Kuwait,", "Mexico,", "Thailand,", "Columbia,", "Korea,", "Canada", "and", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p37_s5", "idA": "886163_15_item1_p11_s2", "sentA": "Beyond the currently approved indications, GSK is also performing development activities to expand the brand into new indications, including pediatric ITP and a number of oncology-related indications.", "sentB": "Beyond the currently-approved indications, Novartis is also performing development activities to expand the brand into new indications, including a number of oncology-related indications including MDS, AML and CIT.", "type": 2, "words": ["<tag1>", "Beyond", "the", "currently", "approved", "indications,", "GSK", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "pediatric", "ITP", "and", "a", "number", "of", "oncology-related", "indications.", "<tag2>", "Beyond", "the", "currently-approved", "indications,", "Novartis", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "a", "number", "of", "oncology-related", "indications", "including", "MDS,", "AML", "and", "CIT.", "<tag3>"], "wordsA": ["Beyond", "the", "currently", "approved", "indications,", "GSK", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "pediatric", "ITP", "and", "a", "number", "of", "oncology-related", "indications."], "wordsB": ["Beyond", "the", "currently-approved", "indications,", "Novartis", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "a", "number", "of", "oncology-related", "indications", "including", "MDS,", "AML", "and", "CIT."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p38_s0", "idA": "886163_15_item1_p12_s0", "sentA": "As of February 2015, there are 43 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.", "sentB": "As of February 2016, there are 42 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.", "type": 2, "words": ["<tag1>", "As", "of", "February", "2015,", "there", "are", "43", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website.", "<tag2>", "As", "of", "February", "2016,", "there", "are", "42", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website.", "<tag3>"], "wordsA": ["As", "of", "February", "2015,", "there", "are", "43", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website."], "wordsB": ["As", "of", "February", "2016,", "there", "are", "42", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p47_s0", "idA": "886163_15_item1_p12_s2", "sentA": "In December 2014, GSK reported the submission of a sNDA to the FDA for Promacta, seeking an additional indication in pediatric patients six years old and older with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "In December 2014, Spectrum submitted a NDA to the FDA.", "type": 2, "words": ["<tag1>", "In", "December", "2014,", "GSK", "reported", "the", "submission", "of", "a", "sNDA", "to", "the", "FDA", "for", "Promacta,", "seeking", "an", "additional", "indication", "in", "pediatric", "patients", "six", "years", "old", "and", "older", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "In", "December", "2014,", "Spectrum", "submitted", "a", "NDA", "to", "the", "FDA.", "<tag3>"], "wordsA": ["In", "December", "2014,", "GSK", "reported", "the", "submission", "of", "a", "sNDA", "to", "the", "FDA", "for", "Promacta,", "seeking", "an", "additional", "indication", "in", "pediatric", "patients", "six", "years", "old", "and", "older", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["In", "December", "2014,", "Spectrum", "submitted", "a", "NDA", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p6_s0", "idA": "886163_15_item1_p12_s2", "sentA": "In December 2014, GSK reported the submission of a sNDA to the FDA for Promacta, seeking an additional indication in pediatric patients six years old and older with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "FDA approved Promacta for the treatment of children six years and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "type": 2, "words": ["<tag1>", "In", "December", "2014,", "GSK", "reported", "the", "submission", "of", "a", "sNDA", "to", "the", "FDA", "for", "Promacta,", "seeking", "an", "additional", "indication", "in", "pediatric", "patients", "six", "years", "old", "and", "older", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "FDA", "approved", "Promacta", "for", "the", "treatment", "of", "children", "six", "years", "and", "older", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag3>"], "wordsA": ["In", "December", "2014,", "GSK", "reported", "the", "submission", "of", "a", "sNDA", "to", "the", "FDA", "for", "Promacta,", "seeking", "an", "additional", "indication", "in", "pediatric", "patients", "six", "years", "old", "and", "older", "with", "chronic", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["FDA", "approved", "Promacta", "for", "the", "treatment", "of", "children", "six", "years", "and", "older", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s4", "idA": "886163_15_item1_p12_s4", "sentA": "Promacta is currently in clinical development for a number of additional indications in oncology including myelodysplastiuc syndromes (MDS), acute myeloid leukemia (AML) and chemotherapy-induced thrombocytopenia (CIT).", "sentB": "Our partners have programs currently in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.", "type": 2, "words": ["<tag1>", "Promacta", "is", "currently", "in", "clinical", "development", "for", "a", "number", "of", "additional", "indications", "in", "oncology", "including", "myelodysplastiuc", "syndromes", "(MDS),", "acute", "myeloid", "leukemia", "(AML)", "and", "chemotherapy-induced", "thrombocytopenia", "(CIT).", "<tag2>", "Our", "partners", "have", "programs", "currently", "in", "clinical", "development", "targeting", "seizure,", "coma,", "cancer,", "diabetes,", "cardiovascular", "disease,", "muscle", "wasting,", "liver", "disease,", "and", "kidney", "disease,", "among", "others.", "<tag3>"], "wordsA": ["Promacta", "is", "currently", "in", "clinical", "development", "for", "a", "number", "of", "additional", "indications", "in", "oncology", "including", "myelodysplastiuc", "syndromes", "(MDS),", "acute", "myeloid", "leukemia", "(AML)", "and", "chemotherapy-induced", "thrombocytopenia", "(CIT)."], "wordsB": ["Our", "partners", "have", "programs", "currently", "in", "clinical", "development", "targeting", "seizure,", "coma,", "cancer,", "diabetes,", "cardiovascular", "disease,", "muscle", "wasting,", "liver", "disease,", "and", "kidney", "disease,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p39_s1", "idA": "886163_15_item1_p14_s3", "sentA": "GSK has listed a patent in the FDA s Orange Book for Promacta with an expiration date in 2027, and absent early termination for bankruptcy or material breach, the term of the agreement expires upon expiration of the obligation to pay royalties.", "sentB": "Novartis has listed a patent in the FDA s, Orange Book for Promacta with an expiration date in 2027, and absent early termination for bankruptcy or material breach, the term of the agreement expires upon expiration of the obligation to pay royalties.", "type": 2, "words": ["<tag1>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties.", "<tag2>", "Novartis", "has", "listed", "a", "patent", "in", "the", "FDA", "s,", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties.", "<tag3>"], "wordsA": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties."], "wordsB": ["Novartis", "has", "listed", "a", "patent", "in", "the", "FDA", "s,", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027,", "and", "absent", "early", "termination", "for", "bankruptcy", "or", "material", "breach,", "the", "term", "of", "the", "agreement", "expires", "upon", "expiration", "of", "the", "obligation", "to", "pay", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p94_s2", "idA": "886163_15_item1_p14_s5", "sentA": "There are no remaining milestones to be paid under the agreement.", "sentB": "There are similar regulations in other countries as well.", "type": 2, "words": ["<tag1>", "There", "are", "no", "remaining", "milestones", "to", "be", "paid", "under", "the", "agreement.", "<tag2>", "There", "are", "similar", "regulations", "in", "other", "countries", "as", "well.", "<tag3>"], "wordsA": ["There", "are", "no", "remaining", "milestones", "to", "be", "paid", "under", "the", "agreement."], "wordsB": ["There", "are", "similar", "regulations", "in", "other", "countries", "as", "well."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p40_s0", "idA": "886163_15_item1_p17_s0", "sentA": "Kyprolis (Amgen) Ligand supplies Captisol to Amgen, Inc. under a 2005 agreement pursuant to an agreement whereby we sell Captisol for use with carfilzomib, and granted an exclusive product-specific license under our patent rights with respect to Captisol.", "sentB": "Kyprolis (Amgen) Ligand supplies Captisol to Amgen for use with carfilzomib, and granted an exclusive product-specific license under our patent rights with respect to Captisol.", "type": 2, "words": ["<tag1>", "Kyprolis", "(Amgen)", "Ligand", "supplies", "Captisol", "to", "Amgen,", "Inc.", "under", "a", "2005", "agreement", "pursuant", "to", "an", "agreement", "whereby", "we", "sell", "Captisol", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol.", "<tag2>", "Kyprolis", "(Amgen)", "Ligand", "supplies", "Captisol", "to", "Amgen", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol.", "<tag3>"], "wordsA": ["Kyprolis", "(Amgen)", "Ligand", "supplies", "Captisol", "to", "Amgen,", "Inc.", "under", "a", "2005", "agreement", "pursuant", "to", "an", "agreement", "whereby", "we", "sell", "Captisol", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol."], "wordsB": ["Kyprolis", "(Amgen)", "Ligand", "supplies", "Captisol", "to", "Amgen", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p59_s0", "idA": "886163_15_item1_p17_s1", "sentA": "In July 2012, Kyprolis was approved by the FDA under accelerated review.", "sentB": "Carbamazepine-IV (Lundbeck) Lundbeck's Carbella is a Captisol-enabled carbamazepine-IV currently under review by the FDA.", "type": 2, "words": ["<tag1>", "In", "July", "2012,", "Kyprolis", "was", "approved", "by", "the", "FDA", "under", "accelerated", "review.", "<tag2>", "Carbamazepine-IV", "(Lundbeck)", "Lundbeck's", "Carbella", "is", "a", "Captisol-enabled", "carbamazepine-IV", "currently", "under", "review", "by", "the", "FDA.", "<tag3>"], "wordsA": ["In", "July", "2012,", "Kyprolis", "was", "approved", "by", "the", "FDA", "under", "accelerated", "review."], "wordsB": ["Carbamazepine-IV", "(Lundbeck)", "Lundbeck's", "Carbella", "is", "a", "Captisol-enabled", "carbamazepine-IV", "currently", "under", "review", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p40_s1", "idA": "886163_15_item1_p18_s0", "sentA": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "Kyprolis is formulated with Ligand s Captisol technology and is approved in the U.S. for the following:", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "approved", "in", "the", "U.S.", "for", "the", "following:", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "approved", "in", "the", "U.S.", "for", "the", "following:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p41_s0", "idA": "886163_15_item1_p18_s0", "sentA": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "In", "combination", "with", "dexamethasone", "or", "with", "lenalidomide", "plus", "dexamethasone", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "to", "three", "lines", "of", "therapy.", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["In", "combination", "with", "dexamethasone", "or", "with", "lenalidomide", "plus", "dexamethasone", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "to", "three", "lines", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p42_s0", "idA": "886163_15_item1_p18_s0", "sentA": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "As", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy.", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["As", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p8_s0", "idA": "886163_15_item1_p18_s0", "sentA": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "On January 21, 2016, Amgen announced that the FDA approved Kyprolis in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "On", "January", "21,", "2016,", "Amgen", "announced", "that", "the", "FDA", "approved", "Kyprolis", "in", "combination", "with", "dexamethasone", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "to", "three", "lines", "of", "therapy.", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["On", "January", "21,", "2016,", "Amgen", "announced", "that", "the", "FDA", "approved", "Kyprolis", "in", "combination", "with", "dexamethasone", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "to", "three", "lines", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p8_s1", "idA": "886163_15_item1_p18_s0", "sentA": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "The FDA also approved Kyprolis as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy, converting to full approval the initial accelerated approval Kyprolis received in July 2012 as a single agent.", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "The", "FDA", "also", "approved", "Kyprolis", "as", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy,", "converting", "to", "full", "approval", "the", "initial", "accelerated", "approval", "Kyprolis", "received", "in", "July", "2012", "as", "a", "single", "agent.", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["The", "FDA", "also", "approved", "Kyprolis", "as", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy,", "converting", "to", "full", "approval", "the", "initial", "accelerated", "approval", "Kyprolis", "received", "in", "July", "2012", "as", "a", "single", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p9_s0", "idA": "886163_15_item1_p18_s0", "sentA": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "On November 19, 2015, Amgen announced the EC approval of Kyprolis in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "On", "November", "19,", "2015,", "Amgen", "announced", "the", "EC", "approval", "of", "Kyprolis", "in", "combination", "with", "lenalidomide", "and", "dexamethasone", "for", "the", "treatment", "of", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy.", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["On", "November", "19,", "2015,", "Amgen", "announced", "the", "EC", "approval", "of", "Kyprolis", "in", "combination", "with", "lenalidomide", "and", "dexamethasone", "for", "the", "treatment", "of", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p30_s1", "idA": "886163_15_item1_p19_s0", "sentA": "This indication for Kyprolis is based on response rate.", "sentB": "The technology is based on novel DNA-based elements that control the dynamic organization of chromatin within mammalian cells and allow for higher and more stable expression of recombinant proteins.", "type": 2, "words": ["<tag1>", "This", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate.", "<tag2>", "The", "technology", "is", "based", "on", "novel", "DNA-based", "elements", "that", "control", "the", "dynamic", "organization", "of", "chromatin", "within", "mammalian", "cells", "and", "allow", "for", "higher", "and", "more", "stable", "expression", "of", "recombinant", "proteins.", "<tag3>"], "wordsA": ["This", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate."], "wordsB": ["The", "technology", "is", "based", "on", "novel", "DNA-based", "elements", "that", "control", "the", "dynamic", "organization", "of", "chromatin", "within", "mammalian", "cells", "and", "allow", "for", "higher", "and", "more", "stable", "expression", "of", "recombinant", "proteins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p2_s0", "idA": "886163_15_item1_p19_s1", "sentA": "In 2014, Amgen announced positive results from the Phase 3 ASPIRE trial.", "sentB": "On December 5, 2015, Amgen announced The Lancet Oncology published results from the Phase 3 ENDEAVOR clinical trial evaluating Kyprolis plus dexamethasone versus Velcade (bortezomib) plus dexamethasone showing that patients with relapsed multiple myeloma treated with Kyprolis lived twice as long without their disease worsening.", "type": 2, "words": ["<tag1>", "In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial.", "<tag2>", "On", "December", "5,", "2015,", "Amgen", "announced", "The", "Lancet", "Oncology", "published", "results", "from", "the", "Phase", "3", "ENDEAVOR", "clinical", "trial", "evaluating", "Kyprolis", "plus", "dexamethasone", "versus", "Velcade", "(bortezomib)", "plus", "dexamethasone", "showing", "that", "patients", "with", "relapsed", "multiple", "myeloma", "treated", "with", "Kyprolis", "lived", "twice", "as", "long", "without", "their", "disease", "worsening.", "<tag3>"], "wordsA": ["In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial."], "wordsB": ["On", "December", "5,", "2015,", "Amgen", "announced", "The", "Lancet", "Oncology", "published", "results", "from", "the", "Phase", "3", "ENDEAVOR", "clinical", "trial", "evaluating", "Kyprolis", "plus", "dexamethasone", "versus", "Velcade", "(bortezomib)", "plus", "dexamethasone", "showing", "that", "patients", "with", "relapsed", "multiple", "myeloma", "treated", "with", "Kyprolis", "lived", "twice", "as", "long", "without", "their", "disease", "worsening."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p3_s0", "idA": "886163_15_item1_p19_s1", "sentA": "In 2014, Amgen announced positive results from the Phase 3 ASPIRE trial.", "sentB": "Melinta announced positive results from a Phase 3 study to evaluate delafloxacin against vancomycin + aztreonam for the treatment of patients with ABSSSI.", "type": 2, "words": ["<tag1>", "In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial.", "<tag2>", "Melinta", "announced", "positive", "results", "from", "a", "Phase", "3", "study", "to", "evaluate", "delafloxacin", "against", "vancomycin", "+", "aztreonam", "for", "the", "treatment", "of", "patients", "with", "ABSSSI.", "<tag3>"], "wordsA": ["In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial."], "wordsB": ["Melinta", "announced", "positive", "results", "from", "a", "Phase", "3", "study", "to", "evaluate", "delafloxacin", "against", "vancomycin", "+", "aztreonam", "for", "the", "treatment", "of", "patients", "with", "ABSSSI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p52_s4", "idA": "886163_15_item1_p19_s1", "sentA": "In 2014, Amgen announced positive results from the Phase 3 ASPIRE trial.", "sentB": "Merck expects initial data from Phase 3 trials in mid-2017.", "type": 2, "words": ["<tag1>", "In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial.", "<tag2>", "Merck", "expects", "initial", "data", "from", "Phase", "3", "trials", "in", "mid-2017.", "<tag3>"], "wordsA": ["In", "2014,", "Amgen", "announced", "positive", "results", "from", "the", "Phase", "3", "ASPIRE", "trial."], "wordsB": ["Merck", "expects", "initial", "data", "from", "Phase", "3", "trials", "in", "mid-2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p5_s0", "idA": "886163_15_item1_p20_s1", "sentA": "In 2015, based on the results from the ASPIRE trial, Amgen announced submissions in the United States and EU for Kyprolis for relapsed multiple myeloma.", "sentB": "Spectrum published results from the pivotal clinical study for EVOMELA in the journal Biology of Blood and Marrow Transplantation .", "type": 2, "words": ["<tag1>", "In", "2015,", "based", "on", "the", "results", "from", "the", "ASPIRE", "trial,", "Amgen", "announced", "submissions", "in", "the", "United", "States", "and", "EU", "for", "Kyprolis", "for", "relapsed", "multiple", "myeloma.", "<tag2>", "Spectrum", "published", "results", "from", "the", "pivotal", "clinical", "study", "for", "EVOMELA", "in", "the", "journal", "Biology", "of", "Blood", "and", "Marrow", "Transplantation", ".", "<tag3>"], "wordsA": ["In", "2015,", "based", "on", "the", "results", "from", "the", "ASPIRE", "trial,", "Amgen", "announced", "submissions", "in", "the", "United", "States", "and", "EU", "for", "Kyprolis", "for", "relapsed", "multiple", "myeloma."], "wordsB": ["Spectrum", "published", "results", "from", "the", "pivotal", "clinical", "study", "for", "EVOMELA", "in", "the", "journal", "Biology", "of", "Blood", "and", "Marrow", "Transplantation", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p44_s2", "idA": "886163_15_item1_p21_s2", "sentA": "Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations such as placing orders under any binding forecasts.", "sentB": "Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations.", "type": 2, "words": ["<tag1>", "Our", "agreement", "with", "Amgen", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Amgen", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts.", "<tag2>", "Our", "agreement", "with", "Amgen", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Amgen", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations.", "<tag3>"], "wordsA": ["Our", "agreement", "with", "Amgen", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Amgen", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations", "such", "as", "placing", "orders", "under", "any", "binding", "forecasts."], "wordsB": ["Our", "agreement", "with", "Amgen", "may", "be", "terminated", "by", "either", "party", "in", "the", "event", "of", "material", "breach", "or", "bankruptcy,", "or", "unilaterally", "by", "Amgen", "with", "prior", "written", "notice,", "subject", "to", "certain", "surviving", "obligations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p44_s4", "idA": "886163_15_item1_p21_s4", "sentA": "Under this agreement, we are entitled to receive remaining milestones of up to $2.5 million, revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis as set forth in the following table:", "sentB": "Under this agreement, we are entitled to receive remaining milestones of up to $2.3 million, revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis.", "type": 2, "words": ["<tag1>", "Under", "this", "agreement,", "we", "are", "entitled", "to", "receive", "remaining", "milestones", "of", "up", "to", "$2.5", "million,", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales", "and", "royalties", "on", "annual", "net", "sales", "of", "Kyprolis", "as", "set", "forth", "in", "the", "following", "table:", "<tag2>", "Under", "this", "agreement,", "we", "are", "entitled", "to", "receive", "remaining", "milestones", "of", "up", "to", "$2.3", "million,", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales", "and", "royalties", "on", "annual", "net", "sales", "of", "Kyprolis.", "<tag3>"], "wordsA": ["Under", "this", "agreement,", "we", "are", "entitled", "to", "receive", "remaining", "milestones", "of", "up", "to", "$2.5", "million,", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales", "and", "royalties", "on", "annual", "net", "sales", "of", "Kyprolis", "as", "set", "forth", "in", "the", "following", "table:"], "wordsB": ["Under", "this", "agreement,", "we", "are", "entitled", "to", "receive", "remaining", "milestones", "of", "up", "to", "$2.3", "million,", "revenue", "from", "clinical", "and", "commercial", "Captisol", "material", "sales", "and", "royalties", "on", "annual", "net", "sales", "of", "Kyprolis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s0", "idA": "886163_15_item1_p22_s0", "sentA": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "Duavee or Duavive (bazedoxifene/conjugated estrogens) and Viviant/Conbriza (Pfizer) Pfizer is marketing bazedoxifene under the brand names Viviant and Conbriza in various territories for the treatment of postmenopausal osteoporosis.", "type": 2, "words": ["<tag1>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "Duavee", "or", "Duavive", "(bazedoxifene/conjugated", "estrogens)", "and", "Viviant/Conbriza", "(Pfizer)", "Pfizer", "is", "marketing", "bazedoxifene", "under", "the", "brand", "names", "Viviant", "and", "Conbriza", "in", "various", "territories", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag3>"], "wordsA": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["Duavee", "or", "Duavive", "(bazedoxifene/conjugated", "estrogens)", "and", "Viviant/Conbriza", "(Pfizer)", "Pfizer", "is", "marketing", "bazedoxifene", "under", "the", "brand", "names", "Viviant", "and", "Conbriza", "in", "various", "territories", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p76_s0", "idA": "886163_15_item1_p22_s0", "sentA": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "Our partner, Deciphera Pharmaceuticals is currently conducting Phase 1 trials for the development of Altiratinib for the treatment of solid tumors.", "type": 2, "words": ["<tag1>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "Our", "partner,", "Deciphera", "Pharmaceuticals", "is", "currently", "conducting", "Phase", "1", "trials", "for", "the", "development", "of", "Altiratinib", "for", "the", "treatment", "of", "solid", "tumors.", "<tag3>"], "wordsA": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["Our", "partner,", "Deciphera", "Pharmaceuticals", "is", "currently", "conducting", "Phase", "1", "trials", "for", "the", "development", "of", "Altiratinib", "for", "the", "treatment", "of", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p81_s0", "idA": "886163_15_item1_p22_s0", "sentA": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "Our partner, VentiRx is currently conducting Phase 2 trials for the development of Motolimod for the treatment of ovarian cancer and head and neck cancer.", "type": 2, "words": ["<tag1>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "Our", "partner,", "VentiRx", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Motolimod", "for", "the", "treatment", "of", "ovarian", "cancer", "and", "head", "and", "neck", "cancer.", "<tag3>"], "wordsA": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["Our", "partner,", "VentiRx", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Motolimod", "for", "the", "treatment", "of", "ovarian", "cancer", "and", "head", "and", "neck", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p84_s2", "idA": "886163_15_item1_p22_s0", "sentA": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "Our partner, Millennium/Takeda is currently conducting Phase 2 trials for the development of Pevonedistat for the treatment of hematological malignancies and solid tumors.", "type": 2, "words": ["<tag1>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Pevonedistat", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors.", "<tag3>"], "wordsA": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Pevonedistat", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p7_s0", "idA": "886163_15_item1_p23_s0", "sentA": "Viviant was approved in 2009 by the European Commission (under the trade name Conbriza) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.", "sentB": "The European Commission approved Revolade (Promacta) for the treatment of adults with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplantation.", "type": 2, "words": ["<tag1>", "Viviant", "was", "approved", "in", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "Conbriza)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture.", "<tag2>", "The", "European", "Commission", "approved", "Revolade", "(Promacta)", "for", "the", "treatment", "of", "adults", "with", "acquired", "SAA", "who", "were", "either", "refractory", "to", "prior", "immunosuppressive", "therapy", "or", "heavily", "pretreated", "and", "are", "unsuitable", "for", "hematopoietic", "stem", "cell", "transplantation.", "<tag3>"], "wordsA": ["Viviant", "was", "approved", "in", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "Conbriza)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture."], "wordsB": ["The", "European", "Commission", "approved", "Revolade", "(Promacta)", "for", "the", "treatment", "of", "adults", "with", "acquired", "SAA", "who", "were", "either", "refractory", "to", "prior", "immunosuppressive", "therapy", "or", "heavily", "pretreated", "and", "are", "unsuitable", "for", "hematopoietic", "stem", "cell", "transplantation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s2", "idA": "886163_15_item1_p24_s2", "sentA": "Pfizer has combined bazedoxifene (discussed above) with the active ingredient in Premarin to create Duavee , a combination therapy for the treatment of post-menopausal symptoms in women.", "sentB": "Pfizer has combined bazedoxifene with the active ingredient in Premarin to create Duavee, a combination therapy for the treatment of post-menopausal symptoms in women.", "type": 2, "words": ["<tag1>", "Pfizer", "has", "combined", "bazedoxifene", "(discussed", "above)", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee", ",", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag2>", "Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee,", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag3>"], "wordsA": ["Pfizer", "has", "combined", "bazedoxifene", "(discussed", "above)", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee", ",", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "wordsB": ["Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee,", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s10", "idA": "886163_15_item1_p24_s4", "sentA": "Pfizer launched Duavee in the United States in the first quarter of 2014.", "sentB": "NOXAFIL-IV is marketed in the United States, EU and Canada.", "type": 2, "words": ["<tag1>", "Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "NOXAFIL-IV", "is", "marketed", "in", "the", "United", "States,", "EU", "and", "Canada.", "<tag3>"], "wordsA": ["Pfizer", "launched", "Duavee", "in", "the", "United", "States", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["NOXAFIL-IV", "is", "marketed", "in", "the", "United", "States,", "EU", "and", "Canada."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s4", "idA": "886163_15_item1_p25_s0", "sentA": "Net royalties on annual net sales of Viviant and Duavee are each payable to us at a rate shown in the table below and are payable through the life of the relevant patents or ten years from the first commercial sale, whichever is longer, on a country by country basis.", "sentB": "Net royalties on annual net sales of Viviant/Conbriza and Duavee/Duavive are each payable to us through the life of the relevant patents or ten years from the first commercial sale, whichever is longer, on a country by country basis.", "type": 2, "words": ["<tag1>", "Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents", "or", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country", "by", "country", "basis.", "<tag2>", "Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant/Conbriza", "and", "Duavee/Duavive", "are", "each", "payable", "to", "us", "through", "the", "life", "of", "the", "relevant", "patents", "or", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country", "by", "country", "basis.", "<tag3>"], "wordsA": ["Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant", "and", "Duavee", "are", "each", "payable", "to", "us", "at", "a", "rate", "shown", "in", "the", "table", "below", "and", "are", "payable", "through", "the", "life", "of", "the", "relevant", "patents", "or", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country", "by", "country", "basis."], "wordsB": ["Net", "royalties", "on", "annual", "net", "sales", "of", "Viviant/Conbriza", "and", "Duavee/Duavive", "are", "each", "payable", "to", "us", "through", "the", "life", "of", "the", "relevant", "patents", "or", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country", "by", "country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s9", "idA": "886163_15_item1_p28_s1", "sentA": "Merck s NOXAFIL -IV, which is a new Captisol-enabled formulation of posaconazole for intravenous (IV) use, was approved by the FDA, EMA and Health Canada in 2014.", "sentB": "We have a supply agreement with Merck related to Merck s NOXAFIL-IV, a Captisol-enabled formulation of posaconazole for IV use.", "type": 2, "words": ["<tag1>", "Merck", "s", "NOXAFIL", "-IV,", "which", "is", "a", "new", "Captisol-enabled", "formulation", "of", "posaconazole", "for", "intravenous", "(IV)", "use,", "was", "approved", "by", "the", "FDA,", "EMA", "and", "Health", "Canada", "in", "2014.", "<tag2>", "We", "have", "a", "supply", "agreement", "with", "Merck", "related", "to", "Merck", "s", "NOXAFIL-IV,", "a", "Captisol-enabled", "formulation", "of", "posaconazole", "for", "IV", "use.", "<tag3>"], "wordsA": ["Merck", "s", "NOXAFIL", "-IV,", "which", "is", "a", "new", "Captisol-enabled", "formulation", "of", "posaconazole", "for", "intravenous", "(IV)", "use,", "was", "approved", "by", "the", "FDA,", "EMA", "and", "Health", "Canada", "in", "2014."], "wordsB": ["We", "have", "a", "supply", "agreement", "with", "Merck", "related", "to", "Merck", "s", "NOXAFIL-IV,", "a", "Captisol-enabled", "formulation", "of", "posaconazole", "for", "IV", "use."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s11", "idA": "886163_15_item1_p28_s2", "sentA": "We will receive our commercial compensation for this program through the sale of Captisol, and we will not receive a royalty on this program.", "sentB": "We receive our commercial compensation for this program through the sale of Captisol, and we do not receive a royalty on this program.", "type": 2, "words": ["<tag1>", "We", "will", "receive", "our", "commercial", "compensation", "for", "this", "program", "through", "the", "sale", "of", "Captisol,", "and", "we", "will", "not", "receive", "a", "royalty", "on", "this", "program.", "<tag2>", "We", "receive", "our", "commercial", "compensation", "for", "this", "program", "through", "the", "sale", "of", "Captisol,", "and", "we", "do", "not", "receive", "a", "royalty", "on", "this", "program.", "<tag3>"], "wordsA": ["We", "will", "receive", "our", "commercial", "compensation", "for", "this", "program", "through", "the", "sale", "of", "Captisol,", "and", "we", "will", "not", "receive", "a", "royalty", "on", "this", "program."], "wordsB": ["We", "receive", "our", "commercial", "compensation", "for", "this", "program", "through", "the", "sale", "of", "Captisol,", "and", "we", "do", "not", "receive", "a", "royalty", "on", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p16_s0", "idA": "886163_15_item1_p29_s3", "sentA": "We are supplying Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "Commercial supply agreement with Gilead Sciences to supply Captisol for use in developing a Captisol-enabled program directed against Ebola virus disease.", "type": 2, "words": ["<tag1>", "We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "Commercial", "supply", "agreement", "with", "Gilead", "Sciences", "to", "supply", "Captisol", "for", "use", "in", "developing", "a", "Captisol-enabled", "program", "directed", "against", "Ebola", "virus", "disease.", "<tag3>"], "wordsA": ["We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["Commercial", "supply", "agreement", "with", "Gilead", "Sciences", "to", "supply", "Captisol", "for", "use", "in", "developing", "a", "Captisol-enabled", "program", "directed", "against", "Ebola", "virus", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s6", "idA": "886163_15_item1_p29_s3", "sentA": "We are supplying Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "We supply Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement.", "type": 2, "words": ["<tag1>", "We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "We", "supply", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag3>"], "wordsA": ["We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["We", "supply", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s8", "idA": "886163_15_item1_p29_s4", "sentA": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through early 2033.", "sentB": "We are entitled to earn royalties on sales of Nexterone through early 2033.", "type": 2, "words": ["<tag1>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2033.", "<tag2>", "We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "of", "Nexterone", "through", "early", "2033.", "<tag3>"], "wordsA": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2033."], "wordsB": ["We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "of", "Nexterone", "through", "early", "2033."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p46_s1", "idA": "886163_15_item1_p29_s9", "sentA": "We have multiple partnered programs in our portfolio that are either in or nearing the regulatory approval process.", "sentB": "Summary of Selected Development-stage Programs We have multiple fully-funded partnered programs that are either in or nearing the regulatory approval process, or given the area of research or value of the license terms are considered particularly noteworthy.", "type": 2, "words": ["<tag1>", "We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process.", "<tag2>", "Summary", "of", "Selected", "Development-stage", "Programs", "We", "have", "multiple", "fully-funded", "partnered", "programs", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process,", "or", "given", "the", "area", "of", "research", "or", "value", "of", "the", "license", "terms", "are", "considered", "particularly", "noteworthy.", "<tag3>"], "wordsA": ["We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process."], "wordsB": ["Summary", "of", "Selected", "Development-stage", "Programs", "We", "have", "multiple", "fully-funded", "partnered", "programs", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process,", "or", "given", "the", "area", "of", "research", "or", "value", "of", "the", "license", "terms", "are", "considered", "particularly", "noteworthy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p48_s0", "idA": "886163_15_item1_p30_s1", "sentA": "The Captisol-enabled, PG-free melphalan program uses a new intravenous formulation of melphalan for the multiple myeloma transplant setting, and has been granted Orphan Designation by the FDA.", "sentB": "Evomela is intended for use in the multiple myeloma stem cell transplant setting, and has been granted Orphan Designation by the FDA.", "type": 2, "words": ["<tag1>", "The", "Captisol-enabled,", "PG-free", "melphalan", "program", "uses", "a", "new", "intravenous", "formulation", "of", "melphalan", "for", "the", "multiple", "myeloma", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA.", "<tag2>", "Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA.", "<tag3>"], "wordsA": ["The", "Captisol-enabled,", "PG-free", "melphalan", "program", "uses", "a", "new", "intravenous", "formulation", "of", "melphalan", "for", "the", "multiple", "myeloma", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA."], "wordsB": ["Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p48_s1", "idA": "886163_15_item1_p30_s2", "sentA": "The formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds.", "sentB": "The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds.", "type": 2, "words": ["<tag1>", "The", "formulation", "avoids", "the", "use", "of", "propylene", "glycol,", "which", "has", "been", "reported", "to", "cause", "renal", "and", "cardiac", "side-effects", "that", "limit", "the", "ability", "to", "deliver", "higher", "quantities", "of", "therapeutic", "compounds.", "<tag2>", "The", "Evomela", "formulation", "avoids", "the", "use", "of", "propylene", "glycol,", "which", "has", "been", "reported", "to", "cause", "renal", "and", "cardiac", "side-effects", "that", "limit", "the", "ability", "to", "deliver", "higher", "quantities", "of", "therapeutic", "compounds.", "<tag3>"], "wordsA": ["The", "formulation", "avoids", "the", "use", "of", "propylene", "glycol,", "which", "has", "been", "reported", "to", "cause", "renal", "and", "cardiac", "side-effects", "that", "limit", "the", "ability", "to", "deliver", "higher", "quantities", "of", "therapeutic", "compounds."], "wordsB": ["The", "Evomela", "formulation", "avoids", "the", "use", "of", "propylene", "glycol,", "which", "has", "been", "reported", "to", "cause", "renal", "and", "cardiac", "side-effects", "that", "limit", "the", "ability", "to", "deliver", "higher", "quantities", "of", "therapeutic", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p24_s1", "idA": "886163_15_item1_p31_s0", "sentA": "Under the terms of the license agreement, we granted an exclusive license to Spectrum under our patent rights to Captisol relating to the melphalan product.", "sentB": "These DMFs contain manufacturing and safety information relating to Captisol that our licensees can reference when developing Captisol-enabled drugs.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "melphalan", "product.", "<tag2>", "These", "DMFs", "contain", "manufacturing", "and", "safety", "information", "relating", "to", "Captisol", "that", "our", "licensees", "can", "reference", "when", "developing", "Captisol-enabled", "drugs.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "melphalan", "product."], "wordsB": ["These", "DMFs", "contain", "manufacturing", "and", "safety", "information", "relating", "to", "Captisol", "that", "our", "licensees", "can", "reference", "when", "developing", "Captisol-enabled", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p49_s0", "idA": "886163_15_item1_p31_s0", "sentA": "Under the terms of the license agreement, we granted an exclusive license to Spectrum under our patent rights to Captisol relating to the melphalan product.", "sentB": "Under the terms of the license agreement, we granted an exclusive license to Spectrum under our patent rights to Captisol relating to the product.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "melphalan", "product.", "<tag2>", "Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "product.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "melphalan", "product."], "wordsB": ["Under", "the", "terms", "of", "the", "license", "agreement,", "we", "granted", "an", "exclusive", "license", "to", "Spectrum", "under", "our", "patent", "rights", "to", "Captisol", "relating", "to", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p50_s0", "idA": "886163_15_item1_p31_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate of 20%.", "sentB": "agreement and royalties on future net sales of the Captisol-enabled melphalan product.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "of", "20%.", "<tag2>", "agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "of", "20%."], "wordsB": ["agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p17_s0", "idA": "886163_15_item1_p33_s0", "sentA": "We have a development agreement with Merck (formerly Schering-Plough) for a beta-secretase, or BACE, inhibitor program for the treatment of Alzheimer s disease.", "sentB": "Clinical use agreement with XTL Biopharmaceuticals to supply Captisol for use in in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus.", "type": 2, "words": ["<tag1>", "We", "have", "a", "development", "agreement", "with", "Merck", "(formerly", "Schering-Plough)", "for", "a", "beta-secretase,", "or", "BACE,", "inhibitor", "program", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag2>", "Clinical", "use", "agreement", "with", "XTL", "Biopharmaceuticals", "to", "supply", "Captisol", "for", "use", "in", "in", "the", "formulation", "of", "its", "lead", "drug,", "hCDR1,", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus.", "<tag3>"], "wordsA": ["We", "have", "a", "development", "agreement", "with", "Merck", "(formerly", "Schering-Plough)", "for", "a", "beta-secretase,", "or", "BACE,", "inhibitor", "program", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "wordsB": ["Clinical", "use", "agreement", "with", "XTL", "Biopharmaceuticals", "to", "supply", "Captisol", "for", "use", "in", "in", "the", "formulation", "of", "its", "lead", "drug,", "hCDR1,", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p51_s0", "idA": "886163_15_item1_p33_s0", "sentA": "We have a development agreement with Merck (formerly Schering-Plough) for a beta-secretase, or BACE, inhibitor program for the treatment of Alzheimer s disease.", "sentB": "Verubecestat (Merck) Our partner, Merck is conducting two Phase 3 trials for Verubecestat (MK-8931), a BACE inhibitor for the treatment of Alzheimer s disease.", "type": 2, "words": ["<tag1>", "We", "have", "a", "development", "agreement", "with", "Merck", "(formerly", "Schering-Plough)", "for", "a", "beta-secretase,", "or", "BACE,", "inhibitor", "program", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag2>", "Verubecestat", "(Merck)", "Our", "partner,", "Merck", "is", "conducting", "two", "Phase", "3", "trials", "for", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag3>"], "wordsA": ["We", "have", "a", "development", "agreement", "with", "Merck", "(formerly", "Schering-Plough)", "for", "a", "beta-secretase,", "or", "BACE,", "inhibitor", "program", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "wordsB": ["Verubecestat", "(Merck)", "Our", "partner,", "Merck", "is", "conducting", "two", "Phase", "3", "trials", "for", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p52_s0", "idA": "886163_15_item1_p34_s0", "sentA": "This disease is characterized by plaques of the toxic amyloid-beta protein within the brain.", "sentB": "Alzheimer s disease is characterized by plaques of amyloid-beta protein within the brain.", "type": 2, "words": ["<tag1>", "This", "disease", "is", "characterized", "by", "plaques", "of", "the", "toxic", "amyloid-beta", "protein", "within", "the", "brain.", "<tag2>", "Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain.", "<tag3>"], "wordsA": ["This", "disease", "is", "characterized", "by", "plaques", "of", "the", "toxic", "amyloid-beta", "protein", "within", "the", "brain."], "wordsB": ["Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p112_s0", "idA": "886163_15_item1_p35_s0", "sentA": "BACE is believed to be a key enzyme in the production of amyloid-beta protein.", "sentB": "the information contained in our website and in the SEC s website is not intended to be a part of this filing.", "type": 2, "words": ["<tag1>", "BACE", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein.", "<tag2>", "the", "information", "contained", "in", "our", "website", "and", "in", "the", "SEC", "s", "website", "is", "not", "intended", "to", "be", "a", "part", "of", "this", "filing.", "<tag3>"], "wordsA": ["BACE", "is", "believed", "to", "be", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein."], "wordsB": ["the", "information", "contained", "in", "our", "website", "and", "in", "the", "SEC", "s", "website", "is", "not", "intended", "to", "be", "a", "part", "of", "this", "filing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p52_s2", "idA": "886163_15_item1_p35_s1", "sentA": "Amyloid-beta is formed when the larger amyloid precursor protein (APP) is cleaved by two enzymes, BACE and gamma-secretase, which releases the amyloid-beta fragment.", "sentB": "Amyloid-beta is formed when the larger amyloid precursor protein is cleaved by two enzymes, BACE and gamma-secretase, which releases the amyloid-beta fragment.", "type": 2, "words": ["<tag1>", "Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "BACE", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment.", "<tag2>", "Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "is", "cleaved", "by", "two", "enzymes,", "BACE", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment.", "<tag3>"], "wordsA": ["Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "BACE", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment."], "wordsB": ["Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "is", "cleaved", "by", "two", "enzymes,", "BACE", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s14", "idA": "886163_15_item1_p37_s0", "sentA": "We are entitled to a royalty on potential future sales by Merck.", "sentB": "We are entitled to earn royalties on sales by Zydus Cadila through at least 2026.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck.", "<tag2>", "We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck."], "wordsB": ["We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p46_s0", "idA": "886163_15_item1_p37_s0", "sentA": "We are entitled to a royalty on potential future sales by Merck.", "sentB": "We are entitled to earn royalties on sales by Zydus Cadila through at least 2026.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck.", "<tag2>", "We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck."], "wordsB": ["We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p73_s0", "idA": "886163_15_item1_p37_s0", "sentA": "We are entitled to a royalty on potential future sales by Merck.", "sentB": "We are entitled to earn regulatory and sales milestones, and royalties on potential future sales through at least 2026.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck.", "<tag2>", "We", "are", "entitled", "to", "earn", "regulatory", "and", "sales", "milestones,", "and", "royalties", "on", "potential", "future", "sales", "through", "at", "least", "2026.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Merck."], "wordsB": ["We", "are", "entitled", "to", "earn", "regulatory", "and", "sales", "milestones,", "and", "royalties", "on", "potential", "future", "sales", "through", "at", "least", "2026."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p53_s1", "idA": "886163_15_item1_p38_s0", "sentA": "In 2011, we entered into a Captisol license agreement with SAGE Therapeutics, Inc. (SAGE) for the development and commercialization of Captisol-enabled(R) therapeutics for a broad range of debilitating central nervous system (CNS) conditions.", "sentB": "Our partner, SAGE, is conducting a Phase 3 clinical trial for the development of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions.", "type": 2, "words": ["<tag1>", "In", "2011,", "we", "entered", "into", "a", "Captisol", "license", "agreement", "with", "SAGE", "Therapeutics,", "Inc.", "(SAGE)", "for", "the", "development", "and", "commercialization", "of", "Captisol-enabled(R)", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "(CNS)", "conditions.", "<tag2>", "Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions.", "<tag3>"], "wordsA": ["In", "2011,", "we", "entered", "into", "a", "Captisol", "license", "agreement", "with", "SAGE", "Therapeutics,", "Inc.", "(SAGE)", "for", "the", "development", "and", "commercialization", "of", "Captisol-enabled(R)", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "(CNS)", "conditions."], "wordsB": ["Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p46_s2", "idA": "886163_15_item1_p38_s1", "sentA": "Under the agreement, Ligand has received upfront and research support payments and has the potential to receive milestone payments and royalties for Captisol-enabled programs.", "sentB": "We are eligible to receive milestone payments and royalties off of these programs.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "Ligand", "has", "received", "upfront", "and", "research", "support", "payments", "and", "has", "the", "potential", "to", "receive", "milestone", "payments", "and", "royalties", "for", "Captisol-enabled", "programs.", "<tag2>", "We", "are", "eligible", "to", "receive", "milestone", "payments", "and", "royalties", "off", "of", "these", "programs.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "Ligand", "has", "received", "upfront", "and", "research", "support", "payments", "and", "has", "the", "potential", "to", "receive", "milestone", "payments", "and", "royalties", "for", "Captisol-enabled", "programs."], "wordsB": ["We", "are", "eligible", "to", "receive", "milestone", "payments", "and", "royalties", "off", "of", "these", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p53_s4", "idA": "886163_15_item1_p38_s1", "sentA": "Under the agreement, Ligand has received upfront and research support payments and has the potential to receive milestone payments and royalties for Captisol-enabled programs.", "sentB": "Ligand has the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "Ligand", "has", "received", "upfront", "and", "research", "support", "payments", "and", "has", "the", "potential", "to", "receive", "milestone", "payments", "and", "royalties", "for", "Captisol-enabled", "programs.", "<tag2>", "Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "Ligand", "has", "received", "upfront", "and", "research", "support", "payments", "and", "has", "the", "potential", "to", "receive", "milestone", "payments", "and", "royalties", "for", "Captisol-enabled", "programs."], "wordsB": ["Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p53_s2", "idA": "886163_15_item1_p39_s0", "sentA": "SAGE s lead clinical program, Captisol-enabled SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of super-refractory status epilepticus, or SRSE.", "sentB": "SAGE s lead clinical program, Captisol-enabled SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABA A receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE.", "type": 2, "words": ["<tag1>", "SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABAA", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "super-refractory", "status", "epilepticus,", "or", "SRSE.", "<tag2>", "SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABA", "A", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE.", "<tag3>"], "wordsA": ["SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABAA", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "super-refractory", "status", "epilepticus,", "or", "SRSE."], "wordsB": ["SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABA", "A", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p83_s0", "idA": "886163_15_item1_p39_s1", "sentA": "SAGE-547 was granted Fast Track designation by the FDA in July 2014 for SRSE.", "sentB": "Motolimod was granted Fast Track and Orphan Designations by the FDA for the treatment of recurrent or persistent ovarian cancer.", "type": 2, "words": ["<tag1>", "SAGE-547", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA", "in", "July", "2014", "for", "SRSE.", "<tag2>", "Motolimod", "was", "granted", "Fast", "Track", "and", "Orphan", "Designations", "by", "the", "FDA", "for", "the", "treatment", "of", "recurrent", "or", "persistent", "ovarian", "cancer.", "<tag3>"], "wordsA": ["SAGE-547", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA", "in", "July", "2014", "for", "SRSE."], "wordsB": ["Motolimod", "was", "granted", "Fast", "Track", "and", "Orphan", "Designations", "by", "the", "FDA", "for", "the", "treatment", "of", "recurrent", "or", "persistent", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p53_s3", "idA": "886163_15_item1_p39_s2", "sentA": "Fast track designation is granted by the FDA to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.", "sentB": "SAGE-547 was granted Fast Track designation, which is intended to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs, and orphan drug designation, which is intended to facilitate drug development for rare diseases, by the FDA for SRSE.", "type": 2, "words": ["<tag1>", "Fast", "track", "designation", "is", "granted", "by", "the", "FDA", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs.", "<tag2>", "SAGE-547", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE.", "<tag3>"], "wordsA": ["Fast", "track", "designation", "is", "granted", "by", "the", "FDA", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs."], "wordsB": ["SAGE-547", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p47_s1", "idA": "886163_15_item1_p39_s3", "sentA": "SAGE-547 also received orphan drug designation, which is intended to facilitate drug development for rare diseases, from the FDA in April 2014.", "sentB": "In October 2015, Spectrum announced that it had received a complete response letter from the FDA requiring additional information regarding its contract manufacturers.", "type": 2, "words": ["<tag1>", "SAGE-547", "also", "received", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "from", "the", "FDA", "in", "April", "2014.", "<tag2>", "In", "October", "2015,", "Spectrum", "announced", "that", "it", "had", "received", "a", "complete", "response", "letter", "from", "the", "FDA", "requiring", "additional", "information", "regarding", "its", "contract", "manufacturers.", "<tag3>"], "wordsA": ["SAGE-547", "also", "received", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "from", "the", "FDA", "in", "April", "2014."], "wordsB": ["In", "October", "2015,", "Spectrum", "announced", "that", "it", "had", "received", "a", "complete", "response", "letter", "from", "the", "FDA", "requiring", "additional", "information", "regarding", "its", "contract", "manufacturers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p26_s0", "idA": "886163_15_item1_p39_s4", "sentA": "In January of 2015, SAGE reported updated data from an ongoing Phase 1/2 clinical trial and its emergency use program of SAGE-547 in patients with SRSE.", "sentB": "In January of 2016, Ligand acquired OMT and the OmniAb Technologies.", "type": 2, "words": ["<tag1>", "In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag2>", "In", "January", "of", "2016,", "Ligand", "acquired", "OMT", "and", "the", "OmniAb", "Technologies.", "<tag3>"], "wordsA": ["In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "wordsB": ["In", "January", "of", "2016,", "Ligand", "acquired", "OMT", "and", "the", "OmniAb", "Technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p4_s0", "idA": "886163_15_item1_p39_s4", "sentA": "In January of 2015, SAGE reported updated data from an ongoing Phase 1/2 clinical trial and its emergency use program of SAGE-547 in patients with SRSE.", "sentB": "SAGE announced initiation of a Phase 3 study designed to evaluate the safety of SAGE-547 in patients with SRSE.", "type": 2, "words": ["<tag1>", "In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag2>", "SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag3>"], "wordsA": ["In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "wordsB": ["SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p4_s1", "idA": "886163_15_item1_p39_s4", "sentA": "In January of 2015, SAGE reported updated data from an ongoing Phase 1/2 clinical trial and its emergency use program of SAGE-547 in patients with SRSE.", "sentB": "SAGE also announced SAGE-547 demonstrated a 77% response rate in evaluable patients with SRSE in a Phase 1/2 clinical trial.", "type": 2, "words": ["<tag1>", "In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag2>", "SAGE", "also", "announced", "SAGE-547", "demonstrated", "a", "77%", "response", "rate", "in", "evaluable", "patients", "with", "SRSE", "in", "a", "Phase", "1/2", "clinical", "trial.", "<tag3>"], "wordsA": ["In", "January", "of", "2015,", "SAGE", "reported", "updated", "data", "from", "an", "ongoing", "Phase", "1/2", "clinical", "trial", "and", "its", "emergency", "use", "program", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "wordsB": ["SAGE", "also", "announced", "SAGE-547", "demonstrated", "a", "77%", "response", "rate", "in", "evaluable", "patients", "with", "SRSE", "in", "a", "Phase", "1/2", "clinical", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s9", "idA": "886163_15_item1_p3_s0", "sentA": "Our business model creates value for stockholders by assembling a diversified portfolio of biotech and pharmaceutical revenue streams and operating that business with an efficient and low corporate cost structure.", "sentB": "Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.", "type": 2, "words": ["<tag1>", "Our", "business", "model", "creates", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure.", "<tag2>", "Our", "business", "model", "creates", "value", "for", "stockholders", "by", "providing", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "product", "revenue", "streams", "that", "are", "supported", "by", "an", "efficient", "and", "low", "corporate", "cost", "structure.", "<tag3>"], "wordsA": ["Our", "business", "model", "creates", "value", "for", "stockholders", "by", "assembling", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "revenue", "streams", "and", "operating", "that", "business", "with", "an", "efficient", "and", "low", "corporate", "cost", "structure."], "wordsB": ["Our", "business", "model", "creates", "value", "for", "stockholders", "by", "providing", "a", "diversified", "portfolio", "of", "biotech", "and", "pharmaceutical", "product", "revenue", "streams", "that", "are", "supported", "by", "an", "efficient", "and", "low", "corporate", "cost", "structure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s11", "idA": "886163_15_item1_p3_s2", "sentA": "Our business model is based on the concept of doing what we do best: drug discovery, reformulation and partnering.", "sentB": "Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering.", "type": 2, "words": ["<tag1>", "Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering.", "<tag2>", "Our", "business", "model", "is", "based", "on", "doing", "what", "we", "do", "best:", "drug", "discovery,", "early-stage", "drug", "development,", "product", "reformulation", "and", "partnering.", "<tag3>"], "wordsA": ["Our", "business", "model", "is", "based", "on", "the", "concept", "of", "doing", "what", "we", "do", "best:", "drug", "discovery,", "reformulation", "and", "partnering."], "wordsB": ["Our", "business", "model", "is", "based", "on", "doing", "what", "we", "do", "best:", "drug", "discovery,", "early-stage", "drug", "development,", "product", "reformulation", "and", "partnering."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p1_s0", "idA": "886163_15_item1_p3_s4", "sentA": "Our revenue consists mostly of license fees, milestones and royalties from the partners that license our drugs and technologies, and Captisol material sales.", "sentB": "Our revenue consists of three primary elements: royalties from commercialized products, license and milestone payments and sale of Captisol material.", "type": 2, "words": ["<tag1>", "Our", "revenue", "consists", "mostly", "of", "license", "fees,", "milestones", "and", "royalties", "from", "the", "partners", "that", "license", "our", "drugs", "and", "technologies,", "and", "Captisol", "material", "sales.", "<tag2>", "Our", "revenue", "consists", "of", "three", "primary", "elements:", "royalties", "from", "commercialized", "products,", "license", "and", "milestone", "payments", "and", "sale", "of", "Captisol", "material.", "<tag3>"], "wordsA": ["Our", "revenue", "consists", "mostly", "of", "license", "fees,", "milestones", "and", "royalties", "from", "the", "partners", "that", "license", "our", "drugs", "and", "technologies,", "and", "Captisol", "material", "sales."], "wordsB": ["Our", "revenue", "consists", "of", "three", "primary", "elements:", "royalties", "from", "commercialized", "products,", "license", "and", "milestone", "payments", "and", "sale", "of", "Captisol", "material."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p1_s1", "idA": "886163_15_item1_p3_s5", "sentA": "In addition to discovering our own proprietary drugs, we use an aggressive acquisition strategy to bring in new assets, pipelines, and technologies to aid in generating additional potential new revenue streams.", "sentB": "In addition to discovering and developing our own proprietary drugs, we selectively pursue acquisitions to bring in new assets, pipelines, and technologies to aid in generating additional potential new revenue streams.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "discovering", "our", "own", "proprietary", "drugs,", "we", "use", "an", "aggressive", "acquisition", "strategy", "to", "bring", "in", "new", "assets,", "pipelines,", "and", "technologies", "to", "aid", "in", "generating", "additional", "potential", "new", "revenue", "streams.", "<tag2>", "In", "addition", "to", "discovering", "and", "developing", "our", "own", "proprietary", "drugs,", "we", "selectively", "pursue", "acquisitions", "to", "bring", "in", "new", "assets,", "pipelines,", "and", "technologies", "to", "aid", "in", "generating", "additional", "potential", "new", "revenue", "streams.", "<tag3>"], "wordsA": ["In", "addition", "to", "discovering", "our", "own", "proprietary", "drugs,", "we", "use", "an", "aggressive", "acquisition", "strategy", "to", "bring", "in", "new", "assets,", "pipelines,", "and", "technologies", "to", "aid", "in", "generating", "additional", "potential", "new", "revenue", "streams."], "wordsB": ["In", "addition", "to", "discovering", "and", "developing", "our", "own", "proprietary", "drugs,", "we", "selectively", "pursue", "acquisitions", "to", "bring", "in", "new", "assets,", "pipelines,", "and", "technologies", "to", "aid", "in", "generating", "additional", "potential", "new", "revenue", "streams."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p22_s0", "idA": "886163_15_item1_p3_s6", "sentA": "The principal elements of our strategy are set forth below.", "sentB": "A variety of technology platforms that enable elements of drug discovery or development form the basis of our portfolio of fully-funded shots on goal.", "type": 2, "words": ["<tag1>", "The", "principal", "elements", "of", "our", "strategy", "are", "set", "forth", "below.", "<tag2>", "A", "variety", "of", "technology", "platforms", "that", "enable", "elements", "of", "drug", "discovery", "or", "development", "form", "the", "basis", "of", "our", "portfolio", "of", "fully-funded", "shots", "on", "goal.", "<tag3>"], "wordsA": ["The", "principal", "elements", "of", "our", "strategy", "are", "set", "forth", "below."], "wordsB": ["A", "variety", "of", "technology", "platforms", "that", "enable", "elements", "of", "drug", "discovery", "or", "development", "form", "the", "basis", "of", "our", "portfolio", "of", "fully-funded", "shots", "on", "goal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p53_s6", "idA": "886163_15_item1_p40_s1", "sentA": "Retrophin is developing Sparsentan for orphan indications of severe kidney diseases including FSGS as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy.", "sentB": "Our partner Retrophin is currently conducting a Phase 2 clinical trial for the development of Sparsentan for orphan indications of severe kidney diseases including FSGS.", "type": 2, "words": ["<tag1>", "Retrophin", "is", "developing", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy.", "<tag2>", "Our", "partner", "Retrophin", "is", "currently", "conducting", "a", "Phase", "2", "clinical", "trial", "for", "the", "development", "of", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS.", "<tag3>"], "wordsA": ["Retrophin", "is", "developing", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy."], "wordsB": ["Our", "partner", "Retrophin", "is", "currently", "conducting", "a", "Phase", "2", "clinical", "trial", "for", "the", "development", "of", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p54_s2", "idA": "886163_15_item1_p41_s2", "sentA": "Retrophin is currently conducting a potentially pivotal Phase 2 clinical trial for Sparsentan and has received orphan drug designation.", "sentB": "In January 2015, the FDA granted Sparsentan orphan drug designation.", "type": 2, "words": ["<tag1>", "Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation.", "<tag2>", "In", "January", "2015,", "the", "FDA", "granted", "Sparsentan", "orphan", "drug", "designation.", "<tag3>"], "wordsA": ["Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation."], "wordsB": ["In", "January", "2015,", "the", "FDA", "granted", "Sparsentan", "orphan", "drug", "designation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p66_s1", "idA": "886163_15_item1_p41_s2", "sentA": "Retrophin is currently conducting a potentially pivotal Phase 2 clinical trial for Sparsentan and has received orphan drug designation.", "sentB": "Viking intends to initiate a Phase 2 trial for VK2809 in hypercholesterolemia and fatty liver disease in 2016.", "type": 2, "words": ["<tag1>", "Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation.", "<tag2>", "Viking", "intends", "to", "initiate", "a", "Phase", "2", "trial", "for", "VK2809", "in", "hypercholesterolemia", "and", "fatty", "liver", "disease", "in", "2016.", "<tag3>"], "wordsA": ["Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation."], "wordsB": ["Viking", "intends", "to", "initiate", "a", "Phase", "2", "trial", "for", "VK2809", "in", "hypercholesterolemia", "and", "fatty", "liver", "disease", "in", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p74_s0", "idA": "886163_15_item1_p41_s2", "sentA": "Retrophin is currently conducting a potentially pivotal Phase 2 clinical trial for Sparsentan and has received orphan drug designation.", "sentB": "Our partner, Cardioxyl (acquired by BMS in 2015) is conducting Phase 2 clinical trials for Captisol-enabled CXL-1427 (nitroxyl donor prodrug) for ADHF.", "type": 2, "words": ["<tag1>", "Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation.", "<tag2>", "Our", "partner,", "Cardioxyl", "(acquired", "by", "BMS", "in", "2015)", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "CXL-1427", "(nitroxyl", "donor", "prodrug)", "for", "ADHF.", "<tag3>"], "wordsA": ["Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation."], "wordsB": ["Our", "partner,", "Cardioxyl", "(acquired", "by", "BMS", "in", "2015)", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "CXL-1427", "(nitroxyl", "donor", "prodrug)", "for", "ADHF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p75_s0", "idA": "886163_15_item1_p41_s2", "sentA": "Retrophin is currently conducting a potentially pivotal Phase 2 clinical trial for Sparsentan and has received orphan drug designation.", "sentB": "Our partner, Eli Lilly is conducting Phase 2 clinical trials for Captisol-enabled LY2606368 (Chk 1/2 inhibitor) for solid tumors.", "type": 2, "words": ["<tag1>", "Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation.", "<tag2>", "Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "LY2606368", "(Chk", "1/2", "inhibitor)", "for", "solid", "tumors.", "<tag3>"], "wordsA": ["Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation."], "wordsB": ["Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "LY2606368", "(Chk", "1/2", "inhibitor)", "for", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p78_s1", "idA": "886163_15_item1_p41_s2", "sentA": "Retrophin is currently conducting a potentially pivotal Phase 2 clinical trial for Sparsentan and has received orphan drug designation.", "sentB": "Our partner, Merrimack Pharmaceuticals is currently conducting a Phase 2/3 trial for the treatment of advanced metastatic HER2-positive breast cancer.", "type": 2, "words": ["<tag1>", "Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation.", "<tag2>", "Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer.", "<tag3>"], "wordsA": ["Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation."], "wordsB": ["Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p89_s2", "idA": "886163_15_item1_p41_s2", "sentA": "Retrophin is currently conducting a potentially pivotal Phase 2 clinical trial for Sparsentan and has received orphan drug designation.", "sentB": "We conducted a Phase 1b trial showing robust effects throughout multiple ascending dosing, and plan to initiate a Phase 2 clinical trial in 2016.", "type": 2, "words": ["<tag1>", "Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation.", "<tag2>", "We", "conducted", "a", "Phase", "1b", "trial", "showing", "robust", "effects", "throughout", "multiple", "ascending", "dosing,", "and", "plan", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "in", "2016.", "<tag3>"], "wordsA": ["Retrophin", "is", "currently", "conducting", "a", "potentially", "pivotal", "Phase", "2", "clinical", "trial", "for", "Sparsentan", "and", "has", "received", "orphan", "drug", "designation."], "wordsB": ["We", "conducted", "a", "Phase", "1b", "trial", "showing", "robust", "effects", "throughout", "multiple", "ascending", "dosing,", "and", "plan", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "in", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p54_s3", "idA": "886163_15_item1_p41_s5", "sentA": "Under our license agreement with Retrophin we are entitled to receive over $75 million in net milestones, as well as 9% in net royalties on future worldwide sales by Retrophin through the life of the relevant patents, which we currently expect to be through at least 2019 and may be extended until 2024.", "sentB": "Under our license agreement with Retrophin we are entitled to receive potential net milestones of over $75 million in the future and net royalties on future worldwide sales by Retrophin through the life of the relevant patents, which we currently expect to be through at least 2019 and may be extended until 2024.", "type": 2, "words": ["<tag1>", "Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "net", "milestones,", "as", "well", "as", "9%", "in", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024.", "<tag2>", "Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "potential", "net", "milestones", "of", "over", "$75", "million", "in", "the", "future", "and", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024.", "<tag3>"], "wordsA": ["Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "over", "$75", "million", "in", "net", "milestones,", "as", "well", "as", "9%", "in", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024."], "wordsB": ["Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "potential", "net", "milestones", "of", "over", "$75", "million", "in", "the", "future", "and", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p57_s0", "idA": "886163_15_item1_p43_s0", "sentA": "Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of quinolone-resistant Gram-positive and Gram-negative bacteria, including quinolone-resistant, methicillin-resistant Staphylococcus aureu, or MRSA.", "sentB": "Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of quinolone-resistant Gram-positive and Gram-negative bacteria, including quinolone-resistant MRSA.", "type": 2, "words": ["<tag1>", "Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureu,", "or", "MRSA.", "<tag2>", "Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant", "MRSA.", "<tag3>"], "wordsA": ["Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureu,", "or", "MRSA."], "wordsB": ["Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant", "MRSA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p56_s0", "idA": "886163_15_item1_p43_s1", "sentA": "In 2015, Melinta reported positive top-line results on the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "sentB": "Baxdela (Melinta) Our partner Melinta is currently completing Phase 3 clinical trials for the development of Baxdela, a Captisol-enabled delafloxacin-IV.", "type": 2, "words": ["<tag1>", "In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag2>", "Baxdela", "(Melinta)", "Our", "partner", "Melinta", "is", "currently", "completing", "Phase", "3", "clinical", "trials", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV.", "<tag3>"], "wordsA": ["In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "wordsB": ["Baxdela", "(Melinta)", "Our", "partner", "Melinta", "is", "currently", "completing", "Phase", "3", "clinical", "trials", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p57_s1", "idA": "886163_15_item1_p43_s1", "sentA": "In 2015, Melinta reported positive top-line results on the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "sentB": "In 2015, Melinta reported positive top-line results on the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of ABSSSI, including infections caused by MRSA.", "type": 2, "words": ["<tag1>", "In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag2>", "In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "ABSSSI,", "including", "infections", "caused", "by", "MRSA.", "<tag3>"], "wordsA": ["In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "wordsB": ["In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "ABSSSI,", "including", "infections", "caused", "by", "MRSA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p61_s1", "idA": "886163_15_item1_p44_s1", "sentA": "We are entitled to a royalty on potential future sales by Melinta.", "sentB": "Under the terms of our agreement with Lundbeck, we may be entitled to development and regulatory milestones, royalties on potential future sales by Lundbeck and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta.", "<tag2>", "Under", "the", "terms", "of", "our", "agreement", "with", "Lundbeck,", "we", "may", "be", "entitled", "to", "development", "and", "regulatory", "milestones,", "royalties", "on", "potential", "future", "sales", "by", "Lundbeck", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta."], "wordsB": ["Under", "the", "terms", "of", "our", "agreement", "with", "Lundbeck,", "we", "may", "be", "entitled", "to", "development", "and", "regulatory", "milestones,", "royalties", "on", "potential", "future", "sales", "by", "Lundbeck", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p13_s0", "idA": "886163_15_item1_p44_s2", "sentA": "We have a development and commercialization agreement for Captisol-enabled carbamazepine-IV with Lundbeck (formerly Ovation Pharmaceuticals) for the use of Captisol in the formulation of CE carbamazepine-IV.", "sentB": "Expanded global license and supply agreements with SAGE to cover the use of Captisol in the development and commercialization of SAGE-689.", "type": 2, "words": ["<tag1>", "We", "have", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "with", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV.", "<tag2>", "Expanded", "global", "license", "and", "supply", "agreements", "with", "SAGE", "to", "cover", "the", "use", "of", "Captisol", "in", "the", "development", "and", "commercialization", "of", "SAGE-689.", "<tag3>"], "wordsA": ["We", "have", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "with", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV."], "wordsB": ["Expanded", "global", "license", "and", "supply", "agreements", "with", "SAGE", "to", "cover", "the", "use", "of", "Captisol", "in", "the", "development", "and", "commercialization", "of", "SAGE-689."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p14_s0", "idA": "886163_15_item1_p44_s2", "sentA": "We have a development and commercialization agreement for Captisol-enabled carbamazepine-IV with Lundbeck (formerly Ovation Pharmaceuticals) for the use of Captisol in the formulation of CE carbamazepine-IV.", "sentB": "License and supply agreement with Vireo Health for use of Captisol in the development and commercialization of cannabinoid-based medications.", "type": 2, "words": ["<tag1>", "We", "have", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "with", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV.", "<tag2>", "License", "and", "supply", "agreement", "with", "Vireo", "Health", "for", "use", "of", "Captisol", "in", "the", "development", "and", "commercialization", "of", "cannabinoid-based", "medications.", "<tag3>"], "wordsA": ["We", "have", "a", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "carbamazepine-IV", "with", "Lundbeck", "(formerly", "Ovation", "Pharmaceuticals)", "for", "the", "use", "of", "Captisol", "in", "the", "formulation", "of", "CE", "carbamazepine-IV."], "wordsB": ["License", "and", "supply", "agreement", "with", "Vireo", "Health", "for", "use", "of", "Captisol", "in", "the", "development", "and", "commercialization", "of", "cannabinoid-based", "medications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p61_s0", "idA": "886163_15_item1_p45_s1", "sentA": "Lundbeck is in the process of responding to a request of Chemistry, Manufacturing and Controls, or CMC, data from the FDA s Complete Response Letter received in late 2014.", "sentB": "to a request of CMC data from the FDA s Complete Response Letter received in late 2014.", "type": 2, "words": ["<tag1>", "Lundbeck", "is", "in", "the", "process", "of", "responding", "to", "a", "request", "of", "Chemistry,", "Manufacturing", "and", "Controls,", "or", "CMC,", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014.", "<tag2>", "to", "a", "request", "of", "CMC", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014.", "<tag3>"], "wordsA": ["Lundbeck", "is", "in", "the", "process", "of", "responding", "to", "a", "request", "of", "Chemistry,", "Manufacturing", "and", "Controls,", "or", "CMC,", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014."], "wordsB": ["to", "a", "request", "of", "CMC", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s12", "idA": "886163_15_item1_p46_s1", "sentA": "The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases.", "sentB": "Our partner, Zydus Cadila s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases.", "type": 2, "words": ["<tag1>", "The", "IRAK-4", "program", "is", "in", "preclinical", "development", "for", "potential", "use", "in", "certain", "cancers", "and", "autoimmune", "diseases.", "<tag2>", "Our", "partner,", "Zydus", "Cadila", "s", "Exemptia", "(adalimumab", "biosimilar)", "is", "marketed", "in", "India", "for", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["The", "IRAK-4", "program", "is", "in", "preclinical", "development", "for", "potential", "use", "in", "certain", "cancers", "and", "autoimmune", "diseases."], "wordsB": ["Our", "partner,", "Zydus", "Cadila", "s", "Exemptia", "(adalimumab", "biosimilar)", "is", "marketed", "in", "India", "for", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p66_s5", "idA": "886163_15_item1_p46_s2", "sentA": "Under the terms of the agreement, we received 125,000 shares of TG Therapeutics common stock, valued at approximately $1.2 million at date of signing, and we are eligible to receive $207.0 million in potential milestone payments.", "sentB": "Under the terms of the agreement we are eligible to receive $207 million in potential milestone payments.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "received", "125,000", "shares", "of", "TG", "Therapeutics", "common", "stock,", "valued", "at", "approximately", "$1.2", "million", "at", "date", "of", "signing,", "and", "we", "are", "eligible", "to", "receive", "$207.0", "million", "in", "potential", "milestone", "payments.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement", "we", "are", "eligible", "to", "receive", "$207", "million", "in", "potential", "milestone", "payments.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "received", "125,000", "shares", "of", "TG", "Therapeutics", "common", "stock,", "valued", "at", "approximately", "$1.2", "million", "at", "date", "of", "signing,", "and", "we", "are", "eligible", "to", "receive", "$207.0", "million", "in", "potential", "milestone", "payments."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement", "we", "are", "eligible", "to", "receive", "$207", "million", "in", "potential", "milestone", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p46_s4", "idA": "886163_15_item1_p46_s3", "sentA": "We are also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.", "sentB": "In the case of Captisol-related programs, we are also eligible to receive revenue for the sale of Captisol material supply.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors.", "<tag2>", "In", "the", "case", "of", "Captisol-related", "programs,", "we", "are", "also", "eligible", "to", "receive", "revenue", "for", "the", "sale", "of", "Captisol", "material", "supply.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors."], "wordsB": ["In", "the", "case", "of", "Captisol-related", "programs,", "we", "are", "also", "eligible", "to", "receive", "revenue", "for", "the", "sale", "of", "Captisol", "material", "supply."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p66_s3", "idA": "886163_15_item1_p46_s3", "sentA": "We are also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.", "sentB": "Our partner, TG Therapeutics is developing our IRAK-4 inhibitors.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors.", "<tag2>", "Our", "partner,", "TG", "Therapeutics", "is", "developing", "our", "IRAK-4", "inhibitors.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors."], "wordsB": ["Our", "partner,", "TG", "Therapeutics", "is", "developing", "our", "IRAK-4", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p66_s6", "idA": "886163_15_item1_p46_s3", "sentA": "We are also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.", "sentB": "We are also eligible to receive royalties on future net sales of licensed products containing patented IRAK-4 inhibitors.", "type": 2, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors.", "<tag2>", "We", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "tiered", "royalties", "of", "6%", "to", "9.5%", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors."], "wordsB": ["We", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "licensed", "products", "containing", "patented", "IRAK-4", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p77_s0", "idA": "886163_15_item1_p48_s0", "sentA": "Lipid-lowering is a major therapeutic area with growing, global unmet needs.", "sentB": "Altiratinib is a Captisol-enabled MET/TIE2/VEGF2/TRK (A,B,C) kinase inhibitor.", "type": 2, "words": ["<tag1>", "Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs.", "<tag2>", "Altiratinib", "is", "a", "Captisol-enabled", "MET/TIE2/VEGF2/TRK", "(A,B,C)", "kinase", "inhibitor.", "<tag3>"], "wordsA": ["Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs."], "wordsB": ["Altiratinib", "is", "a", "Captisol-enabled", "MET/TIE2/VEGF2/TRK", "(A,B,C)", "kinase", "inhibitor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p82_s0", "idA": "886163_15_item1_p48_s0", "sentA": "Lipid-lowering is a major therapeutic area with growing, global unmet needs.", "sentB": "Motolimod is a Captisol-enabled Toll-like Receptor 8 agonist.", "type": 2, "words": ["<tag1>", "Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs.", "<tag2>", "Motolimod", "is", "a", "Captisol-enabled", "Toll-like", "Receptor", "8", "agonist.", "<tag3>"], "wordsA": ["Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs."], "wordsB": ["Motolimod", "is", "a", "Captisol-enabled", "Toll-like", "Receptor", "8", "agonist."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p85_s0", "idA": "886163_15_item1_p48_s0", "sentA": "Lipid-lowering is a major therapeutic area with growing, global unmet needs.", "sentB": "Pevonedistat is a Captisol-enabled Nedd8-Activating Enzyme Inhibitor.", "type": 2, "words": ["<tag1>", "Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs.", "<tag2>", "Pevonedistat", "is", "a", "Captisol-enabled", "Nedd8-Activating", "Enzyme", "Inhibitor.", "<tag3>"], "wordsA": ["Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs."], "wordsB": ["Pevonedistat", "is", "a", "Captisol-enabled", "Nedd8-Activating", "Enzyme", "Inhibitor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s13", "idA": "886163_15_item1_p49_s5", "sentA": "The programs that we acquired in this transaction are based on Selexis technology platform for cell line development and scale-up to manufacturing of therapeutic proteins, and relate to pre-commercialized drugs that are currently being developed; the programs should thus require no funding or technological support from us.", "sentB": "Zydus Cadila uses the Selexis technology platform for Exemptia.", "type": 2, "words": ["<tag1>", "The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us.", "<tag2>", "Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Exemptia.", "<tag3>"], "wordsA": ["The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us."], "wordsB": ["Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Exemptia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s16", "idA": "886163_15_item1_p49_s5", "sentA": "The programs that we acquired in this transaction are based on Selexis technology platform for cell line development and scale-up to manufacturing of therapeutic proteins, and relate to pre-commercialized drugs that are currently being developed; the programs should thus require no funding or technological support from us.", "sentB": "Zydus Cadila uses the Selexis technology platform for Vivitra.", "type": 2, "words": ["<tag1>", "The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us.", "<tag2>", "Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Vivitra.", "<tag3>"], "wordsA": ["The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us."], "wordsB": ["Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Vivitra."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p72_s2", "idA": "886163_15_item1_p49_s5", "sentA": "The programs that we acquired in this transaction are based on Selexis technology platform for cell line development and scale-up to manufacturing of therapeutic proteins, and relate to pre-commercialized drugs that are currently being developed; the programs should thus require no funding or technological support from us.", "sentB": "Coherus uses the Selexis technology platform for CHS-0214.", "type": 2, "words": ["<tag1>", "The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us.", "<tag2>", "Coherus", "uses", "the", "Selexis", "technology", "platform", "for", "CHS-0214.", "<tag3>"], "wordsA": ["The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "us."], "wordsB": ["Coherus", "uses", "the", "Selexis", "technology", "platform", "for", "CHS-0214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p19_s0", "idA": "886163_15_item1_p4_s0", "sentA": "We are assembling a large portfolio of fully-funded programs through acquisition and licensing to drive future profitability.", "sentB": "Ligand acquired OMT in January 2016, conferring ownership of a large portfolio of licenses and the OmniAb platform, for $178 million in cash and stock.", "type": 2, "words": ["<tag1>", "We", "are", "assembling", "a", "large", "portfolio", "of", "fully-funded", "programs", "through", "acquisition", "and", "licensing", "to", "drive", "future", "profitability.", "<tag2>", "Ligand", "acquired", "OMT", "in", "January", "2016,", "conferring", "ownership", "of", "a", "large", "portfolio", "of", "licenses", "and", "the", "OmniAb", "platform,", "for", "$178", "million", "in", "cash", "and", "stock.", "<tag3>"], "wordsA": ["We", "are", "assembling", "a", "large", "portfolio", "of", "fully-funded", "programs", "through", "acquisition", "and", "licensing", "to", "drive", "future", "profitability."], "wordsB": ["Ligand", "acquired", "OMT", "in", "January", "2016,", "conferring", "ownership", "of", "a", "large", "portfolio", "of", "licenses", "and", "the", "OmniAb", "platform,", "for", "$178", "million", "in", "cash", "and", "stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s6", "idA": "886163_15_item1_p4_s3", "sentA": "We assemble this portfolio either by licensing out our own proprietary drug development programs, licensing our Captisol technology to partners for use with their proprietary programs or acquiring existing partnered programs from other companies.", "sentB": "We have assembled our large portfolio of fully-funded programs either by licensing our own proprietary drug development programs, licensing our platform technologies such as Captisol or OmniAb to partners for use with their proprietary programs, or acquiring existing partnered programs from other companies.", "type": 2, "words": ["<tag1>", "We", "assemble", "this", "portfolio", "either", "by", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs,", "licensing", "our", "Captisol", "technology", "to", "partners", "for", "use", "with", "their", "proprietary", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies.", "<tag2>", "We", "have", "assembled", "our", "large", "portfolio", "of", "fully-funded", "programs", "either", "by", "licensing", "our", "own", "proprietary", "drug", "development", "programs,", "licensing", "our", "platform", "technologies", "such", "as", "Captisol", "or", "OmniAb", "to", "partners", "for", "use", "with", "their", "proprietary", "programs,", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies.", "<tag3>"], "wordsA": ["We", "assemble", "this", "portfolio", "either", "by", "licensing", "out", "our", "own", "proprietary", "drug", "development", "programs,", "licensing", "our", "Captisol", "technology", "to", "partners", "for", "use", "with", "their", "proprietary", "programs", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies."], "wordsB": ["We", "have", "assembled", "our", "large", "portfolio", "of", "fully-funded", "programs", "either", "by", "licensing", "our", "own", "proprietary", "drug", "development", "programs,", "licensing", "our", "platform", "technologies", "such", "as", "Captisol", "or", "OmniAb", "to", "partners", "for", "use", "with", "their", "proprietary", "programs,", "or", "acquiring", "existing", "partnered", "programs", "from", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s8", "idA": "886163_15_item1_p4_s4", "sentA": "For our internal programs, we generally plan to advance drug candidates through early-stage drug development and/or clinical proof-of-concept.", "sentB": "For our internal programs, we generally plan to advance drug candidates through early-stage drug development or clinical proof-of-concept.", "type": 2, "words": ["<tag1>", "For", "our", "internal", "programs,", "we", "generally", "plan", "to", "advance", "drug", "candidates", "through", "early-stage", "drug", "development", "and/or", "clinical", "proof-of-concept.", "<tag2>", "For", "our", "internal", "programs,", "we", "generally", "plan", "to", "advance", "drug", "candidates", "through", "early-stage", "drug", "development", "or", "clinical", "proof-of-concept.", "<tag3>"], "wordsA": ["For", "our", "internal", "programs,", "we", "generally", "plan", "to", "advance", "drug", "candidates", "through", "early-stage", "drug", "development", "and/or", "clinical", "proof-of-concept."], "wordsB": ["For", "our", "internal", "programs,", "we", "generally", "plan", "to", "advance", "drug", "candidates", "through", "early-stage", "drug", "development", "or", "clinical", "proof-of-concept."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s13", "idA": "886163_15_item1_p4_s6", "sentA": "We believe that focusing on discovery and early-stage drug development while benefiting from our partners proven development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.", "sentB": "We believe that focusing on discovery and early-stage drug development while benefiting from our partners development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "focusing", "on", "discovery", "and", "early-stage", "drug", "development", "while", "benefiting", "from", "our", "partners", "proven", "development", "and", "commercialization", "expertise", "will", "reduce", "our", "internal", "expenses", "and", "allow", "us", "to", "have", "a", "larger", "number", "of", "drug", "candidates", "progress", "to", "later", "stages", "of", "drug", "development.", "<tag2>", "We", "believe", "that", "focusing", "on", "discovery", "and", "early-stage", "drug", "development", "while", "benefiting", "from", "our", "partners", "development", "and", "commercialization", "expertise", "will", "reduce", "our", "internal", "expenses", "and", "allow", "us", "to", "have", "a", "larger", "number", "of", "drug", "candidates", "progress", "to", "later", "stages", "of", "drug", "development.", "<tag3>"], "wordsA": ["We", "believe", "that", "focusing", "on", "discovery", "and", "early-stage", "drug", "development", "while", "benefiting", "from", "our", "partners", "proven", "development", "and", "commercialization", "expertise", "will", "reduce", "our", "internal", "expenses", "and", "allow", "us", "to", "have", "a", "larger", "number", "of", "drug", "candidates", "progress", "to", "later", "stages", "of", "drug", "development."], "wordsB": ["We", "believe", "that", "focusing", "on", "discovery", "and", "early-stage", "drug", "development", "while", "benefiting", "from", "our", "partners", "development", "and", "commercialization", "expertise", "will", "reduce", "our", "internal", "expenses", "and", "allow", "us", "to", "have", "a", "larger", "number", "of", "drug", "candidates", "progress", "to", "later", "stages", "of", "drug", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p67_s0", "idA": "886163_15_item1_p50_s0", "sentA": "In July 2013, the FDA granted orphan-drug designation for our proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.", "sentB": "The FDA granted our partner, CURx, orphan-drug designation for a proprietary Captisol-enabled Topiramate Injection formulation for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.", "type": 2, "words": ["<tag1>", "In", "July", "2013,", "the", "FDA", "granted", "orphan-drug", "designation", "for", "our", "proprietary", "Captisol-enabled", "Topiramate", "Injection", "for", "the", "treatment", "of", "partial", "onset", "or", "primary", "generalized", "tonic-clonic", "seizures", "in", "hospitalized", "epilepsy", "patients", "who", "are", "unable", "to", "take", "oral", "topiramate.", "<tag2>", "The", "FDA", "granted", "our", "partner,", "CURx,", "orphan-drug", "designation", "for", "a", "proprietary", "Captisol-enabled", "Topiramate", "Injection", "formulation", "for", "the", "treatment", "of", "partial", "onset", "or", "primary", "generalized", "tonic-clonic", "seizures", "in", "hospitalized", "epilepsy", "patients", "who", "are", "unable", "to", "take", "oral", "topiramate.", "<tag3>"], "wordsA": ["In", "July", "2013,", "the", "FDA", "granted", "orphan-drug", "designation", "for", "our", "proprietary", "Captisol-enabled", "Topiramate", "Injection", "for", "the", "treatment", "of", "partial", "onset", "or", "primary", "generalized", "tonic-clonic", "seizures", "in", "hospitalized", "epilepsy", "patients", "who", "are", "unable", "to", "take", "oral", "topiramate."], "wordsB": ["The", "FDA", "granted", "our", "partner,", "CURx,", "orphan-drug", "designation", "for", "a", "proprietary", "Captisol-enabled", "Topiramate", "Injection", "formulation", "for", "the", "treatment", "of", "partial", "onset", "or", "primary", "generalized", "tonic-clonic", "seizures", "in", "hospitalized", "epilepsy", "patients", "who", "are", "unable", "to", "take", "oral", "topiramate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p67_s1", "idA": "886163_15_item1_p50_s2", "sentA": "CURx has made certain milestone payments to us already and may be required to pay us an aggregate of an additional $19.6 million, net of amounts owed to third parties upon the achievement of specified milestones.", "sentB": "Under the terms of our agreement, CURx may be required to pay us an aggregate of $19.6 million, net of amounts owed to third parties upon the achievement of specified milestones.", "type": 2, "words": ["<tag1>", "CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones.", "<tag2>", "Under", "the", "terms", "of", "our", "agreement,", "CURx", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones.", "<tag3>"], "wordsA": ["CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones."], "wordsB": ["Under", "the", "terms", "of", "our", "agreement,", "CURx", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p10_s1", "idA": "886163_15_item1_p50_s3", "sentA": "Additionally, we are owed net tiered royalties on future sales of 6.0% to 7.5%.", "sentB": "Ligand gained rights to royalties on sales of Exemptia in the April 2013 Selexis royalty acquisition.", "type": 2, "words": ["<tag1>", "Additionally,", "we", "are", "owed", "net", "tiered", "royalties", "on", "future", "sales", "of", "6.0%", "to", "7.5%.", "<tag2>", "Ligand", "gained", "rights", "to", "royalties", "on", "sales", "of", "Exemptia", "in", "the", "April", "2013", "Selexis", "royalty", "acquisition.", "<tag3>"], "wordsA": ["Additionally,", "we", "are", "owed", "net", "tiered", "royalties", "on", "future", "sales", "of", "6.0%", "to", "7.5%."], "wordsB": ["Ligand", "gained", "rights", "to", "royalties", "on", "sales", "of", "Exemptia", "in", "the", "April", "2013", "Selexis", "royalty", "acquisition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p67_s2", "idA": "886163_15_item1_p50_s3", "sentA": "Additionally, we are owed net tiered royalties on future sales of 6.0% to 7.5%.", "sentB": "Additionally, we are owed net royalties on future sales.", "type": 2, "words": ["<tag1>", "Additionally,", "we", "are", "owed", "net", "tiered", "royalties", "on", "future", "sales", "of", "6.0%", "to", "7.5%.", "<tag2>", "Additionally,", "we", "are", "owed", "net", "royalties", "on", "future", "sales.", "<tag3>"], "wordsA": ["Additionally,", "we", "are", "owed", "net", "tiered", "royalties", "on", "future", "sales", "of", "6.0%", "to", "7.5%."], "wordsB": ["Additionally,", "we", "are", "owed", "net", "royalties", "on", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p46_s5", "idA": "886163_15_item1_p51_s0", "sentA": "In July 2013, we entered into a license agreement with Azure Biotech, Inc., or Azure.", "sentB": "We have a license agreement with Spectrum related to Evomela, which is a Captisol-enabled melphalan IV formulation.", "type": 2, "words": ["<tag1>", "In", "July", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure.", "<tag2>", "We", "have", "a", "license", "agreement", "with", "Spectrum", "related", "to", "Evomela,", "which", "is", "a", "Captisol-enabled", "melphalan", "IV", "formulation.", "<tag3>"], "wordsA": ["In", "July", "2013,", "we", "entered", "into", "a", "license", "agreement", "with", "Azure", "Biotech,", "Inc.,", "or", "Azure."], "wordsB": ["We", "have", "a", "license", "agreement", "with", "Spectrum", "related", "to", "Evomela,", "which", "is", "a", "Captisol-enabled", "melphalan", "IV", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p67_s4", "idA": "886163_15_item1_p51_s1", "sentA": "Under the agreement, we granted to Azure an exclusive worldwide license to develop and market a novel formulation of lasofoxifene.", "sentB": "Our partner Azure is developing a novel formulation of lasofoxifene.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "we", "granted", "to", "Azure", "an", "exclusive", "worldwide", "license", "to", "develop", "and", "market", "a", "novel", "formulation", "of", "lasofoxifene.", "<tag2>", "Our", "partner", "Azure", "is", "developing", "a", "novel", "formulation", "of", "lasofoxifene.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "we", "granted", "to", "Azure", "an", "exclusive", "worldwide", "license", "to", "develop", "and", "market", "a", "novel", "formulation", "of", "lasofoxifene."], "wordsB": ["Our", "partner", "Azure", "is", "developing", "a", "novel", "formulation", "of", "lasofoxifene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p84_s0", "idA": "886163_15_item1_p51_s1", "sentA": "Under the agreement, we granted to Azure an exclusive worldwide license to develop and market a novel formulation of lasofoxifene.", "sentB": "VentiRx has an exclusive worldwide collaboration with Celgene to develop VTX-2337.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "we", "granted", "to", "Azure", "an", "exclusive", "worldwide", "license", "to", "develop", "and", "market", "a", "novel", "formulation", "of", "lasofoxifene.", "<tag2>", "VentiRx", "has", "an", "exclusive", "worldwide", "collaboration", "with", "Celgene", "to", "develop", "VTX-2337.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "we", "granted", "to", "Azure", "an", "exclusive", "worldwide", "license", "to", "develop", "and", "market", "a", "novel", "formulation", "of", "lasofoxifene."], "wordsB": ["VentiRx", "has", "an", "exclusive", "worldwide", "collaboration", "with", "Celgene", "to", "develop", "VTX-2337."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p67_s5", "idA": "886163_15_item1_p51_s2", "sentA": "We are entitled to receive up to $2.6 million in potential development and regulatory milestones as well as a 5% royalty on future net sales through the later of the life of the relevant patents (currently expected to be at least until 2027) or 10 years after regulatory approval.", "sentB": "Under the terms of our agreement with Azure, we are entitled to receive up to $2.6 million in potential development and regulatory milestones as well as royalties on future net sales through the later of the life of the relevant patents (currently expected to be at least until 2027) or 10 years after regulatory approval.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "up", "to", "$2.6", "million", "in", "potential", "development", "and", "regulatory", "milestones", "as", "well", "as", "a", "5%", "royalty", "on", "future", "net", "sales", "through", "the", "later", "of", "the", "life", "of", "the", "relevant", "patents", "(currently", "expected", "to", "be", "at", "least", "until", "2027)", "or", "10", "years", "after", "regulatory", "approval.", "<tag2>", "Under", "the", "terms", "of", "our", "agreement", "with", "Azure,", "we", "are", "entitled", "to", "receive", "up", "to", "$2.6", "million", "in", "potential", "development", "and", "regulatory", "milestones", "as", "well", "as", "royalties", "on", "future", "net", "sales", "through", "the", "later", "of", "the", "life", "of", "the", "relevant", "patents", "(currently", "expected", "to", "be", "at", "least", "until", "2027)", "or", "10", "years", "after", "regulatory", "approval.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "up", "to", "$2.6", "million", "in", "potential", "development", "and", "regulatory", "milestones", "as", "well", "as", "a", "5%", "royalty", "on", "future", "net", "sales", "through", "the", "later", "of", "the", "life", "of", "the", "relevant", "patents", "(currently", "expected", "to", "be", "at", "least", "until", "2027)", "or", "10", "years", "after", "regulatory", "approval."], "wordsB": ["Under", "the", "terms", "of", "our", "agreement", "with", "Azure,", "we", "are", "entitled", "to", "receive", "up", "to", "$2.6", "million", "in", "potential", "development", "and", "regulatory", "milestones", "as", "well", "as", "royalties", "on", "future", "net", "sales", "through", "the", "later", "of", "the", "life", "of", "the", "relevant", "patents", "(currently", "expected", "to", "be", "at", "least", "until", "2027)", "or", "10", "years", "after", "regulatory", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s7", "idA": "886163_15_item1_p52_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Under the terms of the license agreement we will continue to earn milestone payments, royalties, and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Under", "the", "terms", "of", "the", "license", "agreement", "we", "will", "continue", "to", "earn", "milestone", "payments,", "royalties,", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Under", "the", "terms", "of", "the", "license", "agreement", "we", "will", "continue", "to", "earn", "milestone", "payments,", "royalties,", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p68_s2", "idA": "886163_15_item1_p53_s0", "sentA": "In July 2013, we also entered into a license agreement with Ethicor for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.", "sentB": "Our partner, Ethicor has an agreement with us for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.", "type": 2, "words": ["<tag1>", "In", "July", "2013,", "we", "also", "entered", "into", "a", "license", "agreement", "with", "Ethicor", "for", "the", "manufacture", "and", "distribution", "of", "the", "oral", "formulation", "of", "lasofoxifene", "in", "the", "European", "Economic", "Area,", "Switzerland", "and", "the", "Indian", "Subcontinent.", "<tag2>", "Our", "partner,", "Ethicor", "has", "an", "agreement", "with", "us", "for", "the", "manufacture", "and", "distribution", "of", "the", "oral", "formulation", "of", "lasofoxifene", "in", "the", "European", "Economic", "Area,", "Switzerland", "and", "the", "Indian", "Subcontinent.", "<tag3>"], "wordsA": ["In", "July", "2013,", "we", "also", "entered", "into", "a", "license", "agreement", "with", "Ethicor", "for", "the", "manufacture", "and", "distribution", "of", "the", "oral", "formulation", "of", "lasofoxifene", "in", "the", "European", "Economic", "Area,", "Switzerland", "and", "the", "Indian", "Subcontinent."], "wordsB": ["Our", "partner,", "Ethicor", "has", "an", "agreement", "with", "us", "for", "the", "manufacture", "and", "distribution", "of", "the", "oral", "formulation", "of", "lasofoxifene", "in", "the", "European", "Economic", "Area,", "Switzerland", "and", "the", "Indian", "Subcontinent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p57_s2", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the agreement, we may be entitled to up to $3.6 million of development and regulatory milestones, a royalty on potential future sales by Melinta, and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$3.6", "million", "of", "development", "and", "regulatory", "milestones,", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$3.6", "million", "of", "development", "and", "regulatory", "milestones,", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p68_s3", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and royalties on future net sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p70_s1", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the agreement, we are eligible to receive potential milestone payments, royalties on future net sales and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "eligible", "to", "receive", "potential", "milestone", "payments,", "royalties", "on", "future", "net", "sales", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "eligible", "to", "receive", "potential", "milestone", "payments,", "royalties", "on", "future", "net", "sales", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p74_s1", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the agreement, we may be entitled to development and regulatory milestones, and royalties on potential future sales by BMS and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "development", "and", "regulatory", "milestones,", "and", "royalties", "on", "potential", "future", "sales", "by", "BMS", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "development", "and", "regulatory", "milestones,", "and", "royalties", "on", "potential", "future", "sales", "by", "BMS", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p75_s1", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the agreement, we may be entitled to regulatory milestones, royalties on potential future sales by Eli Lilly and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "regulatory", "milestones,", "royalties", "on", "potential", "future", "sales", "by", "Eli", "Lilly", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "regulatory", "milestones,", "royalties", "on", "potential", "future", "sales", "by", "Eli", "Lilly", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p78_s0", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the clinical-stage agreement, we may be entitled to development milestones from Deciphera and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "may", "be", "entitled", "to", "development", "milestones", "from", "Deciphera", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "may", "be", "entitled", "to", "development", "milestones", "from", "Deciphera", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p80_s0", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the agreement, we may be entitled to development and commercial milestones, royalties on potential future sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "development", "and", "commercial", "milestones,", "royalties", "on", "potential", "future", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "development", "and", "commercial", "milestones,", "royalties", "on", "potential", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p84_s1", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the clinical-stage agreement, we have earned development milestones from VentiRx and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "have", "earned", "development", "milestones", "from", "VentiRx", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "have", "earned", "development", "milestones", "from", "VentiRx", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p85_s1", "idA": "886163_15_item1_p53_s1", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and a 25% royalty on future net sales.", "sentB": "Under the terms of the clinical-stage agreement, we may be entitled to development milestones from Millennium/Takeda and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "may", "be", "entitled", "to", "development", "milestones", "from", "Millennium/Takeda", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "a", "25%", "royalty", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "may", "be", "entitled", "to", "development", "milestones", "from", "Millennium/Takeda", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p18_s0", "idA": "886163_15_item1_p56_s0", "sentA": "In February 2015, we entered into a license agreement with Sermonix for oral lasofoxifene for the United States and additional territories.", "sentB": "License agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the U.S. and additional territories.", "type": 2, "words": ["<tag1>", "In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories.", "<tag2>", "License", "agreement", "with", "Sermonix", "Pharmaceuticals", "for", "the", "development", "and", "commercialization", "of", "oral", "lasofoxifene", "in", "the", "U.S.", "and", "additional", "territories.", "<tag3>"], "wordsA": ["In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories."], "wordsB": ["License", "agreement", "with", "Sermonix", "Pharmaceuticals", "for", "the", "development", "and", "commercialization", "of", "oral", "lasofoxifene", "in", "the", "U.S.", "and", "additional", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s5", "idA": "886163_15_item1_p56_s0", "sentA": "In February 2015, we entered into a license agreement with Sermonix for oral lasofoxifene for the United States and additional territories.", "sentB": "We have a license agreement with Baxter, related to Baxter's Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada.", "type": 2, "words": ["<tag1>", "In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories.", "<tag2>", "We", "have", "a", "license", "agreement", "with", "Baxter,", "related", "to", "Baxter's", "Nexterone,", "a", "Captisol-enabled", "formulation", "of", "amiodarone,", "which", "is", "marketed", "in", "the", "United", "States", "and", "Canada.", "<tag3>"], "wordsA": ["In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories."], "wordsB": ["We", "have", "a", "license", "agreement", "with", "Baxter,", "related", "to", "Baxter's", "Nexterone,", "a", "Captisol-enabled", "formulation", "of", "amiodarone,", "which", "is", "marketed", "in", "the", "United", "States", "and", "Canada."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p69_s1", "idA": "886163_15_item1_p56_s0", "sentA": "In February 2015, we entered into a license agreement with Sermonix for oral lasofoxifene for the United States and additional territories.", "sentB": "Our partner, Sermonix has a license for the development of oral lasofoxifene for the United States and additional territories.", "type": 2, "words": ["<tag1>", "In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories.", "<tag2>", "Our", "partner,", "Sermonix", "has", "a", "license", "for", "the", "development", "of", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories.", "<tag3>"], "wordsA": ["In", "February", "2015,", "we", "entered", "into", "a", "license", "agreement", "with", "Sermonix", "for", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories."], "wordsB": ["Our", "partner,", "Sermonix", "has", "a", "license", "for", "the", "development", "of", "oral", "lasofoxifene", "for", "the", "United", "States", "and", "additional", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p65_s0", "idA": "886163_15_item1_p56_s1", "sentA": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales.", "sentB": "Under the terms of the agreement with Viking, we may be entitled to up to $270 million of development, regulatory and commercial milestones and tiered royalties on potential future sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$270", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "and", "tiered", "royalties", "on", "potential", "future", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$270", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "and", "tiered", "royalties", "on", "potential", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p66_s2", "idA": "886163_15_item1_p56_s1", "sentA": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales.", "sentB": "Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$375", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "and", "tiered", "royalties", "on", "potential", "future", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$375", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "and", "tiered", "royalties", "on", "potential", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p69_s2", "idA": "886163_15_item1_p56_s1", "sentA": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales.", "sentB": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments and royalties on future net sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "tiered", "royalties", "of", "6%", "to", "10%", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p11_s0", "idA": "886163_15_item1_p57_s0", "sentA": "In September 2014, we expanded our global license agreement with CURx to also include the development and commercialization of our Captisol-enabled Lamotrigine program.", "sentB": "Worldwide agreement with Sanofi for SAR-125844, a Captisol-enabled program.", "type": 2, "words": ["<tag1>", "In", "September", "2014,", "we", "expanded", "our", "global", "license", "agreement", "with", "CURx", "to", "also", "include", "the", "development", "and", "commercialization", "of", "our", "Captisol-enabled", "Lamotrigine", "program.", "<tag2>", "Worldwide", "agreement", "with", "Sanofi", "for", "SAR-125844,", "a", "Captisol-enabled", "program.", "<tag3>"], "wordsA": ["In", "September", "2014,", "we", "expanded", "our", "global", "license", "agreement", "with", "CURx", "to", "also", "include", "the", "development", "and", "commercialization", "of", "our", "Captisol-enabled", "Lamotrigine", "program."], "wordsB": ["Worldwide", "agreement", "with", "Sanofi", "for", "SAR-125844,", "a", "Captisol-enabled", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p12_s0", "idA": "886163_15_item1_p57_s0", "sentA": "In September 2014, we expanded our global license agreement with CURx to also include the development and commercialization of our Captisol-enabled Lamotrigine program.", "sentB": "Clinical-stage agreement with AiCuris GmbH Co for an undisclosed anti-infective Captisol-enabled program.", "type": 2, "words": ["<tag1>", "In", "September", "2014,", "we", "expanded", "our", "global", "license", "agreement", "with", "CURx", "to", "also", "include", "the", "development", "and", "commercialization", "of", "our", "Captisol-enabled", "Lamotrigine", "program.", "<tag2>", "Clinical-stage", "agreement", "with", "AiCuris", "GmbH", "Co", "for", "an", "undisclosed", "anti-infective", "Captisol-enabled", "program.", "<tag3>"], "wordsA": ["In", "September", "2014,", "we", "expanded", "our", "global", "license", "agreement", "with", "CURx", "to", "also", "include", "the", "development", "and", "commercialization", "of", "our", "Captisol-enabled", "Lamotrigine", "program."], "wordsB": ["Clinical-stage", "agreement", "with", "AiCuris", "GmbH", "Co", "for", "an", "undisclosed", "anti-infective", "Captisol-enabled", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p112_s1", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "Information related to the operation of the SEC s public reference room may be obtained by calling the SEC at 800-SEC-0330.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "Information", "related", "to", "the", "operation", "of", "the", "SEC", "s", "public", "reference", "room", "may", "be", "obtained", "by", "calling", "the", "SEC", "at", "800-SEC-0330.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["Information", "related", "to", "the", "operation", "of", "the", "SEC", "s", "public", "reference", "room", "may", "be", "obtained", "by", "calling", "the", "SEC", "at", "800-SEC-0330."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p53_s0", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "Merck is responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "Merck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["Merck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p53_s5", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "SAGE is responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "SAGE", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["SAGE", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p55_s0", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "Retrophin is responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "Retrophin", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["Retrophin", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p58_s0", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "Melinta is responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "Melinta", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["Melinta", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p62_s0", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "Lundbeck is responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "Lundbeck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["Lundbeck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p66_s7", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "TG Therapeutics will be responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "TG", "Therapeutics", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["TG", "Therapeutics", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p70_s2", "idA": "886163_15_item1_p57_s2", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "Sanofi will be responsible for all development costs related to the program.", "type": 2, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "Sanofi", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["Sanofi", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s0", "idA": "886163_15_item1_p59_s0", "sentA": "Viking is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.", "sentB": "Overview We are a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.", "type": 2, "words": ["<tag1>", "Viking", "is", "a", "clinical-stage", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "novel,", "first-in-class", "or", "best-in-class", "therapies", "for", "metabolic", "and", "endocrine", "disorders.", "<tag2>", "Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "acquiring", "technologies", "that", "help", "pharmaceutical", "companies", "discover", "and", "develop", "medicines.", "<tag3>"], "wordsA": ["Viking", "is", "a", "clinical-stage", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "novel,", "first-in-class", "or", "best-in-class", "therapies", "for", "metabolic", "and", "endocrine", "disorders."], "wordsB": ["Overview", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "acquiring", "technologies", "that", "help", "pharmaceutical", "companies", "discover", "and", "develop", "medicines."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p23_s0", "idA": "886163_15_item1_p5_s2", "sentA": "Captisol is a well validated chemically-modified cyclodextrin that improves the solubility, stability, and pharmacokinetics of many drugs.", "sentB": "Captisol is Ligand s patented, uniquely-modified cyclodextrin that is specifically designed to maximize safety, while improving the solubility, stability and bioavailability of APIs.", "type": 2, "words": ["<tag1>", "Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs.", "<tag2>", "Captisol", "is", "Ligand", "s", "patented,", "uniquely-modified", "cyclodextrin", "that", "is", "specifically", "designed", "to", "maximize", "safety,", "while", "improving", "the", "solubility,", "stability", "and", "bioavailability", "of", "APIs.", "<tag3>"], "wordsA": ["Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs."], "wordsB": ["Captisol", "is", "Ligand", "s", "patented,", "uniquely-modified", "cyclodextrin", "that", "is", "specifically", "designed", "to", "maximize", "safety,", "while", "improving", "the", "solubility,", "stability", "and", "bioavailability", "of", "APIs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p30_s0", "idA": "886163_15_item1_p5_s2", "sentA": "Captisol is a well validated chemically-modified cyclodextrin that improves the solubility, stability, and pharmacokinetics of many drugs.", "sentB": "The SUREtechnology Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs.", "type": 2, "words": ["<tag1>", "Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs.", "<tag2>", "The", "SUREtechnology", "Platform,", "developed", "and", "owned", "by", "Selexis,", "is", "a", "novel", "technology", "that", "improves", "the", "way", "that", "cells", "are", "utilized", "in", "the", "development", "and", "manufacturing", "of", "recombinant", "proteins", "and", "drugs.", "<tag3>"], "wordsA": ["Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs."], "wordsB": ["The", "SUREtechnology", "Platform,", "developed", "and", "owned", "by", "Selexis,", "is", "a", "novel", "technology", "that", "improves", "the", "way", "that", "cells", "are", "utilized", "in", "the", "development", "and", "manufacturing", "of", "recombinant", "proteins", "and", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p32_s1", "idA": "886163_15_item1_p61_s0", "sentA": "Internal Product Development Programs As summarized in the table below, we are developing several proprietary products for a variety of indications.", "sentB": "In addition to the table below, we also have more than 40 undisclosed programs.", "type": 2, "words": ["<tag1>", "Internal", "Product", "Development", "Programs", "As", "summarized", "in", "the", "table", "below,", "we", "are", "developing", "several", "proprietary", "products", "for", "a", "variety", "of", "indications.", "<tag2>", "In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "40", "undisclosed", "programs.", "<tag3>"], "wordsA": ["Internal", "Product", "Development", "Programs", "As", "summarized", "in", "the", "table", "below,", "we", "are", "developing", "several", "proprietary", "products", "for", "a", "variety", "of", "indications."], "wordsB": ["In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "40", "undisclosed", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p87_s0", "idA": "886163_15_item1_p62_s0", "sentA": "Glucagon Receptor Antagonist Program We are currently developing small molecule glucagon receptor antagonists for the treatment of Type II diabetes mellitus.", "sentB": "We are currently developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus.", "type": 2, "words": ["<tag1>", "Glucagon", "Receptor", "Antagonist", "Program", "We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus.", "<tag2>", "We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag3>"], "wordsA": ["Glucagon", "Receptor", "Antagonist", "Program", "We", "are", "currently", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "II", "diabetes", "mellitus."], "wordsB": ["We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p88_s0", "idA": "886163_15_item1_p63_s0", "sentA": "Compounds that block the action of glucagon may reduce the hyperglycemia that is characteristic of this disease.", "sentB": "Compounds that block the action of glucagon may reduce the hyperglycemia that is characteristic of the disease.", "type": 2, "words": ["<tag1>", "Compounds", "that", "block", "the", "action", "of", "glucagon", "may", "reduce", "the", "hyperglycemia", "that", "is", "characteristic", "of", "this", "disease.", "<tag2>", "Compounds", "that", "block", "the", "action", "of", "glucagon", "may", "reduce", "the", "hyperglycemia", "that", "is", "characteristic", "of", "the", "disease.", "<tag3>"], "wordsA": ["Compounds", "that", "block", "the", "action", "of", "glucagon", "may", "reduce", "the", "hyperglycemia", "that", "is", "characteristic", "of", "this", "disease."], "wordsB": ["Compounds", "that", "block", "the", "action", "of", "glucagon", "may", "reduce", "the", "hyperglycemia", "that", "is", "characteristic", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p64_s0", "idA": "886163_15_item1_p65_s3", "sentA": "In the fourth quarter of 2014, we initiated a Phase 1b trial, and expect results in the second quarter of 2015.", "sentB": "Viking initiated a Phase 2 trial in hip fracture in 2015.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2014,", "we", "initiated", "a", "Phase", "1b", "trial,", "and", "expect", "results", "in", "the", "second", "quarter", "of", "2015.", "<tag2>", "Viking", "initiated", "a", "Phase", "2", "trial", "in", "hip", "fracture", "in", "2015.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2014,", "we", "initiated", "a", "Phase", "1b", "trial,", "and", "expect", "results", "in", "the", "second", "quarter", "of", "2015."], "wordsB": ["Viking", "initiated", "a", "Phase", "2", "trial", "in", "hip", "fracture", "in", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p27_s0", "idA": "886163_15_item1_p68_s0", "sentA": "LTP Platform (Unpartnered, Preclinical, Metabolic and Cardiovascular) Ligand scientists developed a novel pro-drug technology designed to selectively deliver a broad range of pharmaceutical agents to the liver.", "sentB": "The LTP Technology platform is a novel prodrug technology designed to selectively deliver a broad range of pharmaceutical agents to the liver.", "type": 2, "words": ["<tag1>", "LTP", "Platform", "(Unpartnered,", "Preclinical,", "Metabolic", "and", "Cardiovascular)", "Ligand", "scientists", "developed", "a", "novel", "pro-drug", "technology", "designed", "to", "selectively", "deliver", "a", "broad", "range", "of", "pharmaceutical", "agents", "to", "the", "liver.", "<tag2>", "The", "LTP", "Technology", "platform", "is", "a", "novel", "prodrug", "technology", "designed", "to", "selectively", "deliver", "a", "broad", "range", "of", "pharmaceutical", "agents", "to", "the", "liver.", "<tag3>"], "wordsA": ["LTP", "Platform", "(Unpartnered,", "Preclinical,", "Metabolic", "and", "Cardiovascular)", "Ligand", "scientists", "developed", "a", "novel", "pro-drug", "technology", "designed", "to", "selectively", "deliver", "a", "broad", "range", "of", "pharmaceutical", "agents", "to", "the", "liver."], "wordsB": ["The", "LTP", "Technology", "platform", "is", "a", "novel", "prodrug", "technology", "designed", "to", "selectively", "deliver", "a", "broad", "range", "of", "pharmaceutical", "agents", "to", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p28_s2", "idA": "886163_15_item1_p68_s1", "sentA": "The LTP technology is designed to improve the activity and/or safety of existing drugs, develop new agents to treat certain liver disease, and treat diseases caused by homeostasis imbalance of circulating molecules controlled by the liver and is especially applicable to metabolic and cardiovascular indications, among others.", "sentB": "The technology can be used to improve the safety and/or activity of existing drugs, develop new agents to treat certain liver-relayed diseases, and treat diseases caused by imbalances of circulating molecules that are controlled by the liver.", "type": 2, "words": ["<tag1>", "The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others.", "<tag2>", "The", "technology", "can", "be", "used", "to", "improve", "the", "safety", "and/or", "activity", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver-relayed", "diseases,", "and", "treat", "diseases", "caused", "by", "imbalances", "of", "circulating", "molecules", "that", "are", "controlled", "by", "the", "liver.", "<tag3>"], "wordsA": ["The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others."], "wordsB": ["The", "technology", "can", "be", "used", "to", "improve", "the", "safety", "and/or", "activity", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver-relayed", "diseases,", "and", "treat", "diseases", "caused", "by", "imbalances", "of", "circulating", "molecules", "that", "are", "controlled", "by", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p28_s3", "idA": "886163_15_item1_p68_s1", "sentA": "The LTP technology is designed to improve the activity and/or safety of existing drugs, develop new agents to treat certain liver disease, and treat diseases caused by homeostasis imbalance of circulating molecules controlled by the liver and is especially applicable to metabolic and cardiovascular indications, among others.", "sentB": "The technology is especially applicable to metabolic and cardiovascular indications, among others.", "type": 2, "words": ["<tag1>", "The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others.", "<tag2>", "The", "technology", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others.", "<tag3>"], "wordsA": ["The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others."], "wordsB": ["The", "technology", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p70_s0", "idA": "886163_15_item1_p6_s4", "sentA": "Our goal and strategy is to partner our programs early in the development and regulatory life-cycle.", "sentB": "SAR-125844 (Sanofi) Our partner, Sanofi licensed Captisol for use in the development of Captisol-enabled SAR-125844, a potent MET kinase inhibitor.", "type": 2, "words": ["<tag1>", "Our", "goal", "and", "strategy", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle.", "<tag2>", "SAR-125844", "(Sanofi)", "Our", "partner,", "Sanofi", "licensed", "Captisol", "for", "use", "in", "the", "development", "of", "Captisol-enabled", "SAR-125844,", "a", "potent", "MET", "kinase", "inhibitor.", "<tag3>"], "wordsA": ["Our", "goal", "and", "strategy", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle."], "wordsB": ["SAR-125844", "(Sanofi)", "Our", "partner,", "Sanofi", "licensed", "Captisol", "for", "use", "in", "the", "development", "of", "Captisol-enabled", "SAR-125844,", "a", "potent", "MET", "kinase", "inhibitor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p32_s0", "idA": "886163_15_item1_p6_s5", "sentA": "Our Asset Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 100 of which are fully-funded by our partners.", "sentB": "Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 140 of which are fully-funded by our partners.", "type": 2, "words": ["<tag1>", "Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "100", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag2>", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "140", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag3>"], "wordsA": ["Our", "Asset", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "100", "of", "which", "are", "fully-funded", "by", "our", "partners."], "wordsB": ["Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "140", "of", "which", "are", "fully-funded", "by", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p33_s0", "idA": "886163_15_item1_p6_s8", "sentA": "We have multiple partnered programs in our portfolio that have products that are already being commercialized.", "sentB": "Commercial Programs We have multiple programs under license with other companies that have products that are already being commercialized.", "type": 2, "words": ["<tag1>", "We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "have", "products", "that", "are", "already", "being", "commercialized.", "<tag2>", "Commercial", "Programs", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized.", "<tag3>"], "wordsA": ["We", "have", "multiple", "partnered", "programs", "in", "our", "portfolio", "that", "have", "products", "that", "are", "already", "being", "commercialized."], "wordsB": ["Commercial", "Programs", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p33_s1", "idA": "886163_15_item1_p6_s9", "sentA": "These programs represent key components of our current portfolio of revenue-generating assets and potential for near-term growth in royalty and other revenue.", "sentB": "The following programs represent components of our current portfolio of revenue-generating assets and potential for near-term growth in royalty and other revenue.", "type": 2, "words": ["<tag1>", "These", "programs", "represent", "key", "components", "of", "our", "current", "portfolio", "of", "revenue-generating", "assets", "and", "potential", "for", "near-term", "growth", "in", "royalty", "and", "other", "revenue.", "<tag2>", "The", "following", "programs", "represent", "components", "of", "our", "current", "portfolio", "of", "revenue-generating", "assets", "and", "potential", "for", "near-term", "growth", "in", "royalty", "and", "other", "revenue.", "<tag3>"], "wordsA": ["These", "programs", "represent", "key", "components", "of", "our", "current", "portfolio", "of", "revenue-generating", "assets", "and", "potential", "for", "near-term", "growth", "in", "royalty", "and", "other", "revenue."], "wordsB": ["The", "following", "programs", "represent", "components", "of", "our", "current", "portfolio", "of", "revenue-generating", "assets", "and", "potential", "for", "near-term", "growth", "in", "royalty", "and", "other", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p90_s0", "idA": "886163_15_item1_p75_s3", "sentA": "Manufacturing We currently have no manufacturing facilities and rely on third parties, including our collaborative partners, for clinical production.", "sentB": "Manufacturing We currently have no manufacturing facilities and rely on a third party, Hovione, for Captisol production.", "type": 2, "words": ["<tag1>", "Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production.", "<tag2>", "Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "a", "third", "party,", "Hovione,", "for", "Captisol", "production.", "<tag3>"], "wordsA": ["Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "third", "parties,", "including", "our", "collaborative", "partners,", "for", "clinical", "production."], "wordsB": ["Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "a", "third", "party,", "Hovione,", "for", "Captisol", "production."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p90_s1", "idA": "886163_15_item1_p76_s0", "sentA": "We currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a major global supplier with over 50 years of experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates.", "sentB": "Hovione is a global supplier with over 50 years of experience in the development and manufacture of APIs and Drug Product Intermediates.", "type": 2, "words": ["<tag1>", "We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "global", "supplier", "with", "over", "50", "years", "of", "experience", "in", "the", "development", "and", "compliant", "manufacture", "of", "Active", "Pharmaceutical", "Ingredients", "and", "Drug", "Product", "Intermediates.", "<tag2>", "Hovione", "is", "a", "global", "supplier", "with", "over", "50", "years", "of", "experience", "in", "the", "development", "and", "manufacture", "of", "APIs", "and", "Drug", "Product", "Intermediates.", "<tag3>"], "wordsA": ["We", "currently", "outsource", "the", "production", "of", "Captisol", "to", "Hovione", "FarmaCiencia", "SA,", "or", "Hovione,", "a", "major", "global", "supplier", "with", "over", "50", "years", "of", "experience", "in", "the", "development", "and", "compliant", "manufacture", "of", "Active", "Pharmaceutical", "Ingredients", "and", "Drug", "Product", "Intermediates."], "wordsB": ["Hovione", "is", "a", "global", "supplier", "with", "over", "50", "years", "of", "experience", "in", "the", "development", "and", "manufacture", "of", "APIs", "and", "Drug", "Product", "Intermediates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p90_s2", "idA": "886163_15_item1_p77_s0", "sentA": "Hovione operates FDA-inspected sites in the US, Ireland and Portugal.", "sentB": "Hovione operates FDA-inspected sites in the United States, Macau, Ireland and Portugal.", "type": 2, "words": ["<tag1>", "Hovione", "operates", "FDA-inspected", "sites", "in", "the", "US,", "Ireland", "and", "Portugal.", "<tag2>", "Hovione", "operates", "FDA-inspected", "sites", "in", "the", "United", "States,", "Macau,", "Ireland", "and", "Portugal.", "<tag3>"], "wordsA": ["Hovione", "operates", "FDA-inspected", "sites", "in", "the", "US,", "Ireland", "and", "Portugal."], "wordsB": ["Hovione", "operates", "FDA-inspected", "sites", "in", "the", "United", "States,", "Macau,", "Ireland", "and", "Portugal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p90_s3", "idA": "886163_15_item1_p77_s1", "sentA": "Manufacturing operations for Captisol are currently performed in both of Hovione's Portugal and Ireland sites.", "sentB": "Manufacturing operations for Captisol are currently performed in both of Hovione's Portugal and Ireland sites with distribution operations also performed from Hovione's Portugal and Ireland sites.", "type": 2, "words": ["<tag1>", "Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites.", "<tag2>", "Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites", "with", "distribution", "operations", "also", "performed", "from", "Hovione's", "Portugal", "and", "Ireland", "sites.", "<tag3>"], "wordsA": ["Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites."], "wordsB": ["Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites", "with", "distribution", "operations", "also", "performed", "from", "Hovione's", "Portugal", "and", "Ireland", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p90_s7", "idA": "886163_15_item1_p78_s3", "sentA": "In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event or if the unit price of Captisol exceeds a set figure, we may obtain Captisol from an additional third party.", "sentB": "In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event or if the unit price of Captisol exceeds a set figure, we may obtain Captisol from a third party.", "type": 2, "words": ["<tag1>", "In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "an", "additional", "third", "party.", "<tag2>", "In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party.", "<tag3>"], "wordsA": ["In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "an", "additional", "third", "party."], "wordsB": ["In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p111_s3", "idA": "886163_15_item1_p78_s5", "sentA": "In addition, we also distribute and store bulk quantities of Captisol ourselves, utilizing subterranean warehouse space located in Lenexa, Kansas.", "sentB": "In addition, we have previously filed registration statements and other documents with the SEC.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "also", "distribute", "and", "store", "bulk", "quantities", "of", "Captisol", "ourselves,", "utilizing", "subterranean", "warehouse", "space", "located", "in", "Lenexa,", "Kansas.", "<tag2>", "In", "addition,", "we", "have", "previously", "filed", "registration", "statements", "and", "other", "documents", "with", "the", "SEC.", "<tag3>"], "wordsA": ["In", "addition,", "we", "also", "distribute", "and", "store", "bulk", "quantities", "of", "Captisol", "ourselves,", "utilizing", "subterranean", "warehouse", "space", "located", "in", "Lenexa,", "Kansas."], "wordsB": ["In", "addition,", "we", "have", "previously", "filed", "registration", "statements", "and", "other", "documents", "with", "the", "SEC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p90_s8", "idA": "886163_15_item1_p78_s6", "sentA": "The initial term of the agreement with Hovione expires in December 2019.", "sentB": "The current term of the agreement with Hovione is through December 2019.", "type": 2, "words": ["<tag1>", "The", "initial", "term", "of", "the", "agreement", "with", "Hovione", "expires", "in", "December", "2019.", "<tag2>", "The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019.", "<tag3>"], "wordsA": ["The", "initial", "term", "of", "the", "agreement", "with", "Hovione", "expires", "in", "December", "2019."], "wordsB": ["The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p34_s0", "idA": "886163_15_item1_p7_s0", "sentA": "Promacta (GSK) GSK s Promacta (eltrombopag) is an oral medicine that increases the number of platelets in the blood.", "sentB": "We are party to a license agreement with Novartis related to Promacta, which is an oral medicine that increases the number of platelets in the blood.", "type": 2, "words": ["<tag1>", "Promacta", "(GSK)", "GSK", "s", "Promacta", "(eltrombopag)", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood.", "<tag2>", "We", "are", "party", "to", "a", "license", "agreement", "with", "Novartis", "related", "to", "Promacta,", "which", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood.", "<tag3>"], "wordsA": ["Promacta", "(GSK)", "GSK", "s", "Promacta", "(eltrombopag)", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood."], "wordsB": ["We", "are", "party", "to", "a", "license", "agreement", "with", "Novartis", "related", "to", "Promacta,", "which", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p25_s0", "idA": "886163_15_item1_p80_s0", "sentA": "Some of the drugs we and our collaborative partners are developing may compete with existing therapies or other drugs in development by other companies.", "sentB": "Captisol-enabled drugs are marketed in more than 60 countries, and over 45 partners have Captisol-enabled drugs in development.", "type": 2, "words": ["<tag1>", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag2>", "Captisol-enabled", "drugs", "are", "marketed", "in", "more", "than", "60", "countries,", "and", "over", "45", "partners", "have", "Captisol-enabled", "drugs", "in", "development.", "<tag3>"], "wordsA": ["Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "wordsB": ["Captisol-enabled", "drugs", "are", "marketed", "in", "more", "than", "60", "countries,", "and", "over", "45", "partners", "have", "Captisol-enabled", "drugs", "in", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p92_s0", "idA": "886163_15_item1_p80_s0", "sentA": "Some of the drugs we and our collaborative partners are developing may compete with existing therapies or other drugs in development by other companies.", "sentB": "Competition Some of the drugs we and our licensees are developing may compete with existing therapies or other drugs in development by other companies.", "type": 2, "words": ["<tag1>", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag2>", "Competition", "Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag3>"], "wordsA": ["Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "wordsB": ["Competition", "Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s2", "idA": "886163_15_item1_p81_s0", "sentA": "A number of pharmaceutical and biotechnology companies are pursuing intracellular receptor-related approaches to drug discovery and development.", "sentB": "We currently have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with us are currently in various stages of commercialization and development.", "type": 2, "words": ["<tag1>", "A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development.", "<tag2>", "We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "85", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "140", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development.", "<tag3>"], "wordsA": ["A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development."], "wordsB": ["We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "85", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "140", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p26_s2", "idA": "886163_15_item1_p81_s0", "sentA": "A number of pharmaceutical and biotechnology companies are pursuing intracellular receptor-related approaches to drug discovery and development.", "sentB": "The OmniAb platforms consist of genetically-engineered transgenic rodents that produce a broadly diversified repertoire of antibodies and enable novel fully-human antibody drug discovery and development by our OmniAb partners.", "type": 2, "words": ["<tag1>", "A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development.", "<tag2>", "The", "OmniAb", "platforms", "consist", "of", "genetically-engineered", "transgenic", "rodents", "that", "produce", "a", "broadly", "diversified", "repertoire", "of", "antibodies", "and", "enable", "novel", "fully-human", "antibody", "drug", "discovery", "and", "development", "by", "our", "OmniAb", "partners.", "<tag3>"], "wordsA": ["A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development."], "wordsB": ["The", "OmniAb", "platforms", "consist", "of", "genetically-engineered", "transgenic", "rodents", "that", "produce", "a", "broadly", "diversified", "repertoire", "of", "antibodies", "and", "enable", "novel", "fully-human", "antibody", "drug", "discovery", "and", "development", "by", "our", "OmniAb", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p26_s4", "idA": "886163_15_item1_p81_s0", "sentA": "A number of pharmaceutical and biotechnology companies are pursuing intracellular receptor-related approaches to drug discovery and development.", "sentB": "Currently, more than 18 partners are utilizing OmniAb animals in their drug discovery and development efforts.", "type": 2, "words": ["<tag1>", "A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development.", "<tag2>", "Currently,", "more", "than", "18", "partners", "are", "utilizing", "OmniAb", "animals", "in", "their", "drug", "discovery", "and", "development", "efforts.", "<tag3>"], "wordsA": ["A", "number", "of", "pharmaceutical", "and", "biotechnology", "companies", "are", "pursuing", "intracellular", "receptor-related", "approaches", "to", "drug", "discovery", "and", "development."], "wordsB": ["Currently,", "more", "than", "18", "partners", "are", "utilizing", "OmniAb", "animals", "in", "their", "drug", "discovery", "and", "development", "efforts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p92_s2", "idA": "886163_15_item1_p81_s2", "sentA": "Many of our existing or potential competitors, particularly large pharmaceutical companies, have greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market products.", "sentB": "Existing or potential competitors to our licensee s products, particularly large pharmaceutical companies, may have greater financial, technical and human resources than our licensees.", "type": 2, "words": ["<tag1>", "Many", "of", "our", "existing", "or", "potential", "competitors,", "particularly", "large", "pharmaceutical", "companies,", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products.", "<tag2>", "Existing", "or", "potential", "competitors", "to", "our", "licensee", "s", "products,", "particularly", "large", "pharmaceutical", "companies,", "may", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "our", "licensees.", "<tag3>"], "wordsA": ["Many", "of", "our", "existing", "or", "potential", "competitors,", "particularly", "large", "pharmaceutical", "companies,", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products."], "wordsB": ["Existing", "or", "potential", "competitors", "to", "our", "licensee", "s", "products,", "particularly", "large", "pharmaceutical", "companies,", "may", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "our", "licensees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p92_s3", "idA": "886163_15_item1_p81_s2", "sentA": "Many of our existing or potential competitors, particularly large pharmaceutical companies, have greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market products.", "sentB": "Accordingly, these competitors may be better equipped to develop, manufacture and market products.", "type": 2, "words": ["<tag1>", "Many", "of", "our", "existing", "or", "potential", "competitors,", "particularly", "large", "pharmaceutical", "companies,", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products.", "<tag2>", "Accordingly,", "these", "competitors", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products.", "<tag3>"], "wordsA": ["Many", "of", "our", "existing", "or", "potential", "competitors,", "particularly", "large", "pharmaceutical", "companies,", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products."], "wordsB": ["Accordingly,", "these", "competitors", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p92_s7", "idA": "886163_15_item1_p81_s4", "sentA": "Our competitive position also depends upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales.", "sentB": "Our competitive position also depends upon our ability to obtain patent protection or otherwise develop proprietary products or processes.", "type": 2, "words": ["<tag1>", "Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "attract", "and", "retain", "qualified", "personnel,", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes,", "and", "secure", "sufficient", "capital", "resources", "for", "the", "often", "substantial", "period", "between", "technological", "conception", "and", "commercial", "sales.", "<tag2>", "Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes.", "<tag3>"], "wordsA": ["Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "attract", "and", "retain", "qualified", "personnel,", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes,", "and", "secure", "sufficient", "capital", "resources", "for", "the", "often", "substantial", "period", "between", "technological", "conception", "and", "commercial", "sales."], "wordsB": ["Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p93_s0", "idA": "886163_15_item1_p82_s0", "sentA": "The manufacturing and marketing of our products, our ongoing research and development activities and products being developed by our collaborative partners are subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.", "sentB": "The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries.", "type": 2, "words": ["<tag1>", "The", "manufacturing", "and", "marketing", "of", "our", "products,", "our", "ongoing", "research", "and", "development", "activities", "and", "products", "being", "developed", "by", "our", "collaborative", "partners", "are", "subject", "to", "regulation", "for", "safety", "and", "efficacy", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries.", "<tag2>", "The", "research", "and", "development,", "manufacturing", "and", "marketing", "of", "pharmaceutical", "products", "are", "subject", "to", "regulation", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries.", "<tag3>"], "wordsA": ["The", "manufacturing", "and", "marketing", "of", "our", "products,", "our", "ongoing", "research", "and", "development", "activities", "and", "products", "being", "developed", "by", "our", "collaborative", "partners", "are", "subject", "to", "regulation", "for", "safety", "and", "efficacy", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries."], "wordsB": ["The", "research", "and", "development,", "manufacturing", "and", "marketing", "of", "pharmaceutical", "products", "are", "subject", "to", "regulation", "by", "numerous", "governmental", "authorities", "in", "the", "United", "States", "and", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p107_s0", "idA": "886163_15_item1_p83_s0", "sentA": "In the United States, pharmaceuticals are subject to rigorous regulation by federal and various state authorities, including the FDA.", "sentB": "OMT has received patent protection in 27 countries, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in the table below) and has 19 patent applications pending worldwide.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag2>", "OMT", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "wordsB": ["OMT", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p24_s0", "idA": "886163_15_item1_p83_s0", "sentA": "In the United States, pharmaceuticals are subject to rigorous regulation by federal and various state authorities, including the FDA.", "sentB": "Ligand maintains both Type IV and Type V DMFs with the FDA.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag2>", "Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "wordsB": ["Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p93_s1", "idA": "886163_15_item1_p83_s0", "sentA": "In the United States, pharmaceuticals are subject to rigorous regulation by federal and various state authorities, including the FDA.", "sentB": "We and our partners, depending on specific activities performed, are subject to these regulations.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag2>", "We", "and", "our", "partners,", "depending", "on", "specific", "activities", "performed,", "are", "subject", "to", "these", "regulations.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "wordsB": ["We", "and", "our", "partners,", "depending", "on", "specific", "activities", "performed,", "are", "subject", "to", "these", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p94_s0", "idA": "886163_15_item1_p83_s0", "sentA": "In the United States, pharmaceuticals are subject to rigorous regulation by federal and various state authorities, including the FDA.", "sentB": "In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag2>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "regulation", "by", "both", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "wordsB": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "regulation", "by", "both", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p94_s1", "idA": "886163_15_item1_p84_s0", "sentA": "Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products.", "sentB": "The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical products and there are often comparable regulations that apply at the state level.", "type": 2, "words": ["<tag1>", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products.", "<tag2>", "The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "pharmaceutical", "products", "and", "there", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level.", "<tag3>"], "wordsA": ["Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products."], "wordsB": ["The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "pharmaceutical", "products", "and", "there", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p95_s0", "idA": "886163_15_item1_p85_s5", "sentA": "For both currently marketed and future products, failure to comply with applicable regulatory requirements after obtaining regulatory approval can, among other things, result in the suspension of regulatory approval, as well as possible civil and criminal sanctions.", "sentB": "For both currently marketed and products in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions.", "type": 2, "words": ["<tag1>", "For", "both", "currently", "marketed", "and", "future", "products,", "failure", "to", "comply", "with", "applicable", "regulatory", "requirements", "after", "obtaining", "regulatory", "approval", "can,", "among", "other", "things,", "result", "in", "the", "suspension", "of", "regulatory", "approval,", "as", "well", "as", "possible", "civil", "and", "criminal", "sanctions.", "<tag2>", "For", "both", "currently", "marketed", "and", "products", "in", "development,", "failure", "to", "comply", "with", "applicable", "regulatory", "requirements", "can,", "among", "other", "things,", "result", "in", "delays,", "the", "suspension", "of", "regulatory", "approvals,", "as", "well", "as", "possible", "civil", "and", "criminal", "sanctions.", "<tag3>"], "wordsA": ["For", "both", "currently", "marketed", "and", "future", "products,", "failure", "to", "comply", "with", "applicable", "regulatory", "requirements", "after", "obtaining", "regulatory", "approval", "can,", "among", "other", "things,", "result", "in", "the", "suspension", "of", "regulatory", "approval,", "as", "well", "as", "possible", "civil", "and", "criminal", "sanctions."], "wordsB": ["For", "both", "currently", "marketed", "and", "products", "in", "development,", "failure", "to", "comply", "with", "applicable", "regulatory", "requirements", "can,", "among", "other", "things,", "result", "in", "delays,", "the", "suspension", "of", "regulatory", "approvals,", "as", "well", "as", "possible", "civil", "and", "criminal", "sanctions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p95_s1", "idA": "886163_15_item1_p85_s6", "sentA": "In addition, changes in existing regulations could have a material adverse effect on us.", "sentB": "In addition, changes in existing regulations could have a material adverse effect on us or our partners.", "type": 2, "words": ["<tag1>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us.", "<tag2>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us", "or", "our", "partners.", "<tag3>"], "wordsA": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us."], "wordsB": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us", "or", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p98_s1", "idA": "886163_15_item1_p88_s1", "sentA": "Promacta Patents covering Promacta are owned by GSK.", "sentB": "Promacta Patents covering Promacta are owned by Novartis.", "type": 2, "words": ["<tag1>", "Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK.", "<tag2>", "Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "Novartis.", "<tag3>"], "wordsA": ["Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK."], "wordsB": ["Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "Novartis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p98_s3", "idA": "886163_15_item1_p88_s1", "sentA": "Promacta Patents covering Promacta are owned by GSK.", "sentB": "Six months of additional exclusivity has been granted due to pediatric studies conducted by GSK.", "type": 2, "words": ["<tag1>", "Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK.", "<tag2>", "Six", "months", "of", "additional", "exclusivity", "has", "been", "granted", "due", "to", "pediatric", "studies", "conducted", "by", "GSK.", "<tag3>"], "wordsA": ["Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK."], "wordsB": ["Six", "months", "of", "additional", "exclusivity", "has", "been", "granted", "due", "to", "pediatric", "studies", "conducted", "by", "GSK."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p109_s2", "idA": "886163_15_item1_p90_s1", "sentA": "The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2027.", "sentB": "Patents resulting from these applications, if granted, would have a latest expiration date in 2036.", "type": 2, "words": ["<tag1>", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027.", "<tag2>", "Patents", "resulting", "from", "these", "applications,", "if", "granted,", "would", "have", "a", "latest", "expiration", "date", "in", "2036.", "<tag3>"], "wordsA": ["The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027."], "wordsB": ["Patents", "resulting", "from", "these", "applications,", "if", "granted,", "would", "have", "a", "latest", "expiration", "date", "in", "2036."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p98_s2", "idA": "886163_15_item1_p90_s1", "sentA": "The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2027.", "sentB": "The United States patent listed in the FDA s Orange Book relating to Promacta with the latest expiration date is not expected to expire until 2027.", "type": 2, "words": ["<tag1>", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027.", "<tag2>", "The", "United", "States", "patent", "listed", "in", "the", "FDA", "s", "Orange", "Book", "relating", "to", "Promacta", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027.", "<tag3>"], "wordsA": ["The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027."], "wordsB": ["The", "United", "States", "patent", "listed", "in", "the", "FDA", "s", "Orange", "Book", "relating", "to", "Promacta", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p107_s1", "idA": "886163_15_item1_p90_s2", "sentA": "Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033.", "sentB": "The patents and applications owned by OMT are expected to expire between 2028 and 2033 and partners are able to use the OMT patented technology to generate novel antibodies, which may be entitled to additional patent protection.", "type": 2, "words": ["<tag1>", "Patents", "and", "applications", "owned", "by", "Ligand", "relating", "to", "the", "Captisol", "component", "of", "Kyprolis", "are", "not", "expected", "to", "expire", "until", "2033.", "<tag2>", "The", "patents", "and", "applications", "owned", "by", "OMT", "are", "expected", "to", "expire", "between", "2028", "and", "2033", "and", "partners", "are", "able", "to", "use", "the", "OMT", "patented", "technology", "to", "generate", "novel", "antibodies,", "which", "may", "be", "entitled", "to", "additional", "patent", "protection.", "<tag3>"], "wordsA": ["Patents", "and", "applications", "owned", "by", "Ligand", "relating", "to", "the", "Captisol", "component", "of", "Kyprolis", "are", "not", "expected", "to", "expire", "until", "2033."], "wordsB": ["The", "patents", "and", "applications", "owned", "by", "OMT", "are", "expected", "to", "expire", "between", "2028", "and", "2033", "and", "partners", "are", "able", "to", "use", "the", "OMT", "patented", "technology", "to", "generate", "novel", "antibodies,", "which", "may", "be", "entitled", "to", "additional", "patent", "protection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p102_s0", "idA": "886163_15_item1_p90_s3", "sentA": "The type of patent protection ( e.g ., composition of matter or use) for each patent listed in the Orange Book and the expiration dates for each patent listed in the Orange Book are provided in the following table.", "sentB": "expiration dates for each patent listed in the Orange Book are provided in the following table.", "type": 2, "words": ["<tag1>", "The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "dates", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table.", "<tag2>", "expiration", "dates", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "dates", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table."], "wordsB": ["expiration", "dates", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s5", "idA": "886163_15_item1_p92_s0", "sentA": "Captisol Patents and pending patent applications covering Captisol are owned by Ligand.", "sentB": "We have over 500 issued patents worldwide, and over 300 currently pending patent applications.", "type": 2, "words": ["<tag1>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand.", "<tag2>", "We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "300", "currently", "pending", "patent", "applications.", "<tag3>"], "wordsA": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand."], "wordsB": ["We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "300", "currently", "pending", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p109_s0", "idA": "886163_15_item1_p92_s0", "sentA": "Captisol Patents and pending patent applications covering Captisol are owned by Ligand.", "sentB": "LTP Technology Patent applications related to our LTP Technology include three families owned by Ligand and one owned by Omthera.", "type": 2, "words": ["<tag1>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand.", "<tag2>", "LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "three", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera.", "<tag3>"], "wordsA": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand."], "wordsB": ["LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "three", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p109_s3", "idA": "886163_15_item1_p92_s0", "sentA": "Captisol Patents and pending patent applications covering Captisol are owned by Ligand.", "sentB": "Patents and pending patent applications covering LGD-6972 are owned by Ligand.", "type": 2, "words": ["<tag1>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand.", "<tag2>", "Patents", "and", "pending", "patent", "applications", "covering", "LGD-6972", "are", "owned", "by", "Ligand.", "<tag3>"], "wordsA": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand."], "wordsB": ["Patents", "and", "pending", "patent", "applications", "covering", "LGD-6972", "are", "owned", "by", "Ligand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p22_s1", "idA": "886163_15_item1_p92_s1", "sentA": "Other patents and pending patent applications covering methods of making Captisol are owned by Ligand or by Pfizer.", "sentB": "Platform technologies or individual drugs discovered by Ligand are related to a broad estate of intellectual property that includes over 500 issued patents and over 300 pending patent applications.", "type": 2, "words": ["<tag1>", "Other", "patents", "and", "pending", "patent", "applications", "covering", "methods", "of", "making", "Captisol", "are", "owned", "by", "Ligand", "or", "by", "Pfizer.", "<tag2>", "Platform", "technologies", "or", "individual", "drugs", "discovered", "by", "Ligand", "are", "related", "to", "a", "broad", "estate", "of", "intellectual", "property", "that", "includes", "over", "500", "issued", "patents", "and", "over", "300", "pending", "patent", "applications.", "<tag3>"], "wordsA": ["Other", "patents", "and", "pending", "patent", "applications", "covering", "methods", "of", "making", "Captisol", "are", "owned", "by", "Ligand", "or", "by", "Pfizer."], "wordsB": ["Platform", "technologies", "or", "individual", "drugs", "discovered", "by", "Ligand", "are", "related", "to", "a", "broad", "estate", "of", "intellectual", "property", "that", "includes", "over", "500", "issued", "patents", "and", "over", "300", "pending", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p109_s1", "idA": "886163_15_item1_p92_s2", "sentA": "The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 ( see, e.g., WO 2013/130666 (contains composition of matter and use claims; filed Feb. 27, 2013)).", "sentB": "Each of these patent families include claims directed to composition of matter and use.", "type": 2, "words": ["<tag1>", "The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013)).", "<tag2>", "Each", "of", "these", "patent", "families", "include", "claims", "directed", "to", "composition", "of", "matter", "and", "use.", "<tag3>"], "wordsA": ["The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013))."], "wordsB": ["Each", "of", "these", "patent", "families", "include", "claims", "directed", "to", "composition", "of", "matter", "and", "use."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p109_s4", "idA": "886163_15_item1_p92_s2", "sentA": "The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 ( see, e.g., WO 2013/130666 (contains composition of matter and use claims; filed Feb. 27, 2013)).", "sentB": "Patents covering LGD-6972, if issued, with the latest expiration date would not be set to expire until 2035 ( see, e.g., WO 2015/191900 (contains composition of matter and use claims; filed June 11, 2015)).", "type": 2, "words": ["<tag1>", "The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013)).", "<tag2>", "Patents", "covering", "LGD-6972,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2035", "(", "see,", "e.g.,", "WO", "2015/191900", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "June", "11,", "2015)).", "<tag3>"], "wordsA": ["The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013))."], "wordsB": ["Patents", "covering", "LGD-6972,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2035", "(", "see,", "e.g.,", "WO", "2015/191900", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "June", "11,", "2015))."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p109_s5", "idA": "886163_15_item1_p92_s4", "sentA": "The type of patent protection ( e.g ., composition of matter or use) and the expiration dates for several issued patents covering Captisol are provided in the following table.", "sentB": "The type of patent protection ( e.g ., composition of matter or use) and the expiration dates for several issued patents covering LGD-6972 are provided in the following table.", "type": 2, "words": ["<tag1>", "The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "and", "the", "expiration", "dates", "for", "several", "issued", "patents", "covering", "Captisol", "are", "provided", "in", "the", "following", "table.", "<tag2>", "The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "and", "the", "expiration", "dates", "for", "several", "issued", "patents", "covering", "LGD-6972", "are", "provided", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "and", "the", "expiration", "dates", "for", "several", "issued", "patents", "covering", "Captisol", "are", "provided", "in", "the", "following", "table."], "wordsB": ["The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "and", "the", "expiration", "dates", "for", "several", "issued", "patents", "covering", "LGD-6972", "are", "provided", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p111_s0", "idA": "886163_15_item1_p96_s0", "sentA": "Human Resources As of February 1, 2015, we had 19 full-time employees, of whom six are involved directly in scientific research and development activities.", "sentB": "Human Resources As of February 1, 2016, we had 21 full-time employees, of whom seven are involved directly in scientific research and development activities.", "type": 2, "words": ["<tag1>", "Human", "Resources", "As", "of", "February", "1,", "2015,", "we", "had", "19", "full-time", "employees,", "of", "whom", "six", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag2>", "Human", "Resources", "As", "of", "February", "1,", "2016,", "we", "had", "21", "full-time", "employees,", "of", "whom", "seven", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["Human", "Resources", "As", "of", "February", "1,", "2015,", "we", "had", "19", "full-time", "employees,", "of", "whom", "six", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "wordsB": ["Human", "Resources", "As", "of", "February", "1,", "2016,", "we", "had", "21", "full-time", "employees,", "of", "whom", "seven", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p37_s0", "idA": "886163_15_item1_p9_s0", "sentA": "Promacta was first approved by the U.S. Food and Drug Administration, or FDA, in 2008 under an accelerated approval for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "Promacta is currently approved for three indications: (1) the treatment of thrombocytopenia in patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy, (2) Hepatitis-C associated thrombocytopenia and (3) SAA.", "type": 2, "words": ["<tag1>", "Promacta", "was", "first", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "in", "2008", "under", "an", "accelerated", "approval", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA.", "<tag3>"], "wordsA": ["Promacta", "was", "first", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "in", "2008", "under", "an", "accelerated", "approval", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p86_s1", "idA": "886163_15_item1_p9_s3", "sentA": "The timing of the approvals for Promacta in the US and Europe is summarized in the table below.", "sentB": "Royalty tier references for specific rates notated in the table are for up to and including the dollar amount referenced.", "type": 2, "words": ["<tag1>", "The", "timing", "of", "the", "approvals", "for", "Promacta", "in", "the", "US", "and", "Europe", "is", "summarized", "in", "the", "table", "below.", "<tag2>", "Royalty", "tier", "references", "for", "specific", "rates", "notated", "in", "the", "table", "are", "for", "up", "to", "and", "including", "the", "dollar", "amount", "referenced.", "<tag3>"], "wordsA": ["The", "timing", "of", "the", "approvals", "for", "Promacta", "in", "the", "US", "and", "Europe", "is", "summarized", "in", "the", "table", "below."], "wordsB": ["Royalty", "tier", "references", "for", "specific", "rates", "notated", "in", "the", "table", "are", "for", "up", "to", "and", "including", "the", "dollar", "amount", "referenced."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p86_s2", "idA": "886163_15_item1_p9_s3", "sentA": "The timing of the approvals for Promacta in the US and Europe is summarized in the table below.", "sentB": "Higher tiers are only applicable for the dollar ranges specified in the table.", "type": 2, "words": ["<tag1>", "The", "timing", "of", "the", "approvals", "for", "Promacta", "in", "the", "US", "and", "Europe", "is", "summarized", "in", "the", "table", "below.", "<tag2>", "Higher", "tiers", "are", "only", "applicable", "for", "the", "dollar", "ranges", "specified", "in", "the", "table.", "<tag3>"], "wordsA": ["The", "timing", "of", "the", "approvals", "for", "Promacta", "in", "the", "US", "and", "Europe", "is", "summarized", "in", "the", "table", "below."], "wordsB": ["Higher", "tiers", "are", "only", "applicable", "for", "the", "dollar", "ranges", "specified", "in", "the", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p0_s2", "idA": "886163_16_item1_p0_s2", "sentA": "We currently have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with us are currently in various stages of commercialization and development.", "sentB": "We currently have partnerships and license agreements with over 95 pharmaceutical and biotechnology companies, and over 160 different programs under license with us are currently in various stages of commercialization and development.", "type": 2, "words": ["<tag1>", "We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "85", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "140", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development.", "<tag2>", "We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "95", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "160", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development.", "<tag3>"], "wordsA": ["We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "85", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "140", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development."], "wordsB": ["We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "95", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "160", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p0_s5", "idA": "886163_16_item1_p0_s5", "sentA": "We have over 500 issued patents worldwide, and over 300 currently pending patent applications.", "sentB": "We have over 500 issued patents worldwide, and over 200 currently pending patent applications.", "type": 2, "words": ["<tag1>", "We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "300", "currently", "pending", "patent", "applications.", "<tag2>", "We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "200", "currently", "pending", "patent", "applications.", "<tag3>"], "wordsA": ["We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "300", "currently", "pending", "patent", "applications."], "wordsB": ["We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "200", "currently", "pending", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p58_s0", "idA": "886163_16_item1_p0_s7", "sentA": "Fully-funded programs are those for which our partners pay all of the development and commercialization costs.", "sentB": "CorMatrix s products are medical devices that are designed to permit the development and regrowth of human tissue.", "type": 2, "words": ["<tag1>", "Fully-funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs.", "<tag2>", "CorMatrix", "s", "products", "are", "medical", "devices", "that", "are", "designed", "to", "permit", "the", "development", "and", "regrowth", "of", "human", "tissue.", "<tag3>"], "wordsA": ["Fully-funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs."], "wordsB": ["CorMatrix", "s", "products", "are", "medical", "devices", "that", "are", "designed", "to", "permit", "the", "development", "and", "regrowth", "of", "human", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p120_s0", "idA": "886163_16_item1_p101_s0", "sentA": "Kyprolis Patents protecting Kyprolis include those owned by Amgen and those owned by Ligand.", "sentB": "Kyprolis Patents protecting Kyprolis include those owned by Amgen and those owned by us.", "type": 2, "words": ["<tag1>", "Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Amgen", "and", "those", "owned", "by", "Ligand.", "<tag2>", "Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Amgen", "and", "those", "owned", "by", "us.", "<tag3>"], "wordsA": ["Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Amgen", "and", "those", "owned", "by", "Ligand."], "wordsB": ["Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Amgen", "and", "those", "owned", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p120_s1", "idA": "886163_16_item1_p101_s1", "sentA": "The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2027.", "sentB": "The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2029.", "type": 2, "words": ["<tag1>", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027.", "<tag2>", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2029.", "<tag3>"], "wordsA": ["The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027."], "wordsB": ["The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2029."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p122_s0", "idA": "886163_16_item1_p104_s0", "sentA": "Captisol Patents and pending patent applications covering Captisol are owned by Ligand.", "sentB": "Captisol Patents and pending patent applications covering Captisol are owned by us.", "type": 2, "words": ["<tag1>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand.", "<tag2>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "us.", "<tag3>"], "wordsA": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand."], "wordsB": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p122_s2", "idA": "886163_16_item1_p104_s2", "sentA": "The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 ( see, e.g., WO 2013/130666 (contains composition of matter and use claims; filed Feb. 27, 2013)).", "sentB": "The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 ( see, e.g., U.S. Patent No. 9,493,582 (expires Feb. 27, 2033)).", "type": 2, "words": ["<tag1>", "The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013)).", "<tag2>", "The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "U.S.", "Patent", "No.", "9,493,582", "(expires", "Feb.", "27,", "2033)).", "<tag3>"], "wordsA": ["The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013))."], "wordsB": ["The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "U.S.", "Patent", "No.", "9,493,582", "(expires", "Feb.", "27,", "2033))."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p122_s3", "idA": "886163_16_item1_p104_s3", "sentA": "Ligand also owns several patents and pending patent applications covering drug products containing Captisol as a component.", "sentB": "We also own several patents and pending patent applications covering drug products containing Captisol as a component.", "type": 2, "words": ["<tag1>", "Ligand", "also", "owns", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component.", "<tag2>", "We", "also", "own", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component.", "<tag3>"], "wordsA": ["Ligand", "also", "owns", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component."], "wordsB": ["We", "also", "own", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p124_s0", "idA": "886163_16_item1_p107_s0", "sentA": "OMT has received patent protection in 27 countries, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in the table below) and has 19 patent applications pending worldwide.", "sentB": "Ligand has received patent protection in 27 countries, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in the table below) and has 19 patent applications pending worldwide.", "type": 2, "words": ["<tag1>", "OMT", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide.", "<tag2>", "Ligand", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide.", "<tag3>"], "wordsA": ["OMT", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide."], "wordsB": ["Ligand", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p124_s1", "idA": "886163_16_item1_p107_s1", "sentA": "The patents and applications owned by OMT are expected to expire between 2028 and 2033 and partners are able to use the OMT patented technology to generate novel antibodies, which may be entitled to additional patent protection.", "sentB": "The patents and applications owned by Ligand are expected to expire between 2028 and 2033 and partners are able to use the OMT patented technology to generate novel antibodies, which may be entitled to additional patent protection.", "type": 2, "words": ["<tag1>", "The", "patents", "and", "applications", "owned", "by", "OMT", "are", "expected", "to", "expire", "between", "2028", "and", "2033", "and", "partners", "are", "able", "to", "use", "the", "OMT", "patented", "technology", "to", "generate", "novel", "antibodies,", "which", "may", "be", "entitled", "to", "additional", "patent", "protection.", "<tag2>", "The", "patents", "and", "applications", "owned", "by", "Ligand", "are", "expected", "to", "expire", "between", "2028", "and", "2033", "and", "partners", "are", "able", "to", "use", "the", "OMT", "patented", "technology", "to", "generate", "novel", "antibodies,", "which", "may", "be", "entitled", "to", "additional", "patent", "protection.", "<tag3>"], "wordsA": ["The", "patents", "and", "applications", "owned", "by", "OMT", "are", "expected", "to", "expire", "between", "2028", "and", "2033", "and", "partners", "are", "able", "to", "use", "the", "OMT", "patented", "technology", "to", "generate", "novel", "antibodies,", "which", "may", "be", "entitled", "to", "additional", "patent", "protection."], "wordsB": ["The", "patents", "and", "applications", "owned", "by", "Ligand", "are", "expected", "to", "expire", "between", "2028", "and", "2033", "and", "partners", "are", "able", "to", "use", "the", "OMT", "patented", "technology", "to", "generate", "novel", "antibodies,", "which", "may", "be", "entitled", "to", "additional", "patent", "protection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p126_s0", "idA": "886163_16_item1_p109_s0", "sentA": "LTP Technology Patent applications related to our LTP Technology include three families owned by Ligand and one owned by Omthera.", "sentB": "LTP Technology Patent applications related to our LTP Technology include two families owned by Ligand and one owned by Omthera.", "type": 2, "words": ["<tag1>", "LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "three", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera.", "<tag2>", "LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "two", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera.", "<tag3>"], "wordsA": ["LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "three", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera."], "wordsB": ["LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "two", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p128_s0", "idA": "886163_16_item1_p111_s0", "sentA": "Human Resources As of February 1, 2016, we had 21 full-time employees, of whom seven are involved directly in scientific research and development activities.", "sentB": "Human Resources As of February 6, 2016, we had 22 full-time employees, of whom eight are involved directly in scientific research and development activities.", "type": 2, "words": ["<tag1>", "Human", "Resources", "As", "of", "February", "1,", "2016,", "we", "had", "21", "full-time", "employees,", "of", "whom", "seven", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag2>", "Human", "Resources", "As", "of", "February", "6,", "2016,", "we", "had", "22", "full-time", "employees,", "of", "whom", "eight", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["Human", "Resources", "As", "of", "February", "1,", "2016,", "we", "had", "21", "full-time", "employees,", "of", "whom", "seven", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "wordsB": ["Human", "Resources", "As", "of", "February", "6,", "2016,", "we", "had", "22", "full-time", "employees,", "of", "whom", "eight", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p129_s4", "idA": "886163_16_item1_p112_s0", "sentA": "the information contained in our website and in the SEC s website is not intended to be a part of this filing.", "sentB": "These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC s website is not intended to be a part of this filing.", "type": 2, "words": ["<tag1>", "the", "information", "contained", "in", "our", "website", "and", "in", "the", "SEC", "s", "website", "is", "not", "intended", "to", "be", "a", "part", "of", "this", "filing.", "<tag2>", "These", "website", "addresses", "are", "not", "intended", "to", "function", "as", "hyperlinks,", "and", "the", "information", "contained", "in", "our", "website", "and", "in", "the", "SEC", "s", "website", "is", "not", "intended", "to", "be", "a", "part", "of", "this", "filing.", "<tag3>"], "wordsA": ["the", "information", "contained", "in", "our", "website", "and", "in", "the", "SEC", "s", "website", "is", "not", "intended", "to", "be", "a", "part", "of", "this", "filing."], "wordsB": ["These", "website", "addresses", "are", "not", "intended", "to", "function", "as", "hyperlinks,", "and", "the", "information", "contained", "in", "our", "website", "and", "in", "the", "SEC", "s", "website", "is", "not", "intended", "to", "be", "a", "part", "of", "this", "filing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p25_s0", "idA": "886163_16_item1_p14_s0", "sentA": "License and supply agreement with Vireo Health for use of Captisol in the development and commercialization of cannabinoid-based medications.", "sentB": "Global license and supply agreement with Novartis for the development and commercialization of a CE-oral liquid formulation of trametinib.", "type": 2, "words": ["<tag1>", "License", "and", "supply", "agreement", "with", "Vireo", "Health", "for", "use", "of", "Captisol", "in", "the", "development", "and", "commercialization", "of", "cannabinoid-based", "medications.", "<tag2>", "Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib.", "<tag3>"], "wordsA": ["License", "and", "supply", "agreement", "with", "Vireo", "Health", "for", "use", "of", "Captisol", "in", "the", "development", "and", "commercialization", "of", "cannabinoid-based", "medications."], "wordsB": ["Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p20_s0", "idA": "886163_16_item1_p16_s0", "sentA": "Commercial supply agreement with Gilead Sciences to supply Captisol for use in developing a Captisol-enabled program directed against Ebola virus disease.", "sentB": "Worldwide platform license agreement with Gilead Sciences for access to the OmniAb technology.", "type": 2, "words": ["<tag1>", "Commercial", "supply", "agreement", "with", "Gilead", "Sciences", "to", "supply", "Captisol", "for", "use", "in", "developing", "a", "Captisol-enabled", "program", "directed", "against", "Ebola", "virus", "disease.", "<tag2>", "Worldwide", "platform", "license", "agreement", "with", "Gilead", "Sciences", "for", "access", "to", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Commercial", "supply", "agreement", "with", "Gilead", "Sciences", "to", "supply", "Captisol", "for", "use", "in", "developing", "a", "Captisol-enabled", "program", "directed", "against", "Ebola", "virus", "disease."], "wordsB": ["Worldwide", "platform", "license", "agreement", "with", "Gilead", "Sciences", "for", "access", "to", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p106_s2", "idA": "886163_16_item1_p21_s0", "sentA": "Ligand announced results from a Phase 1b trial of LGD-6972 that demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.", "sentB": "We announced results in 2016 from two Phase I clinical trials which demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.", "type": 2, "words": ["<tag1>", "Ligand", "announced", "results", "from", "a", "Phase", "1b", "trial", "of", "LGD-6972", "that", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus.", "<tag2>", "We", "announced", "results", "in", "2016", "from", "two", "Phase", "I", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus.", "<tag3>"], "wordsA": ["Ligand", "announced", "results", "from", "a", "Phase", "1b", "trial", "of", "LGD-6972", "that", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus."], "wordsB": ["We", "announced", "results", "in", "2016", "from", "two", "Phase", "I", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p26_s0", "idA": "886163_16_item1_p21_s0", "sentA": "Ligand announced results from a Phase 1b trial of LGD-6972 that demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.", "sentB": "The single- and multiple-dose Phase 1a and Phase 1b studies demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.", "type": 2, "words": ["<tag1>", "Ligand", "announced", "results", "from", "a", "Phase", "1b", "trial", "of", "LGD-6972", "that", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus.", "<tag2>", "The", "single-", "and", "multiple-dose", "Phase", "1a", "and", "Phase", "1b", "studies", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus.", "<tag3>"], "wordsA": ["Ligand", "announced", "results", "from", "a", "Phase", "1b", "trial", "of", "LGD-6972", "that", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus."], "wordsB": ["The", "single-", "and", "multiple-dose", "Phase", "1a", "and", "Phase", "1b", "studies", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p5_s0", "idA": "886163_16_item1_p24_s0", "sentA": "Ligand maintains both Type IV and Type V DMFs with the FDA.", "sentB": "On December 6, 2016, Sage announced its expedited development plan for Sage-547 for treatment of postpartum depression, from a breakthrough therapy meeting with the FDA.", "type": 2, "words": ["<tag1>", "Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA.", "<tag2>", "On", "December", "6,", "2016,", "Sage", "announced", "its", "expedited", "development", "plan", "for", "Sage-547", "for", "treatment", "of", "postpartum", "depression,", "from", "a", "breakthrough", "therapy", "meeting", "with", "the", "FDA.", "<tag3>"], "wordsA": ["Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA."], "wordsB": ["On", "December", "6,", "2016,", "Sage", "announced", "its", "expedited", "development", "plan", "for", "Sage-547", "for", "treatment", "of", "postpartum", "depression,", "from", "a", "breakthrough", "therapy", "meeting", "with", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p34_s2", "idA": "886163_16_item1_p28_s2", "sentA": "The technology can be used to improve the safety and/or activity of existing drugs, develop new agents to treat certain liver-relayed diseases, and treat diseases caused by imbalances of circulating molecules that are controlled by the liver.", "sentB": "The technology can be used to improve the safety and/or activity of existing drugs, develop new agents to treat certain liver-related diseases, and treat diseases caused by imbalances of circulating molecules that are controlled by the liver.", "type": 2, "words": ["<tag1>", "The", "technology", "can", "be", "used", "to", "improve", "the", "safety", "and/or", "activity", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver-relayed", "diseases,", "and", "treat", "diseases", "caused", "by", "imbalances", "of", "circulating", "molecules", "that", "are", "controlled", "by", "the", "liver.", "<tag2>", "The", "technology", "can", "be", "used", "to", "improve", "the", "safety", "and/or", "activity", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver-related", "diseases,", "and", "treat", "diseases", "caused", "by", "imbalances", "of", "circulating", "molecules", "that", "are", "controlled", "by", "the", "liver.", "<tag3>"], "wordsA": ["The", "technology", "can", "be", "used", "to", "improve", "the", "safety", "and/or", "activity", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver-relayed", "diseases,", "and", "treat", "diseases", "caused", "by", "imbalances", "of", "circulating", "molecules", "that", "are", "controlled", "by", "the", "liver."], "wordsB": ["The", "technology", "can", "be", "used", "to", "improve", "the", "safety", "and/or", "activity", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver-related", "diseases,", "and", "treat", "diseases", "caused", "by", "imbalances", "of", "circulating", "molecules", "that", "are", "controlled", "by", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p35_s0", "idA": "886163_16_item1_p29_s0", "sentA": "Ligand acquired economic rights to over 30 SUREtechnology Platform programs from Selexis in two separate transactions in 2013 and 2015, granting Ligand rights to downstream economics on novel biologics and biosimilars programs.", "sentB": "Ligand acquired economic rights to over 30 SURE technology Platform programs from Selexis in two separate transactions in 2013 and 2015, granting Ligand rights to downstream economics on novel biologics and biosimilars programs.", "type": 2, "words": ["<tag1>", "Ligand", "acquired", "economic", "rights", "to", "over", "30", "SUREtechnology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs.", "<tag2>", "Ligand", "acquired", "economic", "rights", "to", "over", "30", "SURE", "technology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs.", "<tag3>"], "wordsA": ["Ligand", "acquired", "economic", "rights", "to", "over", "30", "SUREtechnology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs."], "wordsB": ["Ligand", "acquired", "economic", "rights", "to", "over", "30", "SURE", "technology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p37_s0", "idA": "886163_16_item1_p29_s0", "sentA": "Ligand acquired economic rights to over 30 SUREtechnology Platform programs from Selexis in two separate transactions in 2013 and 2015, granting Ligand rights to downstream economics on novel biologics and biosimilars programs.", "sentB": "Ligand acquired economic rights to multiple programs owned by CorMatrix in May 2016, granting Ligand rights to receive a portion of revenue (synthetic royalty) from CorMatrix s existing marketed products and rights to future synthetic royalties from potential future products.", "type": 2, "words": ["<tag1>", "Ligand", "acquired", "economic", "rights", "to", "over", "30", "SUREtechnology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs.", "<tag2>", "Ligand", "acquired", "economic", "rights", "to", "multiple", "programs", "owned", "by", "CorMatrix", "in", "May", "2016,", "granting", "Ligand", "rights", "to", "receive", "a", "portion", "of", "revenue", "(synthetic", "royalty)", "from", "CorMatrix", "s", "existing", "marketed", "products", "and", "rights", "to", "future", "synthetic", "royalties", "from", "potential", "future", "products.", "<tag3>"], "wordsA": ["Ligand", "acquired", "economic", "rights", "to", "over", "30", "SUREtechnology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs."], "wordsB": ["Ligand", "acquired", "economic", "rights", "to", "multiple", "programs", "owned", "by", "CorMatrix", "in", "May", "2016,", "granting", "Ligand", "rights", "to", "receive", "a", "portion", "of", "revenue", "(synthetic", "royalty)", "from", "CorMatrix", "s", "existing", "marketed", "products", "and", "rights", "to", "future", "synthetic", "royalties", "from", "potential", "future", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p36_s0", "idA": "886163_16_item1_p30_s0", "sentA": "The SUREtechnology Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs.", "sentB": "The SURE technology Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs.", "type": 2, "words": ["<tag1>", "The", "SUREtechnology", "Platform,", "developed", "and", "owned", "by", "Selexis,", "is", "a", "novel", "technology", "that", "improves", "the", "way", "that", "cells", "are", "utilized", "in", "the", "development", "and", "manufacturing", "of", "recombinant", "proteins", "and", "drugs.", "<tag2>", "The", "SURE", "technology", "Platform,", "developed", "and", "owned", "by", "Selexis,", "is", "a", "novel", "technology", "that", "improves", "the", "way", "that", "cells", "are", "utilized", "in", "the", "development", "and", "manufacturing", "of", "recombinant", "proteins", "and", "drugs.", "<tag3>"], "wordsA": ["The", "SUREtechnology", "Platform,", "developed", "and", "owned", "by", "Selexis,", "is", "a", "novel", "technology", "that", "improves", "the", "way", "that", "cells", "are", "utilized", "in", "the", "development", "and", "manufacturing", "of", "recombinant", "proteins", "and", "drugs."], "wordsB": ["The", "SURE", "technology", "Platform,", "developed", "and", "owned", "by", "Selexis,", "is", "a", "novel", "technology", "that", "improves", "the", "way", "that", "cells", "are", "utilized", "in", "the", "development", "and", "manufacturing", "of", "recombinant", "proteins", "and", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p38_s1", "idA": "886163_16_item1_p31_s1", "sentA": "In addition to these 70 Companies, we have over 15 additional undisclosed partners and licensees, mostly biotech companies.", "sentB": "In addition to these 83 Companies, we have over 12 additional undisclosed partners and licensees, mostly biotech companies.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "these", "70", "Companies,", "we", "have", "over", "15", "additional", "undisclosed", "partners", "and", "licensees,", "mostly", "biotech", "companies.", "<tag2>", "In", "addition", "to", "these", "83", "Companies,", "we", "have", "over", "12", "additional", "undisclosed", "partners", "and", "licensees,", "mostly", "biotech", "companies.", "<tag3>"], "wordsA": ["In", "addition", "to", "these", "70", "Companies,", "we", "have", "over", "15", "additional", "undisclosed", "partners", "and", "licensees,", "mostly", "biotech", "companies."], "wordsB": ["In", "addition", "to", "these", "83", "Companies,", "we", "have", "over", "12", "additional", "undisclosed", "partners", "and", "licensees,", "mostly", "biotech", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p39_s0", "idA": "886163_16_item1_p32_s0", "sentA": "Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 140 of which are fully-funded by our partners.", "sentB": "Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 155 of which are fully-funded by our partners.", "type": 2, "words": ["<tag1>", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "140", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag2>", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "155", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag3>"], "wordsA": ["Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "140", "of", "which", "are", "fully-funded", "by", "our", "partners."], "wordsB": ["Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "155", "of", "which", "are", "fully-funded", "by", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p40_s0", "idA": "886163_16_item1_p33_s0", "sentA": "Commercial Programs We have multiple programs under license with other companies that have products that are already being commercialized.", "sentB": "We have multiple programs under license with other companies that have products that are already being commercialized.", "type": 2, "words": ["<tag1>", "Commercial", "Programs", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized.", "<tag2>", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized.", "<tag3>"], "wordsA": ["Commercial", "Programs", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized."], "wordsB": ["We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p44_s0", "idA": "886163_16_item1_p37_s0", "sentA": "Promacta is currently approved for three indications: (1) the treatment of thrombocytopenia in patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy, (2) Hepatitis-C associated thrombocytopenia and (3) SAA.", "sentB": "Promacta is currently approved for three indications: (1) the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy, (2) Hepatitis-C associated thrombocytopenia and (3) SAA.", "type": 2, "words": ["<tag1>", "Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA.", "<tag2>", "Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "adult", "and", "pediatric", "patients", "1", "year", "and", "older", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA.", "<tag3>"], "wordsA": ["Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA."], "wordsB": ["Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "adult", "and", "pediatric", "patients", "1", "year", "and", "older", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p21_s0", "idA": "886163_16_item1_p37_s2", "sentA": "Promacta is known as Revolade in the EU and other non-US markets.", "sentB": "Newly formed Nucorion, co-founded by Ligand, licensed three programs utilizing Ligand s LTP technology and intends to pursue a pipeline of LTP-based programs for China and other markets.", "type": 2, "words": ["<tag1>", "Promacta", "is", "known", "as", "Revolade", "in", "the", "EU", "and", "other", "non-US", "markets.", "<tag2>", "Newly", "formed", "Nucorion,", "co-founded", "by", "Ligand,", "licensed", "three", "programs", "utilizing", "Ligand", "s", "LTP", "technology", "and", "intends", "to", "pursue", "a", "pipeline", "of", "LTP-based", "programs", "for", "China", "and", "other", "markets.", "<tag3>"], "wordsA": ["Promacta", "is", "known", "as", "Revolade", "in", "the", "EU", "and", "other", "non-US", "markets."], "wordsB": ["Newly", "formed", "Nucorion,", "co-founded", "by", "Ligand,", "licensed", "three", "programs", "utilizing", "Ligand", "s", "LTP", "technology", "and", "intends", "to", "pursue", "a", "pipeline", "of", "LTP-based", "programs", "for", "China", "and", "other", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p47_s0", "idA": "886163_16_item1_p38_s0", "sentA": "As of February 2016, there are 42 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.", "sentB": "As of January 2017, there are 23 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.", "type": 2, "words": ["<tag1>", "As", "of", "February", "2016,", "there", "are", "42", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website.", "<tag2>", "As", "of", "January", "2017,", "there", "are", "23", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website.", "<tag3>"], "wordsA": ["As", "of", "February", "2016,", "there", "are", "42", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website."], "wordsB": ["As", "of", "January", "2017,", "there", "are", "23", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p48_s0", "idA": "886163_16_item1_p39_s0", "sentA": "We are entitled to receive royalties related to Promacta during the life of the relevant patents or at a reduced rate for ten years from the first commercial sale, whichever is longer, on a country-by-country basis.", "sentB": "We are entitled to receive royalties related to Promacta during the life of the relevant patents or following patent expiry, at a reduced rate for ten years from the first commercial sale, whichever is longer, on a country-by-country basis.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "during", "the", "life", "of", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis.", "<tag2>", "We", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "during", "the", "life", "of", "the", "relevant", "patents", "or", "following", "patent", "expiry,", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "during", "the", "life", "of", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis."], "wordsB": ["We", "are", "entitled", "to", "receive", "royalties", "related", "to", "Promacta", "during", "the", "life", "of", "the", "relevant", "patents", "or", "following", "patent", "expiry,", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p12_s0", "idA": "886163_16_item1_p3_s0", "sentA": "Melinta announced positive results from a Phase 3 study to evaluate delafloxacin against vancomycin + aztreonam for the treatment of patients with ABSSSI.", "sentB": "On October 24, 2016, Melinta Therapeutics announced it submitted a NDA for approval of IV Baxdela for the treatment of patients with acute bacterial skin and skin structure infections.", "type": 2, "words": ["<tag1>", "Melinta", "announced", "positive", "results", "from", "a", "Phase", "3", "study", "to", "evaluate", "delafloxacin", "against", "vancomycin", "+", "aztreonam", "for", "the", "treatment", "of", "patients", "with", "ABSSSI.", "<tag2>", "On", "October", "24,", "2016,", "Melinta", "Therapeutics", "announced", "it", "submitted", "a", "NDA", "for", "approval", "of", "IV", "Baxdela", "for", "the", "treatment", "of", "patients", "with", "acute", "bacterial", "skin", "and", "skin", "structure", "infections.", "<tag3>"], "wordsA": ["Melinta", "announced", "positive", "results", "from", "a", "Phase", "3", "study", "to", "evaluate", "delafloxacin", "against", "vancomycin", "+", "aztreonam", "for", "the", "treatment", "of", "patients", "with", "ABSSSI."], "wordsB": ["On", "October", "24,", "2016,", "Melinta", "Therapeutics", "announced", "it", "submitted", "a", "NDA", "for", "approval", "of", "IV", "Baxdela", "for", "the", "treatment", "of", "patients", "with", "acute", "bacterial", "skin", "and", "skin", "structure", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p10_s0", "idA": "886163_16_item1_p42_s0", "sentA": "As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.", "sentB": "On July 4, 2016, Ono Pharmaceuticals, holder of Kyprolis marketing rights in Japan, announced approval in Japan for treatment of patients with relapsed or refractory multiple myeloma.", "type": 2, "words": ["<tag1>", "As", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy.", "<tag2>", "On", "July", "4,", "2016,", "Ono", "Pharmaceuticals,", "holder", "of", "Kyprolis", "marketing", "rights", "in", "Japan,", "announced", "approval", "in", "Japan", "for", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma.", "<tag3>"], "wordsA": ["As", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy."], "wordsB": ["On", "July", "4,", "2016,", "Ono", "Pharmaceuticals,", "holder", "of", "Kyprolis", "marketing", "rights", "in", "Japan,", "announced", "approval", "in", "Japan", "for", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p52_s0", "idA": "886163_16_item1_p43_s1", "sentA": "Kyprolis was initially approved in the U.S. in 2012, and Amgen continues to invest significantly in Kyprolis to further expand its label and geography.", "sentB": "Kyprolis is also approved in multiple countries and Amgen continues to invest significantly in Kyprolis to further expand its label and geography.", "type": 2, "words": ["<tag1>", "Kyprolis", "was", "initially", "approved", "in", "the", "U.S.", "in", "2012,", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography.", "<tag2>", "Kyprolis", "is", "also", "approved", "in", "multiple", "countries", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography.", "<tag3>"], "wordsA": ["Kyprolis", "was", "initially", "approved", "in", "the", "U.S.", "in", "2012,", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography."], "wordsB": ["Kyprolis", "is", "also", "approved", "in", "multiple", "countries", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p59_s3", "idA": "886163_16_item1_p45_s0", "sentA": "Duavee or Duavive (bazedoxifene/conjugated estrogens) and Viviant/Conbriza (Pfizer) Pfizer is marketing bazedoxifene under the brand names Viviant and Conbriza in various territories for the treatment of postmenopausal osteoporosis.", "sentB": "Pfizer is marketing the combination treatment under the brand names Duavee and Duavive in various territories.", "type": 2, "words": ["<tag1>", "Duavee", "or", "Duavive", "(bazedoxifene/conjugated", "estrogens)", "and", "Viviant/Conbriza", "(Pfizer)", "Pfizer", "is", "marketing", "bazedoxifene", "under", "the", "brand", "names", "Viviant", "and", "Conbriza", "in", "various", "territories", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "Pfizer", "is", "marketing", "the", "combination", "treatment", "under", "the", "brand", "names", "Duavee", "and", "Duavive", "in", "various", "territories.", "<tag3>"], "wordsA": ["Duavee", "or", "Duavive", "(bazedoxifene/conjugated", "estrogens)", "and", "Viviant/Conbriza", "(Pfizer)", "Pfizer", "is", "marketing", "bazedoxifene", "under", "the", "brand", "names", "Viviant", "and", "Conbriza", "in", "various", "territories", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["Pfizer", "is", "marketing", "the", "combination", "treatment", "under", "the", "brand", "names", "Duavee", "and", "Duavive", "in", "various", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p65_s0", "idA": "886163_16_item1_p45_s12", "sentA": "Our partner, Zydus Cadila s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases.", "sentB": "Exemptia (Zydus Cadila) Zydus Cadila s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Zydus", "Cadila", "s", "Exemptia", "(adalimumab", "biosimilar)", "is", "marketed", "in", "India", "for", "autoimmune", "diseases.", "<tag2>", "Exemptia", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Exemptia", "(adalimumab", "biosimilar)", "is", "marketed", "in", "India", "for", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Our", "partner,", "Zydus", "Cadila", "s", "Exemptia", "(adalimumab", "biosimilar)", "is", "marketed", "in", "India", "for", "autoimmune", "diseases."], "wordsB": ["Exemptia", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Exemptia", "(adalimumab", "biosimilar)", "is", "marketed", "in", "India", "for", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p66_s0", "idA": "886163_16_item1_p45_s15", "sentA": "Our partner, Zydus Cadila s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer.", "sentB": "Vivitra (Zydus Cadila) Zydus Cadila s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer.", "<tag2>", "Vivitra", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer.", "<tag3>"], "wordsA": ["Our", "partner,", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer."], "wordsB": ["Vivitra", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p59_s2", "idA": "886163_16_item1_p45_s2", "sentA": "Pfizer has combined bazedoxifene with the active ingredient in Premarin to create Duavee, a combination therapy for the treatment of post-menopausal symptoms in women.", "sentB": "Pfizer has combined bazedoxifene with the active ingredient in Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women.", "type": 2, "words": ["<tag1>", "Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee,", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag2>", "Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag3>"], "wordsA": ["Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee,", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "wordsB": ["Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p65_s2", "idA": "886163_16_item1_p46_s0", "sentA": "We are entitled to earn royalties on sales by Zydus Cadila through at least 2026.", "sentB": "We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026.", "<tag2>", "We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "for", "ten", "years", "following", "the", "first", "commercial", "sale.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026."], "wordsB": ["We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "for", "ten", "years", "following", "the", "first", "commercial", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p67_s0", "idA": "886163_16_item1_p46_s0", "sentA": "We are entitled to earn royalties on sales by Zydus Cadila through at least 2026.", "sentB": "We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026.", "<tag2>", "We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "for", "ten", "years", "following", "the", "first", "commercial", "sale.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "through", "at", "least", "2026."], "wordsB": ["We", "are", "entitled", "to", "earn", "royalties", "on", "sales", "by", "Zydus", "Cadila", "for", "ten", "years", "following", "the", "first", "commercial", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p53_s0", "idA": "886163_16_item1_p46_s5", "sentA": "We have a license agreement with Spectrum related to Evomela, which is a Captisol-enabled melphalan IV formulation.", "sentB": "Ligand supplies Captisol to Spectrum for use with Evomela, which is a Captisol-enabled melphalan IV formulation.", "type": 2, "words": ["<tag1>", "We", "have", "a", "license", "agreement", "with", "Spectrum", "related", "to", "Evomela,", "which", "is", "a", "Captisol-enabled", "melphalan", "IV", "formulation.", "<tag2>", "Ligand", "supplies", "Captisol", "to", "Spectrum", "for", "use", "with", "Evomela,", "which", "is", "a", "Captisol-enabled", "melphalan", "IV", "formulation.", "<tag3>"], "wordsA": ["We", "have", "a", "license", "agreement", "with", "Spectrum", "related", "to", "Evomela,", "which", "is", "a", "Captisol-enabled", "melphalan", "IV", "formulation."], "wordsB": ["Ligand", "supplies", "Captisol", "to", "Spectrum", "for", "use", "with", "Evomela,", "which", "is", "a", "Captisol-enabled", "melphalan", "IV", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p3_s0", "idA": "886163_16_item1_p47_s2", "sentA": "Spectrum has indicated that next FDA action date is May 2016.", "sentB": "Ligand acquired the economic rights to multiple medical device programs owned by CorMatrix in May 2016.", "type": 2, "words": ["<tag1>", "Spectrum", "has", "indicated", "that", "next", "FDA", "action", "date", "is", "May", "2016.", "<tag2>", "Ligand", "acquired", "the", "economic", "rights", "to", "multiple", "medical", "device", "programs", "owned", "by", "CorMatrix", "in", "May", "2016.", "<tag3>"], "wordsA": ["Spectrum", "has", "indicated", "that", "next", "FDA", "action", "date", "is", "May", "2016."], "wordsB": ["Ligand", "acquired", "the", "economic", "rights", "to", "multiple", "medical", "device", "programs", "owned", "by", "CorMatrix", "in", "May", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p55_s0", "idA": "886163_16_item1_p48_s0", "sentA": "Evomela is intended for use in the multiple myeloma stem cell transplant setting, and has been granted Orphan Designation by the FDA.", "sentB": "Evomela has been granted Orphan Designation by the FDA for use as a high-dose conditioning regimen for patients with multiple myeloma undergoing ASCT.", "type": 2, "words": ["<tag1>", "Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA.", "<tag2>", "Evomela", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA", "for", "use", "as", "a", "high-dose", "conditioning", "regimen", "for", "patients", "with", "multiple", "myeloma", "undergoing", "ASCT.", "<tag3>"], "wordsA": ["Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA."], "wordsB": ["Evomela", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA", "for", "use", "as", "a", "high-dose", "conditioning", "regimen", "for", "patients", "with", "multiple", "myeloma", "undergoing", "ASCT."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p70_s8", "idA": "886163_16_item1_p48_s0", "sentA": "Evomela is intended for use in the multiple myeloma stem cell transplant setting, and has been granted Orphan Designation by the FDA.", "sentB": "The Breakthrough Therapy Designation is intended to offer a potentially expedited development path and review for promising drug candidates, which includes increased interaction and guidance from the FDA.", "type": 2, "words": ["<tag1>", "Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA.", "<tag2>", "The", "Breakthrough", "Therapy", "Designation", "is", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates,", "which", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA.", "<tag3>"], "wordsA": ["Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA."], "wordsB": ["The", "Breakthrough", "Therapy", "Designation", "is", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates,", "which", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p13_s2", "idA": "886163_16_item1_p48_s2", "sentA": "The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.", "sentB": "The study is anticipated to start enrolling patients in April 2017.", "type": 2, "words": ["<tag1>", "The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy.", "<tag2>", "The", "study", "is", "anticipated", "to", "start", "enrolling", "patients", "in", "April", "2017.", "<tag3>"], "wordsA": ["The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy."], "wordsB": ["The", "study", "is", "anticipated", "to", "start", "enrolling", "patients", "in", "April", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p13_s0", "idA": "886163_16_item1_p4_s0", "sentA": "SAGE announced initiation of a Phase 3 study designed to evaluate the safety of SAGE-547 in patients with SRSE.", "sentB": "On November 10, 2016, Amgen announced a collaboration with Janssen Biotech, Inc. to evaluate the combination of Amgen's Kyprolis (carfilzomib) and Janssen's DARZALEX (daratumumab) in multiple clinical studies in patients with multiple myeloma.", "type": 2, "words": ["<tag1>", "SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag2>", "On", "November", "10,", "2016,", "Amgen", "announced", "a", "collaboration", "with", "Janssen", "Biotech,", "Inc.", "to", "evaluate", "the", "combination", "of", "Amgen's", "Kyprolis", "(carfilzomib)", "and", "Janssen's", "DARZALEX", "(daratumumab)", "in", "multiple", "clinical", "studies", "in", "patients", "with", "multiple", "myeloma.", "<tag3>"], "wordsA": ["SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "wordsB": ["On", "November", "10,", "2016,", "Amgen", "announced", "a", "collaboration", "with", "Janssen", "Biotech,", "Inc.", "to", "evaluate", "the", "combination", "of", "Amgen's", "Kyprolis", "(carfilzomib)", "and", "Janssen's", "DARZALEX", "(daratumumab)", "in", "multiple", "clinical", "studies", "in", "patients", "with", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p56_s1", "idA": "886163_16_item1_p50_s0", "sentA": "agreement and royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "We are eligible to receive over $50 million in potential milestone payments under this agreement and royalties on future net sales of the Captisol-enabled melphalan product.", "type": 2, "words": ["<tag1>", "agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag3>"], "wordsA": ["agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p78_s0", "idA": "886163_16_item1_p51_s0", "sentA": "Verubecestat (Merck) Our partner, Merck is conducting two Phase 3 trials for Verubecestat (MK-8931), a BACE inhibitor for the treatment of Alzheimer s disease.", "sentB": "Our partner, Merck is developing Verubecestat (MK-8931), a BACE inhibitor for the treatment of Alzheimer s disease.", "type": 2, "words": ["<tag1>", "Verubecestat", "(Merck)", "Our", "partner,", "Merck", "is", "conducting", "two", "Phase", "3", "trials", "for", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag2>", "Our", "partner,", "Merck", "is", "developing", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag3>"], "wordsA": ["Verubecestat", "(Merck)", "Our", "partner,", "Merck", "is", "conducting", "two", "Phase", "3", "trials", "for", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "wordsB": ["Our", "partner,", "Merck", "is", "developing", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p6_s0", "idA": "886163_16_item1_p52_s0", "sentA": "Alzheimer s disease is characterized by plaques of amyloid-beta protein within the brain.", "sentB": "Merck announced that it stopped the Phase 2/3 EPOCH study evaluating verubecestat in people with mild-to-moderate Alzheimer s disease due to the conclusion that the efficacy endpoint could not be achieved.", "type": 2, "words": ["<tag1>", "Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain.", "<tag2>", "Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved.", "<tag3>"], "wordsA": ["Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain."], "wordsB": ["Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p79_s0", "idA": "886163_16_item1_p52_s0", "sentA": "Alzheimer s disease is characterized by plaques of amyloid-beta protein within the brain.", "sentB": "Alzheimer s disease is a chronic neurodegenerative disease and responsible for the majority of dementia cases.", "type": 2, "words": ["<tag1>", "Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain.", "<tag2>", "Alzheimer", "s", "disease", "is", "a", "chronic", "neurodegenerative", "disease", "and", "responsible", "for", "the", "majority", "of", "dementia", "cases.", "<tag3>"], "wordsA": ["Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain."], "wordsB": ["Alzheimer", "s", "disease", "is", "a", "chronic", "neurodegenerative", "disease", "and", "responsible", "for", "the", "majority", "of", "dementia", "cases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p80_s0", "idA": "886163_16_item1_p52_s0", "sentA": "Alzheimer s disease is characterized by plaques of amyloid-beta protein within the brain.", "sentB": "The leading hypothesis in the field postulates that plaques of amyloid-beta protein within the brain are the main cause of the disease.", "type": 2, "words": ["<tag1>", "Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain.", "<tag2>", "The", "leading", "hypothesis", "in", "the", "field", "postulates", "that", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain", "are", "the", "main", "cause", "of", "the", "disease.", "<tag3>"], "wordsA": ["Alzheimer", "s", "disease", "is", "characterized", "by", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain."], "wordsB": ["The", "leading", "hypothesis", "in", "the", "field", "postulates", "that", "plaques", "of", "amyloid-beta", "protein", "within", "the", "brain", "are", "the", "main", "cause", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p71_s4", "idA": "886163_16_item1_p52_s3", "sentA": "A BACE inhibitor is expected to reduce amyloid-beta generation in Alzheimer s disease patients.", "sentB": "The royalty term is expected to be 10 years following the first commercial sale.", "type": 2, "words": ["<tag1>", "A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients.", "<tag2>", "The", "royalty", "term", "is", "expected", "to", "be", "10", "years", "following", "the", "first", "commercial", "sale.", "<tag3>"], "wordsA": ["A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients."], "wordsB": ["The", "royalty", "term", "is", "expected", "to", "be", "10", "years", "following", "the", "first", "commercial", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p80_s1", "idA": "886163_16_item1_p52_s3", "sentA": "A BACE inhibitor is expected to reduce amyloid-beta generation in Alzheimer s disease patients.", "sentB": "BACE is a key enzyme in the production of amyloid-beta protein and a BACE inhibitor is expected to reduce amyloid-beta protein generation in Alzheimer s disease patients to prevent plaques formation.", "type": 2, "words": ["<tag1>", "A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients.", "<tag2>", "BACE", "is", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein", "and", "a", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "protein", "generation", "in", "Alzheimer", "s", "disease", "patients", "to", "prevent", "plaques", "formation.", "<tag3>"], "wordsA": ["A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients."], "wordsB": ["BACE", "is", "a", "key", "enzyme", "in", "the", "production", "of", "amyloid-beta", "protein", "and", "a", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "protein", "generation", "in", "Alzheimer", "s", "disease", "patients", "to", "prevent", "plaques", "formation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p80_s2", "idA": "886163_16_item1_p52_s3", "sentA": "A BACE inhibitor is expected to reduce amyloid-beta generation in Alzheimer s disease patients.", "sentB": "Verubecestat is the leading BACE inhibitor in clinic.", "type": 2, "words": ["<tag1>", "A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients.", "<tag2>", "Verubecestat", "is", "the", "leading", "BACE", "inhibitor", "in", "clinic.", "<tag3>"], "wordsA": ["A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients."], "wordsB": ["Verubecestat", "is", "the", "leading", "BACE", "inhibitor", "in", "clinic."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p80_s3", "idA": "886163_16_item1_p52_s4", "sentA": "Merck expects initial data from Phase 3 trials in mid-2017.", "sentB": "In February 2017, Merck halted the first Phase 3 trial in mild-to-moderate Alzheimer s disease for futility and expects initial data readout from the second Phase 3 trial in prodromal Alzheimer s disease in 2019.", "type": 2, "words": ["<tag1>", "Merck", "expects", "initial", "data", "from", "Phase", "3", "trials", "in", "mid-2017.", "<tag2>", "In", "February", "2017,", "Merck", "halted", "the", "first", "Phase", "3", "trial", "in", "mild-to-moderate", "Alzheimer", "s", "disease", "for", "futility", "and", "expects", "initial", "data", "readout", "from", "the", "second", "Phase", "3", "trial", "in", "prodromal", "Alzheimer", "s", "disease", "in", "2019.", "<tag3>"], "wordsA": ["Merck", "expects", "initial", "data", "from", "Phase", "3", "trials", "in", "mid-2017."], "wordsB": ["In", "February", "2017,", "Merck", "halted", "the", "first", "Phase", "3", "trial", "in", "mild-to-moderate", "Alzheimer", "s", "disease", "for", "futility", "and", "expects", "initial", "data", "readout", "from", "the", "second", "Phase", "3", "trial", "in", "prodromal", "Alzheimer", "s", "disease", "in", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p101_s0", "idA": "886163_16_item1_p53_s1", "sentA": "Our partner, SAGE, is conducting a Phase 3 clinical trial for the development of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions.", "sentB": "Esaxerenone (Exelixis) Our partner, Exelixis, entered into a collaboration agreement with Daiichi Sankyo and is conducting a phase 3 pivotal trial (ESAX-HTN) to evaluate esaxerenone (CS-3150) versus eplerenone for essential hypertension in Japanese patients.", "type": 2, "words": ["<tag1>", "Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions.", "<tag2>", "Esaxerenone", "(Exelixis)", "Our", "partner,", "Exelixis,", "entered", "into", "a", "collaboration", "agreement", "with", "Daiichi", "Sankyo", "and", "is", "conducting", "a", "phase", "3", "pivotal", "trial", "(ESAX-HTN)", "to", "evaluate", "esaxerenone", "(CS-3150)", "versus", "eplerenone", "for", "essential", "hypertension", "in", "Japanese", "patients.", "<tag3>"], "wordsA": ["Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions."], "wordsB": ["Esaxerenone", "(Exelixis)", "Our", "partner,", "Exelixis,", "entered", "into", "a", "collaboration", "agreement", "with", "Daiichi", "Sankyo", "and", "is", "conducting", "a", "phase", "3", "pivotal", "trial", "(ESAX-HTN)", "to", "evaluate", "esaxerenone", "(CS-3150)", "versus", "eplerenone", "for", "essential", "hypertension", "in", "Japanese", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p70_s5", "idA": "886163_16_item1_p53_s1", "sentA": "Our partner, SAGE, is conducting a Phase 3 clinical trial for the development of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions.", "sentB": "SAGE is also conducting a Phase 3 clinical trial for the development of a Captisol-enabled treatment of PPD.", "type": 2, "words": ["<tag1>", "Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions.", "<tag2>", "SAGE", "is", "also", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "a", "Captisol-enabled", "treatment", "of", "PPD.", "<tag3>"], "wordsA": ["Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions."], "wordsB": ["SAGE", "is", "also", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "a", "Captisol-enabled", "treatment", "of", "PPD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p70_s1", "idA": "886163_16_item1_p53_s2", "sentA": "SAGE s lead clinical program, Captisol-enabled SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABA A receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE.", "sentB": "SAGE s lead clinical program, Captisol-enabled Brexanolone (SAGE-547), is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE.", "type": 2, "words": ["<tag1>", "SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABA", "A", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE.", "<tag2>", "SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "Brexanolone", "(SAGE-547),", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABAA", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE.", "<tag3>"], "wordsA": ["SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABA", "A", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE."], "wordsB": ["SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "Brexanolone", "(SAGE-547),", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABAA", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p70_s2", "idA": "886163_16_item1_p53_s3", "sentA": "SAGE-547 was granted Fast Track designation, which is intended to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs, and orphan drug designation, which is intended to facilitate drug development for rare diseases, by the FDA for SRSE.", "sentB": "Brexanolone was granted Fast Track designation, which is intended to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs, and orphan drug designation, which is intended to facilitate drug development for rare diseases, by the FDA for SRSE.", "type": 2, "words": ["<tag1>", "SAGE-547", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE.", "<tag2>", "Brexanolone", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE.", "<tag3>"], "wordsA": ["SAGE-547", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE."], "wordsB": ["Brexanolone", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p92_s1", "idA": "886163_16_item1_p53_s3", "sentA": "SAGE-547 was granted Fast Track designation, which is intended to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs, and orphan drug designation, which is intended to facilitate drug development for rare diseases, by the FDA for SRSE.", "sentB": "The FDA has granted fast track designation to facilitate and expedite the development.", "type": 2, "words": ["<tag1>", "SAGE-547", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE.", "<tag2>", "The", "FDA", "has", "granted", "fast", "track", "designation", "to", "facilitate", "and", "expedite", "the", "development.", "<tag3>"], "wordsA": ["SAGE-547", "was", "granted", "Fast", "Track", "designation,", "which", "is", "intended", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs,", "and", "orphan", "drug", "designation,", "which", "is", "intended", "to", "facilitate", "drug", "development", "for", "rare", "diseases,", "by", "the", "FDA", "for", "SRSE."], "wordsB": ["The", "FDA", "has", "granted", "fast", "track", "designation", "to", "facilitate", "and", "expedite", "the", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p37_s2", "idA": "886163_16_item1_p53_s4", "sentA": "Ligand has the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs.", "sentB": "Additionally, Ligand has the rights to receive a share of potential future revenues from CorMatrix s developmental pipeline products.", "type": 2, "words": ["<tag1>", "Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs.", "<tag2>", "Additionally,", "Ligand", "has", "the", "rights", "to", "receive", "a", "share", "of", "potential", "future", "revenues", "from", "CorMatrix", "s", "developmental", "pipeline", "products.", "<tag3>"], "wordsA": ["Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs."], "wordsB": ["Additionally,", "Ligand", "has", "the", "rights", "to", "receive", "a", "share", "of", "potential", "future", "revenues", "from", "CorMatrix", "s", "developmental", "pipeline", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p57_s1", "idA": "886163_16_item1_p53_s4", "sentA": "Ligand has the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs.", "sentB": "In addition, Ligand has the potential to receive a share of revenue and potential milestones from the currently marketed CorMatrix CanGaroo ECM Envelope for cardiac implantable electronic devices.", "type": 2, "words": ["<tag1>", "Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs.", "<tag2>", "In", "addition,", "Ligand", "has", "the", "potential", "to", "receive", "a", "share", "of", "revenue", "and", "potential", "milestones", "from", "the", "currently", "marketed", "CorMatrix", "CanGaroo", "ECM", "Envelope", "for", "cardiac", "implantable", "electronic", "devices.", "<tag3>"], "wordsA": ["Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs."], "wordsB": ["In", "addition,", "Ligand", "has", "the", "potential", "to", "receive", "a", "share", "of", "revenue", "and", "potential", "milestones", "from", "the", "currently", "marketed", "CorMatrix", "CanGaroo", "ECM", "Envelope", "for", "cardiac", "implantable", "electronic", "devices."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p27_s0", "idA": "886163_16_item1_p53_s6", "sentA": "Our partner Retrophin is currently conducting a Phase 2 clinical trial for the development of Sparsentan for orphan indications of severe kidney diseases including FSGS.", "sentB": "Ligand announced initiation of a Phase 2 clinical trial with LGD-6972 for the treatment of T2DM.", "type": 2, "words": ["<tag1>", "Our", "partner", "Retrophin", "is", "currently", "conducting", "a", "Phase", "2", "clinical", "trial", "for", "the", "development", "of", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS.", "<tag2>", "Ligand", "announced", "initiation", "of", "a", "Phase", "2", "clinical", "trial", "with", "LGD-6972", "for", "the", "treatment", "of", "T2DM.", "<tag3>"], "wordsA": ["Our", "partner", "Retrophin", "is", "currently", "conducting", "a", "Phase", "2", "clinical", "trial", "for", "the", "development", "of", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS."], "wordsB": ["Ligand", "announced", "initiation", "of", "a", "Phase", "2", "clinical", "trial", "with", "LGD-6972", "for", "the", "treatment", "of", "T2DM."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p70_s9", "idA": "886163_16_item1_p53_s6", "sentA": "Our partner Retrophin is currently conducting a Phase 2 clinical trial for the development of Sparsentan for orphan indications of severe kidney diseases including FSGS.", "sentB": "Our partner, Retrophin, is developing sparsentan for orphan indications of severe kidney diseases, and has completed a Phase 2 clinical trial of sparsentan for the treatment of FSGS.", "type": 2, "words": ["<tag1>", "Our", "partner", "Retrophin", "is", "currently", "conducting", "a", "Phase", "2", "clinical", "trial", "for", "the", "development", "of", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS.", "<tag2>", "Our", "partner,", "Retrophin,", "is", "developing", "sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases,", "and", "has", "completed", "a", "Phase", "2", "clinical", "trial", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS.", "<tag3>"], "wordsA": ["Our", "partner", "Retrophin", "is", "currently", "conducting", "a", "Phase", "2", "clinical", "trial", "for", "the", "development", "of", "Sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "FSGS."], "wordsB": ["Our", "partner,", "Retrophin,", "is", "developing", "sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases,", "and", "has", "completed", "a", "Phase", "2", "clinical", "trial", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p71_s0", "idA": "886163_16_item1_p54_s0", "sentA": "Certain patient groups with severely compromised renal function exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate.", "sentB": "Certain patient groups with severely compromised renal function, including those with FSGS, exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate.", "type": 2, "words": ["<tag1>", "Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate.", "<tag2>", "Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function,", "including", "those", "with", "FSGS,", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate.", "<tag3>"], "wordsA": ["Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate."], "wordsB": ["Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function,", "including", "those", "with", "FSGS,", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p71_s3", "idA": "886163_16_item1_p54_s3", "sentA": "Under our license agreement with Retrophin we are entitled to receive potential net milestones of over $75 million in the future and net royalties on future worldwide sales by Retrophin through the life of the relevant patents, which we currently expect to be through at least 2019 and may be extended until 2024.", "sentB": "Under our license agreement with Retrophin we are entitled to receive potential net milestones of over $75 million in the future and net royalties on future worldwide sales by Retrophin.", "type": 2, "words": ["<tag1>", "Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "potential", "net", "milestones", "of", "over", "$75", "million", "in", "the", "future", "and", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024.", "<tag2>", "Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "potential", "net", "milestones", "of", "over", "$75", "million", "in", "the", "future", "and", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin.", "<tag3>"], "wordsA": ["Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "potential", "net", "milestones", "of", "over", "$75", "million", "in", "the", "future", "and", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin", "through", "the", "life", "of", "the", "relevant", "patents,", "which", "we", "currently", "expect", "to", "be", "through", "at", "least", "2019", "and", "may", "be", "extended", "until", "2024."], "wordsB": ["Under", "our", "license", "agreement", "with", "Retrophin", "we", "are", "entitled", "to", "receive", "potential", "net", "milestones", "of", "over", "$75", "million", "in", "the", "future", "and", "net", "royalties", "on", "future", "worldwide", "sales", "by", "Retrophin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p67_s6", "idA": "886163_16_item1_p56_s0", "sentA": "Baxdela (Melinta) Our partner Melinta is currently completing Phase 3 clinical trials for the development of Baxdela, a Captisol-enabled delafloxacin-IV.", "sentB": "Baxdela (Melinta) Our partner, Melinta , submitted an NDA for approval of a Captisol-enabled delafloxacin-IV in October 2016 for the development of Baxdela, a Captisol-enabled delafloxacin-IV.", "type": 2, "words": ["<tag1>", "Baxdela", "(Melinta)", "Our", "partner", "Melinta", "is", "currently", "completing", "Phase", "3", "clinical", "trials", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV.", "<tag2>", "Baxdela", "(Melinta)", "Our", "partner,", "Melinta", ",", "submitted", "an", "NDA", "for", "approval", "of", "a", "Captisol-enabled", "delafloxacin-IV", "in", "October", "2016", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV.", "<tag3>"], "wordsA": ["Baxdela", "(Melinta)", "Our", "partner", "Melinta", "is", "currently", "completing", "Phase", "3", "clinical", "trials", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV."], "wordsB": ["Baxdela", "(Melinta)", "Our", "partner,", "Melinta", ",", "submitted", "an", "NDA", "for", "approval", "of", "a", "Captisol-enabled", "delafloxacin-IV", "in", "October", "2016", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p68_s0", "idA": "886163_16_item1_p57_s0", "sentA": "Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of quinolone-resistant Gram-positive and Gram-negative bacteria, including quinolone-resistant MRSA.", "sentB": "Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of disease-causing bacteria-gram-positives, gram-negatives, atypicals and anaerobes, including quinolone-resistant MRSA.", "type": 2, "words": ["<tag1>", "Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant", "MRSA.", "<tag2>", "Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "disease-causing", "bacteria-gram-positives,", "gram-negatives,", "atypicals", "and", "anaerobes,", "including", "quinolone-resistant", "MRSA.", "<tag3>"], "wordsA": ["Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant", "MRSA."], "wordsB": ["Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "disease-causing", "bacteria-gram-positives,", "gram-negatives,", "atypicals", "and", "anaerobes,", "including", "quinolone-resistant", "MRSA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p69_s0", "idA": "886163_16_item1_p57_s2", "sentA": "Under the terms of the agreement, we may be entitled to up to $3.6 million of development and regulatory milestones, a royalty on potential future sales by Melinta, and revenue from Captisol material sales.", "sentB": "Under the terms of the agreement, we may be entitled to up to $2.1 million of development and regulatory milestones, as well as a royalty on potential future sales by Melinta, and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$3.6", "million", "of", "development", "and", "regulatory", "milestones,", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$2.1", "million", "of", "development", "and", "regulatory", "milestones,", "as", "well", "as", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$3.6", "million", "of", "development", "and", "regulatory", "milestones,", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$2.1", "million", "of", "development", "and", "regulatory", "milestones,", "as", "well", "as", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p60_s0", "idA": "886163_16_item1_p59_s0", "sentA": "Carbamazepine-IV (Lundbeck) Lundbeck's Carbella is a Captisol-enabled carbamazepine-IV currently under review by the FDA.", "sentB": "Carnexiv (Lundbeck) Lundbeck's Carnexiv is a Captisol-enabled carbamazepine-IV that was approved by the FDA in October 2016.", "type": 2, "words": ["<tag1>", "Carbamazepine-IV", "(Lundbeck)", "Lundbeck's", "Carbella", "is", "a", "Captisol-enabled", "carbamazepine-IV", "currently", "under", "review", "by", "the", "FDA.", "<tag2>", "Carnexiv", "(Lundbeck)", "Lundbeck's", "Carnexiv", "is", "a", "Captisol-enabled", "carbamazepine-IV", "that", "was", "approved", "by", "the", "FDA", "in", "October", "2016.", "<tag3>"], "wordsA": ["Carbamazepine-IV", "(Lundbeck)", "Lundbeck's", "Carbella", "is", "a", "Captisol-enabled", "carbamazepine-IV", "currently", "under", "review", "by", "the", "FDA."], "wordsB": ["Carnexiv", "(Lundbeck)", "Lundbeck's", "Carnexiv", "is", "a", "Captisol-enabled", "carbamazepine-IV", "that", "was", "approved", "by", "the", "FDA", "in", "October", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p70_s7", "idA": "886163_16_item1_p61_s0", "sentA": "to a request of CMC data from the FDA s Complete Response Letter received in late 2014.", "sentB": "SAGE received Breakthrough Therapy Designation from the FDA for SAGE-547 in PPD in September, 2016.", "type": 2, "words": ["<tag1>", "to", "a", "request", "of", "CMC", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014.", "<tag2>", "SAGE", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "for", "SAGE-547", "in", "PPD", "in", "September,", "2016.", "<tag3>"], "wordsA": ["to", "a", "request", "of", "CMC", "data", "from", "the", "FDA", "s", "Complete", "Response", "Letter", "received", "in", "late", "2014."], "wordsB": ["SAGE", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "for", "SAGE-547", "in", "PPD", "in", "September,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p70_s6", "idA": "886163_16_item1_p64_s0", "sentA": "Viking initiated a Phase 2 trial in hip fracture in 2015.", "sentB": "In July 2016 SAGE reported top-line results from a Phase 2 placebo-controlled trial in women with severe PPD, in which SAGE-547 achieved a significant, rapid and durable reduction in depression scores.", "type": 2, "words": ["<tag1>", "Viking", "initiated", "a", "Phase", "2", "trial", "in", "hip", "fracture", "in", "2015.", "<tag2>", "In", "July", "2016", "SAGE", "reported", "top-line", "results", "from", "a", "Phase", "2", "placebo-controlled", "trial", "in", "women", "with", "severe", "PPD,", "in", "which", "SAGE-547", "achieved", "a", "significant,", "rapid", "and", "durable", "reduction", "in", "depression", "scores.", "<tag3>"], "wordsA": ["Viking", "initiated", "a", "Phase", "2", "trial", "in", "hip", "fracture", "in", "2015."], "wordsB": ["In", "July", "2016", "SAGE", "reported", "top-line", "results", "from", "a", "Phase", "2", "placebo-controlled", "trial", "in", "women", "with", "severe", "PPD,", "in", "which", "SAGE-547", "achieved", "a", "significant,", "rapid", "and", "durable", "reduction", "in", "depression", "scores."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p86_s0", "idA": "886163_16_item1_p65_s0", "sentA": "Under the terms of the agreement with Viking, we may be entitled to up to $270 million of development, regulatory and commercial milestones and tiered royalties on potential future sales.", "sentB": "Under the terms of the agreement with Viking, we may be entitled to up to $270 million of development, regulatory and commercial milestones as well as tiered royalties on potential future sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$270", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "and", "tiered", "royalties", "on", "potential", "future", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$270", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "as", "well", "as", "tiered", "royalties", "on", "potential", "future", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$270", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "and", "tiered", "royalties", "on", "potential", "future", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement", "with", "Viking,", "we", "may", "be", "entitled", "to", "up", "to", "$270", "million", "of", "development,", "regulatory", "and", "commercial", "milestones", "as", "well", "as", "tiered", "royalties", "on", "potential", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p82_s0", "idA": "886163_16_item1_p66_s0", "sentA": "Viking is developing VK2809, a novel selective TR- agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD.", "sentB": "Merck is responsible for all development costs related to the program TR-Beta - VK2809 (Viking) Viking is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD.", "type": 2, "words": ["<tag1>", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD.", "<tag2>", "Merck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program", "TR-Beta", "-", "VK2809", "(Viking)", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-Beta", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD.", "<tag3>"], "wordsA": ["Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD."], "wordsB": ["Merck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program", "TR-Beta", "-", "VK2809", "(Viking)", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-Beta", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p82_s1", "idA": "886163_16_item1_p66_s1", "sentA": "Viking intends to initiate a Phase 2 trial for VK2809 in hypercholesterolemia and fatty liver disease in 2016.", "sentB": "Viking initiated a Phase 2 trial for VK2809 in hypercholesterolemia and fatty liver disease in 2016 and expects primary outcome readout this year.", "type": 2, "words": ["<tag1>", "Viking", "intends", "to", "initiate", "a", "Phase", "2", "trial", "for", "VK2809", "in", "hypercholesterolemia", "and", "fatty", "liver", "disease", "in", "2016.", "<tag2>", "Viking", "initiated", "a", "Phase", "2", "trial", "for", "VK2809", "in", "hypercholesterolemia", "and", "fatty", "liver", "disease", "in", "2016", "and", "expects", "primary", "outcome", "readout", "this", "year.", "<tag3>"], "wordsA": ["Viking", "intends", "to", "initiate", "a", "Phase", "2", "trial", "for", "VK2809", "in", "hypercholesterolemia", "and", "fatty", "liver", "disease", "in", "2016."], "wordsB": ["Viking", "initiated", "a", "Phase", "2", "trial", "for", "VK2809", "in", "hypercholesterolemia", "and", "fatty", "liver", "disease", "in", "2016", "and", "expects", "primary", "outcome", "readout", "this", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p97_s0", "idA": "886163_16_item1_p66_s3", "sentA": "Our partner, TG Therapeutics is developing our IRAK-4 inhibitors.", "sentB": "AM0010+PD-1 (ARMO Biosciences) Our partner, ARMO Biosciences, is developing an anti-PD-1 antibody discovered with the OmniAb platform technology.", "type": 2, "words": ["<tag1>", "Our", "partner,", "TG", "Therapeutics", "is", "developing", "our", "IRAK-4", "inhibitors.", "<tag2>", "AM0010+PD-1", "(ARMO", "Biosciences)", "Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology.", "<tag3>"], "wordsA": ["Our", "partner,", "TG", "Therapeutics", "is", "developing", "our", "IRAK-4", "inhibitors."], "wordsB": ["AM0010+PD-1", "(ARMO", "Biosciences)", "Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p19_s1", "idA": "886163_16_item1_p66_s4", "sentA": "The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases.", "sentB": "The additional antibody is in preclinical development with an undisclosed partner.", "type": 2, "words": ["<tag1>", "The", "IRAK-4", "program", "is", "in", "preclinical", "development", "for", "potential", "use", "in", "certain", "cancers", "and", "autoimmune", "diseases.", "<tag2>", "The", "additional", "antibody", "is", "in", "preclinical", "development", "with", "an", "undisclosed", "partner.", "<tag3>"], "wordsA": ["The", "IRAK-4", "program", "is", "in", "preclinical", "development", "for", "potential", "use", "in", "certain", "cancers", "and", "autoimmune", "diseases."], "wordsB": ["The", "additional", "antibody", "is", "in", "preclinical", "development", "with", "an", "undisclosed", "partner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p75_s0", "idA": "886163_16_item1_p67_s4", "sentA": "Our partner Azure is developing a novel formulation of lasofoxifene.", "sentB": "Our partner Azure is developing a novel formulation of lasofoxifene targeting an underserved market in women s health.", "type": 2, "words": ["<tag1>", "Our", "partner", "Azure", "is", "developing", "a", "novel", "formulation", "of", "lasofoxifene.", "<tag2>", "Our", "partner", "Azure", "is", "developing", "a", "novel", "formulation", "of", "lasofoxifene", "targeting", "an", "underserved", "market", "in", "women", "s", "health.", "<tag3>"], "wordsA": ["Our", "partner", "Azure", "is", "developing", "a", "novel", "formulation", "of", "lasofoxifene."], "wordsB": ["Our", "partner", "Azure", "is", "developing", "a", "novel", "formulation", "of", "lasofoxifene", "targeting", "an", "underserved", "market", "in", "women", "s", "health."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p14_s0", "idA": "886163_16_item1_p68_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Worldwide platform license agreement with Emergent Biosolutions for access to the OmniAb technology.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Worldwide", "platform", "license", "agreement", "with", "Emergent", "Biosolutions", "for", "access", "to", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Worldwide", "platform", "license", "agreement", "with", "Emergent", "Biosolutions", "for", "access", "to", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p15_s0", "idA": "886163_16_item1_p68_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Worldwide platform license agreement with Tizona for access to the OmniAb technology.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Worldwide", "platform", "license", "agreement", "with", "Tizona", "for", "access", "to", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Worldwide", "platform", "license", "agreement", "with", "Tizona", "for", "access", "to", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p16_s0", "idA": "886163_16_item1_p68_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Worldwide platform license agreement with ABBA Therapeutics for access to the OmniAb technology.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Worldwide", "platform", "license", "agreement", "with", "ABBA", "Therapeutics", "for", "access", "to", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Worldwide", "platform", "license", "agreement", "with", "ABBA", "Therapeutics", "for", "access", "to", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p17_s0", "idA": "886163_16_item1_p68_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Worldwide platform license agreement with F-Star for access to the OmniAb technology.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Worldwide", "platform", "license", "agreement", "with", "F-Star", "for", "access", "to", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Worldwide", "platform", "license", "agreement", "with", "F-Star", "for", "access", "to", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p22_s0", "idA": "886163_16_item1_p68_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Worldwide license agreement with Teneobio for access to the OmniAb technology.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p24_s0", "idA": "886163_16_item1_p68_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Worldwide platform license agreement with Ono Pharmaceuticals for access to the OmniAb technology.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Worldwide", "platform", "license", "agreement", "with", "Ono", "Pharmaceuticals", "for", "access", "to", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Worldwide", "platform", "license", "agreement", "with", "Ono", "Pharmaceuticals", "for", "access", "to", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p100_s0", "idA": "886163_16_item1_p68_s3", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and royalties on future net sales.", "sentB": "Under the terms of our agreement with Aldeyra, we are entitled to receive regulatory milestones and royalties on future sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "our", "agreement", "with", "Aldeyra,", "we", "are", "entitled", "to", "receive", "regulatory", "milestones", "and", "royalties", "on", "future", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "our", "agreement", "with", "Aldeyra,", "we", "are", "entitled", "to", "receive", "regulatory", "milestones", "and", "royalties", "on", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p101_s1", "idA": "886163_16_item1_p68_s3", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and royalties on future net sales.", "sentB": "Under the terms of the agreement with Exelixis, we are entitled to receive a royalty on future sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement", "with", "Exelixis,", "we", "are", "entitled", "to", "receive", "a", "royalty", "on", "future", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement", "with", "Exelixis,", "we", "are", "entitled", "to", "receive", "a", "royalty", "on", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p77_s1", "idA": "886163_16_item1_p69_s2", "sentA": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments and royalties on future net sales.", "sentB": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments as well as royalties on future net sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "as", "well", "as", "royalties", "on", "future", "net", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "as", "well", "as", "royalties", "on", "future", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p8_s0", "idA": "886163_16_item1_p6_s0", "sentA": "FDA approved Promacta for the treatment of children six years and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "On April 7, 2016, the European Commission approved Promacta for the treatment of children one year and above with chronic immune thrombocytopenia who have not responded to other treatments.", "type": 2, "words": ["<tag1>", "FDA", "approved", "Promacta", "for", "the", "treatment", "of", "children", "six", "years", "and", "older", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "On", "April", "7,", "2016,", "the", "European", "Commission", "approved", "Promacta", "for", "the", "treatment", "of", "children", "one", "year", "and", "above", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "not", "responded", "to", "other", "treatments.", "<tag3>"], "wordsA": ["FDA", "approved", "Promacta", "for", "the", "treatment", "of", "children", "six", "years", "and", "older", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["On", "April", "7,", "2016,", "the", "European", "Commission", "approved", "Promacta", "for", "the", "treatment", "of", "children", "one", "year", "and", "above", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "not", "responded", "to", "other", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p54_s0", "idA": "886163_16_item1_p70_s0", "sentA": "SAR-125844 (Sanofi) Our partner, Sanofi licensed Captisol for use in the development of Captisol-enabled SAR-125844, a potent MET kinase inhibitor.", "sentB": "The FDA approved Evomela for use in two indications:", "type": 2, "words": ["<tag1>", "SAR-125844", "(Sanofi)", "Our", "partner,", "Sanofi", "licensed", "Captisol", "for", "use", "in", "the", "development", "of", "Captisol-enabled", "SAR-125844,", "a", "potent", "MET", "kinase", "inhibitor.", "<tag2>", "The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:", "<tag3>"], "wordsA": ["SAR-125844", "(Sanofi)", "Our", "partner,", "Sanofi", "licensed", "Captisol", "for", "use", "in", "the", "development", "of", "Captisol-enabled", "SAR-125844,", "a", "potent", "MET", "kinase", "inhibitor."], "wordsB": ["The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p95_s0", "idA": "886163_16_item1_p72_s1", "sentA": "Our partner, Coherus Biosciences is conducting Phase 3 / BLA-enabling clinical trials for CHS-0214 (etanercept biosimilar) for rheumatoid arthritis.", "sentB": "CHS-0214 (Coherus Biosciences) Coherus Biosciences has conducted Phase 3 / MAA-enabling clinical trials for CHS-0214 (etanercept biosimilar) for rheumatoid arthritis and psoriasis.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Coherus", "Biosciences", "is", "conducting", "Phase", "3", "/", "BLA-enabling", "clinical", "trials", "for", "CHS-0214", "(etanercept", "biosimilar)", "for", "rheumatoid", "arthritis.", "<tag2>", "CHS-0214", "(Coherus", "Biosciences)", "Coherus", "Biosciences", "has", "conducted", "Phase", "3", "/", "MAA-enabling", "clinical", "trials", "for", "CHS-0214", "(etanercept", "biosimilar)", "for", "rheumatoid", "arthritis", "and", "psoriasis.", "<tag3>"], "wordsA": ["Our", "partner,", "Coherus", "Biosciences", "is", "conducting", "Phase", "3", "/", "BLA-enabling", "clinical", "trials", "for", "CHS-0214", "(etanercept", "biosimilar)", "for", "rheumatoid", "arthritis."], "wordsB": ["CHS-0214", "(Coherus", "Biosciences)", "Coherus", "Biosciences", "has", "conducted", "Phase", "3", "/", "MAA-enabling", "clinical", "trials", "for", "CHS-0214", "(etanercept", "biosimilar)", "for", "rheumatoid", "arthritis", "and", "psoriasis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p98_s0", "idA": "886163_16_item1_p73_s0", "sentA": "We are entitled to earn regulatory and sales milestones, and royalties on potential future sales through at least 2026.", "sentB": "We are entitled to earn regulatory milestones and royalties on future sales.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "earn", "regulatory", "and", "sales", "milestones,", "and", "royalties", "on", "potential", "future", "sales", "through", "at", "least", "2026.", "<tag2>", "We", "are", "entitled", "to", "earn", "regulatory", "milestones", "and", "royalties", "on", "future", "sales.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "earn", "regulatory", "and", "sales", "milestones,", "and", "royalties", "on", "potential", "future", "sales", "through", "at", "least", "2026."], "wordsB": ["We", "are", "entitled", "to", "earn", "regulatory", "milestones", "and", "royalties", "on", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p87_s0", "idA": "886163_16_item1_p75_s0", "sentA": "Our partner, Eli Lilly is conducting Phase 2 clinical trials for Captisol-enabled LY2606368 (Chk 1/2 inhibitor) for solid tumors.", "sentB": "Our partner, Eli Lilly is conducting Phase 2 clinical trials for Captisol-enabled merestinib (LY2801653, formerly known as c-Met inhibitor) for treatment of cancer.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "LY2606368", "(Chk", "1/2", "inhibitor)", "for", "solid", "tumors.", "<tag2>", "Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "merestinib", "(LY2801653,", "formerly", "known", "as", "c-Met", "inhibitor)", "for", "treatment", "of", "cancer.", "<tag3>"], "wordsA": ["Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "LY2606368", "(Chk", "1/2", "inhibitor)", "for", "solid", "tumors."], "wordsB": ["Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "merestinib", "(LY2801653,", "formerly", "known", "as", "c-Met", "inhibitor)", "for", "treatment", "of", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p102_s0", "idA": "886163_16_item1_p78_s1", "sentA": "Our partner, Merrimack Pharmaceuticals is currently conducting a Phase 2/3 trial for the treatment of advanced metastatic HER2-positive breast cancer.", "sentB": "TAK-020 (Takeda) Our partner, Takeda, is conducting a phase I study for TAK-020 for the treatment of rheumatoid arthritis.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer.", "<tag2>", "TAK-020", "(Takeda)", "Our", "partner,", "Takeda,", "is", "conducting", "a", "phase", "I", "study", "for", "TAK-020", "for", "the", "treatment", "of", "rheumatoid", "arthritis.", "<tag3>"], "wordsA": ["Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer."], "wordsB": ["TAK-020", "(Takeda)", "Our", "partner,", "Takeda,", "is", "conducting", "a", "phase", "I", "study", "for", "TAK-020", "for", "the", "treatment", "of", "rheumatoid", "arthritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p92_s0", "idA": "886163_16_item1_p78_s1", "sentA": "Our partner, Merrimack Pharmaceuticals is currently conducting a Phase 2/3 trial for the treatment of advanced metastatic HER2-positive breast cancer.", "sentB": "Seribantumab-MM-121 (Merrimack Pharmaceuticals) Merrimack Pharmaceuticals is currently conducting a Phase 2 trial of seribantumab (MM-121) in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer whose disease has progressed following immunotherapy.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer.", "<tag2>", "Seribantumab-MM-121", "(Merrimack", "Pharmaceuticals)", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2", "trial", "of", "seribantumab", "(MM-121)", "in", "patients", "with", "heregulin-positive,", "locally", "advanced", "or", "metastatic", "non-small", "cell", "lung", "cancer", "whose", "disease", "has", "progressed", "following", "immunotherapy.", "<tag3>"], "wordsA": ["Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer."], "wordsB": ["Seribantumab-MM-121", "(Merrimack", "Pharmaceuticals)", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2", "trial", "of", "seribantumab", "(MM-121)", "in", "patients", "with", "heregulin-positive,", "locally", "advanced", "or", "metastatic", "non-small", "cell", "lung", "cancer", "whose", "disease", "has", "progressed", "following", "immunotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p99_s0", "idA": "886163_16_item1_p78_s1", "sentA": "Our partner, Merrimack Pharmaceuticals is currently conducting a Phase 2/3 trial for the treatment of advanced metastatic HER2-positive breast cancer.", "sentB": "Our partner, Aldeyra, is conducting a phase II study for ADX-102 for the treatment of ocular inflammation.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer.", "<tag2>", "Our", "partner,", "Aldeyra,", "is", "conducting", "a", "phase", "II", "study", "for", "ADX-102", "for", "the", "treatment", "of", "ocular", "inflammation.", "<tag3>"], "wordsA": ["Our", "partner,", "Merrimack", "Pharmaceuticals", "is", "currently", "conducting", "a", "Phase", "2/3", "trial", "for", "the", "treatment", "of", "advanced", "metastatic", "HER2-positive", "breast", "cancer."], "wordsB": ["Our", "partner,", "Aldeyra,", "is", "conducting", "a", "phase", "II", "study", "for", "ADX-102", "for", "the", "treatment", "of", "ocular", "inflammation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p93_s0", "idA": "886163_16_item1_p79_s0", "sentA": "MM-302 is an antibody-drug conjugated liposomal doxorubicin that was developed using the Selexis SUREtechnology Platform.", "sentB": "an antibody-drug that targets ErbB3 that was developed using the Selexis SUREtechnology Platform.", "type": 2, "words": ["<tag1>", "MM-302", "is", "an", "antibody-drug", "conjugated", "liposomal", "doxorubicin", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform.", "<tag2>", "an", "antibody-drug", "that", "targets", "ErbB3", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform.", "<tag3>"], "wordsA": ["MM-302", "is", "an", "antibody-drug", "conjugated", "liposomal", "doxorubicin", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform."], "wordsB": ["an", "antibody-drug", "that", "targets", "ErbB3", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p91_s1", "idA": "886163_16_item1_p84_s0", "sentA": "VentiRx has an exclusive worldwide collaboration with Celgene to develop VTX-2337.", "sentB": "VentiRx has an exclusive worldwide collaboration with Celgene to develop motolimod.", "type": 2, "words": ["<tag1>", "VentiRx", "has", "an", "exclusive", "worldwide", "collaboration", "with", "Celgene", "to", "develop", "VTX-2337.", "<tag2>", "VentiRx", "has", "an", "exclusive", "worldwide", "collaboration", "with", "Celgene", "to", "develop", "motolimod.", "<tag3>"], "wordsA": ["VentiRx", "has", "an", "exclusive", "worldwide", "collaboration", "with", "Celgene", "to", "develop", "VTX-2337."], "wordsB": ["VentiRx", "has", "an", "exclusive", "worldwide", "collaboration", "with", "Celgene", "to", "develop", "motolimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p102_s1", "idA": "886163_16_item1_p84_s1", "sentA": "Under the terms of the clinical-stage agreement, we have earned development milestones from VentiRx and revenue from Captisol material sales.", "sentB": "We have received an up front fee and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "have", "earned", "development", "milestones", "from", "VentiRx", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag2>", "We", "have", "received", "an", "up", "front", "fee", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "clinical-stage", "agreement,", "we", "have", "earned", "development", "milestones", "from", "VentiRx", "and", "revenue", "from", "Captisol", "material", "sales."], "wordsB": ["We", "have", "received", "an", "up", "front", "fee", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p4_s0", "idA": "886163_16_item1_p84_s2", "sentA": "Our partner, Millennium/Takeda is currently conducting Phase 2 trials for the development of Pevonedistat for the treatment of hematological malignancies and solid tumors.", "sentB": "On September 7, 2016, Retrophin announced results from the Phase 2 DUET study of sparsentan for the treatment of FSGS, a rare kidney disorder without an FDA-approved pharmacological treatment that often leads to end-stage renal disease.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Pevonedistat", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors.", "<tag2>", "On", "September", "7,", "2016,", "Retrophin", "announced", "results", "from", "the", "Phase", "2", "DUET", "study", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS,", "a", "rare", "kidney", "disorder", "without", "an", "FDA-approved", "pharmacological", "treatment", "that", "often", "leads", "to", "end-stage", "renal", "disease.", "<tag3>"], "wordsA": ["Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Pevonedistat", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors."], "wordsB": ["On", "September", "7,", "2016,", "Retrophin", "announced", "results", "from", "the", "Phase", "2", "DUET", "study", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS,", "a", "rare", "kidney", "disorder", "without", "an", "FDA-approved", "pharmacological", "treatment", "that", "often", "leads", "to", "end-stage", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p88_s0", "idA": "886163_16_item1_p84_s2", "sentA": "Our partner, Millennium/Takeda is currently conducting Phase 2 trials for the development of Pevonedistat for the treatment of hematological malignancies and solid tumors.", "sentB": "Our partner, Millennium/Takeda is currently conducting Phase 2 trials for the development of pevonedistat (MLN-4924) for the treatment of hematological malignancies and solid tumors.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Pevonedistat", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors.", "<tag2>", "Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "pevonedistat", "(MLN-4924)", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors.", "<tag3>"], "wordsA": ["Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "Pevonedistat", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors."], "wordsB": ["Our", "partner,", "Millennium/Takeda", "is", "currently", "conducting", "Phase", "2", "trials", "for", "the", "development", "of", "pevonedistat", "(MLN-4924)", "for", "the", "treatment", "of", "hematological", "malignancies", "and", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p97_s1", "idA": "886163_16_item1_p85_s0", "sentA": "Pevonedistat is a Captisol-enabled Nedd8-Activating Enzyme Inhibitor.", "sentB": "AM0010+PD-1 is a therapeutic target for cancer therapy.", "type": 2, "words": ["<tag1>", "Pevonedistat", "is", "a", "Captisol-enabled", "Nedd8-Activating", "Enzyme", "Inhibitor.", "<tag2>", "AM0010+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy.", "<tag3>"], "wordsA": ["Pevonedistat", "is", "a", "Captisol-enabled", "Nedd8-Activating", "Enzyme", "Inhibitor."], "wordsB": ["AM0010+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p106_s4", "idA": "886163_16_item1_p87_s0", "sentA": "We are currently developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus.", "sentB": "We also initiated a Phase 2 clinical trial in September 2016 for the treatment of type 2 diabetes mellitus (T2DM).", "type": 2, "words": ["<tag1>", "We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "trial", "in", "September", "2016", "for", "the", "treatment", "of", "type", "2", "diabetes", "mellitus", "(T2DM).", "<tag3>"], "wordsA": ["We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "trial", "in", "September", "2016", "for", "the", "treatment", "of", "type", "2", "diabetes", "mellitus", "(T2DM)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p99_s1", "idA": "886163_16_item1_p87_s0", "sentA": "We are currently developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus.", "sentB": "ADX-102 is a Captisol-enabled ophthalmic solution for the treatment of allergic conjunctivitis that could be active in a broad array of inflammatory ocular diseases.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "ADX-102", "is", "a", "Captisol-enabled", "ophthalmic", "solution", "for", "the", "treatment", "of", "allergic", "conjunctivitis", "that", "could", "be", "active", "in", "a", "broad", "array", "of", "inflammatory", "ocular", "diseases.", "<tag3>"], "wordsA": ["We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["ADX-102", "is", "a", "Captisol-enabled", "ophthalmic", "solution", "for", "the", "treatment", "of", "allergic", "conjunctivitis", "that", "could", "be", "active", "in", "a", "broad", "array", "of", "inflammatory", "ocular", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p27_s2", "idA": "886163_16_item1_p89_s2", "sentA": "We conducted a Phase 1b trial showing robust effects throughout multiple ascending dosing, and plan to initiate a Phase 2 clinical trial in 2016.", "sentB": "Ligand expects to report the results from the Phase 2 clinical trial in the third quarter of 2017.", "type": 2, "words": ["<tag1>", "We", "conducted", "a", "Phase", "1b", "trial", "showing", "robust", "effects", "throughout", "multiple", "ascending", "dosing,", "and", "plan", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "in", "2016.", "<tag2>", "Ligand", "expects", "to", "report", "the", "results", "from", "the", "Phase", "2", "clinical", "trial", "in", "the", "third", "quarter", "of", "2017.", "<tag3>"], "wordsA": ["We", "conducted", "a", "Phase", "1b", "trial", "showing", "robust", "effects", "throughout", "multiple", "ascending", "dosing,", "and", "plan", "to", "initiate", "a", "Phase", "2", "clinical", "trial", "in", "2016."], "wordsB": ["Ligand", "expects", "to", "report", "the", "results", "from", "the", "Phase", "2", "clinical", "trial", "in", "the", "third", "quarter", "of", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p7_s0", "idA": "886163_16_item1_p8_s0", "sentA": "On January 21, 2016, Amgen announced that the FDA approved Kyprolis in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.", "sentB": "On March 15, 2016, Spectrum announced that the FDA approved Evomela for use in two indications: as a high dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.", "type": 2, "words": ["<tag1>", "On", "January", "21,", "2016,", "Amgen", "announced", "that", "the", "FDA", "approved", "Kyprolis", "in", "combination", "with", "dexamethasone", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "to", "three", "lines", "of", "therapy.", "<tag2>", "On", "March", "15,", "2016,", "Spectrum", "announced", "that", "the", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:", "as", "a", "high", "dose", "conditioning", "treatment", "prior", "to", "hematopoietic", "progenitor", "(stem)", "cell", "transplantation", "(ASCT)", "in", "patients", "with", "multiple", "myeloma", "and", "for", "the", "palliative", "treatment", "of", "patients", "with", "multiple", "myeloma", "for", "whom", "oral", "therapy", "is", "not", "appropriate.", "<tag3>"], "wordsA": ["On", "January", "21,", "2016,", "Amgen", "announced", "that", "the", "FDA", "approved", "Kyprolis", "in", "combination", "with", "dexamethasone", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "to", "three", "lines", "of", "therapy."], "wordsB": ["On", "March", "15,", "2016,", "Spectrum", "announced", "that", "the", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:", "as", "a", "high", "dose", "conditioning", "treatment", "prior", "to", "hematopoietic", "progenitor", "(stem)", "cell", "transplantation", "(ASCT)", "in", "patients", "with", "multiple", "myeloma", "and", "for", "the", "palliative", "treatment", "of", "patients", "with", "multiple", "myeloma", "for", "whom", "oral", "therapy", "is", "not", "appropriate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p6_s3", "idA": "886163_16_item1_p90_s8", "sentA": "The current term of the agreement with Hovione is through December 2019.", "sentB": "Results from the APECS study are expected in February 2019.", "type": 2, "words": ["<tag1>", "The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019.", "<tag2>", "Results", "from", "the", "APECS", "study", "are", "expected", "in", "February", "2019.", "<tag3>"], "wordsA": ["The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019."], "wordsB": ["Results", "from", "the", "APECS", "study", "are", "expected", "in", "February", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p109_s0", "idA": "886163_16_item1_p92_s0", "sentA": "Competition Some of the drugs we and our licensees are developing may compete with existing therapies or other drugs in development by other companies.", "sentB": "Some of the drugs we and our licensees are developing may compete with existing therapies or other drugs in development by other companies.", "type": 2, "words": ["<tag1>", "Competition", "Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag2>", "Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag3>"], "wordsA": ["Competition", "Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "wordsB": ["Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p117_s0", "idA": "886163_16_item1_p98_s1", "sentA": "Promacta Patents covering Promacta are owned by Novartis.", "sentB": "Patents covering Promacta are owned by Novartis.", "type": 2, "words": ["<tag1>", "Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "Novartis.", "<tag2>", "Patents", "covering", "Promacta", "are", "owned", "by", "Novartis.", "<tag3>"], "wordsA": ["Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "Novartis."], "wordsB": ["Patents", "covering", "Promacta", "are", "owned", "by", "Novartis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p13_s1", "idA": "886163_16_item1_p9_s0", "sentA": "On November 19, 2015, Amgen announced the EC approval of Kyprolis in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.", "sentB": "The first study initiated as part of this agreement is a Phase 3 registrational trial evaluating Kyprolis in combination with DARZALEX and dexamethasone compared to Kyprolis and dexamethasone alone in patients with multiple myeloma who have had one, two or three prior lines of therapy.", "type": 2, "words": ["<tag1>", "On", "November", "19,", "2015,", "Amgen", "announced", "the", "EC", "approval", "of", "Kyprolis", "in", "combination", "with", "lenalidomide", "and", "dexamethasone", "for", "the", "treatment", "of", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy.", "<tag2>", "The", "first", "study", "initiated", "as", "part", "of", "this", "agreement", "is", "a", "Phase", "3", "registrational", "trial", "evaluating", "Kyprolis", "in", "combination", "with", "DARZALEX", "and", "dexamethasone", "compared", "to", "Kyprolis", "and", "dexamethasone", "alone", "in", "patients", "with", "multiple", "myeloma", "who", "have", "had", "one,", "two", "or", "three", "prior", "lines", "of", "therapy.", "<tag3>"], "wordsA": ["On", "November", "19,", "2015,", "Amgen", "announced", "the", "EC", "approval", "of", "Kyprolis", "in", "combination", "with", "lenalidomide", "and", "dexamethasone", "for", "the", "treatment", "of", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy."], "wordsB": ["The", "first", "study", "initiated", "as", "part", "of", "this", "agreement", "is", "a", "Phase", "3", "registrational", "trial", "evaluating", "Kyprolis", "in", "combination", "with", "DARZALEX", "and", "dexamethasone", "compared", "to", "Kyprolis", "and", "dexamethasone", "alone", "in", "patients", "with", "multiple", "myeloma", "who", "have", "had", "one,", "two", "or", "three", "prior", "lines", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p9_s0", "idA": "886163_16_item1_p9_s0", "sentA": "On November 19, 2015, Amgen announced the EC approval of Kyprolis in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.", "sentB": "On July 3, 2016, Amgen announced that the European Commission approved an expanded indication for Kyprolis , to be used in combination with dexamethasone alone, for adult patients with multiple myeloma who have received at least one prior therapy.", "type": 2, "words": ["<tag1>", "On", "November", "19,", "2015,", "Amgen", "announced", "the", "EC", "approval", "of", "Kyprolis", "in", "combination", "with", "lenalidomide", "and", "dexamethasone", "for", "the", "treatment", "of", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy.", "<tag2>", "On", "July", "3,", "2016,", "Amgen", "announced", "that", "the", "European", "Commission", "approved", "an", "expanded", "indication", "for", "Kyprolis", ",", "to", "be", "used", "in", "combination", "with", "dexamethasone", "alone,", "for", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy.", "<tag3>"], "wordsA": ["On", "November", "19,", "2015,", "Amgen", "announced", "the", "EC", "approval", "of", "Kyprolis", "in", "combination", "with", "lenalidomide", "and", "dexamethasone", "for", "the", "treatment", "of", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy."], "wordsB": ["On", "July", "3,", "2016,", "Amgen", "announced", "that", "the", "European", "Commission", "approved", "an", "expanded", "indication", "for", "Kyprolis", ",", "to", "be", "used", "in", "combination", "with", "dexamethasone", "alone,", "for", "adult", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "one", "prior", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p0_s2", "idA": "886163_17_item1_p0_s2", "sentA": "We currently have partnerships and license agreements with over 95 pharmaceutical and biotechnology companies, and over 160 different programs under license with us are currently in various stages of commercialization and development.", "sentB": "We currently have partnerships and license agreements with over 95 pharmaceutical and biotechnology companies, and over 165 different programs under license with us are currently in various stages of commercialization and development.", "type": 2, "words": ["<tag1>", "We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "95", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "160", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development.", "<tag2>", "We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "95", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "165", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development.", "<tag3>"], "wordsA": ["We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "95", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "160", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development."], "wordsB": ["We", "currently", "have", "partnerships", "and", "license", "agreements", "with", "over", "95", "pharmaceutical", "and", "biotechnology", "companies,", "and", "over", "165", "different", "programs", "under", "license", "with", "us", "are", "currently", "in", "various", "stages", "of", "commercialization", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p0_s5", "idA": "886163_17_item1_p0_s5", "sentA": "We have over 500 issued patents worldwide, and over 200 currently pending patent applications.", "sentB": "We have over 800 issued patents worldwide.", "type": 2, "words": ["<tag1>", "We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "200", "currently", "pending", "patent", "applications.", "<tag2>", "We", "have", "over", "800", "issued", "patents", "worldwide.", "<tag3>"], "wordsA": ["We", "have", "over", "500", "issued", "patents", "worldwide,", "and", "over", "200", "currently", "pending", "patent", "applications."], "wordsB": ["We", "have", "over", "800", "issued", "patents", "worldwide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p106_s1", "idA": "886163_17_item1_p100_s0", "sentA": "Under the terms of our agreement with Aldeyra, we are entitled to receive regulatory milestones and royalties on future sales.", "sentB": "Under the terms of the agreement, we are entitled to milestones and royalties on future sales of AMG 330 formulated with Captisol.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "our", "agreement", "with", "Aldeyra,", "we", "are", "entitled", "to", "receive", "regulatory", "milestones", "and", "royalties", "on", "future", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "milestones", "and", "royalties", "on", "future", "sales", "of", "AMG", "330", "formulated", "with", "Captisol.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "our", "agreement", "with", "Aldeyra,", "we", "are", "entitled", "to", "receive", "regulatory", "milestones", "and", "royalties", "on", "future", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "milestones", "and", "royalties", "on", "future", "sales", "of", "AMG", "330", "formulated", "with", "Captisol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p108_s0", "idA": "886163_17_item1_p100_s0", "sentA": "Under the terms of our agreement with Aldeyra, we are entitled to receive regulatory milestones and royalties on future sales.", "sentB": "Under the terms of the agreement with Aptevo, we are entitled to milestones and royalties on future sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "our", "agreement", "with", "Aldeyra,", "we", "are", "entitled", "to", "receive", "regulatory", "milestones", "and", "royalties", "on", "future", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement", "with", "Aptevo,", "we", "are", "entitled", "to", "milestones", "and", "royalties", "on", "future", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "our", "agreement", "with", "Aldeyra,", "we", "are", "entitled", "to", "receive", "regulatory", "milestones", "and", "royalties", "on", "future", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement", "with", "Aptevo,", "we", "are", "entitled", "to", "milestones", "and", "royalties", "on", "future", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p15_s2", "idA": "886163_17_item1_p101_s0", "sentA": "Esaxerenone (Exelixis) Our partner, Exelixis, entered into a collaboration agreement with Daiichi Sankyo and is conducting a phase 3 pivotal trial (ESAX-HTN) to evaluate esaxerenone (CS-3150) versus eplerenone for essential hypertension in Japanese patients.", "sentB": "Following approval, Melinta Therapeutics entered into a $90 million loan and securities financing agreement with Oberland Capital Management, LLC to fund commercialization activities and indication expansion of Baxdela.", "type": 2, "words": ["<tag1>", "Esaxerenone", "(Exelixis)", "Our", "partner,", "Exelixis,", "entered", "into", "a", "collaboration", "agreement", "with", "Daiichi", "Sankyo", "and", "is", "conducting", "a", "phase", "3", "pivotal", "trial", "(ESAX-HTN)", "to", "evaluate", "esaxerenone", "(CS-3150)", "versus", "eplerenone", "for", "essential", "hypertension", "in", "Japanese", "patients.", "<tag2>", "Following", "approval,", "Melinta", "Therapeutics", "entered", "into", "a", "$90", "million", "loan", "and", "securities", "financing", "agreement", "with", "Oberland", "Capital", "Management,", "LLC", "to", "fund", "commercialization", "activities", "and", "indication", "expansion", "of", "Baxdela.", "<tag3>"], "wordsA": ["Esaxerenone", "(Exelixis)", "Our", "partner,", "Exelixis,", "entered", "into", "a", "collaboration", "agreement", "with", "Daiichi", "Sankyo", "and", "is", "conducting", "a", "phase", "3", "pivotal", "trial", "(ESAX-HTN)", "to", "evaluate", "esaxerenone", "(CS-3150)", "versus", "eplerenone", "for", "essential", "hypertension", "in", "Japanese", "patients."], "wordsB": ["Following", "approval,", "Melinta", "Therapeutics", "entered", "into", "a", "$90", "million", "loan", "and", "securities", "financing", "agreement", "with", "Oberland", "Capital", "Management,", "LLC", "to", "fund", "commercialization", "activities", "and", "indication", "expansion", "of", "Baxdela."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p9_s0", "idA": "886163_17_item1_p101_s0", "sentA": "Esaxerenone (Exelixis) Our partner, Exelixis, entered into a collaboration agreement with Daiichi Sankyo and is conducting a phase 3 pivotal trial (ESAX-HTN) to evaluate esaxerenone (CS-3150) versus eplerenone for essential hypertension in Japanese patients.", "sentB": "Exelixis announced that Daiichi Sankyo reported positive top-line results from a Phase 3 pivotal trial of esaxerenone in patients with essential hypertension in Japan and that a Japanese regulatory application is expected to be submitted in 2018.", "type": 2, "words": ["<tag1>", "Esaxerenone", "(Exelixis)", "Our", "partner,", "Exelixis,", "entered", "into", "a", "collaboration", "agreement", "with", "Daiichi", "Sankyo", "and", "is", "conducting", "a", "phase", "3", "pivotal", "trial", "(ESAX-HTN)", "to", "evaluate", "esaxerenone", "(CS-3150)", "versus", "eplerenone", "for", "essential", "hypertension", "in", "Japanese", "patients.", "<tag2>", "Exelixis", "announced", "that", "Daiichi", "Sankyo", "reported", "positive", "top-line", "results", "from", "a", "Phase", "3", "pivotal", "trial", "of", "esaxerenone", "in", "patients", "with", "essential", "hypertension", "in", "Japan", "and", "that", "a", "Japanese", "regulatory", "application", "is", "expected", "to", "be", "submitted", "in", "2018.", "<tag3>"], "wordsA": ["Esaxerenone", "(Exelixis)", "Our", "partner,", "Exelixis,", "entered", "into", "a", "collaboration", "agreement", "with", "Daiichi", "Sankyo", "and", "is", "conducting", "a", "phase", "3", "pivotal", "trial", "(ESAX-HTN)", "to", "evaluate", "esaxerenone", "(CS-3150)", "versus", "eplerenone", "for", "essential", "hypertension", "in", "Japanese", "patients."], "wordsB": ["Exelixis", "announced", "that", "Daiichi", "Sankyo", "reported", "positive", "top-line", "results", "from", "a", "Phase", "3", "pivotal", "trial", "of", "esaxerenone", "in", "patients", "with", "essential", "hypertension", "in", "Japan", "and", "that", "a", "Japanese", "regulatory", "application", "is", "expected", "to", "be", "submitted", "in", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p15_s1", "idA": "886163_17_item1_p101_s1", "sentA": "Under the terms of the agreement with Exelixis, we are entitled to receive a royalty on future sales.", "sentB": "As a result of the approval, Ligand earned a $1.5 million milestone payment and will earn a 2.5% royalty on Baxdela IV sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement", "with", "Exelixis,", "we", "are", "entitled", "to", "receive", "a", "royalty", "on", "future", "sales.", "<tag2>", "As", "a", "result", "of", "the", "approval,", "Ligand", "earned", "a", "$1.5", "million", "milestone", "payment", "and", "will", "earn", "a", "2.5%", "royalty", "on", "Baxdela", "IV", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement", "with", "Exelixis,", "we", "are", "entitled", "to", "receive", "a", "royalty", "on", "future", "sales."], "wordsB": ["As", "a", "result", "of", "the", "approval,", "Ligand", "earned", "a", "$1.5", "million", "milestone", "payment", "and", "will", "earn", "a", "2.5%", "royalty", "on", "Baxdela", "IV", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p111_s0", "idA": "886163_17_item1_p104_s0", "sentA": "We are currently developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus.", "sentB": "We are currently developing a small molecule glucagon receptor antagonist for the treatment of T2 DM.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "T2", "DM.", "<tag3>"], "wordsA": ["We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "T2", "DM."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p113_s2", "idA": "886163_17_item1_p106_s2", "sentA": "We announced results in 2016 from two Phase I clinical trials which demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.", "sentB": "We announced results in 2016 from two Phase 1 clinical trials which demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with T2 DM.", "type": 2, "words": ["<tag1>", "We", "announced", "results", "in", "2016", "from", "two", "Phase", "I", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus.", "<tag2>", "We", "announced", "results", "in", "2016", "from", "two", "Phase", "1", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "T2", "DM.", "<tag3>"], "wordsA": ["We", "announced", "results", "in", "2016", "from", "two", "Phase", "I", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus."], "wordsB": ["We", "announced", "results", "in", "2016", "from", "two", "Phase", "1", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "T2", "DM."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p3_s0", "idA": "886163_17_item1_p106_s2", "sentA": "We announced results in 2016 from two Phase I clinical trials which demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.", "sentB": "Sage Therapeutics announced positive top-line results from two Phase 3 trials of brexanolone in severe PPD and in moderate PPD.", "type": 2, "words": ["<tag1>", "We", "announced", "results", "in", "2016", "from", "two", "Phase", "I", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus.", "<tag2>", "Sage", "Therapeutics", "announced", "positive", "top-line", "results", "from", "two", "Phase", "3", "trials", "of", "brexanolone", "in", "severe", "PPD", "and", "in", "moderate", "PPD.", "<tag3>"], "wordsA": ["We", "announced", "results", "in", "2016", "from", "two", "Phase", "I", "clinical", "trials", "which", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus."], "wordsB": ["Sage", "Therapeutics", "announced", "positive", "top-line", "results", "from", "two", "Phase", "3", "trials", "of", "brexanolone", "in", "severe", "PPD", "and", "in", "moderate", "PPD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p8_s0", "idA": "886163_17_item1_p106_s4", "sentA": "We also initiated a Phase 2 clinical trial in September 2016 for the treatment of type 2 diabetes mellitus (T2DM).", "sentB": "Marinus Pharmaceuticals announced that it had initiated a Phase 2 double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and pharmacokinetics of ganaxolone IV in women diagnosed with severe postpartum depression.", "type": 2, "words": ["<tag1>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "trial", "in", "September", "2016", "for", "the", "treatment", "of", "type", "2", "diabetes", "mellitus", "(T2DM).", "<tag2>", "Marinus", "Pharmaceuticals", "announced", "that", "it", "had", "initiated", "a", "Phase", "2", "double-blind,", "placebo-controlled", "clinical", "trial", "to", "evaluate", "the", "safety,", "efficacy", "and", "pharmacokinetics", "of", "ganaxolone", "IV", "in", "women", "diagnosed", "with", "severe", "postpartum", "depression.", "<tag3>"], "wordsA": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "trial", "in", "September", "2016", "for", "the", "treatment", "of", "type", "2", "diabetes", "mellitus", "(T2DM)."], "wordsB": ["Marinus", "Pharmaceuticals", "announced", "that", "it", "had", "initiated", "a", "Phase", "2", "double-blind,", "placebo-controlled", "clinical", "trial", "to", "evaluate", "the", "safety,", "efficacy", "and", "pharmacokinetics", "of", "ganaxolone", "IV", "in", "women", "diagnosed", "with", "severe", "postpartum", "depression."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p13_s0", "idA": "886163_17_item1_p106_s5", "sentA": "The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin.", "sentB": "Opthea announced the dosing of the first patient in the Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) and the commencement a Phase 1b/2a trial evaluating the safety and efficacy of OPT-302 in patients with center-involved diabetic macular edema.", "type": 2, "words": ["<tag1>", "The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin.", "<tag2>", "Opthea", "announced", "the", "dosing", "of", "the", "first", "patient", "in", "the", "Phase", "2b", "trial", "of", "OPT-302", "for", "wet", "age-related", "macular", "degeneration", "(AMD)", "and", "the", "commencement", "a", "Phase", "1b/2a", "trial", "evaluating", "the", "safety", "and", "efficacy", "of", "OPT-302", "in", "patients", "with", "center-involved", "diabetic", "macular", "edema.", "<tag3>"], "wordsA": ["The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin."], "wordsB": ["Opthea", "announced", "the", "dosing", "of", "the", "first", "patient", "in", "the", "Phase", "2b", "trial", "of", "OPT-302", "for", "wet", "age-related", "macular", "degeneration", "(AMD)", "and", "the", "commencement", "a", "Phase", "1b/2a", "trial", "evaluating", "the", "safety", "and", "efficacy", "of", "OPT-302", "in", "patients", "with", "center-involved", "diabetic", "macular", "edema."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p115_s0", "idA": "886163_17_item1_p107_s0", "sentA": "Manufacturing We currently have no manufacturing facilities and rely on a third party, Hovione, for Captisol production.", "sentB": "Manufacturing We contract with a third party manufacturer, Hovione, for Captisol production.", "type": 2, "words": ["<tag1>", "Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "a", "third", "party,", "Hovione,", "for", "Captisol", "production.", "<tag2>", "Manufacturing", "We", "contract", "with", "a", "third", "party", "manufacturer,", "Hovione,", "for", "Captisol", "production.", "<tag3>"], "wordsA": ["Manufacturing", "We", "currently", "have", "no", "manufacturing", "facilities", "and", "rely", "on", "a", "third", "party,", "Hovione,", "for", "Captisol", "production."], "wordsB": ["Manufacturing", "We", "contract", "with", "a", "third", "party", "manufacturer,", "Hovione,", "for", "Captisol", "production."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p115_s3", "idA": "886163_17_item1_p107_s3", "sentA": "Manufacturing operations for Captisol are currently performed in both of Hovione's Portugal and Ireland sites with distribution operations also performed from Hovione's Portugal and Ireland sites.", "sentB": "Manufacturing operations for Captisol are currently performed at two sites, in both of Hovione's Portugal and Ireland facilities with distribution operations also performed from Hovione's Portugal and Ireland sites.", "type": 2, "words": ["<tag1>", "Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites", "with", "distribution", "operations", "also", "performed", "from", "Hovione's", "Portugal", "and", "Ireland", "sites.", "<tag2>", "Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "at", "two", "sites,", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "facilities", "with", "distribution", "operations", "also", "performed", "from", "Hovione's", "Portugal", "and", "Ireland", "sites.", "<tag3>"], "wordsA": ["Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites", "with", "distribution", "operations", "also", "performed", "from", "Hovione's", "Portugal", "and", "Ireland", "sites."], "wordsB": ["Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "at", "two", "sites,", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "facilities", "with", "distribution", "operations", "also", "performed", "from", "Hovione's", "Portugal", "and", "Ireland", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p115_s13", "idA": "886163_17_item1_p107_s4", "sentA": "We have ongoing minimum purchase commitments under the agreement and are required to pay Hovione an aggregate minimum amount during the agreement term.", "sentB": "We have ongoing minimum purchase commitments under the agreement.", "type": 2, "words": ["<tag1>", "We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement", "and", "are", "required", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term.", "<tag2>", "We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement.", "<tag3>"], "wordsA": ["We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement", "and", "are", "required", "to", "pay", "Hovione", "an", "aggregate", "minimum", "amount", "during", "the", "agreement", "term."], "wordsB": ["We", "have", "ongoing", "minimum", "purchase", "commitments", "under", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p115_s8", "idA": "886163_17_item1_p107_s7", "sentA": "In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event or if the unit price of Captisol exceeds a set figure, we may obtain Captisol from a third party.", "sentB": "In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event, we may also obtain Captisol from a third party and have previously identified such parties.", "type": 2, "words": ["<tag1>", "In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party.", "<tag2>", "In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event,", "we", "may", "also", "obtain", "Captisol", "from", "a", "third", "party", "and", "have", "previously", "identified", "such", "parties.", "<tag3>"], "wordsA": ["In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party."], "wordsB": ["In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event,", "we", "may", "also", "obtain", "Captisol", "from", "a", "third", "party", "and", "have", "previously", "identified", "such", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p115_s9", "idA": "886163_17_item1_p107_s8", "sentA": "The current term of the agreement with Hovione is through December 2019.", "sentB": "The current term of the agreement with Hovione is through December 2024.", "type": 2, "words": ["<tag1>", "The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019.", "<tag2>", "The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2024.", "<tag3>"], "wordsA": ["The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019."], "wordsB": ["The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2024."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p32_s1", "idA": "886163_17_item1_p107_s8", "sentA": "The current term of the agreement with Hovione is through December 2019.", "sentB": "Ligand originally licensed U.S. rights to oral lasofoxifene to Sermonix in February of 2015, and expanded the agreement to include the rest of the world.", "type": 2, "words": ["<tag1>", "The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019.", "<tag2>", "Ligand", "originally", "licensed", "U.S.", "rights", "to", "oral", "lasofoxifene", "to", "Sermonix", "in", "February", "of", "2015,", "and", "expanded", "the", "agreement", "to", "include", "the", "rest", "of", "the", "world.", "<tag3>"], "wordsA": ["The", "current", "term", "of", "the", "agreement", "with", "Hovione", "is", "through", "December", "2019."], "wordsB": ["Ligand", "originally", "licensed", "U.S.", "rights", "to", "oral", "lasofoxifene", "to", "Sermonix", "in", "February", "of", "2015,", "and", "expanded", "the", "agreement", "to", "include", "the", "rest", "of", "the", "world."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p118_s0", "idA": "886163_17_item1_p109_s0", "sentA": "Some of the drugs we and our licensees are developing may compete with existing therapies or other drugs in development by other companies.", "sentB": "Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies.", "type": 2, "words": ["<tag1>", "Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag2>", "Some", "of", "the", "drugs", "we", "and", "our", "licensees", "and", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag3>"], "wordsA": ["Some", "of", "the", "drugs", "we", "and", "our", "licensees", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "wordsB": ["Some", "of", "the", "drugs", "we", "and", "our", "licensees", "and", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p32_s0", "idA": "886163_17_item1_p114_s2", "sentA": "We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.", "sentB": "Expansion of Ligand s license with Sermonix Pharmaceuticals to include worldwide rights to develop and commercialize oral lasofoxifene.", "type": 2, "words": ["<tag1>", "We", "also", "rely", "upon", "trade", "secrets,", "know-how,", "continuing", "technological", "innovations", "and", "licensing", "opportunities", "to", "develop", "and", "maintain", "our", "competitive", "position.", "<tag2>", "Expansion", "of", "Ligand", "s", "license", "with", "Sermonix", "Pharmaceuticals", "to", "include", "worldwide", "rights", "to", "develop", "and", "commercialize", "oral", "lasofoxifene.", "<tag3>"], "wordsA": ["We", "also", "rely", "upon", "trade", "secrets,", "know-how,", "continuing", "technological", "innovations", "and", "licensing", "opportunities", "to", "develop", "and", "maintain", "our", "competitive", "position."], "wordsB": ["Expansion", "of", "Ligand", "s", "license", "with", "Sermonix", "Pharmaceuticals", "to", "include", "worldwide", "rights", "to", "develop", "and", "commercialize", "oral", "lasofoxifene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p11_s0", "idA": "886163_17_item1_p115_s0", "sentA": "Patents are issued or pending for the following key products or product families.", "sentB": "Aldeyra announced the following for reproxalap (ADX-102):", "type": 2, "words": ["<tag1>", "Patents", "are", "issued", "or", "pending", "for", "the", "following", "key", "products", "or", "product", "families.", "<tag2>", "Aldeyra", "announced", "the", "following", "for", "reproxalap", "(ADX-102):", "<tag3>"], "wordsA": ["Patents", "are", "issued", "or", "pending", "for", "the", "following", "key", "products", "or", "product", "families."], "wordsB": ["Aldeyra", "announced", "the", "following", "for", "reproxalap", "(ADX-102):"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p133_s0", "idA": "886163_17_item1_p124_s0", "sentA": "Ligand has received patent protection in 27 countries, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in the table below) and has 19 patent applications pending worldwide.", "sentB": "OmniChicken Ligand has received patent protection in 27 countries, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in the table below) and has 19 patent applications pending worldwide.", "type": 2, "words": ["<tag1>", "Ligand", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide.", "<tag2>", "OmniChicken", "Ligand", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide.", "<tag3>"], "wordsA": ["Ligand", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide."], "wordsB": ["OmniChicken", "Ligand", "has", "received", "patent", "protection", "in", "27", "countries,", "including", "the", "United", "States,", "multiple", "countries", "throughout", "Europe,", "Japan", "and", "China", "(see", "selected", "cases", "listed", "in", "the", "table", "below)", "and", "has", "19", "patent", "applications", "pending", "worldwide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p115_s4", "idA": "886163_17_item1_p126_s0", "sentA": "LTP Technology Patent applications related to our LTP Technology include two families owned by Ligand and one owned by Omthera.", "sentB": "Additionally, we also store and distribute Captisol from a subterranean warehouse controlled by Ligand and located in Kansas.", "type": 2, "words": ["<tag1>", "LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "two", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera.", "<tag2>", "Additionally,", "we", "also", "store", "and", "distribute", "Captisol", "from", "a", "subterranean", "warehouse", "controlled", "by", "Ligand", "and", "located", "in", "Kansas.", "<tag3>"], "wordsA": ["LTP", "Technology", "Patent", "applications", "related", "to", "our", "LTP", "Technology", "include", "two", "families", "owned", "by", "Ligand", "and", "one", "owned", "by", "Omthera."], "wordsB": ["Additionally,", "we", "also", "store", "and", "distribute", "Captisol", "from", "a", "subterranean", "warehouse", "controlled", "by", "Ligand", "and", "located", "in", "Kansas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p135_s1", "idA": "886163_17_item1_p126_s4", "sentA": "Patents covering LGD-6972, if issued, with the latest expiration date would not be set to expire until 2035 ( see, e.g., WO 2015/191900 (contains composition of matter and use claims; filed June 11, 2015)).", "sentB": "Patents covering various forms of LGD-6972, if issued, with the latest expiration date would not be expected to expire until 2039.", "type": 2, "words": ["<tag1>", "Patents", "covering", "LGD-6972,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2035", "(", "see,", "e.g.,", "WO", "2015/191900", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "June", "11,", "2015)).", "<tag2>", "Patents", "covering", "various", "forms", "of", "LGD-6972,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "expected", "to", "expire", "until", "2039.", "<tag3>"], "wordsA": ["Patents", "covering", "LGD-6972,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2035", "(", "see,", "e.g.,", "WO", "2015/191900", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "June", "11,", "2015))."], "wordsB": ["Patents", "covering", "various", "forms", "of", "LGD-6972,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "expected", "to", "expire", "until", "2039."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p137_s0", "idA": "886163_17_item1_p128_s0", "sentA": "Human Resources As of February 6, 2016, we had 22 full-time employees, of whom eight are involved directly in scientific research and development activities.", "sentB": "Human Resources As of February 16, 2018, we had 39 full-time employees, of whom 25 are involved directly in scientific research and development activities.", "type": 2, "words": ["<tag1>", "Human", "Resources", "As", "of", "February", "6,", "2016,", "we", "had", "22", "full-time", "employees,", "of", "whom", "eight", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag2>", "Human", "Resources", "As", "of", "February", "16,", "2018,", "we", "had", "39", "full-time", "employees,", "of", "whom", "25", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["Human", "Resources", "As", "of", "February", "6,", "2016,", "we", "had", "22", "full-time", "employees,", "of", "whom", "eight", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "wordsB": ["Human", "Resources", "As", "of", "February", "16,", "2018,", "we", "had", "39", "full-time", "employees,", "of", "whom", "25", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p15_s0", "idA": "886163_17_item1_p12_s0", "sentA": "On October 24, 2016, Melinta Therapeutics announced it submitted a NDA for approval of IV Baxdela for the treatment of patients with acute bacterial skin and skin structure infections.", "sentB": "Melinta Therapeutics announced that the FDA approved both IV and oral Baxdela (delafloxacin) for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.", "type": 2, "words": ["<tag1>", "On", "October", "24,", "2016,", "Melinta", "Therapeutics", "announced", "it", "submitted", "a", "NDA", "for", "approval", "of", "IV", "Baxdela", "for", "the", "treatment", "of", "patients", "with", "acute", "bacterial", "skin", "and", "skin", "structure", "infections.", "<tag2>", "Melinta", "Therapeutics", "announced", "that", "the", "FDA", "approved", "both", "IV", "and", "oral", "Baxdela", "(delafloxacin)", "for", "the", "treatment", "of", "adults", "with", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI)", "caused", "by", "susceptible", "bacteria.", "<tag3>"], "wordsA": ["On", "October", "24,", "2016,", "Melinta", "Therapeutics", "announced", "it", "submitted", "a", "NDA", "for", "approval", "of", "IV", "Baxdela", "for", "the", "treatment", "of", "patients", "with", "acute", "bacterial", "skin", "and", "skin", "structure", "infections."], "wordsB": ["Melinta", "Therapeutics", "announced", "that", "the", "FDA", "approved", "both", "IV", "and", "oral", "Baxdela", "(delafloxacin)", "for", "the", "treatment", "of", "adults", "with", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI)", "caused", "by", "susceptible", "bacteria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p7_s0", "idA": "886163_17_item1_p13_s1", "sentA": "The first study initiated as part of this agreement is a Phase 3 registrational trial evaluating Kyprolis in combination with DARZALEX and dexamethasone compared to Kyprolis and dexamethasone alone in patients with multiple myeloma who have had one, two or three prior lines of therapy.", "sentB": "Merrimack announced that it had enrolled the last patient in the ongoing CARRIE study, a Phase 2, double-blind, placebo-controlled, randomized trial evaluating MM-141 (istiratumab) in combination with standard of care in previously untreated patients with metastatic pancreatic cancer.", "type": 2, "words": ["<tag1>", "The", "first", "study", "initiated", "as", "part", "of", "this", "agreement", "is", "a", "Phase", "3", "registrational", "trial", "evaluating", "Kyprolis", "in", "combination", "with", "DARZALEX", "and", "dexamethasone", "compared", "to", "Kyprolis", "and", "dexamethasone", "alone", "in", "patients", "with", "multiple", "myeloma", "who", "have", "had", "one,", "two", "or", "three", "prior", "lines", "of", "therapy.", "<tag2>", "Merrimack", "announced", "that", "it", "had", "enrolled", "the", "last", "patient", "in", "the", "ongoing", "CARRIE", "study,", "a", "Phase", "2,", "double-blind,", "placebo-controlled,", "randomized", "trial", "evaluating", "MM-141", "(istiratumab)", "in", "combination", "with", "standard", "of", "care", "in", "previously", "untreated", "patients", "with", "metastatic", "pancreatic", "cancer.", "<tag3>"], "wordsA": ["The", "first", "study", "initiated", "as", "part", "of", "this", "agreement", "is", "a", "Phase", "3", "registrational", "trial", "evaluating", "Kyprolis", "in", "combination", "with", "DARZALEX", "and", "dexamethasone", "compared", "to", "Kyprolis", "and", "dexamethasone", "alone", "in", "patients", "with", "multiple", "myeloma", "who", "have", "had", "one,", "two", "or", "three", "prior", "lines", "of", "therapy."], "wordsB": ["Merrimack", "announced", "that", "it", "had", "enrolled", "the", "last", "patient", "in", "the", "ongoing", "CARRIE", "study,", "a", "Phase", "2,", "double-blind,", "placebo-controlled,", "randomized", "trial", "evaluating", "MM-141", "(istiratumab)", "in", "combination", "with", "standard", "of", "care", "in", "previously", "untreated", "patients", "with", "metastatic", "pancreatic", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p25_s0", "idA": "886163_17_item1_p17_s0", "sentA": "Worldwide platform license agreement with F-Star for access to the OmniAb technology.", "sentB": "W orldwide platform license agreement with bluebird bio, Inc.", "type": 2, "words": ["<tag1>", "Worldwide", "platform", "license", "agreement", "with", "F-Star", "for", "access", "to", "the", "OmniAb", "technology.", "<tag2>", "W", "orldwide", "platform", "license", "agreement", "with", "bluebird", "bio,", "Inc.", "<tag3>"], "wordsA": ["Worldwide", "platform", "license", "agreement", "with", "F-Star", "for", "access", "to", "the", "OmniAb", "technology."], "wordsB": ["W", "orldwide", "platform", "license", "agreement", "with", "bluebird", "bio,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p25_s3", "idA": "886163_17_item1_p18_s0", "sentA": "Current OmniAb licensee exercised its option to expand access to the OmniAb platform.", "sentB": "Ligand previously disclosed rights to a single-antibody partnership had been licensed to bluebird, but this new agreement gives bluebird full access to the OmniAb platform.", "type": 2, "words": ["<tag1>", "Current", "OmniAb", "licensee", "exercised", "its", "option", "to", "expand", "access", "to", "the", "OmniAb", "platform.", "<tag2>", "Ligand", "previously", "disclosed", "rights", "to", "a", "single-antibody", "partnership", "had", "been", "licensed", "to", "bluebird,", "but", "this", "new", "agreement", "gives", "bluebird", "full", "access", "to", "the", "OmniAb", "platform.", "<tag3>"], "wordsA": ["Current", "OmniAb", "licensee", "exercised", "its", "option", "to", "expand", "access", "to", "the", "OmniAb", "platform."], "wordsB": ["Ligand", "previously", "disclosed", "rights", "to", "a", "single-antibody", "partnership", "had", "been", "licensed", "to", "bluebird,", "but", "this", "new", "agreement", "gives", "bluebird", "full", "access", "to", "the", "OmniAb", "platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p19_s0", "idA": "886163_17_item1_p22_s0", "sentA": "Worldwide license agreement with Teneobio for access to the OmniAb technology.", "sentB": "Janssen filed an IND application for an antibody discovered using Ligand s OmniAb technology.", "type": 2, "words": ["<tag1>", "Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology.", "<tag2>", "Janssen", "filed", "an", "IND", "application", "for", "an", "antibody", "discovered", "using", "Ligand", "s", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology."], "wordsB": ["Janssen", "filed", "an", "IND", "application", "for", "an", "antibody", "discovered", "using", "Ligand", "s", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p19_s2", "idA": "886163_17_item1_p22_s0", "sentA": "Worldwide license agreement with Teneobio for access to the OmniAb technology.", "sentB": "Janssen has a royalty-free license to the OmniAb technology (entered into with OMT in October of 2013), but will potentially pay Ligand further development and commercial milestones upon clinical success and regulatory approval of any therapeutic developed using the OmniAb technology.", "type": 2, "words": ["<tag1>", "Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology.", "<tag2>", "Janssen", "has", "a", "royalty-free", "license", "to", "the", "OmniAb", "technology", "(entered", "into", "with", "OMT", "in", "October", "of", "2013),", "but", "will", "potentially", "pay", "Ligand", "further", "development", "and", "commercial", "milestones", "upon", "clinical", "success", "and", "regulatory", "approval", "of", "any", "therapeutic", "developed", "using", "the", "OmniAb", "technology.", "<tag3>"], "wordsA": ["Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology."], "wordsB": ["Janssen", "has", "a", "royalty-free", "license", "to", "the", "OmniAb", "technology", "(entered", "into", "with", "OMT", "in", "October", "of", "2013),", "but", "will", "potentially", "pay", "Ligand", "further", "development", "and", "commercial", "milestones", "upon", "clinical", "success", "and", "regulatory", "approval", "of", "any", "therapeutic", "developed", "using", "the", "OmniAb", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p23_s0", "idA": "886163_17_item1_p22_s0", "sentA": "Worldwide license agreement with Teneobio for access to the OmniAb technology.", "sentB": "Worldwide license agreements with Surface Oncology, xCella Biosciences, Ferring Pharmaceuticals and Glenmark Pharmaceuticals to use the OmniAb platform technologies to discover fully human antibodies.", "type": 2, "words": ["<tag1>", "Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology.", "<tag2>", "Worldwide", "license", "agreements", "with", "Surface", "Oncology,", "xCella", "Biosciences,", "Ferring", "Pharmaceuticals", "and", "Glenmark", "Pharmaceuticals", "to", "use", "the", "OmniAb", "platform", "technologies", "to", "discover", "fully", "human", "antibodies.", "<tag3>"], "wordsA": ["Worldwide", "license", "agreement", "with", "Teneobio", "for", "access", "to", "the", "OmniAb", "technology."], "wordsB": ["Worldwide", "license", "agreements", "with", "Surface", "Oncology,", "xCella", "Biosciences,", "Ferring", "Pharmaceuticals", "and", "Glenmark", "Pharmaceuticals", "to", "use", "the", "OmniAb", "platform", "technologies", "to", "discover", "fully", "human", "antibodies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p27_s0", "idA": "886163_17_item1_p25_s0", "sentA": "Global license and supply agreement with Novartis for the development and commercialization of a CE-oral liquid formulation of trametinib.", "sentB": "Commercial license and supply agreement with Amgen granting rights to use Captisol in the formulation of AMG 330, an anti-CD33 x anti-CD3 (BiTE ) bispecific antibody construct.", "type": 2, "words": ["<tag1>", "Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib.", "<tag2>", "Commercial", "license", "and", "supply", "agreement", "with", "Amgen", "granting", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "AMG", "330,", "an", "anti-CD33", "x", "anti-CD3", "(BiTE", ")", "bispecific", "antibody", "construct.", "<tag3>"], "wordsA": ["Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib."], "wordsB": ["Commercial", "license", "and", "supply", "agreement", "with", "Amgen", "granting", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "AMG", "330,", "an", "anti-CD33", "x", "anti-CD3", "(BiTE", ")", "bispecific", "antibody", "construct."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p28_s0", "idA": "886163_17_item1_p25_s0", "sentA": "Global license and supply agreement with Novartis for the development and commercialization of a CE-oral liquid formulation of trametinib.", "sentB": "Commercial license and supply agreement with Marinus Pharmaceuticals granting rights to use Captisol in the formulation of IV ganaxolone.", "type": 2, "words": ["<tag1>", "Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib.", "<tag2>", "Commercial", "license", "and", "supply", "agreement", "with", "Marinus", "Pharmaceuticals", "granting", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "IV", "ganaxolone.", "<tag3>"], "wordsA": ["Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib."], "wordsB": ["Commercial", "license", "and", "supply", "agreement", "with", "Marinus", "Pharmaceuticals", "granting", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "IV", "ganaxolone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p29_s0", "idA": "886163_17_item1_p25_s0", "sentA": "Global license and supply agreement with Novartis for the development and commercialization of a CE-oral liquid formulation of trametinib.", "sentB": "Commercial license and supply agreement with Interventional AnalgesiX granting rights to use Captisol in the formulation of an undisclosed compound.", "type": 2, "words": ["<tag1>", "Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib.", "<tag2>", "Commercial", "license", "and", "supply", "agreement", "with", "Interventional", "AnalgesiX", "granting", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "an", "undisclosed", "compound.", "<tag3>"], "wordsA": ["Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib."], "wordsB": ["Commercial", "license", "and", "supply", "agreement", "with", "Interventional", "AnalgesiX", "granting", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "an", "undisclosed", "compound."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p30_s0", "idA": "886163_17_item1_p25_s0", "sentA": "Global license and supply agreement with Novartis for the development and commercialization of a CE-oral liquid formulation of trametinib.", "sentB": "Commercial license and supply agreements with both Par Pharmaceuticals and Meridian Labs granting each rights to use Captisol in the formulation of separate undisclosed compounds.", "type": 2, "words": ["<tag1>", "Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib.", "<tag2>", "Commercial", "license", "and", "supply", "agreements", "with", "both", "Par", "Pharmaceuticals", "and", "Meridian", "Labs", "granting", "each", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "separate", "undisclosed", "compounds.", "<tag3>"], "wordsA": ["Global", "license", "and", "supply", "agreement", "with", "Novartis", "for", "the", "development", "and", "commercialization", "of", "a", "CE-oral", "liquid", "formulation", "of", "trametinib."], "wordsB": ["Commercial", "license", "and", "supply", "agreements", "with", "both", "Par", "Pharmaceuticals", "and", "Meridian", "Labs", "granting", "each", "rights", "to", "use", "Captisol", "in", "the", "formulation", "of", "separate", "undisclosed", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p35_s0", "idA": "886163_17_item1_p27_s0", "sentA": "Ligand announced initiation of a Phase 2 clinical trial with LGD-6972 for the treatment of T2DM.", "sentB": "Ligand announced initiation of an internally-funded program to develop contrast agents with reduced renal toxicity for diagnostic imaging procedures through proof-of-concept, followed by sale or out-license for further development and commercialization.", "type": 2, "words": ["<tag1>", "Ligand", "announced", "initiation", "of", "a", "Phase", "2", "clinical", "trial", "with", "LGD-6972", "for", "the", "treatment", "of", "T2DM.", "<tag2>", "Ligand", "announced", "initiation", "of", "an", "internally-funded", "program", "to", "develop", "contrast", "agents", "with", "reduced", "renal", "toxicity", "for", "diagnostic", "imaging", "procedures", "through", "proof-of-concept,", "followed", "by", "sale", "or", "out-license", "for", "further", "development", "and", "commercialization.", "<tag3>"], "wordsA": ["Ligand", "announced", "initiation", "of", "a", "Phase", "2", "clinical", "trial", "with", "LGD-6972", "for", "the", "treatment", "of", "T2DM."], "wordsB": ["Ligand", "announced", "initiation", "of", "an", "internally-funded", "program", "to", "develop", "contrast", "agents", "with", "reduced", "renal", "toxicity", "for", "diagnostic", "imaging", "procedures", "through", "proof-of-concept,", "followed", "by", "sale", "or", "out-license", "for", "further", "development", "and", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p113_s4", "idA": "886163_17_item1_p27_s1", "sentA": "The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin.", "sentB": "In September 2017, we presented positive top-line results from a Phase 2 clinical study evaluating the efficacy and safety of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM inadequately controlled on metformin monotherapy.", "type": 2, "words": ["<tag1>", "The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin.", "<tag2>", "In", "September", "2017,", "we", "presented", "positive", "top-line", "results", "from", "a", "Phase", "2", "clinical", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "inadequately", "controlled", "on", "metformin", "monotherapy.", "<tag3>"], "wordsA": ["The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin."], "wordsB": ["In", "September", "2017,", "we", "presented", "positive", "top-line", "results", "from", "a", "Phase", "2", "clinical", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "inadequately", "controlled", "on", "metformin", "monotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p33_s0", "idA": "886163_17_item1_p27_s1", "sentA": "The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin.", "sentB": "Ligand announced positive top-line results from its Phase 2 clinical study evaluating the efficacy and safety of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM inadequately controlled on metformin monotherapy.", "type": 2, "words": ["<tag1>", "The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin.", "<tag2>", "Ligand", "announced", "positive", "top-line", "results", "from", "its", "Phase", "2", "clinical", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "inadequately", "controlled", "on", "metformin", "monotherapy.", "<tag3>"], "wordsA": ["The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin."], "wordsB": ["Ligand", "announced", "positive", "top-line", "results", "from", "its", "Phase", "2", "clinical", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "inadequately", "controlled", "on", "metformin", "monotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p4_s0", "idA": "886163_17_item1_p27_s2", "sentA": "Ligand expects to report the results from the Phase 2 clinical trial in the third quarter of 2017.", "sentB": "Viking Therapeutics announced positive results from a 12-week, Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.", "type": 2, "words": ["<tag1>", "Ligand", "expects", "to", "report", "the", "results", "from", "the", "Phase", "2", "clinical", "trial", "in", "the", "third", "quarter", "of", "2017.", "<tag2>", "Viking", "Therapeutics", "announced", "positive", "results", "from", "a", "12-week,", "Phase", "2", "clinical", "trial", "of", "VK5211", "in", "patients", "who", "recently", "suffered", "a", "hip", "fracture.", "<tag3>"], "wordsA": ["Ligand", "expects", "to", "report", "the", "results", "from", "the", "Phase", "2", "clinical", "trial", "in", "the", "third", "quarter", "of", "2017."], "wordsB": ["Viking", "Therapeutics", "announced", "positive", "results", "from", "a", "12-week,", "Phase", "2", "clinical", "trial", "of", "VK5211", "in", "patients", "who", "recently", "suffered", "a", "hip", "fracture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p90_s0", "idA": "886163_17_item1_p27_s2", "sentA": "Ligand expects to report the results from the Phase 2 clinical trial in the third quarter of 2017.", "sentB": "Viking announced positive results from its Phase 2 trial in patients who suffered hip fracture in the fourth quarter of 2017.", "type": 2, "words": ["<tag1>", "Ligand", "expects", "to", "report", "the", "results", "from", "the", "Phase", "2", "clinical", "trial", "in", "the", "third", "quarter", "of", "2017.", "<tag2>", "Viking", "announced", "positive", "results", "from", "its", "Phase", "2", "trial", "in", "patients", "who", "suffered", "hip", "fracture", "in", "the", "fourth", "quarter", "of", "2017.", "<tag3>"], "wordsA": ["Ligand", "expects", "to", "report", "the", "results", "from", "the", "Phase", "2", "clinical", "trial", "in", "the", "third", "quarter", "of", "2017."], "wordsB": ["Viking", "announced", "positive", "results", "from", "its", "Phase", "2", "trial", "in", "patients", "who", "suffered", "hip", "fracture", "in", "the", "fourth", "quarter", "of", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p36_s1", "idA": "886163_17_item1_p28_s1", "sentA": "Platform technologies or individual drugs discovered by Ligand are related to a broad estate of intellectual property that includes over 500 issued patents and over 200 pending patent applications.", "sentB": "Platform technologies or individual drugs discovered by Ligand are related to a broad estate of intellectual property that includes over 800 issued patents.", "type": 2, "words": ["<tag1>", "Platform", "technologies", "or", "individual", "drugs", "discovered", "by", "Ligand", "are", "related", "to", "a", "broad", "estate", "of", "intellectual", "property", "that", "includes", "over", "500", "issued", "patents", "and", "over", "200", "pending", "patent", "applications.", "<tag2>", "Platform", "technologies", "or", "individual", "drugs", "discovered", "by", "Ligand", "are", "related", "to", "a", "broad", "estate", "of", "intellectual", "property", "that", "includes", "over", "800", "issued", "patents.", "<tag3>"], "wordsA": ["Platform", "technologies", "or", "individual", "drugs", "discovered", "by", "Ligand", "are", "related", "to", "a", "broad", "estate", "of", "intellectual", "property", "that", "includes", "over", "500", "issued", "patents", "and", "over", "200", "pending", "patent", "applications."], "wordsB": ["Platform", "technologies", "or", "individual", "drugs", "discovered", "by", "Ligand", "are", "related", "to", "a", "broad", "estate", "of", "intellectual", "property", "that", "includes", "over", "800", "issued", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p2_s0", "idA": "886163_17_item1_p2_s0", "sentA": "Ligand acquired OMT in January 2016, conferring ownership of a large portfolio of licenses and the OmniAb platform, for $173.4 million in cash and stock.", "sentB": "In October 2017, Ligand acquired Crystal Bioscience and its OmniChicken antibody discovery technology for $25 million in cash at closing, up to $10.5 million of success-based milestones and revenue sharing from existing licensees for a defined period.", "type": 2, "words": ["<tag1>", "Ligand", "acquired", "OMT", "in", "January", "2016,", "conferring", "ownership", "of", "a", "large", "portfolio", "of", "licenses", "and", "the", "OmniAb", "platform,", "for", "$173.4", "million", "in", "cash", "and", "stock.", "<tag2>", "In", "October", "2017,", "Ligand", "acquired", "Crystal", "Bioscience", "and", "its", "OmniChicken", "antibody", "discovery", "technology", "for", "$25", "million", "in", "cash", "at", "closing,", "up", "to", "$10.5", "million", "of", "success-based", "milestones", "and", "revenue", "sharing", "from", "existing", "licensees", "for", "a", "defined", "period.", "<tag3>"], "wordsA": ["Ligand", "acquired", "OMT", "in", "January", "2016,", "conferring", "ownership", "of", "a", "large", "portfolio", "of", "licenses", "and", "the", "OmniAb", "platform,", "for", "$173.4", "million", "in", "cash", "and", "stock."], "wordsB": ["In", "October", "2017,", "Ligand", "acquired", "Crystal", "Bioscience", "and", "its", "OmniChicken", "antibody", "discovery", "technology", "for", "$25", "million", "in", "cash", "at", "closing,", "up", "to", "$10.5", "million", "of", "success-based", "milestones", "and", "revenue", "sharing", "from", "existing", "licensees", "for", "a", "defined", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p3_s1", "idA": "886163_17_item1_p30_s0", "sentA": "Ligand maintains both Type IV and Type V DMFs with the FDA.", "sentB": "Sage plans to file an NDA with the FDA in 2018.", "type": 2, "words": ["<tag1>", "Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA.", "<tag2>", "Sage", "plans", "to", "file", "an", "NDA", "with", "the", "FDA", "in", "2018.", "<tag3>"], "wordsA": ["Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA."], "wordsB": ["Sage", "plans", "to", "file", "an", "NDA", "with", "the", "FDA", "in", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p78_s2", "idA": "886163_17_item1_p30_s0", "sentA": "Ligand maintains both Type IV and Type V DMFs with the FDA.", "sentB": "SAGE plans to file a NDA with the FDA in 2018.", "type": 2, "words": ["<tag1>", "Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA.", "<tag2>", "SAGE", "plans", "to", "file", "a", "NDA", "with", "the", "FDA", "in", "2018.", "<tag3>"], "wordsA": ["Ligand", "maintains", "both", "Type", "IV", "and", "Type", "V", "DMFs", "with", "the", "FDA."], "wordsB": ["SAGE", "plans", "to", "file", "a", "NDA", "with", "the", "FDA", "in", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p25_s1", "idA": "886163_17_item1_p32_s1", "sentA": "OmniAb includes three complementary and globally-branded platforms named OmniRat, OmniMouse and OmniFlic.", "sentB": "Under the license, bluebird will be able to use the OmniRat , OmniMouse and OmniFlic platforms to discover fully human mono- and bispecific antibodies and antibody fragments.", "type": 2, "words": ["<tag1>", "OmniAb", "includes", "three", "complementary", "and", "globally-branded", "platforms", "named", "OmniRat,", "OmniMouse", "and", "OmniFlic.", "<tag2>", "Under", "the", "license,", "bluebird", "will", "be", "able", "to", "use", "the", "OmniRat", ",", "OmniMouse", "and", "OmniFlic", "platforms", "to", "discover", "fully", "human", "mono-", "and", "bispecific", "antibodies", "and", "antibody", "fragments.", "<tag3>"], "wordsA": ["OmniAb", "includes", "three", "complementary", "and", "globally-branded", "platforms", "named", "OmniRat,", "OmniMouse", "and", "OmniFlic."], "wordsB": ["Under", "the", "license,", "bluebird", "will", "be", "able", "to", "use", "the", "OmniRat", ",", "OmniMouse", "and", "OmniFlic", "platforms", "to", "discover", "fully", "human", "mono-", "and", "bispecific", "antibodies", "and", "antibody", "fragments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p37_s1", "idA": "886163_17_item1_p32_s2", "sentA": "The OmniAb platforms consist of genetically-engineered transgenic rodents that produce a broadly diversified repertoire of antibodies and enable novel fully-human antibody drug discovery and development by our OmniAb partners.", "sentB": "These platforms consist of genetically-engineered transgenic rodents that produce a broadly diversified repertoire of antibodies and enable novel fully-human antibody drug discovery and development by our OmniAb partners.", "type": 2, "words": ["<tag1>", "The", "OmniAb", "platforms", "consist", "of", "genetically-engineered", "transgenic", "rodents", "that", "produce", "a", "broadly", "diversified", "repertoire", "of", "antibodies", "and", "enable", "novel", "fully-human", "antibody", "drug", "discovery", "and", "development", "by", "our", "OmniAb", "partners.", "<tag2>", "These", "platforms", "consist", "of", "genetically-engineered", "transgenic", "rodents", "that", "produce", "a", "broadly", "diversified", "repertoire", "of", "antibodies", "and", "enable", "novel", "fully-human", "antibody", "drug", "discovery", "and", "development", "by", "our", "OmniAb", "partners.", "<tag3>"], "wordsA": ["The", "OmniAb", "platforms", "consist", "of", "genetically-engineered", "transgenic", "rodents", "that", "produce", "a", "broadly", "diversified", "repertoire", "of", "antibodies", "and", "enable", "novel", "fully-human", "antibody", "drug", "discovery", "and", "development", "by", "our", "OmniAb", "partners."], "wordsB": ["These", "platforms", "consist", "of", "genetically-engineered", "transgenic", "rodents", "that", "produce", "a", "broadly", "diversified", "repertoire", "of", "antibodies", "and", "enable", "novel", "fully-human", "antibody", "drug", "discovery", "and", "development", "by", "our", "OmniAb", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p38_s1", "idA": "886163_17_item1_p34_s4", "sentA": "Currently 3 partners are utilizing the LTP Technology or related platform(s).", "sentB": "Currently, more than 30 partners are utilizing OmniAb animals in their drug discovery and development efforts.", "type": 2, "words": ["<tag1>", "Currently", "3", "partners", "are", "utilizing", "the", "LTP", "Technology", "or", "related", "platform(s).", "<tag2>", "Currently,", "more", "than", "30", "partners", "are", "utilizing", "OmniAb", "animals", "in", "their", "drug", "discovery", "and", "development", "efforts.", "<tag3>"], "wordsA": ["Currently", "3", "partners", "are", "utilizing", "the", "LTP", "Technology", "or", "related", "platform(s)."], "wordsB": ["Currently,", "more", "than", "30", "partners", "are", "utilizing", "OmniAb", "animals", "in", "their", "drug", "discovery", "and", "development", "efforts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p109_s2", "idA": "886163_17_item1_p38_s0", "sentA": "Partners and Licensees The following table lists our disclosed partners and licensees.", "sentB": "The following table represents substantially all of the disclosed information about our royalty arrangements:", "type": 2, "words": ["<tag1>", "Partners", "and", "Licensees", "The", "following", "table", "lists", "our", "disclosed", "partners", "and", "licensees.", "<tag2>", "The", "following", "table", "represents", "substantially", "all", "of", "the", "disclosed", "information", "about", "our", "royalty", "arrangements:", "<tag3>"], "wordsA": ["Partners", "and", "Licensees", "The", "following", "table", "lists", "our", "disclosed", "partners", "and", "licensees."], "wordsB": ["The", "following", "table", "represents", "substantially", "all", "of", "the", "disclosed", "information", "about", "our", "royalty", "arrangements:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p115_s5", "idA": "886163_17_item1_p39_s0", "sentA": "Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 155 of which are fully-funded by our partners.", "sentB": "We believe we maintain adequate inventory of Captisol to meet our current and future partner needs.", "type": 2, "words": ["<tag1>", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "155", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag2>", "We", "believe", "we", "maintain", "adequate", "inventory", "of", "Captisol", "to", "meet", "our", "current", "and", "future", "partner", "needs.", "<tag3>"], "wordsA": ["Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "155", "of", "which", "are", "fully-funded", "by", "our", "partners."], "wordsB": ["We", "believe", "we", "maintain", "adequate", "inventory", "of", "Captisol", "to", "meet", "our", "current", "and", "future", "partner", "needs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p47_s0", "idA": "886163_17_item1_p39_s0", "sentA": "Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 155 of which are fully-funded by our partners.", "sentB": "Portfolio We have a large portfolio of current and future potential revenue-generating programs, over 165 of which are fully-funded by our partners.", "type": 2, "words": ["<tag1>", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "155", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag2>", "Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "165", "of", "which", "are", "fully-funded", "by", "our", "partners.", "<tag3>"], "wordsA": ["Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "155", "of", "which", "are", "fully-funded", "by", "our", "partners."], "wordsB": ["Portfolio", "We", "have", "a", "large", "portfolio", "of", "current", "and", "future", "potential", "revenue-generating", "programs,", "over", "165", "of", "which", "are", "fully-funded", "by", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p109_s1", "idA": "886163_17_item1_p39_s1", "sentA": "In addition to the table below, we also have more than 40 undisclosed programs.", "sentB": "In addition to the table below, we have generally described a typical Captisol and OmniAb royalty arrangement as low- to mid-single digit royalties.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "40", "undisclosed", "programs.", "<tag2>", "In", "addition", "to", "the", "table", "below,", "we", "have", "generally", "described", "a", "typical", "Captisol", "and", "OmniAb", "royalty", "arrangement", "as", "low-", "to", "mid-single", "digit", "royalties.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "40", "undisclosed", "programs."], "wordsB": ["In", "addition", "to", "the", "table", "below,", "we", "have", "generally", "described", "a", "typical", "Captisol", "and", "OmniAb", "royalty", "arrangement", "as", "low-", "to", "mid-single", "digit", "royalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p47_s1", "idA": "886163_17_item1_p39_s1", "sentA": "In addition to the table below, we also have more than 40 undisclosed programs.", "sentB": "In addition to the table below, we also have more than 48 undisclosed programs.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "40", "undisclosed", "programs.", "<tag2>", "In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "48", "undisclosed", "programs.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "40", "undisclosed", "programs."], "wordsB": ["In", "addition", "to", "the", "table", "below,", "we", "also", "have", "more", "than", "48", "undisclosed", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p109_s0", "idA": "886163_17_item1_p40_s0", "sentA": "We have multiple programs under license with other companies that have products that are already being commercialized.", "sentB": "Royalties We have multiple programs under license with other companies that have products that are already being commercialized.", "type": 2, "words": ["<tag1>", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized.", "<tag2>", "Royalties", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized.", "<tag3>"], "wordsA": ["We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized."], "wordsB": ["Royalties", "We", "have", "multiple", "programs", "under", "license", "with", "other", "companies", "that", "have", "products", "that", "are", "already", "being", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p49_s0", "idA": "886163_17_item1_p41_s0", "sentA": "We are party to a license agreement with Novartis related to Promacta, which is an oral medicine that increases the number of platelets in the blood.", "sentB": "Promacta (Novartis) We are party to a license agreement with Novartis related to Promacta, which is an oral medicine that increases the number of platelets in the blood.", "type": 2, "words": ["<tag1>", "We", "are", "party", "to", "a", "license", "agreement", "with", "Novartis", "related", "to", "Promacta,", "which", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood.", "<tag2>", "Promacta", "(Novartis)", "We", "are", "party", "to", "a", "license", "agreement", "with", "Novartis", "related", "to", "Promacta,", "which", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood.", "<tag3>"], "wordsA": ["We", "are", "party", "to", "a", "license", "agreement", "with", "Novartis", "related", "to", "Promacta,", "which", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood."], "wordsB": ["Promacta", "(Novartis)", "We", "are", "party", "to", "a", "license", "agreement", "with", "Novartis", "related", "to", "Promacta,", "which", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p21_s0", "idA": "886163_17_item1_p42_s0", "sentA": "Platelets are one of the three components of blood and facilitate clotting in the blood.", "sentB": "Amgen announced at ASH in December and published in the Journal of Clinical Oncology in January the positive overall survival results of the Kyprolis ASPIRE trial.", "type": 2, "words": ["<tag1>", "Platelets", "are", "one", "of", "the", "three", "components", "of", "blood", "and", "facilitate", "clotting", "in", "the", "blood.", "<tag2>", "Amgen", "announced", "at", "ASH", "in", "December", "and", "published", "in", "the", "Journal", "of", "Clinical", "Oncology", "in", "January", "the", "positive", "overall", "survival", "results", "of", "the", "Kyprolis", "ASPIRE", "trial.", "<tag3>"], "wordsA": ["Platelets", "are", "one", "of", "the", "three", "components", "of", "blood", "and", "facilitate", "clotting", "in", "the", "blood."], "wordsB": ["Amgen", "announced", "at", "ASH", "in", "December", "and", "published", "in", "the", "Journal", "of", "Clinical", "Oncology", "in", "January", "the", "positive", "overall", "survival", "results", "of", "the", "Kyprolis", "ASPIRE", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p52_s0", "idA": "886163_17_item1_p44_s0", "sentA": "Promacta is currently approved for three indications: (1) the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy, (2) Hepatitis-C associated thrombocytopenia and (3) SAA.", "sentB": "Promacta is currently approved for three indications: (1) the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy; (2) thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy; and (3) patients with SAA who have had an insufficient response to immunosuppressive therapy.", "type": 2, "words": ["<tag1>", "Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "adult", "and", "pediatric", "patients", "1", "year", "and", "older", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA.", "<tag2>", "Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "adult", "and", "pediatric", "patients", "1", "year", "and", "older", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy;", "(2)", "thrombocytopenia", "in", "patients", "with", "chronic", "hepatitis", "C", "to", "allow", "the", "initiation", "and", "maintenance", "of", "interferon-based", "therapy;", "and", "(3)", "patients", "with", "SAA", "who", "have", "had", "an", "insufficient", "response", "to", "immunosuppressive", "therapy.", "<tag3>"], "wordsA": ["Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "adult", "and", "pediatric", "patients", "1", "year", "and", "older", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy,", "(2)", "Hepatitis-C", "associated", "thrombocytopenia", "and", "(3)", "SAA."], "wordsB": ["Promacta", "is", "currently", "approved", "for", "three", "indications:", "(1)", "the", "treatment", "of", "thrombocytopenia", "in", "adult", "and", "pediatric", "patients", "1", "year", "and", "older", "with", "ITP", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy;", "(2)", "thrombocytopenia", "in", "patients", "with", "chronic", "hepatitis", "C", "to", "allow", "the", "initiation", "and", "maintenance", "of", "interferon-based", "therapy;", "and", "(3)", "patients", "with", "SAA", "who", "have", "had", "an", "insufficient", "response", "to", "immunosuppressive", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p52_s5", "idA": "886163_17_item1_p46_s0", "sentA": "Beyond the currently-approved indications, Novartis is also performing development activities to expand the brand into new indications, including a number of oncology-related indications including MDS, AML and CIT.", "sentB": "Beyond the currently-approved indications, Novartis is also performing or supporting development activities to expand the brand into new indications, including first-line use in SAA and oncology-related indications.", "type": 2, "words": ["<tag1>", "Beyond", "the", "currently-approved", "indications,", "Novartis", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "a", "number", "of", "oncology-related", "indications", "including", "MDS,", "AML", "and", "CIT.", "<tag2>", "Beyond", "the", "currently-approved", "indications,", "Novartis", "is", "also", "performing", "or", "supporting", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "first-line", "use", "in", "SAA", "and", "oncology-related", "indications.", "<tag3>"], "wordsA": ["Beyond", "the", "currently-approved", "indications,", "Novartis", "is", "also", "performing", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "a", "number", "of", "oncology-related", "indications", "including", "MDS,", "AML", "and", "CIT."], "wordsB": ["Beyond", "the", "currently-approved", "indications,", "Novartis", "is", "also", "performing", "or", "supporting", "development", "activities", "to", "expand", "the", "brand", "into", "new", "indications,", "including", "first-line", "use", "in", "SAA", "and", "oncology-related", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p53_s0", "idA": "886163_17_item1_p47_s0", "sentA": "As of January 2017, there are 23 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.", "sentB": "As of February 2018, there are 24 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.", "type": 2, "words": ["<tag1>", "As", "of", "January", "2017,", "there", "are", "23", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website.", "<tag2>", "As", "of", "February", "2018,", "there", "are", "24", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website.", "<tag3>"], "wordsA": ["As", "of", "January", "2017,", "there", "are", "23", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website."], "wordsB": ["As", "of", "February", "2018,", "there", "are", "24", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p5_s0", "idA": "886163_17_item1_p4_s0", "sentA": "On September 7, 2016, Retrophin announced results from the Phase 2 DUET study of sparsentan for the treatment of FSGS, a rare kidney disorder without an FDA-approved pharmacological treatment that often leads to end-stage renal disease.", "sentB": "Retrophin presented new data from the open-label extension portion of the Phase 2 DUET study of sparsentan for the treatment of FSGS at the American Society of Nephrology Kidney Week 2017.", "type": 2, "words": ["<tag1>", "On", "September", "7,", "2016,", "Retrophin", "announced", "results", "from", "the", "Phase", "2", "DUET", "study", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS,", "a", "rare", "kidney", "disorder", "without", "an", "FDA-approved", "pharmacological", "treatment", "that", "often", "leads", "to", "end-stage", "renal", "disease.", "<tag2>", "Retrophin", "presented", "new", "data", "from", "the", "open-label", "extension", "portion", "of", "the", "Phase", "2", "DUET", "study", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS", "at", "the", "American", "Society", "of", "Nephrology", "Kidney", "Week", "2017.", "<tag3>"], "wordsA": ["On", "September", "7,", "2016,", "Retrophin", "announced", "results", "from", "the", "Phase", "2", "DUET", "study", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS,", "a", "rare", "kidney", "disorder", "without", "an", "FDA-approved", "pharmacological", "treatment", "that", "often", "leads", "to", "end-stage", "renal", "disease."], "wordsB": ["Retrophin", "presented", "new", "data", "from", "the", "open-label", "extension", "portion", "of", "the", "Phase", "2", "DUET", "study", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS", "at", "the", "American", "Society", "of", "Nephrology", "Kidney", "Week", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p33_s1", "idA": "886163_17_item1_p4_s1", "sentA": "The study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period.", "sentB": "The study achieved statistical significance (p 0.0001) in the primary endpoint of change from baseline in hemoglobin A1c (HbA1c) after 12 weeks of treatment at all doses tested, demonstrating a robust, dose-dependent reduction in HbA1c of 0.90%, 0.92% and 1.20% with 5 mg, 10 mg and 15 mg of LGD-6972, respectively, compared to a 0.15% reduction with placebo.", "type": 2, "words": ["<tag1>", "The", "study", "achieved", "statistical", "significance", "in", "the", "primary", "efficacy", "endpoint", "for", "the", "overall", "sparsentan", "treatment", "group,", "demonstrating", "a", "greater", "than", "two-fold", "reduction", "of", "proteinuria", "compared", "to", "irbesartan", "after", "the", "eight-week,", "double-blind", "treatment", "period.", "<tag2>", "The", "study", "achieved", "statistical", "significance", "(p", "0.0001)", "in", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "hemoglobin", "A1c", "(HbA1c)", "after", "12", "weeks", "of", "treatment", "at", "all", "doses", "tested,", "demonstrating", "a", "robust,", "dose-dependent", "reduction", "in", "HbA1c", "of", "0.90%,", "0.92%", "and", "1.20%", "with", "5", "mg,", "10", "mg", "and", "15", "mg", "of", "LGD-6972,", "respectively,", "compared", "to", "a", "0.15%", "reduction", "with", "placebo.", "<tag3>"], "wordsA": ["The", "study", "achieved", "statistical", "significance", "in", "the", "primary", "efficacy", "endpoint", "for", "the", "overall", "sparsentan", "treatment", "group,", "demonstrating", "a", "greater", "than", "two-fold", "reduction", "of", "proteinuria", "compared", "to", "irbesartan", "after", "the", "eight-week,", "double-blind", "treatment", "period."], "wordsB": ["The", "study", "achieved", "statistical", "significance", "(p", "0.0001)", "in", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "hemoglobin", "A1c", "(HbA1c)", "after", "12", "weeks", "of", "treatment", "at", "all", "doses", "tested,", "demonstrating", "a", "robust,", "dose-dependent", "reduction", "in", "HbA1c", "of", "0.90%,", "0.92%", "and", "1.20%", "with", "5", "mg,", "10", "mg", "and", "15", "mg", "of", "LGD-6972,", "respectively,", "compared", "to", "a", "0.15%", "reduction", "with", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p107_s0", "idA": "886163_17_item1_p51_s0", "sentA": "As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.", "sentB": "There is a high unmet medical need for targeted immunotherapies such as APVO436, that can potentially treat patients with relapsed or refractory disease, or patients who cannot tolerate traditional chemotherapy.", "type": 2, "words": ["<tag1>", "As", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy.", "<tag2>", "There", "is", "a", "high", "unmet", "medical", "need", "for", "targeted", "immunotherapies", "such", "as", "APVO436,", "that", "can", "potentially", "treat", "patients", "with", "relapsed", "or", "refractory", "disease,", "or", "patients", "who", "cannot", "tolerate", "traditional", "chemotherapy.", "<tag3>"], "wordsA": ["As", "a", "single", "agent", "for", "the", "treatment", "of", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "who", "have", "received", "one", "or", "more", "lines", "of", "therapy."], "wordsB": ["There", "is", "a", "high", "unmet", "medical", "need", "for", "targeted", "immunotherapies", "such", "as", "APVO436,", "that", "can", "potentially", "treat", "patients", "with", "relapsed", "or", "refractory", "disease,", "or", "patients", "who", "cannot", "tolerate", "traditional", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p58_s0", "idA": "886163_17_item1_p52_s0", "sentA": "Kyprolis is also approved in multiple countries and Amgen continues to invest significantly in Kyprolis to further expand its label and geography.", "sentB": "Kyprolis is also approved in multiple countries outside the U.S. and Amgen continues to invest significantly in Kyprolis to further expand its label and geography.", "type": 2, "words": ["<tag1>", "Kyprolis", "is", "also", "approved", "in", "multiple", "countries", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography.", "<tag2>", "Kyprolis", "is", "also", "approved", "in", "multiple", "countries", "outside", "the", "U.S.", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography.", "<tag3>"], "wordsA": ["Kyprolis", "is", "also", "approved", "in", "multiple", "countries", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography."], "wordsB": ["Kyprolis", "is", "also", "approved", "in", "multiple", "countries", "outside", "the", "U.S.", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p106_s0", "idA": "886163_17_item1_p54_s0", "sentA": "The FDA approved Evomela for use in two indications:", "sentB": "AMG-330 (Amgen) Our licensee, Amgen, is developing AMG 330 for use in humans for a wide variety of therapeutic indications.", "type": 2, "words": ["<tag1>", "The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:", "<tag2>", "AMG-330", "(Amgen)", "Our", "licensee,", "Amgen,", "is", "developing", "AMG", "330", "for", "use", "in", "humans", "for", "a", "wide", "variety", "of", "therapeutic", "indications.", "<tag3>"], "wordsA": ["The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:"], "wordsB": ["AMG-330", "(Amgen)", "Our", "licensee,", "Amgen,", "is", "developing", "AMG", "330", "for", "use", "in", "humans", "for", "a", "wide", "variety", "of", "therapeutic", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p106_s3", "idA": "886163_17_item1_p54_s0", "sentA": "The FDA approved Evomela for use in two indications:", "sentB": "Marinus has exclusive worldwide rights to Captisol-enabled ganaxolone for use in humans.", "type": 2, "words": ["<tag1>", "The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:", "<tag2>", "Marinus", "has", "exclusive", "worldwide", "rights", "to", "Captisol-enabled", "ganaxolone", "for", "use", "in", "humans.", "<tag3>"], "wordsA": ["The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:"], "wordsB": ["Marinus", "has", "exclusive", "worldwide", "rights", "to", "Captisol-enabled", "ganaxolone", "for", "use", "in", "humans."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p37_s0", "idA": "886163_17_item1_p54_s0", "sentA": "The FDA approved Evomela for use in two indications:", "sentB": "O ur OmniAb technology includes our OmniRat, OmniMouse, OmniFlic and OmniChicken technology platforms for use in discovering fully human antibodies.", "type": 2, "words": ["<tag1>", "The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:", "<tag2>", "O", "ur", "OmniAb", "technology", "includes", "our", "OmniRat,", "OmniMouse,", "OmniFlic", "and", "OmniChicken", "technology", "platforms", "for", "use", "in", "discovering", "fully", "human", "antibodies.", "<tag3>"], "wordsA": ["The", "FDA", "approved", "Evomela", "for", "use", "in", "two", "indications:"], "wordsB": ["O", "ur", "OmniAb", "technology", "includes", "our", "OmniRat,", "OmniMouse,", "OmniFlic", "and", "OmniChicken", "technology", "platforms", "for", "use", "in", "discovering", "fully", "human", "antibodies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p24_s0", "idA": "886163_17_item1_p56_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement and royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "receive annual access payments, milestone payments and royalties on future net sales of any antibodies discovered under these licenses.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "receive", "annual", "access", "payments,", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales", "of", "any", "antibodies", "discovered", "under", "these", "licenses.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement", "and", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["receive", "annual", "access", "payments,", "milestone", "payments", "and", "royalties", "on", "future", "net", "sales", "of", "any", "antibodies", "discovered", "under", "these", "licenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p70_s0", "idA": "886163_17_item1_p57_s0", "sentA": "CorMatrix Portfolio (CorMatrix) Ligand receives a share of revenue from the currently marketed CorMatrix portfolio of vascular, cardiac and pericardial tissue repair products.", "sentB": "Aziyo Portfolio (Aziyo) Ligand receives a share of revenue from the currently marketed Aziyo portfolio of commercial pericardial repair and CanGaroo Envelope extracellular matrix (ECM) products.", "type": 2, "words": ["<tag1>", "CorMatrix", "Portfolio", "(CorMatrix)", "Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "CorMatrix", "portfolio", "of", "vascular,", "cardiac", "and", "pericardial", "tissue", "repair", "products.", "<tag2>", "Aziyo", "Portfolio", "(Aziyo)", "Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "Aziyo", "portfolio", "of", "commercial", "pericardial", "repair", "and", "CanGaroo", "Envelope", "extracellular", "matrix", "(ECM)", "products.", "<tag3>"], "wordsA": ["CorMatrix", "Portfolio", "(CorMatrix)", "Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "CorMatrix", "portfolio", "of", "vascular,", "cardiac", "and", "pericardial", "tissue", "repair", "products."], "wordsB": ["Aziyo", "Portfolio", "(Aziyo)", "Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "Aziyo", "portfolio", "of", "commercial", "pericardial", "repair", "and", "CanGaroo", "Envelope", "extracellular", "matrix", "(ECM)", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p70_s1", "idA": "886163_17_item1_p57_s1", "sentA": "In addition, Ligand has the potential to receive a share of revenue and potential milestones from the currently marketed CorMatrix CanGaroo ECM Envelope for cardiac implantable electronic devices.", "sentB": "In addition, Ligand has the potential to receive a share of revenue and potential milestones from the currently marketed CanGaroo ECM Envelope for cardiac implantable electronic devices.", "type": 2, "words": ["<tag1>", "In", "addition,", "Ligand", "has", "the", "potential", "to", "receive", "a", "share", "of", "revenue", "and", "potential", "milestones", "from", "the", "currently", "marketed", "CorMatrix", "CanGaroo", "ECM", "Envelope", "for", "cardiac", "implantable", "electronic", "devices.", "<tag2>", "In", "addition,", "Ligand", "has", "the", "potential", "to", "receive", "a", "share", "of", "revenue", "and", "potential", "milestones", "from", "the", "currently", "marketed", "CanGaroo", "ECM", "Envelope", "for", "cardiac", "implantable", "electronic", "devices.", "<tag3>"], "wordsA": ["In", "addition,", "Ligand", "has", "the", "potential", "to", "receive", "a", "share", "of", "revenue", "and", "potential", "milestones", "from", "the", "currently", "marketed", "CorMatrix", "CanGaroo", "ECM", "Envelope", "for", "cardiac", "implantable", "electronic", "devices."], "wordsB": ["In", "addition,", "Ligand", "has", "the", "potential", "to", "receive", "a", "share", "of", "revenue", "and", "potential", "milestones", "from", "the", "currently", "marketed", "CanGaroo", "ECM", "Envelope", "for", "cardiac", "implantable", "electronic", "devices."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p71_s0", "idA": "886163_17_item1_p58_s0", "sentA": "CorMatrix s products are medical devices that are designed to permit the development and regrowth of human tissue.", "sentB": "Aziyo s products are medical devices that are designed to permit the development and regrowth of human tissue.", "type": 2, "words": ["<tag1>", "CorMatrix", "s", "products", "are", "medical", "devices", "that", "are", "designed", "to", "permit", "the", "development", "and", "regrowth", "of", "human", "tissue.", "<tag2>", "Aziyo", "s", "products", "are", "medical", "devices", "that", "are", "designed", "to", "permit", "the", "development", "and", "regrowth", "of", "human", "tissue.", "<tag3>"], "wordsA": ["CorMatrix", "s", "products", "are", "medical", "devices", "that", "are", "designed", "to", "permit", "the", "development", "and", "regrowth", "of", "human", "tissue."], "wordsB": ["Aziyo", "s", "products", "are", "medical", "devices", "that", "are", "designed", "to", "permit", "the", "development", "and", "regrowth", "of", "human", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p63_s0", "idA": "886163_17_item1_p60_s0", "sentA": "Carnexiv (Lundbeck) Lundbeck's Carnexiv is a Captisol-enabled carbamazepine-IV that was approved by the FDA in October 2016.", "sentB": "Baxdela (Melinta) Melinta s Baxdela is a Captisol-enabled delafloxacin-IV that was approved by the FDA in June 2017 for the treatment of acute bacterial skin and skin structure infections.", "type": 2, "words": ["<tag1>", "Carnexiv", "(Lundbeck)", "Lundbeck's", "Carnexiv", "is", "a", "Captisol-enabled", "carbamazepine-IV", "that", "was", "approved", "by", "the", "FDA", "in", "October", "2016.", "<tag2>", "Baxdela", "(Melinta)", "Melinta", "s", "Baxdela", "is", "a", "Captisol-enabled", "delafloxacin-IV", "that", "was", "approved", "by", "the", "FDA", "in", "June", "2017", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections.", "<tag3>"], "wordsA": ["Carnexiv", "(Lundbeck)", "Lundbeck's", "Carnexiv", "is", "a", "Captisol-enabled", "carbamazepine-IV", "that", "was", "approved", "by", "the", "FDA", "in", "October", "2016."], "wordsB": ["Baxdela", "(Melinta)", "Melinta", "s", "Baxdela", "is", "a", "Captisol-enabled", "delafloxacin-IV", "that", "was", "approved", "by", "the", "FDA", "in", "June", "2017", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p17_s0", "idA": "886163_17_item1_p66_s0", "sentA": "Vivitra (Zydus Cadila) Zydus Cadila s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer.", "sentB": "Zydus Cadila announced that it received approval to market its bevacizumab biosimilar in India and subsequently launched the drug, which is marketed as Bryxta.", "type": 2, "words": ["<tag1>", "Vivitra", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer.", "<tag2>", "Zydus", "Cadila", "announced", "that", "it", "received", "approval", "to", "market", "its", "bevacizumab", "biosimilar", "in", "India", "and", "subsequently", "launched", "the", "drug,", "which", "is", "marketed", "as", "Bryxta.", "<tag3>"], "wordsA": ["Vivitra", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer."], "wordsB": ["Zydus", "Cadila", "announced", "that", "it", "received", "approval", "to", "market", "its", "bevacizumab", "biosimilar", "in", "India", "and", "subsequently", "launched", "the", "drug,", "which", "is", "marketed", "as", "Bryxta."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p74_s0", "idA": "886163_17_item1_p66_s0", "sentA": "Vivitra (Zydus Cadila) Zydus Cadila s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer.", "sentB": "Bryxta (Zydus Cadila) Zydus Cadila s Bryxta (bevacizumab biosimilar) is marketed in India for non-small cell lung cancer.", "type": 2, "words": ["<tag1>", "Vivitra", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer.", "<tag2>", "Bryxta", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Bryxta", "(bevacizumab", "biosimilar)", "is", "marketed", "in", "India", "for", "non-small", "cell", "lung", "cancer.", "<tag3>"], "wordsA": ["Vivitra", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer."], "wordsB": ["Bryxta", "(Zydus", "Cadila)", "Zydus", "Cadila", "s", "Bryxta", "(bevacizumab", "biosimilar)", "is", "marketed", "in", "India", "for", "non-small", "cell", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p74_s1", "idA": "886163_17_item1_p66_s1", "sentA": "Zydus Cadila uses the Selexis technology platform for Vivitra.", "sentB": "Zydus Cadila uses the Selexis technology platform for Bryxta.", "type": 2, "words": ["<tag1>", "Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Vivitra.", "<tag2>", "Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Bryxta.", "<tag3>"], "wordsA": ["Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Vivitra."], "wordsB": ["Zydus", "Cadila", "uses", "the", "Selexis", "technology", "platform", "for", "Bryxta."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p76_s0", "idA": "886163_17_item1_p67_s1", "sentA": "Summary of Selected Development-stage Programs We have multiple fully-funded partnered programs that are either in or nearing the regulatory approval process, or given the area of research or value of the license terms are considered particularly noteworthy.", "sentB": "Summary of Selected Development-stage Programs We have multiple fully-funded partnered programs that are either in or nearing the regulatory approval process, or given the area of research or value of the license terms we consider particularly noteworthy.", "type": 2, "words": ["<tag1>", "Summary", "of", "Selected", "Development-stage", "Programs", "We", "have", "multiple", "fully-funded", "partnered", "programs", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process,", "or", "given", "the", "area", "of", "research", "or", "value", "of", "the", "license", "terms", "are", "considered", "particularly", "noteworthy.", "<tag2>", "Summary", "of", "Selected", "Development-stage", "Programs", "We", "have", "multiple", "fully-funded", "partnered", "programs", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process,", "or", "given", "the", "area", "of", "research", "or", "value", "of", "the", "license", "terms", "we", "consider", "particularly", "noteworthy.", "<tag3>"], "wordsA": ["Summary", "of", "Selected", "Development-stage", "Programs", "We", "have", "multiple", "fully-funded", "partnered", "programs", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process,", "or", "given", "the", "area", "of", "research", "or", "value", "of", "the", "license", "terms", "are", "considered", "particularly", "noteworthy."], "wordsB": ["Summary", "of", "Selected", "Development-stage", "Programs", "We", "have", "multiple", "fully-funded", "partnered", "programs", "that", "are", "either", "in", "or", "nearing", "the", "regulatory", "approval", "process,", "or", "given", "the", "area", "of", "research", "or", "value", "of", "the", "license", "terms", "we", "consider", "particularly", "noteworthy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p25_s2", "idA": "886163_17_item1_p67_s2", "sentA": "We are eligible to receive milestone payments and royalties off of these programs.", "sentB": "Ligand is eligible to receive annual platform access payments, development milestone payments and royalties for each product incorporating an OmniAb antibody.", "type": 2, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "milestone", "payments", "and", "royalties", "off", "of", "these", "programs.", "<tag2>", "Ligand", "is", "eligible", "to", "receive", "annual", "platform", "access", "payments,", "development", "milestone", "payments", "and", "royalties", "for", "each", "product", "incorporating", "an", "OmniAb", "antibody.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "milestone", "payments", "and", "royalties", "off", "of", "these", "programs."], "wordsB": ["Ligand", "is", "eligible", "to", "receive", "annual", "platform", "access", "payments,", "development", "milestone", "payments", "and", "royalties", "for", "each", "product", "incorporating", "an", "OmniAb", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p64_s1", "idA": "886163_17_item1_p69_s0", "sentA": "Under the terms of the agreement, we may be entitled to up to $2.1 million of development and regulatory milestones, as well as a royalty on potential future sales by Melinta, and revenue from Captisol material sales.", "sentB": "Under the terms of the agreement, we may be entitled to regulatory milestones, as well as a royalty on potential future sales by Melinta, and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$2.1", "million", "of", "development", "and", "regulatory", "milestones,", "as", "well", "as", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "regulatory", "milestones,", "as", "well", "as", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "up", "to", "$2.1", "million", "of", "development", "and", "regulatory", "milestones,", "as", "well", "as", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "may", "be", "entitled", "to", "regulatory", "milestones,", "as", "well", "as", "a", "royalty", "on", "potential", "future", "sales", "by", "Melinta,", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p14_s0", "idA": "886163_17_item1_p6_s0", "sentA": "Merck announced that it stopped the Phase 2/3 EPOCH study evaluating verubecestat in people with mild-to-moderate Alzheimer s disease due to the conclusion that the efficacy endpoint could not be achieved.", "sentB": "Merck announced it stopped the Phase 2/3 EPOCH and Phase 3 APECS studies evaluating verubecestat in people with mild-to-moderate and prodromal Alzheimer s disease due to the conclusion that the efficacy endpoint could not be achieved.", "type": 2, "words": ["<tag1>", "Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved.", "<tag2>", "Merck", "announced", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "and", "Phase", "3", "APECS", "studies", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "and", "prodromal", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved.", "<tag3>"], "wordsA": ["Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved."], "wordsB": ["Merck", "announced", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "and", "Phase", "3", "APECS", "studies", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "and", "prodromal", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p22_s0", "idA": "886163_17_item1_p6_s0", "sentA": "Merck announced that it stopped the Phase 2/3 EPOCH study evaluating verubecestat in people with mild-to-moderate Alzheimer s disease due to the conclusion that the efficacy endpoint could not be achieved.", "sentB": "Amgen announced that the overall survival data from the ENDEAVOR trial was added to the Kyprolis label.", "type": 2, "words": ["<tag1>", "Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved.", "<tag2>", "Amgen", "announced", "that", "the", "overall", "survival", "data", "from", "the", "ENDEAVOR", "trial", "was", "added", "to", "the", "Kyprolis", "label.", "<tag3>"], "wordsA": ["Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved."], "wordsB": ["Amgen", "announced", "that", "the", "overall", "survival", "data", "from", "the", "ENDEAVOR", "trial", "was", "added", "to", "the", "Kyprolis", "label."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p4_s2", "idA": "886163_17_item1_p6_s1", "sentA": "Results from EPOCH will be analyzed and presented at an upcoming scientific meeting.", "sentB": "Viking intends to present additional results from the study at an upcoming scientific conference.", "type": 2, "words": ["<tag1>", "Results", "from", "EPOCH", "will", "be", "analyzed", "and", "presented", "at", "an", "upcoming", "scientific", "meeting.", "<tag2>", "Viking", "intends", "to", "present", "additional", "results", "from", "the", "study", "at", "an", "upcoming", "scientific", "conference.", "<tag3>"], "wordsA": ["Results", "from", "EPOCH", "will", "be", "analyzed", "and", "presented", "at", "an", "upcoming", "scientific", "meeting."], "wordsB": ["Viking", "intends", "to", "present", "additional", "results", "from", "the", "study", "at", "an", "upcoming", "scientific", "conference."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p77_s0", "idA": "886163_17_item1_p70_s0", "sentA": "Our partner, SAGE, is conducting a Phase 3 clinical trial for the development of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions.", "sentB": "Our partner, SAGE, is developing novel medicines to treat life altering central nervous system disorders.", "type": 2, "words": ["<tag1>", "Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions.", "<tag2>", "Our", "partner,", "SAGE,", "is", "developing", "novel", "medicines", "to", "treat", "life", "altering", "central", "nervous", "system", "disorders.", "<tag3>"], "wordsA": ["Our", "partner,", "SAGE,", "is", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "Captisol-enabled", "therapeutics", "for", "a", "broad", "range", "of", "debilitating", "central", "nervous", "system", "conditions."], "wordsB": ["Our", "partner,", "SAGE,", "is", "developing", "novel", "medicines", "to", "treat", "life", "altering", "central", "nervous", "system", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p27_s1", "idA": "886163_17_item1_p70_s3", "sentA": "Ligand has the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs.", "sentB": "Ligand is eligible to receive milestone payments, royalties and revenue from Captisol material sales related to AMG 330.", "type": 2, "words": ["<tag1>", "Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs.", "<tag2>", "Ligand", "is", "eligible", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "related", "to", "AMG", "330.", "<tag3>"], "wordsA": ["Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs."], "wordsB": ["Ligand", "is", "eligible", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "related", "to", "AMG", "330."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p28_s1", "idA": "886163_17_item1_p70_s3", "sentA": "Ligand has the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs.", "sentB": "Ligand is entitled to milestone payments, royalties and revenue from Captisol material sales related to IV ganaxolone.", "type": 2, "words": ["<tag1>", "Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs.", "<tag2>", "Ligand", "is", "entitled", "to", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "related", "to", "IV", "ganaxolone.", "<tag3>"], "wordsA": ["Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs."], "wordsB": ["Ligand", "is", "entitled", "to", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "related", "to", "IV", "ganaxolone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p29_s1", "idA": "886163_17_item1_p70_s3", "sentA": "Ligand has the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs.", "sentB": "Ligand is eligible to receive milestone payments, tiered royalties of 5%-10% and revenue from Captisol material sales.", "type": 2, "words": ["<tag1>", "Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs.", "<tag2>", "Ligand", "is", "eligible", "to", "receive", "milestone", "payments,", "tiered", "royalties", "of", "5%-10%", "and", "revenue", "from", "Captisol", "material", "sales.", "<tag3>"], "wordsA": ["Ligand", "has", "the", "potential", "to", "receive", "milestone", "payments,", "royalties", "and", "revenue", "from", "Captisol", "material", "sales", "for", "Captisol-enabled", "programs."], "wordsB": ["Ligand", "is", "eligible", "to", "receive", "milestone", "payments,", "tiered", "royalties", "of", "5%-10%", "and", "revenue", "from", "Captisol", "material", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p6_s0", "idA": "886163_17_item1_p70_s5", "sentA": "SAGE is also conducting a Phase 3 clinical trial for the development of a Captisol-enabled treatment of PPD.", "sentB": "conducting feasibility analyses and engaging regulatory agencies with the expectation of initiating a clinical trial for sparsentan in IgA nephropathy (IgAN), an immune-complex mediated glomerulonephritis, in 2018.", "type": 2, "words": ["<tag1>", "SAGE", "is", "also", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "a", "Captisol-enabled", "treatment", "of", "PPD.", "<tag2>", "conducting", "feasibility", "analyses", "and", "engaging", "regulatory", "agencies", "with", "the", "expectation", "of", "initiating", "a", "clinical", "trial", "for", "sparsentan", "in", "IgA", "nephropathy", "(IgAN),", "an", "immune-complex", "mediated", "glomerulonephritis,", "in", "2018.", "<tag3>"], "wordsA": ["SAGE", "is", "also", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "a", "Captisol-enabled", "treatment", "of", "PPD."], "wordsB": ["conducting", "feasibility", "analyses", "and", "engaging", "regulatory", "agencies", "with", "the", "expectation", "of", "initiating", "a", "clinical", "trial", "for", "sparsentan", "in", "IgA", "nephropathy", "(IgAN),", "an", "immune-complex", "mediated", "glomerulonephritis,", "in", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p77_s1", "idA": "886163_17_item1_p70_s5", "sentA": "SAGE is also conducting a Phase 3 clinical trial for the development of a Captisol-enabled treatment of PPD.", "sentB": "In November 2017 SAGE announced positive top-line results from two Phase 3 clinical trials with its proprietary IV formulation of brexanolone (formerly SAGE-547); Study 202B in severe PPD and Study 202C in moderate PPD.", "type": 2, "words": ["<tag1>", "SAGE", "is", "also", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "a", "Captisol-enabled", "treatment", "of", "PPD.", "<tag2>", "In", "November", "2017", "SAGE", "announced", "positive", "top-line", "results", "from", "two", "Phase", "3", "clinical", "trials", "with", "its", "proprietary", "IV", "formulation", "of", "brexanolone", "(formerly", "SAGE-547);", "Study", "202B", "in", "severe", "PPD", "and", "Study", "202C", "in", "moderate", "PPD.", "<tag3>"], "wordsA": ["SAGE", "is", "also", "conducting", "a", "Phase", "3", "clinical", "trial", "for", "the", "development", "of", "a", "Captisol-enabled", "treatment", "of", "PPD."], "wordsB": ["In", "November", "2017", "SAGE", "announced", "positive", "top-line", "results", "from", "two", "Phase", "3", "clinical", "trials", "with", "its", "proprietary", "IV", "formulation", "of", "brexanolone", "(formerly", "SAGE-547);", "Study", "202B", "in", "severe", "PPD", "and", "Study", "202C", "in", "moderate", "PPD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p20_s0", "idA": "886163_17_item1_p70_s7", "sentA": "SAGE received Breakthrough Therapy Designation from the FDA for SAGE-547 in PPD in September, 2016.", "sentB": "Novartis announced that Promacta received Breakthrough Therapy designation for first-line use in SAA from the FDA.", "type": 2, "words": ["<tag1>", "SAGE", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "for", "SAGE-547", "in", "PPD", "in", "September,", "2016.", "<tag2>", "Novartis", "announced", "that", "Promacta", "received", "Breakthrough", "Therapy", "designation", "for", "first-line", "use", "in", "SAA", "from", "the", "FDA.", "<tag3>"], "wordsA": ["SAGE", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "for", "SAGE-547", "in", "PPD", "in", "September,", "2016."], "wordsB": ["Novartis", "announced", "that", "Promacta", "received", "Breakthrough", "Therapy", "designation", "for", "first-line", "use", "in", "SAA", "from", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p21_s1", "idA": "886163_17_item1_p70_s7", "sentA": "SAGE received Breakthrough Therapy Designation from the FDA for SAGE-547 in PPD in September, 2016.", "sentB": "Amgen has submitted the data to the FDA for inclusion in the label.", "type": 2, "words": ["<tag1>", "SAGE", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "for", "SAGE-547", "in", "PPD", "in", "September,", "2016.", "<tag2>", "Amgen", "has", "submitted", "the", "data", "to", "the", "FDA", "for", "inclusion", "in", "the", "label.", "<tag3>"], "wordsA": ["SAGE", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "for", "SAGE-547", "in", "PPD", "in", "September,", "2016."], "wordsB": ["Amgen", "has", "submitted", "the", "data", "to", "the", "FDA", "for", "inclusion", "in", "the", "label."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p78_s0", "idA": "886163_17_item1_p70_s8", "sentA": "The Breakthrough Therapy Designation is intended to offer a potentially expedited development path and review for promising drug candidates, which includes increased interaction and guidance from the FDA.", "sentB": "SAGE has received Breakthrough Therapy Designation from the FDA and PRIority MEdicines (PRIME) designation by the EMA for SAGE-547 in PPD, which are intended to offer a potentially expedited development path and review for promising drug candidates.", "type": 2, "words": ["<tag1>", "The", "Breakthrough", "Therapy", "Designation", "is", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates,", "which", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA.", "<tag2>", "SAGE", "has", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "and", "PRIority", "MEdicines", "(PRIME)", "designation", "by", "the", "EMA", "for", "SAGE-547", "in", "PPD,", "which", "are", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates.", "<tag3>"], "wordsA": ["The", "Breakthrough", "Therapy", "Designation", "is", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates,", "which", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA."], "wordsB": ["SAGE", "has", "received", "Breakthrough", "Therapy", "Designation", "from", "the", "FDA", "and", "PRIority", "MEdicines", "(PRIME)", "designation", "by", "the", "EMA", "for", "SAGE-547", "in", "PPD,", "which", "are", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p78_s1", "idA": "886163_17_item1_p70_s8", "sentA": "The Breakthrough Therapy Designation is intended to offer a potentially expedited development path and review for promising drug candidates, which includes increased interaction and guidance from the FDA.", "sentB": "This includes increased interaction and guidance from the FDA and EMA.", "type": 2, "words": ["<tag1>", "The", "Breakthrough", "Therapy", "Designation", "is", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates,", "which", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA.", "<tag2>", "This", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA", "and", "EMA.", "<tag3>"], "wordsA": ["The", "Breakthrough", "Therapy", "Designation", "is", "intended", "to", "offer", "a", "potentially", "expedited", "development", "path", "and", "review", "for", "promising", "drug", "candidates,", "which", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA."], "wordsB": ["This", "includes", "increased", "interaction", "and", "guidance", "from", "the", "FDA", "and", "EMA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p12_s0", "idA": "886163_17_item1_p70_s9", "sentA": "Our partner, Retrophin, is developing sparsentan for orphan indications of severe kidney diseases, and has completed a Phase 2 clinical trial of sparsentan for the treatment of FSGS.", "sentB": "Presentation of data from its Phase 2 clinical trial of reproxalap in noninfectious anterior uveitis at the American Uveitis Society Fall Meeting.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Retrophin,", "is", "developing", "sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases,", "and", "has", "completed", "a", "Phase", "2", "clinical", "trial", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS.", "<tag2>", "Presentation", "of", "data", "from", "its", "Phase", "2", "clinical", "trial", "of", "reproxalap", "in", "noninfectious", "anterior", "uveitis", "at", "the", "American", "Uveitis", "Society", "Fall", "Meeting.", "<tag3>"], "wordsA": ["Our", "partner,", "Retrophin,", "is", "developing", "sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases,", "and", "has", "completed", "a", "Phase", "2", "clinical", "trial", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS."], "wordsB": ["Presentation", "of", "data", "from", "its", "Phase", "2", "clinical", "trial", "of", "reproxalap", "in", "noninfectious", "anterior", "uveitis", "at", "the", "American", "Uveitis", "Society", "Fall", "Meeting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p78_s6", "idA": "886163_17_item1_p70_s9", "sentA": "Our partner, Retrophin, is developing sparsentan for orphan indications of severe kidney diseases, and has completed a Phase 2 clinical trial of sparsentan for the treatment of FSGS.", "sentB": "Retrophin announced plans to initiate a single Phase 3 clinical trial to enable an NDA filing for sparsentan fo the treatment of FSGS.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Retrophin,", "is", "developing", "sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases,", "and", "has", "completed", "a", "Phase", "2", "clinical", "trial", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS.", "<tag2>", "Retrophin", "announced", "plans", "to", "initiate", "a", "single", "Phase", "3", "clinical", "trial", "to", "enable", "an", "NDA", "filing", "for", "sparsentan", "fo", "the", "treatment", "of", "FSGS.", "<tag3>"], "wordsA": ["Our", "partner,", "Retrophin,", "is", "developing", "sparsentan", "for", "orphan", "indications", "of", "severe", "kidney", "diseases,", "and", "has", "completed", "a", "Phase", "2", "clinical", "trial", "of", "sparsentan", "for", "the", "treatment", "of", "FSGS."], "wordsB": ["Retrophin", "announced", "plans", "to", "initiate", "a", "single", "Phase", "3", "clinical", "trial", "to", "enable", "an", "NDA", "filing", "for", "sparsentan", "fo", "the", "treatment", "of", "FSGS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p106_s2", "idA": "886163_17_item1_p73_s0", "sentA": "Our partner, Eli Lilly is conducting Phase 2 clinical trials for Captisol-enabled LY2606368 (Chk 1/2 inhibitor) for solid tumors.", "sentB": "Our partner, Marinus, is preparing to initiate clinical trials with Captisol-enabled ganaxolone IV in patients with postpartum depression (PPD) and status epilepticus (SE).", "type": 2, "words": ["<tag1>", "Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "LY2606368", "(Chk", "1/2", "inhibitor)", "for", "solid", "tumors.", "<tag2>", "Our", "partner,", "Marinus,", "is", "preparing", "to", "initiate", "clinical", "trials", "with", "Captisol-enabled", "ganaxolone", "IV", "in", "patients", "with", "postpartum", "depression", "(PPD)", "and", "status", "epilepticus", "(SE).", "<tag3>"], "wordsA": ["Our", "partner,", "Eli", "Lilly", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "LY2606368", "(Chk", "1/2", "inhibitor)", "for", "solid", "tumors."], "wordsB": ["Our", "partner,", "Marinus,", "is", "preparing", "to", "initiate", "clinical", "trials", "with", "Captisol-enabled", "ganaxolone", "IV", "in", "patients", "with", "postpartum", "depression", "(PPD)", "and", "status", "epilepticus", "(SE)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p83_s0", "idA": "886163_17_item1_p74_s0", "sentA": "Our partner, Cardioxyl (acquired by BMS in 2015) is conducting Phase 2 clinical trials for Captisol-enabled CXL-1427 (nitroxyl donor prodrug) for ADHF.", "sentB": "Our partner, BMS, is conducting Phase 2 clinical trials for Captisol-enabled CXL-1427 (nitroxyl donor prodrug) for ADHF.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Cardioxyl", "(acquired", "by", "BMS", "in", "2015)", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "CXL-1427", "(nitroxyl", "donor", "prodrug)", "for", "ADHF.", "<tag2>", "Our", "partner,", "BMS,", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "CXL-1427", "(nitroxyl", "donor", "prodrug)", "for", "ADHF.", "<tag3>"], "wordsA": ["Our", "partner,", "Cardioxyl", "(acquired", "by", "BMS", "in", "2015)", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "CXL-1427", "(nitroxyl", "donor", "prodrug)", "for", "ADHF."], "wordsB": ["Our", "partner,", "BMS,", "is", "conducting", "Phase", "2", "clinical", "trials", "for", "Captisol-enabled", "CXL-1427", "(nitroxyl", "donor", "prodrug)", "for", "ADHF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p84_s0", "idA": "886163_17_item1_p76_s0", "sentA": "Lasofoxifene is an estrogen partial agonist for osteoporosis treatment and other diseases, discovered through the research collaboration between us and Pfizer.", "sentB": "Lasofoxifene (Sermonix, and Azure Biotech) Lasofoxifene is an estrogen partial agonist for osteoporosis treatment and other diseases, discovered through the research collaboration between us and Pfizer.", "type": 2, "words": ["<tag1>", "Lasofoxifene", "is", "an", "estrogen", "partial", "agonist", "for", "osteoporosis", "treatment", "and", "other", "diseases,", "discovered", "through", "the", "research", "collaboration", "between", "us", "and", "Pfizer.", "<tag2>", "Lasofoxifene", "(Sermonix,", "and", "Azure", "Biotech)", "Lasofoxifene", "is", "an", "estrogen", "partial", "agonist", "for", "osteoporosis", "treatment", "and", "other", "diseases,", "discovered", "through", "the", "research", "collaboration", "between", "us", "and", "Pfizer.", "<tag3>"], "wordsA": ["Lasofoxifene", "is", "an", "estrogen", "partial", "agonist", "for", "osteoporosis", "treatment", "and", "other", "diseases,", "discovered", "through", "the", "research", "collaboration", "between", "us", "and", "Pfizer."], "wordsB": ["Lasofoxifene", "(Sermonix,", "and", "Azure", "Biotech)", "Lasofoxifene", "is", "an", "estrogen", "partial", "agonist", "for", "osteoporosis", "treatment", "and", "other", "diseases,", "discovered", "through", "the", "research", "collaboration", "between", "us", "and", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p35_s1", "idA": "886163_17_item1_p77_s1", "sentA": "Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments as well as royalties on future net sales.", "sentB": "This development program will leverage Ligand s Captisol technology, as well as intellectual property obtained through its acquisition of Verrow Pharmaceuticals for $2 million in cash plus earn outs.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "as", "well", "as", "royalties", "on", "future", "net", "sales.", "<tag2>", "This", "development", "program", "will", "leverage", "Ligand", "s", "Captisol", "technology,", "as", "well", "as", "intellectual", "property", "obtained", "through", "its", "acquisition", "of", "Verrow", "Pharmaceuticals", "for", "$2", "million", "in", "cash", "plus", "earn", "outs.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "up", "to", "$45", "million", "in", "potential", "regulatory", "and", "commercial", "milestone", "payments", "as", "well", "as", "royalties", "on", "future", "net", "sales."], "wordsB": ["This", "development", "program", "will", "leverage", "Ligand", "s", "Captisol", "technology,", "as", "well", "as", "intellectual", "property", "obtained", "through", "its", "acquisition", "of", "Verrow", "Pharmaceuticals", "for", "$2", "million", "in", "cash", "plus", "earn", "outs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p106_s4", "idA": "886163_17_item1_p78_s0", "sentA": "Our partner, Merck is developing Verubecestat (MK-8931), a BACE inhibitor for the treatment of Alzheimer s disease.", "sentB": "Our partner, Aptevo, is developing APVO436 for the treatment of acute myeloid leukemia.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Merck", "is", "developing", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag2>", "Our", "partner,", "Aptevo,", "is", "developing", "APVO436", "for", "the", "treatment", "of", "acute", "myeloid", "leukemia.", "<tag3>"], "wordsA": ["Our", "partner,", "Merck", "is", "developing", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "wordsB": ["Our", "partner,", "Aptevo,", "is", "developing", "APVO436", "for", "the", "treatment", "of", "acute", "myeloid", "leukemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p86_s0", "idA": "886163_17_item1_p82_s0", "sentA": "Merck is responsible for all development costs related to the program TR-Beta - VK2809 (Viking) Viking is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD.", "sentB": "TR-Beta - VK2809 (Viking) Viking is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD.", "type": 2, "words": ["<tag1>", "Merck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program", "TR-Beta", "-", "VK2809", "(Viking)", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-Beta", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD.", "<tag2>", "TR-Beta", "-", "VK2809", "(Viking)", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-Beta", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD.", "<tag3>"], "wordsA": ["Merck", "is", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program", "TR-Beta", "-", "VK2809", "(Viking)", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-Beta", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD."], "wordsB": ["TR-Beta", "-", "VK2809", "(Viking)", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-Beta", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p88_s0", "idA": "886163_17_item1_p83_s1", "sentA": "Our partner Viking is developing VK5211, a novel, potentially best-in-class SARM for patients recovering from hip-fracture.", "sentB": "SARM - VK5211 (Viking) Our partner, Viking, is developing VK5211, a novel, potentially best-in-class SARM for patients recovering from hip-fracture.", "type": 2, "words": ["<tag1>", "Our", "partner", "Viking", "is", "developing", "VK5211,", "a", "novel,", "potentially", "best-in-class", "SARM", "for", "patients", "recovering", "from", "hip-fracture.", "<tag2>", "SARM", "-", "VK5211", "(Viking)", "Our", "partner,", "Viking,", "is", "developing", "VK5211,", "a", "novel,", "potentially", "best-in-class", "SARM", "for", "patients", "recovering", "from", "hip-fracture.", "<tag3>"], "wordsA": ["Our", "partner", "Viking", "is", "developing", "VK5211,", "a", "novel,", "potentially", "best-in-class", "SARM", "for", "patients", "recovering", "from", "hip-fracture."], "wordsB": ["SARM", "-", "VK5211", "(Viking)", "Our", "partner,", "Viking,", "is", "developing", "VK5211,", "a", "novel,", "potentially", "best-in-class", "SARM", "for", "patients", "recovering", "from", "hip-fracture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p99_s0", "idA": "886163_17_item1_p93_s0", "sentA": "an antibody-drug that targets ErbB3 that was developed using the Selexis SUREtechnology Platform.", "sentB": "Seribantumab is an antibody-drug that targets ErbB3 that was developed using the Selexis SUREtechnology Platform.", "type": 2, "words": ["<tag1>", "an", "antibody-drug", "that", "targets", "ErbB3", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform.", "<tag2>", "Seribantumab", "is", "an", "antibody-drug", "that", "targets", "ErbB3", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform.", "<tag3>"], "wordsA": ["an", "antibody-drug", "that", "targets", "ErbB3", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform."], "wordsB": ["Seribantumab", "is", "an", "antibody-drug", "that", "targets", "ErbB3", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p95_s0", "idA": "886163_17_item1_p97_s0", "sentA": "AM0010+PD-1 (ARMO Biosciences) Our partner, ARMO Biosciences, is developing an anti-PD-1 antibody discovered with the OmniAb platform technology.", "sentB": "Our partner, Janssen, is developing a BCMAxCD3 antibody discovered with the OmniAb platform technology.", "type": 2, "words": ["<tag1>", "AM0010+PD-1", "(ARMO", "Biosciences)", "Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology.", "<tag2>", "Our", "partner,", "Janssen,", "is", "developing", "a", "BCMAxCD3", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology.", "<tag3>"], "wordsA": ["AM0010+PD-1", "(ARMO", "Biosciences)", "Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology."], "wordsB": ["Our", "partner,", "Janssen,", "is", "developing", "a", "BCMAxCD3", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p95_s2", "idA": "886163_17_item1_p97_s0", "sentA": "AM0010+PD-1 (ARMO Biosciences) Our partner, ARMO Biosciences, is developing an anti-PD-1 antibody discovered with the OmniAb platform technology.", "sentB": "Our partner, ARMO Biosciences, is developing an anti-PD-1 antibody discovered with the OmniAb platform technology.", "type": 2, "words": ["<tag1>", "AM0010+PD-1", "(ARMO", "Biosciences)", "Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology.", "<tag2>", "Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology.", "<tag3>"], "wordsA": ["AM0010+PD-1", "(ARMO", "Biosciences)", "Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology."], "wordsB": ["Our", "partner,", "ARMO", "Biosciences,", "is", "developing", "an", "anti-PD-1", "antibody", "discovered", "with", "the", "OmniAb", "platform", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p95_s1", "idA": "886163_17_item1_p97_s1", "sentA": "AM0010+PD-1 is a therapeutic target for cancer therapy.", "sentB": "Janssen is currently conducting a Phase I trial for cancer therapy.", "type": 2, "words": ["<tag1>", "AM0010+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy.", "<tag2>", "Janssen", "is", "currently", "conducting", "a", "Phase", "I", "trial", "for", "cancer", "therapy.", "<tag3>"], "wordsA": ["AM0010+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy."], "wordsB": ["Janssen", "is", "currently", "conducting", "a", "Phase", "I", "trial", "for", "cancer", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p96_s0", "idA": "886163_17_item1_p97_s1", "sentA": "AM0010+PD-1 is a therapeutic target for cancer therapy.", "sentB": "AM0001+PD-1 is a therapeutic target for cancer therapy.", "type": 2, "words": ["<tag1>", "AM0010+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy.", "<tag2>", "AM0001+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy.", "<tag3>"], "wordsA": ["AM0010+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy."], "wordsB": ["AM0001+PD-1", "is", "a", "therapeutic", "target", "for", "cancer", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p26_s1", "idA": "886163_17_item1_p98_s0", "sentA": "We are entitled to earn regulatory milestones and royalties on future sales.", "sentB": "Ligand is also entitled to future milestones and royalties from this antibody.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "earn", "regulatory", "milestones", "and", "royalties", "on", "future", "sales.", "<tag2>", "Ligand", "is", "also", "entitled", "to", "future", "milestones", "and", "royalties", "from", "this", "antibody.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "earn", "regulatory", "milestones", "and", "royalties", "on", "future", "sales."], "wordsB": ["Ligand", "is", "also", "entitled", "to", "future", "milestones", "and", "royalties", "from", "this", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p32_s2", "idA": "886163_17_item1_p98_s0", "sentA": "We are entitled to earn regulatory milestones and royalties on future sales.", "sentB": "Ligand is entitled to commercial milestones and royalties on net sales ranging from 6-10% upon commercialization of oral lasofoxifene.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "earn", "regulatory", "milestones", "and", "royalties", "on", "future", "sales.", "<tag2>", "Ligand", "is", "entitled", "to", "commercial", "milestones", "and", "royalties", "on", "net", "sales", "ranging", "from", "6-10%", "upon", "commercialization", "of", "oral", "lasofoxifene.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "earn", "regulatory", "milestones", "and", "royalties", "on", "future", "sales."], "wordsB": ["Ligand", "is", "entitled", "to", "commercial", "milestones", "and", "royalties", "on", "net", "sales", "ranging", "from", "6-10%", "upon", "commercialization", "of", "oral", "lasofoxifene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p103_s0", "idA": "886163_17_item1_p99_s0", "sentA": "Our partner, Aldeyra, is conducting a phase II study for ADX-102 for the treatment of ocular inflammation.", "sentB": "Our partner, Aldeyra, is conducting a Phase 2 study for ADX-102 for the treatment of ocular inflammation.", "type": 2, "words": ["<tag1>", "Our", "partner,", "Aldeyra,", "is", "conducting", "a", "phase", "II", "study", "for", "ADX-102", "for", "the", "treatment", "of", "ocular", "inflammation.", "<tag2>", "Our", "partner,", "Aldeyra,", "is", "conducting", "a", "Phase", "2", "study", "for", "ADX-102", "for", "the", "treatment", "of", "ocular", "inflammation.", "<tag3>"], "wordsA": ["Our", "partner,", "Aldeyra,", "is", "conducting", "a", "phase", "II", "study", "for", "ADX-102", "for", "the", "treatment", "of", "ocular", "inflammation."], "wordsB": ["Our", "partner,", "Aldeyra,", "is", "conducting", "a", "Phase", "2", "study", "for", "ADX-102", "for", "the", "treatment", "of", "ocular", "inflammation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
